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complex	 interactions	 between	 cancer	 cells	 and	 surrounding	 stromal	 cells.	 A	 critical	
component	 of	 this	 environment	 are	 myeloid-derived	 suppressor	 cells	 (MDSCs),	 a	
heterogeneous	 group	 of	 immature	 myeloid	 cells	 arrested	 at	 different	 stages	 of	
differentiation	and	expanded	 in	 response	 to	a	variety	of	 tumour	 factors.	MDSCs	exert	




In	 this	 project,	 we	 sought	 to	 quantify	 and	 characterise	MDSC	 populations	 in	 patients	
with	 Acute	Myeloid	 Leukaemia	 (AML)	 and	 delineate	 the	mechanisms	 underlying	 their	
expansion.	We	 have	 demonstrated	 that	 immune	 suppressive	MDSCs	 are	 expanded	 in	
the	peripheral	blood	and	bone	marrow	of	patients	with	AML.	 Furthermore,	AML	cells	
secrete	 extra-cellular	 vesicles	 (EVs)	 that	 skew	 the	 tumour	 microenvironment	 from	
antigen-presentation	 to	 a	 tumour	 tolerogenic	 environment,	 through	 the	 expansion	 of	
MDSCs.	We	then	demonstrated	that	MDSC	expansion	 is	dependent	on	tumour	and	EV	
expression	 of	 the	 oncoproteins	 MUC1	 and	 c-Myc.	 Furthermore,	 we	 determined	 that	
MUC1	 signalling	 promotes	 c-MYC	 expression	 in	 a	 microRNA	 (miRNA)	 dependent	
mechanism.	 This	 observation	 lead	 us	 to	 elucidate	 the	 critical	 role	 of	 MUC1	 in	
suppressing	microRNA-genesis	in	AML,	via	the	down-regulation	of	the	DICER	protein,	a	
key	component	of	miRNA	processing	machinery.		Finally,	exploiting	this	critical	pathway,	
we	 showed	 that	MDSCs	 can	be	 targeted	by	MUC1	 inhibition	or	by	 the	use	of	 a	novel	
hypomethylating	agent	SGI-110.	
	
These	 studies	 highlight	 the	 critical	 role	 that	 MDSCs	 play	 in	 mediating	 immune	
































































Cabozantinib	 eradicates	 advanced	 murine	 prostate	 cancer	 by	 activating	 neutrophil-
mediated	anti-tumour	innate	immunity	
















































































































































































































































































Seminal	mouse	 experiments	 in	 the	 1950s	 demonstrated	 that	 the	 immune	 system	has	
the	capacity	to	target	malignant	cells	and	destroy	them.	Medawar	and	colleagues	used	
non-inbred	strains	of	immune-competent	mice	to	show	that	immune	cells	can	recognise	
and	 destroy	 allogeneic	 transplanted	 tumours1,2.	 Moreover,	 mice	 that	 were	 lympho-
depleted	did	 not	 reject	 allografted	 tumours	 confirming	 the	 immune	mediation.	 These	
discoveries	 led	 Burnet	 and	 Thomas	 to	 publish	 their	 hypothesis	 of	 cancer	
immunosurveillance3,4,	 describing	 a	 state	 of	 frequent	 subclinical	 malignant	
transformation	 that	 the	 immune	 system	 continually	 surveys	 and	 destroys.	 In	 further	
support	 of	 immune	 surveillance,	 large	 scale	 epidemiological	 studies	 confirmed	 that	
human	 patients	with	well	 described	 immune	 defects	 had	 higher	 rates	 of	malignancy,	
over	 and	 above	 virus-induced	 cancers5.	 Moreover,	 the	 advent	 of	 haematopoietic	
transplantation	heralded	the	observation	that	allogeneic	transplantation	is	curative	for	a	
subset	 of	 cancer	 patients	 due	 to	 the	 activation	 and	 expansion	 of	 alloreactive	
lymphocytes6.	





Cancer	 cells	 frequently	 have	 altered	 expression	 of	 surface	 and	 intracellular	 proteins	
rendering	 them	 more	 virulent,	 but	 also	 a	 target	 for	 immune	 mediated	 destruction.	
These	proteins,	or	 tumour	antigens,	 can	broadly	be	divided	 into	 four	groups.	The	 first	






molecules	 and	 therefore	 these	 proteins	will	 have	 never	 been	 seen	 by	 T	 lymphocytes,	
and	are	therefore	effectively	tumour	specific.	The	third	category	of	tumour	antigen	are	
antigens	normally	found	in	healthy	tissue	but	highly	over	expressed	in	cancerous	cells,	
compared	 to	 their	 normal	 counterparts7	 and	 termed	 tumour-associated	 antigens.	 The	
final	category	of	tumour	antigen	are	normal	antigens	which	undergo	post	translational	
modifications	 which	 alter	 them	 and	 make	 them	 phenotypically	 different	 to	 healthy	
tissue	and	another	subset	of	tumour-associate	antigen.	An	example	of	this	is	an	under-
glycosylated	 mucin,	 MUC1,	 which	 is	 over	 expressed	 by	 many	 epithelial	 and	
haematological	cancers8.	
Although	these	alterations	in	the	repertoire	of	proteins	in	cancer,	ought	to	make	them	
recognizable	 and	 targeted	 for	 destruction	 by	 effector	 cells	 of	 the	 immune	 system,	 in	
practice,	in	is	rare	for	an	established	tumour	to	undergo	spontaneous	immune	mediated	
destruction	and	usually	only	 seen	 in	highly	 immunogenic	 cancers	 such	as	melanoma9.	
Moreover,	 if	 the	 immune	 system	 is	 so	 finely	 tuned	 to	 seek	 out	 and	 destroy	 early	




Screiber	 et	 al	 have	 proposed	 “the	 three	 Es	 of	 cancer	 immune	 editing:	 elimination,	
equilibrium,	and	escape”10.	The	first	phase	“elimination”,	describes	the	original	concept	
of	cancer	immune-surveillance,	that	is,	the	emerging	tumour	is	 identified	as	foreign	by	
the	 innate	 and	 adaptive	 immune	 system	 and	 destroyed,	 and	 there	 is	 no	 need	 of	
progression	to	the	subsequent	phases.		
The	second	phase	“equilibrium”,	represents	the	longest	phase	in	immune	editing.	In	the	
equilibrium	 phase,	 tumour	 variants	 or	 sub-clones	 that	 have	 survived	 the	 elimination	
phase	and	the	host	immune	system	enter	into	a	dynamic	equilibrium,	which	can	last	for	




















is	 downregulating	of	 antigen	presentation	machinery.	 Loss	of	MHC	Class	 I	 expression,	
loss	of	 individual	HLA	alleles	and	mutations	of	the	transporter	associated	with	antigen	
processing	 (TAP)	molecules	 can	 reduce	antigen	presentation.	 	 Furthermore,	malignant	
cells	 can	 inhibit	 the	 function	 of	 antigen	 presenting	 cells	 such	 as	 dendritic	 cells,	 by	
secreting	 molecules	 such	 as	 Il-1015	 and	 	 VEGF16,	 inhibiting	 maturation	 and	 polarizing	
them	 to	 a	 tolerogenic	 phenotype17.	 In	 addition,	 when	 dendritic	 cells	 present	 antigen	
near	 tumour	 cells,	 it	 results	 in	 T	 cell	 tolerance	 rather	 than	 T	 cell	 priming18,	 and	 this	
appears	 to	 be	 due	 to	 the	 lack	 of	 inflammation	 surrounding	 poorly	 immunogenic	
tumours.	There	are	clinically	important	quantitative19	and	qualitative	defects	in	antigen	
presenting	 cells	 of	 cancer	 patients.	 They	 appear	 of	 an	 immature	 phenotype	 as	
evidenced	by	their	low	expression	of	the	co-stimulatory	molecules	CD80	and	CD8620,21.	







regulatory	 cells	 (TRegs)25.	 These	 CD4+	 CD25+	 cells	 forkhead	 box	 P3	 (FOXP3)+	 cells	
produce	 high	 levels	 of	 immune	 suppressive	 Il-10.	 Il-10	 acts	 on	 T	 cells	 and	 antigen-
presenting	cells	causing	anergy.	 It	appears	 that	numbers	of	circulating	TRegs	predict	a	
poorer	 prognosis	 of	 in	 cancer	 patients26,27.	 Expansion	 of	 TRegs	 has	 been	 noted	 in	
patients	with	different	solid	cancers	and	moreover,	in	haematological	malignancies28,29.	
Similarly	 to	 regulatory	 T	 cells,	 Myeloid-derived	 suppressor	 cells30	 are	 expanded	 in	
patients	 with	 cancer	 and	 are	 associated	 with	 T	 cell	 anergy	 and	 poor	 prognosis	 of	
disease.	They	will	be	described	in	further	detail	later.	
Tumour	cells	may	express	T	cell	inhibitory	molecules	such	as	B7-H131,	HLA-G32	and	HLA-
E33.	 Furthermore,	 they	may	 also	 up-regulate	 the	 CTLA-4	 and	 PDL-1/PD-1	 negative	 co-
stimulatory	pathways34,35,	which	are	permissive	to	the	growth	and	survival	of	malignant	
cells.	 The	 importance	 of	 immune	 modulation	 in	 determining	 the	 balance	 between	
immune	activation	and	disease	has	been	highlighted	by	recent	observations	 that	PD-1	
blockade	 alone	 is	 capable	 of	 inducing	 sustained	 disease	 response	 in	 patients	 with	
advanced	solid	malignancies36.	Lastly,	a	variety	of	tumour	derived	soluble	factors	such	as	
indolamine37,	 VEGF,	 TGFB	 and	 IL-10	 inhibit	 both	 effector	 T	 cell	 function	 and	dendritic	
cell	maturation38.		
These	 extensive	 data	 demonstrate	 the	 importance	 of	 a	 two-pronged	 approach	 in	 any	
attempt	 to	 harness	 the	 power	 of	 the	 immune	 system	 to	 eliminate	 tumour	 cells.	 The	




Acute	 myeloid	 leukaemia	 or	 acute	 myelogenous	 leukaemia	 (AML),	 is	 a	 highly	 lethal	
cancer	 of	 the	 myeloid	 lineage	 of	 blood	 cells,	 characterized	 by	 the	 rapid	 growth	 of	
abnormal	white	blood	cells	in	the	bone	marrow	and	peripheral	blood.	The	bone	marrow	
quickly	 becomes	 densely	 packed	 with	 leukaemic	 cells	 known	 as	 blasts,	 and	 the	




year,	 the	majority	 in	 adults,	 and	 roughly	 10,000	 deaths	 from	 AML.	 The	mean	 age	 at	
diagnosis	 of	 AML	 is	 67,	 and	 is	 uncommon	 in	 people	 less	 than	 45	 years	 old.	 The	
cumulative	lifetime	risk	of	a	person	developing	AML	is	less	than	0.5%39.		
The	 malignant	 cell	 in	 AML	 is	 a	 myeloblast,	 an	 immature	 precursor	 of	 myeloid	 white	
blood	 cells	 such	as	 granulocytes	and	macrophages.	 In	AML,	 a	 transformed	myeloblast	
accumulates	 genetic	 mutations	 prevent	 its	 differentiation	 into	 mature	 cells.	 This	
"differentiation	 arrest"	 is	 combined	 with	 subsequent	 mutations	 lead	 to	 aberrant	
uncontrolled	 proliferation,	 defined	 as	 AML	 when	 the	 bone	 marrow	 infiltrate	 of	 the	
malignant	clone	reaches	20%40.	
The	 causes	 of	 these	 mutations	 are	 varied.	 Some	 are	 associated	 with	 pre-malignant	
states	such	as	myelodysplastic	syndrome	(MDS)	or	myeloproliferative	neoplasms	(MPN),	
whereby	accumulation	of	mutations	due	to	age	or	exposure	to	carcinogens,	can	lead	to	
a	 relatively	 slowly	proliferating,	 less	 invasive	clone	which	can	exist	 for	decades	before	
transforming	into	invasive	high	grade	leukaemia,	and	in	many	classes,	not	at	all41.		
There	are	various	chemicals	and	drugs	that	increase	a	person’s	likelihood	of	developing	
acute	 leukaemia,	 thought	 related	 to	 the	 accumulation	 of	 genetic	 changes.	










Lastly,	 the	 majority	 of	 cases	 of	 AML	 are	 de	 novo,	 and	 although	 there	 are	 multiple	




of	 the	 blasts	 (French-American-British	 (FAB))	 47,48	 but	 in	 2001,	 the	 World	 Health	
Organisation	 (WHO)	 classification	 incorporated	 clinical	 features,	 immunophenotyping	
and	cytogenetics	 into	 the	standard	morphological	 stratification,	 in	order	 to	 reflect	 the	











































The	 most	 important	 prognostic	 factor	 in	 AML	 is	 cytogenetic	 abnormality	 of	 the	
leukaemic	 cell,	 as	 summarized	 in	 Table	 2.	 	 Certain	 cytogenetic	 abnormalities	 are	
associated	 with	 better	 outcomes	 (for	 example,	 the	 (15;17)	 translocation	 in	 acute	
promyelocytic	 leukaemia).	Patients	with	“good”	cytogenetics	are	more	 likely	to	have	a	
remission	sustained	at	5	years.	Roughly	half	of	AML	patients	have	"normal"	cytogenetics	
and	 so	 fall	 into	 an	 “intermediate”	 risk	 group.	 The	 remaining	 patients	 with	 complex	

















Good	 t(8;21),	t(15;17),	inv(16)	 70%	 33%	
Intermediate	 Normal,	 +8,	 +21,	 +22,	 del(7q),	 del(9q),	
Abnormal	 11q23,	 all	 other	 structural	 or	
numerical	changes	
48%	 50%	






are	 not	 medically	 fit	 for	 aggressive	 treatments,	 and	 are	 treated	 with	 a	 palliative	




mortality.	 Novel	 molecular	 and	 immune	 based	 therapies	 that	 specifically	 target	 a	
cytogenetic	aberration	responsible	for	the	malignant	clone,	or	a	protein	specifically	and	
















Historically,	 the	 mainstays	 of	 treatment	 for	 the	 induction	 of	 remission	 were	 the	
anthracycline	antibiotics	daunorubicin	and	mitoxantrone,	alongside	the	podophyllotoxin	
etoposide,	 and	 the	 anti-metabolite	 cytarabine	 (ara-c).	 The	 combination	 DA	
(daunorubicin	and	ara-c)	 resulted	 in	an	 initial	 complete	 remission	 (CR)	 rate	of	60-65%	
when	 introduced	 and	 became	 the	 chemotherapy	 standard	 of	 care	 for	 modern	
chemotherapy	 regimens	 in	 AML51.	 The	 current	 options	 for	 front	 line	 treatment	 for	










in	 younger	 AML	 patients	 with	 high-risk	 of	 relapsed	 disease.	 After	 myelo-ablation	 by	
chemo/radiotherapy,	 patients	 are	 given	 stem	 cells	 harvested	 from	another	 individual,	
which	will	repopulate	the	bone	marrow,	creating	a	chimera.	Immuno-competent	donor	
T	cells	in	the	graft	will	recognize	and	destroy	residual	malignant	cells,	termed	the	graft-
versus-leukaemia	 effect	 (GVL),	 as	 is	 thought	 responsible	 for	 the	 pervasive	 remissions	
seen	 post	 allograft.	 However,	 these	 donor	 T	 cells	 can	 also	 recognize	 healthy	 non-
leukaemic	 host	 cells	 causing	 the	 life	 threatening	 complication	 of	 graft-versus-host	
disease	(GVHD)52.	
Carefully	designed	studies	examining	the	risk	of	relapse	in	variously	risk	stratified	groups	
of	 patients,	 and	 comparing	 this	 to	 the	 risk	 of	 treatment	 related	 mortality,	 have	
determined	 that	 allogeneic	 HSCT	 is	 not	 recommended	 for	 patients	 in	 CR1	 with	 a	
“favourable	 risk”	 profile53	 but	 is	 highly	 desirable	 in	 the	 “poor	 risk”	 group.	 The	
“intermediate	 risk”	 category	poses	an	 interesting	conundrum,	where	despite	a	 lack	of	
strong	 evidence	 either	 way,	 allogeneic	 HSCT	 is	 generally	 favoured	 by	 physicians	 and	
study	consortia54.		
Older	patients	comprise	 the	majority	of	AML	patients	and	given	the	prevalence	of	co-
morbidities	 in	 this	 age	 group	 that	may	 preclude	 traditional	 myelo-ablative	 allogeneic	
transplantation,	new	approaches	have	been	necessary.	Reduced-intensity	conditioning	
(RIC)	 uses	 immune	 suppression	 rather	 than	 immune	 ablation,	 to	 allow	 some	
engraftment	 of	 donor	 cells,	 followed	 by	 repeated	 donor	 lymphocyte	 infusions	 to	
improve	engraftment	and	exploit	the	graft	vs.	 leukaemia	effect.	This	results	in	less	risk	
of	 graft	 vs.	 host	 disease	which	 is	 life	 threatening	 to	 a	more	 vulnerable	 older	 patient.	
Despite	 a	 lack	 of	 large	 scale	 prospective	 randomised	 controlled	 trial	 data,	 reduced	
intensity	transplants	now	comprise	27%	of	allogeneic	stem	cell	transplants	in	Europe55.	





treatment	 in	AML	patients	 have	 been	published.	 Ringden	 et	 al	 demonstrated	 that,	 of	
434	 AML	 patients,	 the	 roughly	 half	 that	 underwent	 RIC	 had	 lower	 treatment	 related	
mortality	at	2	years	compared	with	patients	who	received	a	MAC	regimen	(25%	v	39%,	P	
=	 .003).	 However	 there	was	 a	 higher	 cumulative	 incidence	 of	 relapse	 (CIR)	 in	 the	 RIC	
compared	 to	 the	MAC	 group	 (42%	 v	 29%,	 P	 =	 .015)	 (19652066).	 Despite	 such	mixed	
evidence,	 it	 is	 known	 that	 older	 patients	who	 survive	 through	 any	 type	 of	 allogeneic	
transplant,	 in	 first	 remission,	 have	 a	 lower	 risk	 of	 relapsing	 compared	 to	 those	 not	
receiving	a	transplant	(22%	v	62%,	P	<.001),	although	this	was	tempered	by	an	increase	
in	treatment	related	mortality	(21%	v	35%,	P	<.001)56.	
In	 contrast	 to	 allogeneic	 transplantation,	 whereby	 patients	 are	 re-constituted	 with	
donor	cells,	the	role	of	autologous	transplantation	remains	unclear	in	the	treatment	of	
AML57,58.	The	rationale	for	autologous	transplantation	is	the	ability	to	give	higher	doses	
of	 chemotherapy	 as	 salvage,	 with	 the	 patient’s	 own	 cells	 as	 rescue.	 However	 the	
theoretical	risk	of	re-infusing	leukaemia	cells	into	the	patient	lead	to	efforts	to	purge	the	




As	 depicted	 in	 the	 schema	 and	 described	 in	 the	 literature,	 conventional	 cytotoxic	
chemotherapy	agents	are	not	the	only	method	of	induction	of	remission.	So	far,	the	only	
targeted	molecular	 therapy	 to	 be	 approved	 for	 the	 treatment	 of	 AML	was	 the	 CD33	
monoclonal	antibody	gemtuzumab	ozogamycin,	which	was	voluntarily	withdrawn	from	




the	 repression	 of	 tumour-suppressor	 genes	 (TSGs),	 epigenetic	 changes	 play	 an	








compared	 to	 standard	of	 care	 regimens.	 The	overall	 survival	 (OS)	 for	patients	 treated	
with	 azacitidine	 was	 10.4	 months,	 compared	 to	 6.5	 months	 for	 patients	 receiving	
conventional	 care,	 which	 was	 not	 statistically	 significant61.	 Azacitidine’s	 deoxy	
derivative,	 decitabine	was	 compared	 to	 low-dose	 cytarabine	 in	 485	 newly	 diagnosed,	
older	AML	patients.	The	complete	remission	rate	for	the	decitabine	arm	was	16%	vs.	7%	
in	the	cytarabine	arm,	and	the	median	overall	survival	was	7.7	months	vs.	5.0	months62.	
Second-generation	 DNMT	 inhibitors	 have	 been	 developed	 such	 as	 the	 drug	 SGI-110,	
designed	 to	 enhance	 the	 efficacy	 of	 decitabine	 by	 combining	 it	with	 deoxyguanosine.	
This	confers	resistance	to	degradation	by	cytidine	deaminase,	therefore	 increasing	the	
half-life	 of	 the	 drug.	 A	 phase	 II	 trial	 of	 SGI-110	 in	 relapsed	 and	 refractory	 or	 elderly	
newly	 diagnosed	 AML	 patients	 demonstrated	 an	 overall	 remission	 rate	 of	 16%	 and	
42.5%%	respectively63.	
Histones	play	an	important	role	in	forming	nucleosomes	with	DNA,	and	the	activities	of	




Cyclin-dependent	 kinase	 inhibitors	 (CDKIs)	 are	 capable	 of	 inducing	 apoptosis	 in	
malignant	 cells	 and	 can	 also	 inhibit	 global	 cellular	 transcription.	 Although	 no	 CDKI	 is	
approved	for	use,	the	FDA	recently	granted	“orphan	drug”	designation	to	alvocidib	for	
AML,	 following	 	 	 promising	 results	 as	 part	 of	 induction	 chemotherapy	 in	 a	 phase	 II	
study66.	
FLT3,	 an	 often	 mutated	 receptor	 tyrosine	 kinase	 involved	 in	 cell	 signalling	 and	





lestaurtinib,	 trialled	at	 first	 relapse	of	AML,	unfortunately	 failed	 to	 improve	OS	or	 the	
CR,	and	was	more	toxic	when	compared	to	the	control	group67.	Sorafenib,	a	multikinase	
inhibitor	with	 approval	 in	 several	 solid	 cancers,	 is	 also	 a	 potent	 FLT3	 inhibitor.	 Some	
small	phase	I	studies	of	sorafenib	in	AML	showed	encouraging	results68,69,	and	a	phase	II	
in	 combination	 with	 cytarabine,	 demonstrated	 an	 ORR	 of	 46%	 in	 the	 37	 evaluable	
patients70.	
The	interleukin	three	receptor	alpha	(IL3RA;	CD123)	molecule	 is	overexpressed	in	AML	
cells71	and	 is	 therefore	a	 target	of	 treatment.	SL-401,	a	drug	comprised	of	human	 IL-3	
coupled	 to	 a	 truncated	 diphtheria	 toxin	 payload	 that	 inhibits	 protein	 synthesis,	 was	
trialled	 in	 59	 patients	 with	 relapsed	 or	 refractory	 AML	 and	 11	 patients	 with	 new	
diagnoses	of	AML	who	were	unfit	for	chemotherapy.	SL-401	demonstrated	single	agent	
anti-tumour	activity,	was	well	 tolerated	and	a	randomized	Phase	2b	trial	 is	planned	 in	
relapsed	refractory	AML72.	
The	 Bcl-2	 family	 of	 proteins	 are	 critical	 to	 the	 balance	 between	 cellular	 survival	 and	
death.	ABT-199	is	a	highly	selective	Bcl-2	antagonist	that	retains	significant	anti-tumour	
activity	 and	 is	 currently	 in	 phase	 II	 trial	 in	 AML.	 Notably,	 oblimersen,	 an	 anti-sense	
oligonucleotide	 against	 Bcl-2,	 failed	 to	 show	 any	 benefit	 in	 phase	 III	 clinical	 trials	 in	
combination	with	chemotherapy	in	older	patients	 in	AML73,	despite	promising	phase	II	
results	in	combination	with	GO	74.	
The	 PI3K/AKT/MTOR	 pathway	 is	 an	 intracellular	 signalling	 pathway	 important	 in	
regulating	 the	 cell	 cycle.	 Several	 drugs	 of	 interest	 currently	 in	 trial,	 which	 target	 this	
pathway,	include	AZD-536375,	NVP-BGT22676,	OSI-02777	and	PP24278.	
Farnesyltransferase	 inhibitors	 target	 the	 protein	 farnesyltransferase	 with	 the	
downstream	effect	of	preventing	Ras	protein	signalling,	which	is	commonly	abnormally	
active	 in	 haematological	 malignancy79	 .	 The	 farnesyltransferase	 inhibitor	 tipifarnib80	
resulted	in	an	overall	response	rate	(CR	+	CRi	+	PR)	of	20%	in	newly	diagnosed	AML.		The	
addition	of	 tipifarnib	 to	 low	dose	 cytarabine	did	not,	 however,	 improve	outcomes	 for	
older	patients	with	AML	in	the	AML-16	trial81.	
Athalia	Rachel	Pyzer	 Chapter	1:	Introduction:	The	Immune	System	in	AML	
The	UK’s	MRC	AML-18	pilot	 trial	will	 evaluate	 the	 safety,	 tolerability	 and	 feasibility	of	
three	drugs	 that	are	planned	 to	be	 included	 in	 the	 subsequent	NCRI	AML18	 trial.	 The	
Tyrosine	 Kinase	 Inhibitor	 AC220,	 the	 CXCR4	 inhibitor	 plerixafor,	 or	 ganetespib,	 small	
molecule	 inhibitor	of	heat	 shock	protein	90	 (Hsp90),	will	be	evaluated	 in	 combination	






subsequently	 noted	 that	 injection	 of	 solid	 tumours	 with	 Streptococcus	 resulted	 in	
tumour	 regression	 in	 some	cases.	This	observation	 that	 infection	can	prime	or	 tip	 the	
balance	 of	 the	 immune	 system	 in	 favour	 of	 immune	mediated	 tumour	 targeting,	 has	
since	 been	 seen	 in	 several	 cases	 of	 AML	 spontaneously	 remitting	 after	 invasive	
infection83–86.	The	advent	of	allogeneic	bone	marrow	transplantation	in	the	1960s,	with	




Despite	 these	 promising	 observations	 that	 the	 immune	 system	 has	 the	 capability	 to	










Negative	 co-stimulation	 and	 immune	 checkpoint	 signalling,	 are	 critical	 in	 immune	
homeostasis	and	their	up-regulation	is	a	key	mechanism	of	tumour	cell	immune	evasion.	
The	 importance	 of	 targeting	 inhibitory	 signals	 is	 key	 to	 unlocking	 the	 full	 potential	 of	
immune	targeting	on	tumour	cells,	and	 is	highlighted	by	 impressive	results	of	 immune	
checkpoint	blockade	in	solid	tumours91.		
The	 PD1/PD-L1	 immune	 checkpoint	 is	 a	 key	 inhibitory	 checkpoint	 in	 immune	
homeostasis.	 When	 tumour	 expressed	 PD-L1	 binds	 to	 its	 receptor,	 PD-1,	 found	 on	






The	 Tim-3/Gal-9	 pathway	 regulates	 activated	 immune	 responses	 in	 leukaemia	 via	
several	mechanisms.	Firstly,	the	binding	of	TIM3	on	exhausted	T	cells97	with	Galectin-9	
on	 tumour	 cells,	 triggers	 apoptosis	 in	 Th1	 cells.	 In	 addition,	 TIM3/Gal9	 signalling	may	
expand	 the	 immune	 suppressing	 MDSC	 population98.	 Another	 group	 has	 shown	 that	
TIM3/Gal9	 interactions	constitute	an	autocrine	 loop	that	 is	critical	for	the	self-renewal	
of	leukaemic	stem	cells99.	Furthermore,	the	TIM3/Gal9	interaction	may	induce	NK	cells	
to	 produce	 IFNγ,	which	while	may	 initially	 be	 helpful,	 induces	 IDO	 expression	 in	 AML	
blasts	which	 in	turn	down-regulates	NK	cell	activity100.	Given	these	varied	mechanisms	









Leukaemic	blasts	secrete	 immune	suppressive	 inhibitory	molecules	 in	a	similar	 fashion	
to	 innately	 suppressive	 cells	 such	 as	 MDSCs	 and	 TRegs.	 Arginase-1	 production	 by	
tumour	 cells	 depletes	 L-Arginine,	 a	 key	 nutrient	 for	 lymphocytes.	 Arginine	 starvation	
inhibits	T	cell	proliferation	via	decreased	CD3	theta	chain	expression104	and	prevents	the	
expression	of	cell	cycle	regulators	cyclinD3	and	cdk4105	resulting	in	cell	cycle	arrest	of	T	
cells.	 In	 addition,	 Arginase-1	 inhibits	 NK	 cell	 proliferation	 and	 secretion	 of	 IFN-Y	
suggesting	widespread	immune	suppressive	effects	of	this	enzyme106.	It	has	been	shown	
that	AML	blasts	produce	an	Arginase-1	rich	environment107,108.		
Indolamine	2,3-dioxygenase	 (IDO)	 is	an	enzyme	that	catalyses	 the	 rate-limiting	step	 in	
tryptophan	 degradation	 along	 the	 kynurenine	 pathway.	 Kynurenine,	 in	 turn,	 inhibits	
effector	 T	 cells	 and	promotes	 regulatory	 T-cell	 (TReg)	 differentiation109,110.	 In	 immune	
homeostasis,	IDO	is	produced	by	some	alternatively	activated	M2	macrophages.	In	AML,	
IDO	mRNA	and	activity	in	mononuclear	cells	was	detected	in	52%	of	patients	but	absent	
in	 normal	 subjects.	 Treatment	 of	 AML	 blasts	 with	 an	 IDO	 inhibitor	 1MT,	 showed	 no	






autoimmunity112.	 In	 patients	 with	 leukaemia,	 increased	 numbers	 of	 circulating	 TRegs	













Dendritic	 cells	 in	 leukaemia	 patients	 are	 quantitatively122	 and	 functionally	 deficient	 in	
presenting	 antigen123.	 Furthermore,	 there	 is	 a	 skew	 of	 polarity	 towards	 a	 tolerogenic	
phenotype124	 with	 the	 ratio	 of	 tolerogenic	 plasmacytoid	 Dendritic	 Cells	 (pDCs)	 to	
monocytoid	Dendritic	Cells	(mDCs)	being	altered	in	favour	of	tumour	tolerogenicty125.		
Mucin	1	(MUC1)	
Mucin	 1	 (MUC1)	 is	 a	 heterodimeric	 protein	 that	 regulates	 critical	 pathways	 of	
oncogenesis	 including	 those	 governing	 cell	 proliferation,	 self-renewal,	 tissue	 invasion,	
and	 apoptosis8.	 MUC1	 is	 aberrantly	 expressed	 in	 epithelial	 tumours	 and	 selected	
haematologic	 malignancies	 including	 multiple	 myeloma126,127	 and	 acute	 myeloid	
leukaemia128,129.	MUC1	has	been	identified	as	a	uniquely	important	oncoprotein	in	AML	
and	AML	stem	cells	that	exerts	immune-modulatory	effects8.	It	has	been	demonstrated	
that	 MUC1	 is	 selectively	 expressed	 on	 AML	 stem	 cells	 as	 compared	 to	 normal	













Despite	 the	 extensive	measures	 AML	 tumour	 cells	 take	 to	 evade	 the	 immune	 system	








Dendritic	 cells	 are	a	heterogeneous	population	of	bone	marrow	derived	 immune	cells	
with	potent	antigen	presenting	abilities133–135.	Crucially,	dendritic	cells	strongly	express	
the	 co-stimulatory	molecules	 required	 to	 induce	 primary	 immunity134.	 Ex	 vivo	 studies	






patients	with	malignancy	 by	ex	 vivo	 by	 culture	 in	 the	 presence	 of	 cytokines.	 As	 such,	
dendritic	cells	manipulated	to	present	tumour	antigen	have	the	potential	to	elicit	potent	
anti-tumour	immunity.		
A	 variety	 of	 strategies	 for	 loading	 tumour	 antigens	 onto	 dendritic	 cells	 have	 been	






the	 DC.	 Previous	 efforts	 have	 investigated	 the	 used	 of	 (i)	 peptide	 based	 vaccines137,	
often	 with	 an	 immune	 adjuvant138,	 (ii)	 DNA139–141	 or	 RNA	 coding142,143	 for	 a	 specific	
antigen,	 (iii)	 viral/fungal	 vectors	expressing	 cancer	antigens144–146	or	 tumour	apoptotic	
bodies147.	Ex	vivo	data	has	shown	varying	immunogenic	responses	to	these	techniques	
and	some	of	the	limitations	proposed	have	been	the	need	for	HLA	matching	of	peptide	




tumour	 have	 included	 the	 whole	 intact	 tumour	 cell150,	 cell	 lysate151,152,	 apoptotic	
bodies153,154	or	whole	cell	DNA	or	RNA151,155.	Another	interesting	approach	has	been	to	
target	 antigens	 towards	 dendritic	 cells	 in	 vivo,	 by	 linking	 antigens	 to	 nanoparticles	




An	 approach	 to	 introducing	 primed	 or	 naïve	 dendritic	 cells	 to	 patients	 is	 vaccination	
with	 a	 protein	 or	 peptide	 capable	 of	 recruiting	 and	 stimulating	 native	 dendritic	 cells.	
Several	 groups	 have	 conducted	 feasibility	 and	 phase	 I/II	 trials	 of	 peptide	 vaccination	
with	peptides	derived	from	the	leukaemia	associated	antigen	WT1,	in	combination	with	
immune	 adjuvants157.	 Oka	 et	 al	 vaccinated	 14	 patients	 with	 AML	 with	 WT1	 peptide	
emulsified	with	montanide	ISA51	adjuvant	at	two	weekly	intervals.	9	of	the	13	evaluable	
patients	 with	 leukaemia	 demonstrated	 immunological	 response	 as	 defined	 by	 a	 1.5x	
increase	in	WT1-specific	CTLs	determined	by	tetramer	assay.	Moreover,	this	correlated	











A	 novel	 approach	 to	 augment	 antigen-presenting	 activity	 in	 patients	 with	 cancer	 has	
been	to	vaccinate	them	with	 irradiated	autologous	tumour	cells	engineered	to	secrete	
GM-CSF.	 It	 is	 thought	 that	 paracrine	 production	 of	 GM-CSF	 can	 stimulate	 the	
recruitment,	 maturation,	 and	 function	 of	 dendritic	 cells	 in	 vivo160,161,	 overcoming	 the	
described	qualitative	and	quantitative	deficiencies	of	antigen	presenting	cells	in	cancer	
patients.	 Ho	 et	 al.	 conducted	 a	 Phase	 I	 clinical	 trial	 whereby	 high-risk	 acute	myeloid	
leukaemia	or	patients	with	MDS	were	immunized	with	autologous,	irradiated,	GM-CSF-
secreting	 tumour	 cells	 early	 after	 allogeneic,	 nonmyeloablative	 HSCT160.	 The	
immunization	was	broadly	well	 tolerated	with	one	patient	 suffering	a	GVHD	 type	 skin	
reaction.	 Six	 long-term	 responders	 showed	marked	 decreases	 in	 the	 levels	 of	 soluble	





10	 patients	 with	 AML	 in	 at	 least	 partial	 remission,	 were	 treated	 with	 four	 bi-weekly	
vaccinations.	Their	vaccination	was	well	tolerated	and	two	patients	who	were	in	partial	
remission	 after	 chemotherapy	 were	 converted	 into	 complete	 remission	 after	
vaccination,	 and	 this	 was	 associated	 with	 increases	 in	 WT1-specific	 CD8+	T	 cell	
frequencies,	as	demonstrated	by	tetramer	staining162.	
	
Vaccines	using	apoptotic	bodies	derived	 from	 tumour	 cells:	A	recent	area	of	 interest	
has	been	the	priming	of	dendritic	cells	with	tumour	associated	antigen,	 in	the	form	of	







A	 similar	 approach	 to	 priming	 dendritic	 cells	 was	 investigated	 in	 the	 setting	 of	 AML.	
Kitawaki	 et	 al.	 treated	 four	 AML	 patients	 (with	 <20%	 blasts	 on	 Bone	Marrow	 biopsy	
after	standard	of	care	chemotherapy),	with	five	doses	of	a	vaccine	generated	by	pulsing	
dendritic	cells	with	autologous	apoptotic	blasts,	alongside	KLH.	Two	of	the	four	treated	
patients	 showed	 immune	 responses	 as	 determined	 by	 raised	 IFN	 levels,	 and	 the	 one	
HLA-A*2402-positive	patient	was	shown	to	have	had	induction	of	CD8+T-cell	responses	
to	WT1-	and	human	telomerase	reverse	transcriptase,	indicating	success	of	the	dendritic	





AML	 patients	who	 achieve	 remission	 following	 standard	 cytotoxic	 therapy	 underwent	
serial	vaccination	with	DC/AML	fusions.		Vaccination	resulted	in	the	dramatic	induction	
of	 leukaemia	specific	 immunity,	as	measured	by	a	mean	fold	 increase	of	CD4	and	CD8	
cells	 expressing	 IFN-γ	 in	 response	 to	 ex	 vivo	 exposure	 to	 autologous	 leukaemia	 cell	
lysates	and	the	associated	expansion	of	T	cells	in	the	peripheral	blood	and	bone	marrow	


















the	 immunologic	milieu	 into	which	the	vaccine	 is	being	administered.	Tumour	 induced	
immune	 suppression	 may	 blunt	 immune	 response	 to	 vaccination	 in	 patients	 with	
advanced	disease.	Factors	contributing	to	tumour	induced	immune	suppression	include	
an	 increased	 presence	 of	 regulatory	 T	 cells167,	 increased	 circulating	 myeloid	 derived	
suppressor	 cells30	 and	 the	 skew	 of	 polarity	 of	 dendritic	 cells	 towards	 a	 tolerogenic	
phenotype124.	Additionally,	a	variety	of	soluble	factors	such	as	indolamine,	VEGF,	TGFB	
and	 IL-10	 inhibit	 both	 effector	 T	 cell	 function	 and	 dendritic	 cell	maturation38.	Moving	
forward,	 ongoing	 and	 future	 studies	 that	 incorporate	 vaccination	 in	 minimal	 disease	
states,	following	chemotherapy	and	following	transplantation,	hold	promise	as	a	means	
of	eradicating	minimal	residual	disease	and	preventing	relapse.	We	have	identified	the	
post	 allograft	 setting	 as	 an	 optimal	 time	 for	 immunotherapy	 as	 during	 lymphopoietic	
reconstitution	 there	 is	 a	 relative	 depletion	 of	 immune	 suppressive	 regulatory	 T	 cells	
which	would	otherwise	limit	the	response	to	vaccination168.		
A	second	approach	toward	enhancing	response	to	vaccination	is	combining	vaccination	
with	 stimulatory	 cytokines,	 immune-modulatory	 drugs,	 and	 immune	 checkpoint	
blockade.	
While	 pre-clinical	 studies	 have	 used	 immune	 stimulating	 cytokines	 such	 as	 Il-2	 in	
combination	 with	 various	 immune	 therapies,	 in	 an	 attempt	 to	 enhance	 immune	
responses,	clinical	trials	have	been	limited	to	the	use	of	GM-CSF.	In	the	setting	of	AML,	
Borello	 et.al	 conducted	 a	 phase	 II	 trial	 where	 28	 patients	 were	 given	 induction	
chemotherapy,	 followed	 by	 a	 single	 immunotherapy	 treatment	 of	 allogeneic	





CSF169.	 Patients’	 primed	 lymphocytes	 were	 collected	 by	 plasmapheresis	 and	 then	
underwent	autologous	 stem	cell	 transplantation,	 receiving	 the	primed	 lymphocytes	 at	
day	0,	 followed	by	 eight	 further	 immunotherapy	 treatments	over	 a	 six	month	period.	
Treatment	with	 the	 immunotherapy	 lead	 to	 a	 decrease	 in	WT1	 transcripts	 in	 69%	 of	
patients	after	their	first	immune	therapy,	and	increase	in	CD4+	derived	IFN-gamma	and	
granzyme.	 The	 immune	 therapy	 lead	 to	 an	 overall	 survival	 of	 73.4%	 vs.	 57.4%	 for	
patients	 who	 were	 ineligible	 for	 the	 immunotherapy.	 Of	 note,	 only	 six	 patients	 had	
detectable	 levels	of	GM-CSF	at	any	one	time	point	and	importantly,	the	study	was	not	
designed	to	demonstrate	the	superiority	of	GMCSF	modified	K562	cells	over	wildtype.	
Lenalidomide	 is	 a	 second-generation	 thalidomide	 analogue	 used	 in	 the	 treatment	 of	
myeloma.	Lenalidomide	has	potent	immunomodulatory	functions	which	have	not	been	
fully	elucidated	but	are	 thought	 to	enhance	activation	of	T	and	NK	cells.	 In	preclinical	
studies,	 lenalidomide	enhanced	 immune	response	 to	vaccination127,	and	a	clinical	 trial	
combining	lenalidomide	with	vaccination	is	planned.		
The	 PD1/PDL1	 pathway	 serves	 as	 a	 negative	 checkpoint	 for	 T	 cell	 activation	 and	CTL-
mediated	targeting	of	tumour	cells.	In	patients	with	cancer,	up-regulated	expression	of	
PD-1	on	T	cell	binds	PDL-1	on	tumour	cell,	resulting	in	the	suppression	of	T	cell	capacity	
to	 secrete	 stimulatory	 cytokines96,168.	 Following	 autologous	 transplantation	 for	
myeloma,	T-cell	expression	of	PD-1	was	observed	to	return	to	normal	 levels.	 In	our	Ex	
vivo	study,	the	effect	of	PD-1	blockade	on	T-cell	response	to	DC/whole	tumour	fusions	
was	 investigated.	 The	 presence	 the	 anti-PD1	 antibody	 CT-011,	 promoted	 the	 vaccine-
induced	 T-cell	 polarization	 towards	 an	 activated	 Th1	 phenotype	 from	 a	 Th2	 cytokine	
profile.	 Interestingly,	a	concomitant	decrease	in	regulatory	T	cells	and	enhanced	killing	












(control).	 After	 three	 years,	 treatment	with	 HDC/IL-2	was	 found	 to	 improve	 LFS	 over	
control,	with	3-year	LFS	estimates	of	40%	(HDC/IL-2)	compared	with	26%	(control).	Side	





cells,	 without	 the	 requirement	 of	 pre-	 or	 co-stimulation171.	 Blinatumomab,	 a	 BiTE	
antibody	directed	at	the	CD19	B-cell	surface	antigen	and	the	CD3e	component	of	the	T-
cell	 receptor	 complex,	 has	 shown	 some	 early	 success	 in	 ALL172	 and	 based	 on	 these	
observations,	 a	 similar	 construct	 targeting	 CD33	 has	 been	 developed	 for	 AML	 (AMG	
330).	
Dual	 affinity	 retargeting	 (DART)	 molecules	 are	 comprised	 of	 heavy	 and	 light	 chain	
variable	 domains	 of	 two	 antigen-binding	 specificities	 on	 independent	 polypeptide	
chains,	which	 are	 stabilized	 through	an	engineered	C-terminal	 bridge.	A	DART	against	




engineered	 to	express	 chimeric	 antigen	 receptors	 (CARs).	An	antibody	 that	binds	 to	 a	
tumour-associated	 epitope	 is	 engrafted	 onto	 T	 cells,	 allowing	 for	 targeting	 of	 tumour	
cells	 triggering	 T	 cell	 activation	 and	 cell-mediated	 lysis.	 Efficacy	 is	 dependent	 on	 the	
insertion	 of	 co-stimulatory	 molecules	 such	 as	 CD28	 or	 BB14	 that	 promote	 T	 cell	
expansion	 and	 persistence	 in	 the	 circulation.		 Initial	 clinical	 results	 targeting	 CD19	 in	
patients	 with	 CLL	 demonstrated	 durable	 regressions	 in	 a	 subset	 of	 patients	 with	
Athalia	Rachel	Pyzer	 Chapter	1:	Introduction:	Myeloid-derived	Suppressor	Cells	
advanced	 disease174.		 More	 recently,	 patients	 with	 refractory	 ALL	 have	 shown	
remarkable	 responses	 following	 the	 infusion	 of	 CD19	 CARs175.	 While	 these	 dramatic	
successes	have	offered	a	paradigm	shift	for	cancer	therapy,	the	further	development	of	
this	 technology	and	 its	 successful	extension	 to	other	 tumour	settings	 is	dependent	on	
overcoming	 several	 critical	 issues.	 These	 include	 the	 selection	 of	 appropriate	 tumour	
antigens	 that	 effectively	 capture	 tumour	 heterogeneity	 but	 limit	 targeting	 of	 normal	
tissues,	the	identification	of	antibody	epitopes	that	are	close	to	the	cell	surface	allowing	
for	 cell	 mediated	 lysis	 of	 the	 tumour	 target,	 an	 ongoing	 source	 of	 co-stimulation	 to	




was	 able	 to	 enhance	 the	 anti-leukaemic	 function	 of	 CIK	 cells,	 in	 ex	 vivo	 assays176.	
























Reactive	 Oxygen	 Species	 (ROS)186	 and	 Arginase-1	 (Arg-1)187	 were	 elucidated	 as	
mediators	 of	 immature	 myeloid	 cell	 T	 cell	 suppression182,188.	 Concurrent	 studies	
confirmed	a	similar	population	of	cells	 in	humans31,189–191.	Gabrilovich	et	al	coined	the	
term	 Myeloid-derived	 Suppressor	 Cells	 (MDSCs)	 192	 to	 describe	 this	 heterogeneous	
mixture	of	myeloid	cells	with	an	 immature	phenotype	and	expanded	 in	 response	 to	a	
variety	of	tumour-derived	cytokines	30.	
During	 the	 last	 decade,	 it	 has	 been	 shown	 that	 MDSCs	 exert	 diverse	 effects	 in	
modulating	 the	 interactions	 between	 immune	 effector	 cells	 and	 the	 malignant	 cells.	
Increased	 presence	 of	 MDSCs	 is	 associated	 with	 pro-tumoural	 processes	 such	 as	
angiogenesis193,194,	 tumour	 progression195,	 metastatic	 spread196	 and	 poorer	
outcomes197.	Moreover,	MDSCs	have	been	demonstrated	to	reduce	the	effectiveness	of	
immunotherapeutic	 strategies198.	 Efforts	 to	 target	 MDSCs	 to	 maximize	 responses	 to	













Under	 physiological	 conditions,	 mice	 bone	 marrow,	 unlike	 in	 humans,	 contains	 a	
significant	proportion	of	Gr1+	CD11b+	cells,	ranging	from	12%201	to	60%202	 in	different	
strains.	Only	a	 subset	of	 these	cells	will	be	 true	MDSCs,	with	 the	capacity	 to	suppress	
immune	 responses,	 reinforcing	 both	 the	 need	 to	 define	 MDSCs	 as	 cells	 with	 an	
immature	 myeloid	 phenotype	 and	 immune	 suppressive	 function,	 and	 the	 need	 to	
elucidate	more	specific	markers	for	these	cells.		
1.5.3	Characterization	of	murine	MDSCs	
There	have	been	 several	other	proposed	markers	 for	murine	MDSCs,	but	all	 lack	high	
sensitivity	or	specificity.	The	integrin	subunit	CD49d	has	been	reported	as	a	marker	for	
monocytic	 MDSCs	 in	 mice,	 differentiation	 suppressive	 from	 non-suppressive	 cells203,	
although	another	study	disputed	this	separation204.	
The	 suppressive	 activity	 of	 monocytic	 MDSCs	 correlated	 with	 the	 expression	 of	 the	
macrophage	 colony-stimulating	 factor	 receptor	 CD115	 (CSF-1R),	 in	 murine	 models	 of	
colon	 cancer205	 and	 melanoma206.	 However	 CD115	 is	 also	 expressed	 on	 monocytes,	
macrophages,	 osteoclasts,	 as	 well	 as	 on	 common	 dendritic	 cell	 precursors	 and	
macrophage/dendritic	cell	precursors,	rendering	its	solo	specificity	low.		
In	 a	murine	model	 of	 lymphoma,	 CD244	 (commonly	 found	 on	Natural	 Killer	 cells	 and	
















models	 of	 cancer209,211	 and	 exert	 similar	 suppressive	 effects	 to	 human	 MDSCs.	 It	 is	
notable	 that	monocytic	murine	MDSCs	are	 thought	 to	be	more	suppressive	 than	 their	
granulocytic	 counterparts,	 predominantly	 exerting	 their	 effects	 via	 the	 production	 of	






While	 both	 subtypes	 are	 present	 at	 low	 levels	 in	 healthy	 subjects	 213,	 they	 are	
ubiquitously	 expanded	 in	 patients	 with	 cancer30,	 and	 various	 inflammatory214,215	 and	
pre-malignant	conditions216.		
In	 addition	 to	 the	 granulocytic	 and	 monocytic	 subtypes,	 a	 third	 subset	 of	 putative	
MDSCs	 with	 the	 phenotype	 Lin-/HLADR-/CD33+/CD11b+/CD14-	 and	 a	 promyelocytic	





There	 has	 been	 much	 effort	 to	 identify	 more	 specific	 MDSC	 markers,	 as	 myeloid	







The	 granulocyte	 marker	 CD66b	 is	 commonly	 but	 not	 ubiquitously	 expressed	 on	
granulocytic	MDSCs	 in	humans,	and	can	be	used	 in	 lieu	of	CD15,	but	 is	of	 course	also	
expressed	 by	 “non-MDSC”	 granulocytes.	 	 VEGFR1	was	 reportedly	 highly	 expressed	 on	
granulocytic220	MDSCs	in	humans,	although	another	study	reportedly	lower	levels221.	
CD124,	 also	 known	 as	 the	 alpha-chain	 of	 the	 receptor	 for	 IL-4	 (IL4Ralpha),	 was	
demonstrated	to	be	expressed	on	suppressive	polymorphonuclear	cells	and	was	critical	
for	 their	negative	activity	on	CD8	T	cells222,	but	 is	also	expressed	on	mature	T	 cells,	B	
cells	and	monocytes.		
Following	 revealing	 studies	 in	 mice210	 the	 myeloid	 pro-inflammatory	 protein	 S100A9,	
and	 to	 a	 lesser	 degree	 its	 closely	 related	 proteins	 S100A8	 and	 S100A12,	 were	
demonstrated	to	be	10-fold	to	15-fold	higher	expressed	in	MDSC	than	in	monocytes	and	
strongly	associated	with	immune	suppressive	NOS	expression223,	and	in	another	study	in	
NSCLC,	 Arginase-1	 expression223,	 NOS	 and	 Arginase-1	 production	 being	 hallmark	
features	of	MDSCs.	Furthermore,	a	study	 in	gastric	cancer	showed	 levels	of	circulating	
S100A8	and	S100A9	were	increased	compared	to	healthy	controls,	and	correlated	with	
MDSC	 numbers224.	 However	 S100A8	 and	 S100A9	 are	 found	 in	 wider	 populations	 of	
granulocytes,	 monocytes	 and	 the	 early	 differentiation	 stages	 of	 macrophages.	 A	
functional	limitation	of	using	S100	family	members	to	phenotype	cells	is	that	they	are	all	
intracellular	proteins,	limiting	their	use	in	functional	studies	where	live	cells	need	to	be	
retained225.	 Building	 on	 these	 observations,	 Qin	 et	 al	 identified	 two	 phage	 eluted	
peptides	 corresponding	 to	 parts	 of,	 and	 co-immunoprecipitating	 with	 S100A8	 and	
S100A9,	and	were	able	to	partially	deplete	both	granulocytic	and	monocytic	MDSCs	in	a	
murine	model,	resulting	in	inhibition	of	tumour	growth226.	However	there	was	some	off	
target	 depletion	 of	 NK	 cells	 in	 this	 model,	 reminding	 us	 that	 currently,	 there	 is	 no	
marker	 that	 is	 100%	 sensitive	 and	 specific	 for	 MDSCs.	 	 We	 speculate	 that	 while	 it	















PBMCs	 following	 gradient	 centrifugation.	 The	 rationale	 for	 this	 is	 that	 whole	 blood	
includes	 a	 large	 population	 of	 polymorphonuclear	 cells,	 phenotypically	 indiscriminate	
from	granulocytic	MDSCs.	When	whole	blood	 is	 analysed,	 higher	density	PMNs	which	
are	 excluded	 from	 gradient	 centrifugated	 PBMCs,	 showed	 no	 suppressive	 activities,	
compared	 to	 lower	 density	 PMN	 cells	 –	 the	 population	 that	 includes	 granulocytic	
MDSCs227,	 justifying	 the	 continued	 use	 of	 techniques	 such	 as	 ficoll	 density	
centrifugation.		
Cryopreservation	
Several	 studies	 have	 investigated	 the	 effect	 of	 cryopreservation	 on	 the	 quantity	 and	
function	 of	 MDSCs,	 the	 consensus	 being	 that	 frozen	 samples	 retain	 their	 monocytic	
fraction	 of	MDSCs	 but	 granulocytic	MDSCs	 do	 not	 survive	 the	 thawing	 process228–230.	
Moreover,	 both	 subtypes	 lost	 their	 immune	 suppressing	 effects	 on	 T	 cells	 after	
cryopreservation	 and	 thawing230.	 In	 conclusion,	 until	 better	 methods	 of	 freezing	 and	
thawing	 cells	 are	 developed	 and	 validated,	 studies	 involving	 MDSCs	 should	 be	
performed	on	fresh	samples.	
1.5.6	The	Expansion	and	Activation	of	MDSCs	







and	 macrophages231.	 In	 the	 setting	 of	 chronic	 infection,	 inflammation,	 trauma	 or	
malignancy,	the	associated	cytokine	milieu	favours	abnormal	accumulation	of	immature	
myeloid	cells	that	manifest	an	immune-suppressive	phenotype	30.	This	likely	represents	
a	 compensatory	 response	 to	 chronic	 immune	 stimulation	 preventing	 the	 over-
stimulation	 of	 immune	 effector	 cells	 that	 can	 result	 in	 by-stander	 damage232.	 In	
malignancy,	 however,	 this	 alteration	 in	 the	 immunologic	milieu	 is	 utilized	 to	 facilitate	
promotion	of	tumour	growth233,	and	dissemination234,	the	immune-paresis	of	malignant	
disease235,	and	limiting	response	to	immune-based	therapies236.		
MDSC	 expansion	 has	 been	 described	 in	 many	 cancer	 models	 including	 Renal	








In	 a	 recent	 report,	MDSCs	 (CD11b+CD14-HLA-DR-/lowCD33+CD15+)	were	expanded	 in	
the	 peripheral	 blood	 and	 the	 bone	 marrow	 of	 patients	 with	 multiple	 myeloma	 as	












While	 increased	 numbers	 of	 MDSCs	 have	 been	 suggested	 in	 patients	 with	
Myelodysplastic	syndrome,	with	concurrent	increases	in	MDSC	derived	TGF-β,	VEGF	and	
IL-10216,	 there	 has	 been	 little	 published	 about	MDSC	 populations	 or	 their	 function	 in	






A	 series	 of	murine	 and	 human	 in	 vitro	 and	 ex	 vivo	 studies	 suggest	 that	 tumour	 cells	
secrete	factors	into	the	microenvironment	that	promote	MDSC	expansion.		
In	 human	 studies,	 tumour-conditioned	 medium	 has	 been	 used	 to	 expand	 MDSC-like	
cells	 from	 peripheral	 blood	mononuclear	 cells256	 with	 GM-CSF	 an	 IL-6	 proving	 critical	
mediators	of	this	expansion.		











complex	 nomenclature,	 which	 includes	 the	 terms	 exosomes,	 microvesicles	 and	
oncosomes,	defined	by	size,	and	ranging	from	40-1000nM269–271.	While	their	biological	
relevance	in	cancer	has	yet	to	be	fully	elucidated,	it	 is	generally	agreed	that	they	carry	
biologically	 relevant	proteins,	mRNAs	and	microRNAs271.	 In	a	murine	 in	vitro	model	of	
Breast	cancer,	tumour	secreted	exosomes	contained	PGE-2	and	TFG-B	which	 led	to	an	





a	 critical	 role	 in	 mediating	 both	 the	 expansion	 of	 MDSCs	 and	 their	 function	 in	
suppressing	immune	cells274–276.	Unsurprisingly,	inhibitors	of	STAT	activation	have	been	
used	to	attempt	to	target	this	population,	as	we	will	 later	discuss.	STAT3277	and	STAT5	
have	 key	 roles	 in	MDSC	expansion,	putatively	 via	 their	 roles	 in	 inflammatory	 cytokine	
production278.	STAT3	inhibition	has	been	shown	to	mediate	differentiation	of	MDSC	into	
mature	Dendritic	Cells,	 indicating	aberrant	 STAT3	 signalling	plays	 an	 important	 role	 in	
cancer,	 in	 maintaining	 myeloid	 cells	 in	 an	 immature,	 more	 immune-suppressive	
state274,279.	 In	 head	 and	 neck	 cancers	 STAT3	was	 shown	 to	 control	MDSC	 function	 by	
regulating	 Arg-1	 activity280.	 MDSCs	 from	 tumour	 bearing	 mice	 have	 high	 levels	 of	
activated	STAT3281.	The	inhibition	of	STAT3	with	the	tyrosine	kinase	inhibitor	sunitinib,	
blocked	 expansion	 of	 MDSC	 in	 tumour	 bearing	 mice282.	 Consistent	 with	 this	 finding,	
activation	and	overexpression	of	STAT3	in	myeloid	cells	led	to	an	expansion	of	MDSC	in	
murine	model	 of	 lung	 cancer283.	 STAT3	 activation	 up-regulated	 the	 pro-inflammatory	
protein	S100A8/9,	which	inhibits	the	differentiation	of	DCs	and	macrophages,	leading	to	
an	accumulation	of	MDSCs210.	There	is	an	inverse	correlation	between	the	percentage	of	






MDSCs	 and	 CD4	 T	 cells	 from	 healthy	 donors	 led	 to	 reduced	 IFN-y	 responsiveness284.	
STAT6-deficient	MDSCs	fail	to	inhibit	T	cell	activation	as	they	failed	to	up-regulate	iNOS	
or	make	Arg-1285.		
The	 transcription	 factor	 Twist	 is	 associated	 with	 diverse	 malignancies.	 In	 one	 study,	
overexpression	of	Twist	in	cancer	cell	lines	was	associated	with	an	expansion	of	murine	
MDSCs	 in	 co-cultured	 myeloid	 precursor	 cells.	 Conversely,	 siRNA	 silencing	 of	 Twist	
expression	partly	abrogated	the	expansion	of	MDSCs	in	this	model286.		
The	 RAS	 signalling	 pathways	 are	 key	 regulators	 of	 normal	 cell	 growth	 and	malignant	
transformation287.	Ras	signalling	plays	a	key	role	in	myeloid	development	and	promotes	
granulopoeisis,	 and	 thereby	 the	 production	 of	 granulocytic	MDSCs,	 by	 increasing	 the	
binding	 of	 C/EBP	 alpha	 to	 the	 GCSF	 receptor288.	 Overexpression	 of	 kRas	 in	 a	 murine	
model	 of	 pancreatic	 cancer	 cells	 led	 to	 increased	 expression	 of	 the	 chemoattractant	
cytokines	 MIP-2	 and	 MCP-1,	 which	 promote	 the	 recruitment	 of	 macrophages	 and	
MDSCs	into	the	tumour	microenvironment289.	
PI3K/Akt	 signalling	 affects	 cell	 growth,	 survival	 migration	 and	 metabolism	 that	 is	
thought	to	play	a	significant	role	in	MDSC	expansion.	Aging	mice	accumulate	MDSCs	in	






















Hypoxia	 is	 a	 common	 feature	of	 solid	 tumours	 as	 they	outgrow	 their	 blood	 supply296,	
and	 has	 implicated	 in	 mediating	 resistance	 to	 chemotherapy297,298,	 the	 promotion	 of	
metastases299,	as	well	as	resulting	in	an	immune	privileged	niche93,300–302.	 	Hypoxia	has	
been	shown	to	promote	the	expansion	of	 immune-suppressive	MDSCs303,304,	as	well	as	
mediating	 the	 differentiation	 of	 MDSCs	 into	 immune-suppressive	 tumour	 associated	
macrophages	(TAMs),	upon	arrival	in	the	hypoxic	tumour	bed302.	
While	 the	 presence	 of	 tumours	 has	 been	 clearly	 demonstrated	 to	 result	 in	 the	
recruitment	 and	 proliferation	 of	 MDSCs,	 various	 cancer	 treatments	 have	 also	 been	
implicated	 in	 further	 expanding	 this	 population.	 Several	 cytotoxic	 chemotherapeutic	




promoting	 cytokine,	 although	 evidence	 of	 MDSC	 expansion	 in	 GM-CSF	 containing	
treatments	remains	conflicting308.		
While	we	have	divided	MDSC	 inducing	factors	 into	discrete	sections,	 it	 is	 important	to	
note	 that	 there	 is	 a	 huge	 amount	 of	 cross-talk	 and	 overlap	 in	 these	 pathways,	 with	









MDSCs	 inhibit	 the	 function	 of	 effector	 and	 antigen	 presenting	 cells	 in	 the	 tumour	
microenvironment	prevention	the	effective	activation	of	tumour	specific	immunity.		
MDSCs	and	T	cells	
A	 critical	 mechanism	 by	 which	 MDSCS	 directly	 induce	 lymphocyte	 suppression	 is	 L-
Arginine	depletion,	a	key	nutrient	for	lymphocytes.	Arginase-1	catabolizes	L-Arginine	to	
urea	 and	 ornithine309,310.	 Arginine	 starvation	 inhibits	 T	 cell	 proliferation	 through	
decreased	 CD3	 theta	 chain	 expression104	 and	 prevents	 the	 expression	 of	 cell	 cycle	
regulators	 cyclinD3	 and	 cdk4105,	 resulting	 in	 cell	 cycle	 arrest	 of	 T	 cells.	 In	 addition,	
Arginase-1	 inhibits	 NK	 cell	 proliferation	 and	 secretion	 of	 IFN-Y,	 suggesting	 a	 broader	
immune-suppressive	 effect	 on	 effector	 cell	 function	 106.	 Furthermore,	 treatment	with	
the	 Arginase	 inhibitor	 nor-NOHA	 delayed	 the	 growth	 of	 tumours	 in	 an	 immune-
competent	murine	model	of	lung	cancer104,	highlighting	the	importance	of	this	pathway	
in	 regulating	 tumour	 growth.	Of	 note	only	 granulocytic	MDSCs	produce	high	 levels	 of	
Arginase-1	 in	 humans,	 whereas	 in	 mice	 both	 monocytic	 and	 granulocytic	 fractions	
demonstrate	this	capacity	311.	
MDSCs	 generate	 oxidative	 stress	 by	 increasing	 levels	 of	 ROS	 and	 iNOS	with	 resultant	
immunosuppressive	 effects.	 ROS	 and	 iNOS	 activity	 lead	 to	 the	 production	 of	 reactive	
nitrogen	 species	 such	 as	 perioxynitrite,	 H202	 and	 NO309,310.	 	 NO	 suppresses	 T	 cell	
function	via	the	Jak/Stat	signalling	pathway312,	reducing	MHC	expression313,	 inducing	T	
cell	 apoptosis314,	 promoting	 the	 loss	 of	 theta	 expression315	 and	 the	 nitration	 and	
desensitization	of	the	TCR316.	This	mechanism	has	been	demonstrated	 in	patients	with	
pancreatic	cancer	whose	granulocytic	MDSCs	reduced	CD3	theta	chain	expression	via	an	







MDSC	 produce	 more	 ROS	 than	 monocytic	 MDSC207,	 who	 act	 primarily	 via	 iNOS	
production318.	
Indoleamine	2,3-dioxygenase	(IDO)	is	an	immunomodulatory	enzyme	known	to	polarize	
antigen-presenting	 cells	 towards	 a	 tolerizing	 phenotype.	 In	 CLL,	 monocytic	 MDSCs	
express	 high	 levels	 of	 IDO.	 	 Conversely,	 	 blocking	 IDO	 in	 this	 setting	 resulted	 in	 an	
increase	 in	 T-cell	 proliferation	and	a	decrease	 in	 regulatory	 T	 cell	 induction249.	 Similar	
findings	were	 reported	 in	 the	post-allograft	 setting,	where	monocytic	MDSCs	exert	an	
immunosuppressive	effect	via	IDO	production319.	
The	 PD1/PD-L1	 signalling	 pathway	 is	 a	 critical	 mediator	 of	 immune	 tolerance	 in	 the	
tumour	 microenvironment.	 MDSC	 express	 the	 immune	 inhibitory	 ligand,	 PD-L1,	 (93)	
which	 engages	 PD-1	on	 T	 cells	 resulting	 in	 an	 exhausted	phenotype.	 Similarly,	MDSCs	
express	 Galectin	 3,	 the	 ligand	 for	 TIM-3	 on	 lymphocytes,	 capable	 of	 inducing	 T	 cell	
apoptosis320.	 PD-L1	 signalling	 was	 important	 to	 the	 immune	 suppressive	 activity	 of	
MDSCs	 in	 mouse	models	 of	 several	 cancer	 types93	 and	 delivery	 of	 a	 lentiviral	 vector	
carrying	shRNA	against	PD-L1	abrogated	MDSC	immune	suppression	in	a	murine	ex	vivo	
model	of	melanoma321.	However,	the	significance	of	PD-L1	expression	on	human	MDSCs	
remains	 ambiguous.	 In	 one	 example,	 patients	 with	 melanoma	 were	 found	 to	 have	
circulating	 monocytes	 with	 a	 suppressive	 phenotype	 and	 high	 levels	 of	 PD-L1	
expression,	 inversely	 correlated	 with	 HLA-DR	 expression	 and	 suggestive	 of	 MDSC	
phenotype322.	 	 However	 in	 patients	 with	 glioma,	 PD-L1	 could	 not	 be	 detected	 in	 any	
subset	of	MDSC242.		
TGF-beta	 is	 produced	 by	 immature	 myeloid	 Cells	 from	 tumour	 bearing	 mice	 that,	 in	
conjunction	 with	 NO,	 inhibits	 T	 cell	 proliferation	 in	 vitro323.	 Blocking	 TFG-beta	 or	
depleting	 MDSCs	 prevented	 tumour	 recurrence	 showing	 that	 TGF-beta	 production	 is	
crucial	 to	 their	 immune	 suppressive	 activity324.	 TGF-beta,	 in	 turn,	 induces	 MDSC	
proliferation	 by	 promoting	 MDSC	 miR494	 expression325.	 Furthermore,	 blocking	






effector	 responses	 in	 a	 contact	 dependent	 manner	 via	 membrane	 bound	 TFG-beta	
which	can	induce	anergy	in	NK	cells326.		
The	 prostanoid	 PGE2	 has	 both	 pro-inflammatory	 and	 immune-suppressive	 properties	
and	is	synthesized	by	COX2.	PGE2,	induced	by	tumour-derived	factors327,	signals	through	
PGE2	receptor	E-prostanoid	4	which	 induces	Arginase	1	production	 in	MDSCs328,329.	 	 In	
vivo	 administration	 of	 COX2	 inhibitors	 reduced	 MDSC	 accumulation	 in	 lung	 cancer	
bearing	mice328.		
Tumour-derived	IL-1B	has	been	shown	to	induce	the	accumulation	of	MDSCs267	but	it	is	




T	 cells	 in	 the	 setting	 of	malignancy.	 	MDSCs	were	 shown	 to	 specifically	 induce	 T	 cell	
tolerance	 against	 peptides	 presented	 by	 MHC	 class	 I	 on	 the	 MDSC	 332.	 This	 studies	
suggest	antigen-specific	T	cell	tolerance	requires	direct	cell	contact	and	is	mediated	by	
the	 production	 of	 ROS333.	 However	 the	 presence	 and	 mechanism	 of	 CD4	 T	 cell	
suppression	remains	less	clear.	While	some	groups	have	reported	MDSC-induced	CD4	T	
cell	 tolerance285,334,335,	 other	 studies	 have	 failed	 to	 demonstrate	 this	 186,336.	 More	
recently,	Nagaraj	et	al	demonstrated	that	MDSCs	can	indeed	induce	CD4	T	cell	tolerance	
via	MHC	 class	 II	 expression,	 however	 in	 tumour	 bearing	mice,	MHC	 class	 II	 is	 down-
regulated	compared	to	healthy	mice337.	This	down-regulation	of	MHC	Class	II,	putatively	











Regulatory	 T	 cells	 (TRegs)	 are	 a	 critical	 component	 of	 tumour-related	 immune	
suppression	 subject	 to	 regulatory	 influences	 by	MDSCs.	 TRegs	 are	 recruited	 by	MDSC	
production	 of	 TGF-B	 and	 IL-10205	 and	 through	 CD40-CD40L	 interactions239.	 MDSCs	
generated	 by	 GMCSF	 in	 mice,	 were	 found	 to	 delay	 skin	 allograft	 rejection	 in	 a	 TReg	
generating	mechanism,	 raising	 the	 potential	 for	MDSCs	 to	 be	 used	 in	 the	 non-cancer	
setting339.	One	group	has	succinctly	demonstrated	that	FOXP3	positive	TRegs	could	be	
induced	from	Th17cells	by	MDSC-derived	TGF-beta	and	retinoic	acid340.	Furthermore,	in	
vitro	 and	 in	 vivo	 inhibition	 of	 MDSC	 activity	 with	 the	 Arginase-I	 inhibitor	 NOHA	 or	
Sildenafil	 abrogated	 TReg	 proliferation341.	 	 MDSCs	 from	 patients	 with	 hepatocellular	






MDSCs	 from	 patients	 with	 hepatocellular	 carcinoma	 inhibited	 autologous	 NK	 cell	
cytotoxicity	 and	 IFN-Y	 in	 an	 in	 vitro	 model.	 This	 suppression	 was	 dependent	 on	 cell	
contact	and	relied	on	the	NKp30	ligand	on	NK	cells342.	Moreover,	there	appears	to	be	a	
feedback	 mechanism	 between	 MDSCs	 and	 NK	 cells,	 with	 NK	 cells	 regulating	 MDSC	
expansion246.		
MDSCs	and	Dendritic	Cells	(DCs)	











a	 differentiation	 block	 on	myeloid	 differentiation.	 Indeed,	 under	 the	 right	 conditions,	
MDSCs	may	be	forcibly	differentiated	into	dendritic	cells344.		
MDSCs	 inhibit	 DC	 function	 by	 producing	 IL-10,	 which	 inhibits	 DC	 TLR-induced	 IL12,	





MDSCs	 are	 strong	 producers	 of	 IL-10,	 which	 acts	 on	 macrophages	 which,	 in	 turn,	
produce	 IL-10	 and	 are	 predisposed	 to	 Th2	 reactions347.	 It	 appears	 there	 is	 a	 bi-
directional	model	 of	 cross	 talk	 between	MDSCs	 and	macrophages,	with	macrophages	
themselves	stimulating	MDSCs	to	produce	more	IL-10347.		Furthermore,	MDSCs	recruited	
into	 the	 tumour	bed	may	become	differentiated	 into	 tumour-associated	macrophages	




inhibit	 their	 function	 to	 enhance	 tumour	 specific	 immunity	 and	 effectively	 target	
malignant	cells	alone	or	in	combination	with	other	immunotherapeutic	strategies.		
Inhibition	of	MDSC	recruitment	 to	 the	 tumour	microenvironment	has	been	attempted	












where	mice	 treated	with	 a	 HER-2/neu	 vaccine,	 anti-GITR	 antibodies	 and	Gemcitabine	
had	stronger	anti-tumour	immunity	compared	with	non-	Gemcitabine	treated	mice354.		
ATRA	was	 successfully	 used	 to	deplete	MDSCs	 in	murine	models	 of	 adeno-	 and	 fibro-
sarcoma	 treated	 with	 a	 C3-peptide	 vaccine	 or	 p53-based	 vaccine,	 with	 ATRA-treated	
mice	 showing	 improved	 CD4	 and	 CD8	 T	 cell	 mediated	 tumour-specific	 immune	
responses	and	prolonged	anti-tumour	responses355.	
	
In	 a	murine	 study,	mice	 treated	with	 sunitinib	demonstrated	depletion	of	MDSCs	and	
associated	levels	of	TRegs	resulting	improved	anti-tumour	immunological	responses356.	
The	addition	of	sunitinib	to	vaccine	against	human	papillomavirus	(HPV)-induced	cancer,	
demonstrated	 increased	 survival	 mirrored	 by	 encouraging	 immunological	 responses,	
compared	 to	 vaccine	 alone236.	 In	 a	 murine	 model	 of	 melanoma,	 ovalbumin	 (OVA)	
peptide-pulsed	 dendritic	 cell	 vaccine	 was	 given	 to	 mice,	 with	 or	 without	 sunitinib	
treatment.	 In	 a	 third	 murine	 study	 of	 sunitinib,	 lung	 carcinoma	 bearing	 mice	 were	
treated	with	intra-tumoural	IL-12	gene	delivery	by	adenoviral	vector	+	4-1BB	activation,	
with	or	without	sunitinib.	Mice	treated	with	sunitinib	had	fewer	MDSCs	and	TRegs,	but	
moreover,	 the	 expression	 of	 negative	 co-stimulatory	 molecules	 CTLA4	 and	 PD-1	 in	 T	
cells	and	PDL-1	expression	on	MDSC	and	dendritic	cells,	was	also	significantly	decreased.	




chimeric	 antigen	 receptors	 (CAR)	 is	 a	 promising	 development	 for	 the	 treatment	 of	
cancers358.	MDSCs	have	been	implicated	in	limiting	the	response	to	CAR-T	cell	therapy,	
in	murine	models	 of	 osteosarcoma359	 and	 liver	 cancer360.	Moreover,	 depleting	MDSCs	
improved	 anti-tumour	 efficacy	 in	 both	 models.	 Furthermore,	 in	 a	 murine	 model	 of	
breast	cancer,	a	combination	treatment	of	anti-Her2	CAR-T	cells	and	PD-1	blockade	had	






tumour	 burden	 or,	 as	 the	 authors	 suggest,	 a	 direct	 effect	 of	 PD-1	 blockade	 on	 small	


















Sunitinib	 Inhibition	 of	 STAT3	































































































TroVax	 vaccine	 for	 patients	 with	 metastatic	 renal	 cell	 cancer,	 which	 included	 a	
treatment	 arm	 containing	 sunitinib	 treatment,	 failed	 to	 show	 improvement	 in	
survival397.		
In	 a	 phase	 II/III	 clinical	 trial	 of	 patients	with	 extensive	 small	 cell	 lung	 cancer,	 patients	
were	randomized	to	undergo	vaccination	dendritic	cells	transduced	with	wild	type	p-53,	
no	treatment,	or	p53	vaccine	plus	ATRA.	ATRA	was	demonstrated	to	deplete	MDSCs	in	
treated	 patients	 and	 41.7%	 of	 those	 treated	 with	 p53	 vaccine	 and	 ATRA	 had	 IFN-Y	
Elispot	responses	to	p53,	compared	to	20%	in	vaccine	alone398.		
	
Whilst	 clinical	 trials	 involving	 MDSC	 depletion	 and	 immunotherapy	 are	 still	 in	 their	
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While	 standard	 cytotoxic	 chemotherapy	 regimens	 can	 effectively	 reduce	 the	 disease	
burden	 in	 patients	 with	 haematologic	 malignancies,	 patients	 often	 subsequently	
succumb	to	relapsed	disease	due	to	the	emergence	of	resistant	clones	400.		In	contrast,	
the	unique	potency	of	cellular	immunotherapy	in	the	treatment	of	cancer	is	highlighted	
by	 the	 observation	 that	 allogeneic	 transplantation	 is	 curative	 for	 a	 subset	 of	 patients	
due	 to	 the	activation	and	expansion	of	alloreactive	 lymphocytes401.	However	 targeted	
immune	 therapies	 have	 demonstrated	 somewhat	 variable	 clinical	 outcomes	 for	
patients,	 believed	 to	 be	 in	 part	 due	 to	 the	 suppressive	 tumour	 microenvironment.	
MDSCs	 form	a	 critical	 component	 responsible	 for	maintaining	 the	 immunosuppressive	
milieu	 of	 the	 tumour	 microenvironment.	 	 The	 importance	 of	 immune	 modulation	 in	
determining	the	balance	between	immune	activation	and	disease	has	been	highlighted	
by	 recent	 observations	 that	 PD-1	 blockade	 alone	 is	 capable	 of	 inducing	 sustained	
disease	response	in	patients	with	advanced	solid	malignancies35.	Further	work	is	needed	
to	elucidate	 specific	markers	 for	MDSCs,	potentially	 combining	 traditional	 surface	and	
function	 markers	 with	 next	 generation	 modalities	 such	 as	 RNA	 and	 MicroRNA	 array	
derived	signatures	for	MDSCs.	Improving	specificity	in	targeting	key	immune	suppressive	
components	 of	 the	 tumour	 milieu	 whilst	 sparing	 tumour	 targeting	 populations,	 may	
bridge	 the	gap	between	encouraging	pre-clinical	data,	and	the	execution	of	 successful	
clinical	studies.		Successfully	depleting	this	population	might	hold	the	key	to	maximizing	










While	 standard	 cytotoxic	 chemotherapy	 regimens	 can	 effectively	 reduce	 a	 patient’s	




curative	 for	 a	 subset	 of	 patients	 due	 to	 the	 activation	 and	 expansion	 of	 alloreactive	
lymphocytes401.	 However	 targeted	 immune	 therapies	 have	 demonstrated	 somewhat	
variable	 clinical	 outcomes	 for	 patients,	 believed	 to	 be	 in	 part	 due	 to	 the	 suppressive	
tumour	microenvironment.	The	 importance	of	 immune	modulation	 in	determining	the	
balance	 between	 immune	 activation	 and	 disease	 has	 been	 highlighted	 by	 recent	
observations	that	PD-1	blockade	alone	is	capable	of	inducing	sustained	disease	response	
in	 patients	 with	 advanced	 solid	 malignancies35.	 Further	 work	 is	 needed	 to	 elucidate	
specific	 markers	 for	 MDSCs,	 potentially	 combining	 traditional	 surface	 and	 function	
markers	 with	 next	 generation	 modalities	 such	 as	 RNA	 and	 MicroRNA	 array	 derived	
signatures	 for	 MDSCs.	 Improving	 specificity	 in	 targeting	 key	 immune	 suppressive	
components	 of	 the	 tumour	 milieu	 whilst	 sparing	 tumour	 targeting	 populations,	 may	
bridge	 the	gap	between	encouraging	pre-clinical	data,	and	the	execution	of	 successful	
clinical	studies.		Successfully	depleting	this	population	might	hold	the	key	to	maximizing	
immunological	 responses	 to	 immune-based	 therapies	 and	 improving	 the	 outcomes	 of	
patients	with	malignant	diseases.	
To	address	my	hypothesis	that	MDSCs	play	a	role	in	mediating	an	immune	suppressive	
microenvironment,	 I	 investigated	 the	 signalling	pathways	underlying	 the	accumulation	








MDSCs	 represent	 a	 heterogeneous	 population	 of	 immature	 myeloid	 cells	 that	 exert	
immunosuppressive	 effects	 and	 play	 a	 critical	 role	 in	 promoting	 immune	 tolerance	 in	
cancer.		The	critical	nature	of	the	bone	marrow	microenvironment	in	patients	with	AML	
in	 creating	 an	 immunosuppressive	 niche	 that	 fosters	 disease	 growth	 and	 immune	
escape	has	heightened	interest	in	the	role	of	MDSCs	in	AML.		However,	there	has	been	
very	 little	discovered	about	MDSC	populations	or	 their	 function	 in	patients	with	AML.	
This	 is	 likely	 to	 be	 due,	 in	 part,	 to	 the	 fact	 that	 MDSCs	 and	 AML	 blasts	 have	 an	
overlapping	phenotype,	making	them	difficult	to	differentiate	by	surface	markers	alone.	
Given	 that	MDSCs	 appear	 to	 have	 critical	 importance	 in	 the	 tumour	 derived	 immune	
suppressive	 environment	 in	 other	 haematological	 malignancies,	 much	 effort	 is	 being	
made	 to	overcome	these	 limiting	 technical	 issues	and	elucidate	 the	 role	of	 this	 cell	 in	
this	highly	lethal	leukaemia.		
Of	 note,	 immature	 myeloid	 cells	 such	 as	 MDSCs	 share	 common	 characteristics	 with	




with	 age	 and	 is	 considered	 the	 pre-malignant	 condition	 often	 preceding	 the	
development	of	AML.	It	has	been	reported	that	there	are	increased	numbers	of	MDSCs	
in	the	bone	marrow	aspirates	of	patients	with	MDS,	with	concurrent	increases	in	MDSC	
derived	 TGF-β,	 VEGF	 and	 IL-10.	 The	 authors	 postulated	 that	 these	 expanded	 pool	 of	










The	 aim	of	 this	 study	was	 to	 quantify	 the	MDSC	 population	 in	 the	 bone	marrow	 and	
peripheral	blood	aspirates	of	patients	with	active	AML.	We	further	sought	to	elucidate	if	
there	was	a	requirement	for	MDSCs	to	be	clonally	related	or	distinct	from	the	leukaemic	
cells.	 Finally,	 we	 sought	 to	 characterize	 the	 immune	 suppressive	 capabilities	 of	 these	





Ethical	 approval	 for	 the	 study	 was	 obtained	 from	 the	 Dana-Farber/Harvard	 Cancer	
Center	 Institutional	 Review	 Board.	 Samples	 of	 peripheral	 blood	 and	 bone	 marrow	
aspirates	were	obtained	from	AML	patients	in	accordance	with	a	protocol	approved	by	





Peripheral	 blood	 (PB)	 and	 bone	marrow	 (BM)	 aspirates	 were	 obtained	 from	 patients	






























Isolation	 of	 Peripheral	 Blood	 and	 Bone	Marrow	Mononuclear	 Cells	 by	 Ficoll	 density	
Centrifugation		
	
In	 order	 to	 isolate	 PB	 mononuclear	 cells	 and	 BM	 mononuclear	 cells,	 samples	 were	






50ml	 Falcon	 tubes.	 The	 tubes	 were	 centrifuged	 at	 1800rpm	 for	 25	minutes	 with	 the	






Cell	 counts	and	viability	 assessment	was	performed	using	Trypan	Blue	 (Sigma	Aldrich)	
exclusion	using	a	haemocytometer.	10μl	of	cells	diluted	1:2	in	trypan	blue	were	added	
to	 the	 chamber	 of	 the	 haemocytometer.	 Cells	 were	 examined	 under	 a	 x10	 objective	























penicillin,	 100	 µg/mL	 streptomycin	 (Cellgro,	 Manassas,	 VA)	 and	 2.5µg/mL	 Plasmocin	








Samples	 to	 be	 stained	 were	 washed	 with	 sterile	 PBS,	 re-suspended	 in	 PBS	 at	
approximately	 107	 cells/mL	 and	 divided	 into	 FACS	 tubes	 (106	 cells	 in	 100µl/tube)	 and	
incubated	with	 1µl	 of	 each	 antibody,	 or	 isotype	 control,	 at	 4ºC	 for	 30	minutes.	 	 Cells	








a	 subset	 of	 the	myeloid	 cells,	 allowing	 for	 the	 identification	 and	 selection	 of	 partially	
differentiated	myeloid	precursors	distinct	 from	the	AML	cells.	 	 	 In	patients	with	active	
disease,	 MDSC	 were	 segregated	 from	 leukaemic	 cells	 first	 using	 Flow	 Cytometric	
analysis	of	size	and	granularity	 (forward	and	side	scatter	properties).	 In	some	patients	
the	blast	population	is	so	overwhelming	that	it	obliterates	all	other	cell	populations	by	
flow	 cytometry,	 and	 it	 was	 impossible	 to	 assess	 these	 patients	 for	 MDSCs.	 As	 an	
example,	 in	Figure	2,	this	patient	has	a	CD14-	blast	population	shown	in	gate	D	on	the	
HLADR	 CD14	 plot	 that	 obliterates	 the	 clear	 positive	 and	 negative	 populations	 usually	
seen	 in	 the	 CD33	 CD15	 plot.	 Compare	 this	 to	 the	 patient	 shown	 in	 Figure	 3,	 whose	
smaller	 blast	 percentage	 and	 blast	 HLADR	 positivity	 renders	 it	 easier	 to	 exclude	 this	


























times	 and	 250ul	 of	 Geimsa	 solution	 added	 for	 one	 minute.	 Slides	 were	 washed	 as	
previously	and	air	dried,	before	being	imaged.	
Immune	competent	murine	model	of	murine	AML		
1x105	 GFP	 tagged	 C1498	murine	 AML	 cells	 were	 injected	 retro-orbitally	 into	 C57BL/6	
mice	 (Jackson	 Laboratories,	 Bar	 Harbor,	 ME).	 Following	 establishment	 of	 disease,	
defined	as	reduced	physical	activity	and	weight	loss	or	visible	orbital	tumour	(chloroma)	
development,	all	mice	would	be	euthanized.	Mice	started	to	become	symptomatic	at	21	
days,	 upon	 which	 all	 mice	 were	 analysed.	 Mice	 were	 euthanized,	 alongside	 healthy	
control	C57BL/6	mice,	and	their	femurs	and	spleen	were	harvested.		Bone	marrow	cells	
were	flushed	from	the	femur	bone	marrow	cavity	into	sterile	RPMI	1640	media.		Spleens	
were	 emulsified	 to	 obtain	 a	 cell	 suspension.	 	 Bone	 marrow	 and	 spleen	 cells	 were	
washed	 prior	 to	 further	 analysis	 by	 flow	 cytometry.	 Engraftment,	 as	 defined	 by	 >1%	




well	 plates	 (Corning,	NY)	 at	 1.5x10	 6	 cells	 per	well.	 	AML	 cells	 from	 cell	 lines	 or	 FACS	
isolated	 from	 primary	 samples	 from	 AML	 patients	 were	 irradiated	 at	 7500Rad	 to	
prevent	 proliferation	 and	 fluorescently	 labelled	 red	 with	 GranToxiLux	 (OncoImmunin,	
MD).	1.5x104	AML	cells	were	added	to	test	wells	(ratio	of	100:1).	Cells	were	cultured	at	
37ºC	 in	 a	 humidified	 5%	CO2	 incubator	 and	maintained	 in	 RPMI	 1640	media	 (Cellgro,	
Manassas,	VA)	supplemented	with	heat-inactivated	10%	human	serum	albumin	(Sigma,	
St.	Louis,	MO)	and	100	IU/mL	penicillin	and	100	µg/mL	streptomycin	(Cellgro,	Manassas,	









subjected	 to	 Ficoll	 density	 centrifugation	 and	 washed	 as	 described.	 Samples	 were	
labelled	with	markers	 for	 T	 cells	 (CD3),	 tumour	 cells	 (CD33,	 or	 identified	 via	 FSC	 and	




To	 separate	 primary	 samples	 of	 peripheral	 blood	 into	 T	 cells	 and	monocytes,	 PBMCs	
(after	Ficoll	density	 centrifugation)	were	 re-suspended	 in	 complete	media	 (RPMI	1640	
media	 (Cellgro,	Manassas,	VA)	supplemented	with	heat-inactivated	10%	human	serum	
albumin	 (Sigma,	 St.	 Louis,	 MO)	 and	 100	 IU/mL	 penicillin,	 100	 µg/mL	 streptomycin	
(Cellgro,	Manassas,	VA))	at	a	 concentration	of	6x106	cells	per	ml.	Cells	were	placed	 in	
flasks	and	 incubated	 for	45	minutes	 in	a	37ºC,	humidified	5%	CO2	 incubator.	After	45	
minutes	 the	 non-adherent	 fraction	 was	 removed	 into	 fresh	 flasks	 and	 supplemented	






FISH	 analysis	 is	 employed	 to	 identify	 chromosomal	 aberrations	 in	 AML	 cells	 using	
fluorescent	 probes	 targeting	 a	 previously	 identified	 mutational	 sequence	
complementarity.	 	We	 employed	 FISH	 analysis	 of	 the	 leukaemic	 clone	 and	 associated	
MDSC	population	to	interrogate	the	clonal	relationship	between	these	cell	subsets.		To	
assess	whether	MDSCs	may	share	a	common	derivation	with	pre-leukaemia	malignant	











a	 three-colour	 FISH	 probe	 (Vysis	 LSI	 D20S108	 SpectrumOrange	 labelled	 201	 kb	 DNA	
segment	including	the	20q12	D20S108	locus,	Vysis	D8Z2/CEP8	SpectrumGreen	labelled	














cells)	 to	 assess	 presence	 of	 a	 deleted	 chromosome	 7	 (del(7)(q22)).	 Chromosomal	







MDSCs	 and	 tumour	 cells	 were	 isolated	 from	 patient	 #8	 by	 FACS	 sorting.	 	 CD15+	
granulocytic	MDSCs	and	a	CD15-	blast	population	were	spun	onto	Poly-L-Lysine	coated	
slides	(LabScientific,	Inc.,	NJ)	and	fixed	in	4%	PFA	for	7	minutes	and	stored	in	PBS	at	4°C.	









CD3/CD28	 was	 accomplished	 by	 coating	 24-well	 non-tissue	 culture-treated	 plates	
(Falcon,	Fisher,	Pittsburgh,	PA,	USA)	or	96-well	opaque	flat	bottom	plates	(Corning,	NY)	
with	 anti-CD3	 (clone-UCHT1;	 Pharmingen,	 San	 Diego,	 CA,	 USA)	 and	 anti-CD28	 (clone-
CD28.2;	Pharmingen,	San	Diego,	CA,	USA)	at	the	concentration	of	1	μg/mL	in	phosphate-
buffered	saline	 (PBS)	at	0.3	mL/well	overnight	at	4	 °C.	The	plates	were	washed	 in	1	×	












at	 4ºC	 for	 30	minutes.	 Cells	 were	 washed	 with	 PBS	 and	 then	 then	 permeabilised	 by	
incubation	 in	 200µl	 Cyto-fix/Cytoperm	 plus™(Pharmingen,	 San	 Diego,	 CA,	 USA)	
containing	 formaldehyde	 and	 saponin	 for	 30	 min	 at	 4	 °C,	 before	 being	 washed	 in	
Perm/Wash™	solution	 (Pharmingen,	 San	 Diego,	 CA,	 USA).	 Subsequently	 cells	 were	
incubated	 with	 2	 µl	 PE-conjugated	 IFN-γ	 (Invitrogen,	 Camarillo,	 CA,	 USA),	 IL-10	





Cells	 in	 96	well	 plates	were	 analysed	 for	 proliferation	 by	 bringing	 plates	 to	 21°C	 and	










compared	 to	 healthy	 controls.	 Ten	 PB	 samples	 from	AML	 patients	were	 discarded	 as	





in	 Table	 4.	 Total	 MDSCs	 were	 defined	 as	 CD11b+	 CD33+	 HLADRlow/-	 with	 the	 gating	









0.88),	p<0.05	 (Figure	4B).	When	expressed	as	a	percentage	of	 immature	myeloid	 cells	
(CD11b+,	HLADRlow/-),	as	in	all	subsequent	graphs,	patients	with	AML	had	a	mean	of	23%	
MDSCs	 (range	6-40)	 compared	 to	5.2%	 in	healthy	patients	 (range	0-15),	p<0.05.	Upon	
further	characterization,	these	MDSCs	were	predominantly	CD15+	Granulocytic	MDSCs,	
with	patients	with	active	AML	having	a	mean	Granulocytic	MDSC	percentage	of	17.2%	
(range	 2-42)	 compared	 to	 1.8%	 in	 healthy	 patients	 (range	 0-7.8),	 p=0.01	 (Figure	 4C).	
Monocytic	subsets	of	MDSCs	showed	a	trend	toward	expansion	in	patients	with	AML.	Of	







Figure	 4.	MDSCs	 are	 expanded	 in	 patients	with	 AML.	 Peripheral	 blood	mononuclear	
cells	 (PBMCs)	were	 isolated	 by	 Ficoll	 density	 gradient	 centrifugation	 and	 stained	with	
antibodies	 for	 CD11b,	 HLADR,	 CD14,	 CD15	 and	 CD33	 expression.	 The	 cells	were	 then	
analysed	 by	 Flow	 Cytometry.	 (A)	 Representative	 example	 of	 patient	 #2	 is	 shown.	
CD11b+	 HLADR+	 CD14-	 blasts	 are	 shown	 in	 gate	 ‘I’	 (light	 blue).	 Monocytic	 MDSCs	





from	 AML	 patients	 and	 healthy	 controls	 were	 isolated	 by	 Ficoll	 density	 gradient	
centrifugation	 and	 stained	with	 antibodies	 for	 CD11b,	 HLADR,	 CD14,	 CD15	 and	 CD33	
expression.	 The	 cells	were	 then	 analysed	 by	 Flow	Cytometry.	 If	 present,	 tumour	 cells	
were	gated	out	based	on	forward	scatter/side	scatter	and	known	blast	phenotype,	and	
total	 MDSCs	 (CD33+CD15-	 or	 CD33+CD15+)	 were	 quantified	 as	 a	 percentage	 of	 total	
cells	 (n=8;	 p<0.05),	 and	 as	 a	 percentage	 of	 gated	 immature	 CD11b+/HLADR-	myeloid	
cells	 (n=7;	 p<0.05).	 (C)	 MDSCs	 were	 further	 characterized	 as	 Granulocytic,	 by	 the	
presence	 of	 CD15+,	 or	 monocytic,	 by	 CD15-	 and	 side	 scatter.	 Granulocytic	 and	
Monocytic	MDSCs	in	AML	(n=7)	vs.	healthy	donors	(n=9)	is	shown.	MDSCs	are	shown	as	
a	 percentage	 of	 gated	 immature	 CD11b+/HLADR-	 myeloid	 cells.	 p<0.05	 for	 both	
monocytic	 and	 granulocytic	 MDSCs	 in	 AML	 vs.	 healthy	 donors.	 (D)	 MDSCs	 were	
quantified,	 as	 described,	 in	 the	 bone	marrow	 aspirates	 from	 patients	 with	 AML,	 and	

















1	 30	 5.3	 relapsed	 -	 -	 normal	 CD11b-	HLADR-	
CD33+	
2	 84	 15.5	 diagnosis	 +	 -	 normal	 CD11b-	HLADR+	
CD33+/-	









AML.	 	 In	 a	 murine	 model,	 leukaemic	 engraftment	 was	 associated	 with	 increased	
presence	of	MDSCs	in	the	spleen	and	BM.		Mice	underwent	retro-orbital	injection	with	
1x105	cells	of	the	syngeneic	murine	AML	cell	line,	TIB-49.	After	three	weeks,	at	the	onset	











4	 93	 37.4	 diagnosis	 -	 -	 Complex	 CD11b+	HLADR+	
CD33+	
5	 40	 8.9	 relapsed	 +	 -	 Complex	 CD11b+	HLADR+	
CD33+	




7	 69	 4.3	 diagnosis	 -	 +	 Complex	(-7)	 CD11b-	not	
available	
HLADR+	CD33+	






an	 effect	 mediated	 by	 soluble	 factors	 derived	 from	 the	 tumour	 (Figure	 5C).	 An	
expansion	of	MDSCs	was	also	seen	in	an	autologous	system,	whereby	patient	#7	blasts	




Fig	 5.	 MDSCs	 are	 expanded	 in	 the	 presence	 of	 AML	 blasts.	 C57BL/6	 mice	 were	
inoculated	 using	 retro-orbital	 injections,	 with	 1x105	 GFP	 stably	 transduced	 murine	
syngeneic	AML	TIB-49	cells.	At	the	onset	of	symptomatic	disease	at	21	days,	mice	were	
analysed.	 (A)	 Bone	marrow	and	 splenocytes	were	 analysed	by	 flow	 cytometry	 for	 the	

















































































































Patient #7 PBMCs Patient #7 PBMCs + 
















donors	 were	 co-cultured	 in	 direct	 contact	 with	 irradiated,	 fluorescently	 labelled	 AML	
cells	at	a	 ratio	of	100:1.	After	5	days,	 cells	were	analysed	by	 flow	cytometry.	 Labelled	
tumour	 cells	 were	 excluded	 and	 total	 MDSCs	 were	 quantified	 as	 a	 percentage	 of	
immature	 CD11b+/HLADR-	myeloid	 cells	 (n=3,	 p<0.05	 for	MOLM-14	 and	 patient	 AML	
cells).	(C)	Healthy	donor	PBMCs	and	AML	cells	were	co-cultured	in	direct	contact	or	with	
Transwell	 insert	 and	 MDSCs	 were	 quantified	 as	 a	 percentage	 of	 immature	
CD11b+/HLADR-	 myeloid	 cells	 (n=3,	 p<0.05).	 (D)	 PMBCs	 from	 (patient	 #7)	 an	 AML	
patient	in	remission,	were	co-cultured	in	direct	contact	with	irradiated,	autologous	AML	
cells	 at	a	 ratio	of	100:1.	After	5	days,	 cells	were	analysed	by	 flow	cytometry.	HLADR+	
tumour	 cells	 were	 excluded	 and	 total	 MDSCs	 were	 quantified	 as	 a	 percentage	 of	
immature	CD11b+/HLADR-	myeloid	cells.		
	






could	 be	 scored,	 43	 and	 45	 cells	 by	 first	 and	 second	 observer	 respectively.	 A	 normal	
signal	 pattern	 of	 2-Orange,	Green	 and	Aqua	 signals	was	 observed	 in	 86%	 (86/100)	 of	
cells	 scored	 in	 sample	 NA	 10851	 (normal	 sample	 Figure	 6A).	 Our	 FISH	 results	 on	 the	
tumour	(Figure	6B)	and	MDSC	cells	(Figure	6C)	confirmed	monosomy	of	chromosome	7,	
with	a	single	Aqua	signal	noted	in	98%	(98/100)	of	the	tumour	and	98.8%	(87/88)	of	the	








also	had	~14.8%	 (13/88)	 cells	with	no	Orange	 signal,	 indicative	of	 a	deletion	 that	had	
occurred	 in	both	 copies	of	 chromosome	20	 (q12	 region),	 or	potentially	 loss	of	one	or	
both	copies	of	chromosome	20.		
	
In	 summary,	 the	 AML	 blasts	 contain	 3	 cytogenetic	 abnormalities,	 del7	 –	 strongly	
associated	with	the	MDS	phenotype,	del	20,	and	trisomy	8.	The	“MDSCs”	however,	only	
have	del	 7	 and	del20.	 These	 cytogenetic	 results	 suggest	 that	 in	 this	 particular	 patient	






































Figure	 6.	 MDSCs	 were	 cytogenetically	 related	 to	 the	 AML	 blasts,	 in	 a	 patient	 with	
MDS-AML.	MDSCs	 and	 blast	 cells	 were	 isolated	 using	 Flow	 Cytometry	 sorting	 from	
peripheral	blood	sample	 from	a	patient	with	active	AML.	FISH	analysis	was	performed	
for	known	cytogenetic	abnormalities.	The	cells	were	probed	 for	del7	 (blue),	 trisomy	8	
(green)	and	del20	(red).	100	cells	were	scored	and	healthy	control	cells	(A),	AML	blasts	
(B)	 and	 MDSCs	 (C)	 are	 shown	 as	 representative	 examples.	 (D)	 Frequencies	 of	 Cells	
shown	are	tabulated.		





normal	 signal	pattern	of	 two	Orange	 (Or)	and	 two	Green	 (Gr)	 signals	was	observed	 in	
96%	 (96/100)	 of	 nuclei	 scored	 from	 the	 normal	 sample;	 a	 single	 “false	 positive”	 cell	
(1/100)	with	 the	1Or	2Gr	 signal	pattern	expected	 from	a	del(7)(q22)	was	 seen	 (Figure	
7A).	








































Figure	 7.	 MDSCs	 were	 cytogenetically	 related	 to	 the	 AML	 blasts,	 in	 a	 patient	 with	
MDS-AML.	MDSCs	 and	 blast	 cells	 were	 isolated	 using	 Flow	 Cytometry	 sorting	 from	
peripheral	blood	sample	 from	a	patient	with	active	AML.	FISH	analysis	was	performed	




In	 a	 patient	 with	 NPM1	 mutated,	 cytogenetically	 normal	 AML,	 MDSCs	 were	 clonally	
distinct	from	the	leukaemic	blast	population	
Similarly,	 we	 explored	 the	 derivation	 of	 MDSCs	 in	 a	 patient	 de-novo	 leukaemia	
characterized	by	the	presence	of	a	NPM1	mutation	and	associated	more	differentiated	
phenotype.	MDSCs	were	 FACS	 sorted	 from	 a	 peripheral	 blood	 sample	 from	 a	 patient	
(patient	 #8)	with	 active	NPM1	mutated	 AML	 and	 immuno-histochemically	 stained	 for	
NPM1.	Wildtype	NPM1	 localizes	only	 to	the	nucleus	whereas	mutated	NPM1	 is	visible	
throughout	 the	 cytoplasm.	 The	 NPM1	 mutated	 AML	 cell	 line	 OCI/2	 was	 used	 as	 a	
positive	 control	 for	 NPM1	mutant	 (Figure	 8A),	 and	 the	 NPM1	wildtype	 AML	 cell	 line	





(Figure	 8D).	 As	 a	 very	 small	 number	 of	MDSCs	were	 sorted	 from	 this	 patient	 sample	

















AML	 cell	 line	 THP-1	was	 used	 as	 a	 control	 for	NPM1	WT	 (B).	 20	 cells	were	 scored	 in	
patients	blasts	(C)	and	sorted	MDSCs	(D).	
MDSCs	are	suppressive	of	T	cell	activation	and	proliferation.	
We	 subsequently	 interrogated	 the	 functional	 properties	 of	 the	 AML	 induced	 MDSC	
population	 with	 respect	 to	 their	 immunosuppressive	 characteristics.	 	 T	 cells	 were	
stimulated	with	CD3/CD28	and	co-cultured	with	autologous	MDSCs.	After	three	days	in	
culture,	 cells	 were	 analysed	 for	 proliferation.	 T	 cells	 in	 co-culture	 with	 THP-1	 and	
MOLM-14	derived	MDSCs	were	suppressive	of	T	cell	proliferation,	 showing	a	45%	and	
70%	reduction	in	the	proliferative	index,	respectively	(Figure	9A).		
T	 cells	 in	 co-culture	 with	 autologous	 MDSCs	 showed	 a	 46%	 reduction	 intracellular	
expression	of	CD8	IFN-γ	(Figure	9B),	a	40%	reduction	in	the	expression	of	the	markers	of	
T	cell	activation	(CD69,	CD25,	CD4)	(Figure	9C),	and	a	12	fold	concurrent	increase	in	CD4	








sorting.	 T	 cells	 autologous	 to	 the	 MDSCs	 were	 isolated	 and	 stimulated	 with	 anti-
CD3/CD28	ligation.	MDSCs	were	added	at	a	2:1	ratio	(Tc:MDSCs).	(A)	After	three	days	of	
culture,	T	cells	were	analysed	for	proliferation	using	CellTiterGlo	Cell	luminescence	assay	














































































































































































































































Direct	 contact	 co-culture	 of	 tumour	 cells	 and	 healthy	 donor	 PBMCs	 elicited	 a	 robust	
expansion	 of	 MDSCs	 suggesting	 that	 tumour	 cells	 induce	MDSCs,	 perhaps	 to	 protect	
their	 immune	 privileged	 niche.	 This	 finding	 was	 also	 observed	 in	 immune-competent	
mice	engrafted	with	leukaemia.	These	observations	are	in	keeping	with	similar	studies	in	
solid	 tumours,	 where	 co-culture	 of	 tumour	 cells	 with	 donor	 PBMCs	 elicited	 similar	
repsonses256.	 These	 MDSCs,	 so	 far	 defined	 by	 surface	 markers,	 were	 functionally	
suppressive	of	 autologous	T	 cell	 proliferation	and	promoted	a	 switch	 from	a	Th1	 to	a	
Th2	T	cell	phenotype,	fulfilling	the	“Suppressor”	part	of	their	name.		
We	next	sought	to	determine	 if	MDSCs	 in	AML	were	clonally	related	to	the	 leukaemic	
cells	 or	 were	 derived	 from	 normal	 myeloid	 precursors	 in	 which	 the	 tumour	
microenvironment	 favoured	 their	 selective	 expansion.	 	 MDSCs	 isolated	 by	 flow	
cytometric	 sorting	 were	 interrogated	 for	 the	 presence	 of	 cytogenetic	 or	 molecular	
abnormalities	that	had	previously	been	identified	in	the	leukaemic	clone.	These	studies	
demonstrated	 diversity	with	 respect	 to	 the	 origin	 of	 the	MDSC	 population	 suggesting	
they	 did	 not	 exclusively	 arise	 from	 the	 leukaemic	 clone.	 In	 a	 patient	 with	 AML	 cells	
exhibiting	3	 cytogenetic	 abnormalities,	 (del7,	del20,	 and	 trisomy	8),	MDSCs	expressed	
only	del	7	and	del20	suggesting	a	common	clonal	origin	with	leukaemic	precursor	prior	






characterized	by	a	NPM1	mutation,	 the	MDSC	population	was	 found	 to	have	 the	wild	
type	 form	 of	 NPM1	 suggestive	 of	 a	 lack	 of	 common	 clonal	 derivation	 with	 the	 AML	
population.	 While	 deep	 sequencing	 of	 these	 apparently	 clonally	 distinct	 or	 “normal”	






It	 remained	unclear	 as	 to	how	AML	 cells	 elicit	 the	expansion	of	MDSCs	 in	 vivo	 and	 in	
vitro.	 Previous	 investigators	 in	 other	 cancer	 models	 have	 shown	 the	 importance	 of	
soluble	 tumour	 derived	 factors	 such	 as	 GMCSF	 and	 IL-1	 and	 IL-6256,	 however	 we	
observed	 that	MDSC	 expansion	 was	 abrogated	 in	 Transwell	 plates	 suggesting	 that	 in	
AML,	MDSC	expansion	is	not	purely	cytokine	mediated.	Transwell	plates	prevent	direct	
cell-cell	 contact	 between	 cells	 in	 each	 chamber,	 and	 also,	 at	 0.4um	 pore	 diameter,	









Extracellular	 vesicles	 (EVs)	 are	membrane	bound	vesicles	 released	by	 virtually	 all	 cells	
and	 which	 can	 be	 found	 in	 the	 majority	 of	 bodily	 fluids.	 EVs	 have	 a	 complex	






Some	 vesicles	 originate	 by	 straightforward	 budding	 of	 the	 cell’s	 external	 plasma	
membrane,	 while	 others	 originate	 by	 “reverse	 budding”	 from	 the	 late	 endosomal	
compartment,	 which	 then	 becomes	 known	 as	 a	 multivesicular	 body	 (MVB)	 or	 a	









Figure	 10.	 Extracellular	 vesicle	 formation.	 Extracellular	 vesicles:	 Exosomes,	
microvesicles,	and	friends.	Raposo	et.	al.	JCB	2013411	
	
Extracellular	 vesicles	 have	 been	 demonstrated	 to	 contain	 proteins412,	 particularly	 the	




be	 enriched	 in	 EVs,	 compared	 to	 in	 the	 cytosol.	 This	 could	 be	 explained	 by	 the	
observation	 that	 the	RISC	machinery	 that	processes	miRNAs	has	been	 localized	 to	 the	
surface	of	MVBs418.	
	
While	 some	 groups	 purport	 that	 extracellular	 vesicle	 contents	 are	 merely	 a	 random	
sample	of	the	cytosol	with	no	directed	selectivity	of	their	contents411,	there	is	mounting	





weight	 to	 the	 arguments	 that	 their	 loading	 is	 selective	 and	 that	 EV-miRNAs	 are	
functionally	relevant	mediators	of	inter-cellular	communication271,407,416,418.	Of	concern,	
quantitative	 analysis	 of	 EV-miRNA	 content	 has	 demonstrated	 that	 individual	 vesicles	
contain	 extremely	 small	 numbers	 of	miRNA	molecules,	 and	 it	 has	 been	 concluded	 by	
some	 that	 this	 implies	 that	 EV-miRNA	 could	 not	 function	 stoichiometrically	 in	 cells	





The	 ubiquitous	 presence	 of	 EVs	 in	 healthy	 individuals	 suggests	 that	 they	 serve	 an	
important	function,	although	this	remains	broadly	unelucidated.	Various	biological	roles	
have	 been	 proposed,	 including	 the	 disposal	 of	 harmful	 cellular	waste	 products423	 and	
the	transmission	of	elements	of	intercellular	communication.	EV	mediated	intercellular	
communication	 has	 been	 most	 thoroughly	 studied	 in	 immune	 cell	 communication,	
where	EVs	appear	to	serve	important	roles	both	in	the	delivery	of	pathogenic	materials	
to	antigen	presenting	cells	(APCs)424,	and	also	a	mechanism	by	which	infected	cells	can	






the	 diagnosis	 or	 treatment	 of	 cancer.	 This	 effort	 is	 complicated	 by	 the	 fact	 that	 EVs	









function,	 on	 balance,	 serves	 the	 tumour,	 with	 roles	 in	 the	 promotion	 of	 tumour	
growth429	 and	 proliferation430,	 metastasis431,	 and	 immune	 suppression271,432.	 More	
recently,	 TEVs	 have	 been	 demonstrated	 to	 be	 an	 important	 mediator	 of	 MDSC	
expansion272,273,279,433–435.	 Of	 relevance,	 the	 tumour	 suppressing	 MicroRNA	 miR34a,	 a	










from	 patients	 with	 AML	 carried	 blast	 markers	 CD33,	 CD34,	 CD117	 and	 TGFβ1	 and	
suppressed	 allogeneic	 cytotoxic	 activity	 of	 NK	 cells	 and	 promoted	 TReg	 expansion438.	
AML	cell	 line	K562	secreted	TEVs	containing	the	pro-angiogenic	miRNA	miR92439.	 In	an	
intriguing	 work	 by	 Jiminez	 et	 al,	 drug	 resistance	 AML	 cells	 secreted	 vesicles	 carrying	
anti-apoptotic	proteins	which	were	taken	up	by	drug	sensitive	clones,	suggesting	TEVs	
represent	a	mechanism	of	the	propagation	of	therapeutic	resistance440.	Finally,	patient	
derived	 AML	 TEVs	 educated	 AML	 cell	 lines	 blasts	 to	 increase	 homing	 to	 the	 bone	











lower	 speeds	 with	 density	 gradient	 centrifugation442,	 are	 the	 most-commonly	 used	




In	 an	 effort	 to	 isolate	 vesicles	 based	 on	 size,	 several	 commercially	 available	 filtration	






















lipid	 bilayers,	 which	 can	 sometimes	 appear	 cup-like	 due	 to	 the	 drying	 and	 freezing	
preparatory	 processes448.	 Nano-particle	 tracking	 analysis,	 such	 as	 NanoSight449,	 which	




While	 the	 lower	 limit	 of	 detection	 for	 convention	 Flow	 Cytometers	 is	 approximately	
300nm,	next	generation	high	resolution	flow	cytometers	have	been	developed,	capable	
of	detection	micro-particles	down	to	the	100nm	size	and	utilizing	standardized	beads	to	
accurately	 size	 and	quantitate	 EVs	 in	 solution452,453.	 	 Furthermore,	 EVs	 can	be	 stained	
with	fluorescent	antibodies	to	detect	surface	proteins,	with	or	without	mounting	of	EVs	




EV	 proteins	 may	 be	 extracted	 utilizing	 standard	 cell	 lysis	 buffers	 and	 detected	 by	








RNA	may	 be	 isolated	 from	 EVs	 and	 subjected	 to	 conventional	 RT-PCR	 or	micro-array.	
The	choice	of	RNA	isolation	is	important	because	the	RNA	in	EVs	is	mostly	small	RNAs,	
which	 may	 sometimes	 be	 lost	 in	 standard	 RNA	 isolation	 techniques460.	 Phenol-based	





EVs	 are	 an	 attractive	 source	 of	 biomaterial	 for	 biomarker	 studies	 because	 they	 are	
abundant	and	easily	accessible	in	blood	and	other	bodily	fluids	such	as	urine462,	amniotic	
fluid	and	ascites463,	saliva464	and	even	tears465.		EVs	could	be	used	in	the	early	diagnosis	







not	 in	 standard	 clinical	 use,	 several	 studies	 have	 delineated	 EV	 miRNA	 signatures	 of	






















called	 “suicide	 proteins”481,	 and	 drugs482	 that	 are	 limited	 by	 a	 short	 half-life407.	
Advantages	 of	 this	 approach	 include	 the	 biological	 tolerability	 of	 these	 endogenous	
vehicles,	 and	 their	 abundance	 without	 the	 need	 for	 a	 lengthy	 manufacturing	
processes483.	They	can	pass	the	blood	brain	barrier480,	and	there	is	some	evidence	that	
EVs	may	 be	 naturally	 targeted484,	 or	 at	 least	may	 be	 exogenously	manipulated	 to	 be	
targetable,	to	specific	tissues480,482,485.	
	








determine	 if	 they	 carry	 known	 AML	 antigens.	 Furthermore,	 we	 sought	 to	 elucidate	






cells	 were	 cultured	 in	 media	 supplemented	 with	 exosome-depleted	 FBS,	 for	 all	 EV	
experiments.	EVs	were	isolated	from	MOLM-14	and	THP-1	cell	culture	supernatant	using	
the	 Total	 Exosome	 Isolation	 Kit	 (Invitrogen,	 Camarillo,	 CA,	 USA),	 and	 in	 latter	
experiments	 with	 Exoeasy	 spin	 columns	 (Qiagen,	 Germany)	 as	 per	 manufacturers	




Extra-cellular	 vesicles	 were	 isolated	 as	 before,	 and	 re-suspended	 in	 PBS	 or	 Exoeasy	
column	elution	buffer.	Cells	were	run	on	a	MoFlo®	Astrios™	flow	cytometer	(Beckman-
























lysate	 were	 made	 up	 to	 50µl	 of	 laemmli	 buffer	 and	 BME	 and	 boiled	 at	 100°C	 for	 5	
minutes	in	a	heat	block.	Equal	amounts	of	protein	were	loaded	into	a	10%	gel	alongside	
5µl	 ladder	and	10µl	 laemmli	buffer	and	BME	 into	blank	wells.	Gels	were	run	at	80v	 in	
running	 buffer,	 until	 the	 lowest	 band	 had	 reached	 the	 bottom	 of	 the	 gel.	 Gels	 were	
transferred	 onto	 PVDF	 membrane	 using	 a	 semi-dry	 transfer	 machine	 at	 15V	 for	 43	
minutes.	Membranes	were	subsequently	blocked	for	one	hour	on	a	rocking	platform	in	
5%	milk	 solution	 in	 TBST.	 Membranes	 were	 washed	 for	 3x20minutes	 on	 the	 rocking	
platform	 in	 TBST	 before	 1:1000	 dilutions	 of	 primary	 antibody	 (anti-MUC1-C	 (Thermo	
Scientific,	Waltham,	MA)	 or	 anti-c-Myc	 (Cell	 Signalling,	 Danvers,	MA))	made	 up	 in	 5%	
milk	in	TBST	were	added	and	membranes	incubated	overnight	at	4°C.	The	next	morning,	






manner	 as	 the	 primary.	 After	 one	 hour,	 the	membranes	 were	 washed	 and	 activated	





MOLM-14	 cells	were	 fluorescently	 labelled	 red	with	GranToxiLux	 (OncoImmunin,	MD)	
and	treated	with	SYTO®	RNASelect™	Green	Fluorescent	cell	Stain	(Invitrogen,	Camarillo,	
CA,	USA)	for	30	minutes,	as	per	manufacturer’s	protocol.	Cells	were	washed	three	times	
in	 PBS	 in	 co-cultured	 for	 four	 hours	 at	 37ºC	 in	 a	 humidified	 5%	 CO2	 incubator,	 with	
healthy	donor	PBMCs	 in	a	 ratio	of	1:10	 tumour	cells	 to	PBMCs.	After	 four	hours,	 cells	
were	stained	with	CD11b-APC-Cy7,	HLADR-PE-Cy7	and	CD33-PE.	Using	Flow	Cytometry,	
tumour	 cells	 were	 excluded	 with	 the	 red	 dye,	 and	 the	 green	 SYTO	 dye	 (indicating	
exosomal	mRNA)	was	quantified	in	the	PBMCs.		
In	 parallel,	 MOLM-14	 cells	 were	 fluorescently	 labelled	 red	 with	 GranToxiLux	
(OncoImmunin,	MD)	and	 treated	with	SYTO®	RNASelect™	Green	Fluorescent	cell	 Stain	
(Invitrogen,	 Camarillo,	 CA,	 USA)	 for	 30	minutes,	 as	 per	manufacturer’s	 protocol.	 Cells	
were	washed	 three	 times	 in	 PBS	 and	 then	 cultured	 overnight	 in	 RPMI	 supplemented	
with	 bovine	 exosome	 depleted	 FBS.	 EVs	 were	 isolated	 as	 described,	 protein	 was	

















MOLM-14	 AML	 EVs	 were	 isolated	 using	 a	 spin-column	 and	 characterized	 by	 flow	
cytometry.	Background	noise	is	shown	in	(A)	and	the	negative	control	of	PBS	is	shown	in	



















lipid	 rich	 membrane	 and	 demonstrates	 multiple	 rounded	 structures	 measuring	 100-
200nM	in	diameter	and	bound	by	darkly	staining	membrane	(Figure	12).	Taken	together	
we	estimate	the	size	of	AML	EVs	to	be	around	200nm,	as	the	dehydration	step	prior	to	
























MOLM-14	 and	 THP-1	 AML	 EVs	 were	 isolated	 using	 a	 spin-column,	 and	 lysates	 were	





























































































































EVs	 are	 shown	 in	 (A)	 and	 EVs	 from	 SYTO	 treated	 AML	 cells	 are	 shown	 in	 (n=2)	 (B).	
Healthy	donor	PBMCs	were	co-cultured	with	SYTO	stained	EVs.	After	six	hours,	PBMCs	
were	assessed	for	the	presence	of	SYTO	fluorescence,	indicating	uptake	of	AML	RNA,	by	
flow	 cytometry	 (C	 and	 D)	 (n=3).	 Subsequently,	 to	 determine	 if	 AML	 EVs	 export	 to	
surrounding	 cells,	 PBMCs	 were	 co-cultured	 in	 direct	 contact	 or	 in	 Transwell,	 with	
MOLM-14	AML	 cells	 pre-treated	with	 SYTO	RNA	dye	 (530nm).	After	 six	hours,	MDSCs	
were	 quantified	 for	 AML	 SYTO	 RNA	 dye	 using	 flow	 cytometry.	 Summary	 of	 three	
experiments	 is	 shown	 in	 (n=3)	 (E).	EVs	were	 isolated	 from	cell	 culture	 supernatant	 as	
previously	described.	 (F)	0.4uM	Transwells	were	 set	up	as	 shown	and	 incubated	 for	3	
hours	at	 room	temperature.	Thereafter,	400ul	of	RPMI	was	sampled	 from	the	bottom	








stained	 EVs	 after	 6	 hours,	 indicating	 EV	 export	 and	 uptake	 by	 surrounding	 cells.	 To	






















cytometry.	 In	 the	PBMCs	 co-cultured	with	 EVs,	 the	proportion	of	MDSCs	 increased	8-













































































These	 data	 collectively	 demonstrate	 that	MOLM-14	 and	 THP-1	 AML	 cell	 lines	 secrete	
extra-cellular	vesicles.	These	vesicles	had	a	size	of	between	200-300nM	when	measured	
by	 Flow	 Cytometry,	 and	 of	 100-200nM	when	measured	 by	 Electron	microscopy.	 This	
disparity	 is	 in	 keeping	 with	 published	 comparisons	 between	measuring	 modalities488,	
which	 suggest	 that	 flow	 cytometry	 may	 be	 a	 slightly	 more	 accurate	 method	 of	
measurement,	 given	 the	 changes	 to	 vesicle	 structure	 upon	 dehydration,	 fixation	 and	
freezing	for	electron	microscopy.	 In	this	study,	we	can	conclude	that	vesicles	probably	
have	 a	 size	 distribution	 around	 200nM,	with	 THP-1	 EVs	 appearing	 slightly	 larger	 than	




c-Myc.	 This	 observation	 is	 important	 as	 it	 suggests	 that	 AML	 EVs	 may	 be	 pro-
tumourigenic	and	 immune	suppressive,	by	carrying	these	well-studied	oncoproteins	to	
surrounding	cells.	Conversely,	AML	EVs	may	serve	 to	educate	nearby	 immune	cells	by	







cells.	 Utilizing	 a	 RNA-specific	 fluorescent	 dye,	 we	 demonstrated	 that	 RNA	 containing	
AML	 EVs	 export	 to,	 and	 are	 taken	 up	 by,	 co-cultured	 PBMCs.	 Importantly,	 we	





previous	 studies406,407,	 and	 hypothetically	 due	 to	 EVs	 aggregating	 into	 larger	 particles	
which	are	sterically	hindered	from	traversing	the	Transwell	pores.	
	
Finally,	 to	 elucidate	 the	 effect	 of	 AML	 EVs	 on	 surrounding	 cells,	 flow	 cytometry	 for	
markers	 of	 immature	 myeloid	 cells	 (MDSCs)	 and	 mature	 myeloid	 cells	 (DCs)	 was	
performed	on	PBMCs	 treated	with	AML	EVs.	After	 three	days	of	 EV-PBMC	co-culture,	
there	was	an	increased	proportion	of	cells	carrying	the	MDSC	markers	(CD33+,	HLADR-,	
CD11b+)	 and	 a	 statistically	 significant	 decrease	 in	 cells	 carrying	markers	 of	 a	 mature	




The	 mechanism	 by	 which	 this	 skewing	 occurs	 remained	 to	 be	 elucidated.	 We	






We	 hypothesized	 that	 AML	 cells	may	 release	 in	 EVs,	 an	 element	 such	 as	 a	 protein,	 a	
miRNA,	 or	 set	 of	miRNAs,	 that	 promotes	 this	 proliferation	of	 immature	myeloid	 cells.	
Given	the	widely	reported	similarity	in	content	of	EVs	to	their	parental	cell	line,	and	the	
significantly	 increased	ease	 in	studying	cell	contents	 instead	of	EV	content,	we	started	
by	investigating	proteins	and	miRNAs	in	AML	cells	that	may	promote	MDSC	expansion.		
	





oncogenesis	 including	 those	 governing	 cell	 proliferation,	 self-renewal,	 tissue	 invasion,	
and	apoptosis8.	MUC1	has	been	identified	as	a	uniquely	important	oncoprotein	in	AML	
and	AML	stem	cells	that	exerts	immune-modulatory	effects8.	It	has	been	demonstrated	
that	 MUC1	 is	 selectively	 expressed	 on	 AML	 stem	 cells	 as	 compared	 to	 normal	
haematopoietic	 stem	 cells,	 and	 is	 critically	 involved	 in	 the	 self-renewal	 capacity	 of	
malignant	cells128.	 In	 this	 study	we	had	observed	 that	MUC1	was	present	 in	AML	EVs.	
Given	the	critically	important	role	of	MUC1	in	AML,	and	its	immune	suppressive	effects,	






A	 series	 of	murine	 and	 human	 in	 vitro	 and	 ex	 vivo	 studies	 suggest	 that	 tumour	 cells	
secrete	 factors	 into	 the	microenvironment	 that	 promote	MDSC	 expansion.	 In	 human	
studies,	 tumour-conditioned	 medium	 has	 been	 used	 to	 expand	MDSC-like	 cells	 from	
peripheral	blood	mononuclear	cells256	with	GM-CSF	an	IL-6	proving	critical	mediators	of	
this	expansion.		








a	 critical	 role	 in	 mediating	 both	 the	 expansion	 of	 MDSCs	 and	 their	 function	 in	
suppressing	immune	cells274–276.	Unsurprisingly,	inhibitors	of	STAT	activation	have	been	
used	to	attempt	to	target	this	population,	as	we	will	 later	discuss.	STAT3277	and	STAT5	
have	 key	 roles	 in	MDSC	expansion,	putatively	 via	 their	 roles	 in	 inflammatory	 cytokine	
production278.	STAT3	inhibition	has	been	shown	to	mediate	differentiation	of	MDSC	into	
mature	Dendritic	Cells,	 indicating	aberrant	 STAT3	 signalling	plays	 an	 important	 role	 in	
cancer,	 in	 maintaining	 myeloid	 cells	 in	 an	 immature,	 more	 immune-suppressive	
state274,279.	 In	 head	 and	 neck	 cancers	 STAT3	was	 shown	 to	 control	MDSC	 function	 by	
regulating	 Arg-1	 activity280.	 MDSCs	 from	 tumour	 bearing	 mice	 have	 high	 levels	 of	
activated	STAT3281.	The	inhibition	of	STAT3	with	the	tyrosine	kinase	inhibitor	Sunitinib,	





murine	model	 of	 lung	 cancer283.	 STAT3	 activation	 up-regulated	 the	 pro-inflammatory	
protein	S100A8/9,	which	inhibits	the	differentiation	of	DCs	and	macrophages,	leading	to	
an	accumulation	of	MDSCs210.	There	is	an	inverse	correlation	between	the	percentage	of	
granulocytic	MDSCs	 and	 levels	 of	 STAT1	 phosphorylation	 in	 CD4	 T	 cells.	 Co-culture	 of	
MDSCs	 and	 CD4	 T	 cells	 from	 healthy	 donors	 led	 to	 reduced	 IFN-y	 responsiveness284.	
STAT6-deficient	MDSCs	fail	to	inhibit	T	cell	activation	as	they	failed	to	up-regulate	iNOS	
or	make	Arg-1285.		
The	 transcription	 factor	 Twist	 is	 associated	 with	 diverse	 malignancies.	 In	 one	 study,	
overexpression	of	Twist	in	cancer	cell	lines	was	associated	with	an	expansion	of	murine	
MDSCs	 in	 co-cultured	 myeloid	 precursor	 cells.	 Conversely,	 siRNA	 silencing	 of	 Twist	
expression	partly	abrogated	the	expansion	of	MDSCs	in	this	model286.		
The	 RAS	 signalling	 pathways	 are	 key	 regulators	 of	 normal	 cell	 growth	 and	malignant	
transformation287.	Ras	signalling	plays	a	key	role	in	myeloid	development	and	promotes	
granulopoeisis,	 and	 thereby	 the	 production	 of	 granulocytic	MDSCs,	 by	 increasing	 the	
binding	 of	 C/EBP	 alpha	 to	 the	 GCSF	 receptor288.	 Overexpression	 of	 kRas	 in	 a	 murine	
model	 of	 pancreatic	 cancer	 cells	 led	 to	 increased	 expression	 of	 the	 chemoattractant	
cytokines	 MIP-2	 and	 MCP-1,	 which	 promote	 the	 recruitment	 of	 macrophages	 and	
MDSCs	into	the	tumour	microenvironment289.	
PI3K/Akt	 signalling	 affects	 cell	 growth,	 survival	 migration	 and	 metabolism	 that	 is	
thought	to	play	a	significant	role	in	MDSC	expansion.	Aging	mice	accumulate	MDSCs	in	















during	 the	 induction	 of	 MDSC	 from	 the	 bone	 marrow	 cells	 by	 GM-CSF	 and	 IL-6	 and	
targeting	these	miRNAs	abrogated	cytokine	induced	MDSC	expansion	in	vitro293.	miR155	






Hypoxia	 is	 a	 common	 feature	of	 solid	 tumours	 as	 they	outgrow	 their	 blood	 supply296,	
and	 has	 implicated	 in	 mediating	 resistance	 to	 chemotherapy297,298,	 the	 promotion	 of	
metastases299,	as	well	as	resulting	in	an	immune	privileged	niche93,300–302.	 	Hypoxia	has	
been	shown	to	promote	the	expansion	of	 immune-suppressive	MDSCs303,304,	as	well	as	
mediating	 the	 differentiation	 of	 MDSCs	 into	 immune-suppressive	 tumour	 associated	
macrophages	(TAMs),	upon	arrival	in	the	hypoxic	tumour	bed302.	
While	 the	 presence	 of	 tumours	 has	 been	 clearly	 demonstrated	 to	 result	 in	 the	
recruitment	 and	 proliferation	 of	 MDSCs,	 various	 cancer	 treatments	 have	 also	 been	
implicated	 in	 further	 expanding	 this	 population.	 Several	 cytotoxic	 chemotherapeutic	





promoting	 cytokine,	 although	 evidence	 of	 MDSC	 expansion	 in	 GM-CSF	 containing	
treatments	remains	conflicting308.		
While	we	have	divided	MDSC	 inducing	factors	 into	discrete	sections,	 it	 is	 important	to	
note	 that	 there	 is	 a	 huge	 amount	 of	 cross-talk	 and	 overlap	 in	 these	 pathways,	 with	
transcription	 factors	 mediating	 cytokine	 release,	 and	 miRNAs,	 such	 as	 miR155,	
implicated	in	promoting	transcription	factor	STAT3	activity277.		








The	 MUC1	 oncogene	 is	 aberrantly	 expressed	 in	 solid	 tumours131	 and	 haematologic	
malignancies	 including	 AML128	 and	 plays	 a	 critical	 role	 in	 maintaining	 the	 malignant	
phenotype489–491.	 	Signalling	via	the	MUC1-C	subunit	supports	tumour	cell	proliferation	
and	resistance	to	apoptosis492.		Recent	studies	have	suggested	that	MUC1	demonstrates	






of	 MUC1-C,	 the	 active	 cytoplasmic	 domain	 of	 the	 MUC1	 molecule30.	 Thereafter,	 we	
would	 repeat	 the	 co-culture	 experiment,	 incubating	 MUC1	 silenced	 AML	 cells	 with	
healthy	donor	PBMCs,	to	elucidate	if	MUC1	silencing	would	diminish	MDSC	expansion	in	
Athalia	Rachel	Pyzer	 Chapter	4:	MDSC	Expansion	and	MUC1:	Methods			
















were	 transduced	 with	 lentiviral	 vectors	 expressing	MUC1-C,	 or	 control	MUC1-C(AQA)	
shRNA	 (Sigma,	 St.	 Louis,	MO)	 and	maintained	 in	 2µg/ml	 Puromycin	 (Sigma,	 St.	 Louis,	
MO)	to	select	for	successfully	transduced	clones.	
In	 addition,	 CRISPR/Cas9	 technology	 was	 employed.	 CRISPR	 systems	 are	 adaptable	
immune	mechanisms	used	by	many	bacteria	to	protect	themselves	from	foreign	nucleic	
acids,	 such	as	viruses	or	plasmids,	by	 incorporating	 them	 into	 their	own	genome.	The	
addition	of	 a	 sequence	of	DNA	 corresponding	 to	 the	 gene	of	 interest,	 directs	Cas9	 to	
cleave	 complementary	 target	 DNA	 sequences.	 Thus,	 with	 this	 system,	 Cas9	 nuclease	
activity	 can	 be	 directed	 to	 ‘chop	 out’	 any	 particular	 DNA	 sequence.32	 For	 the	 CRISPR	


























buffer	 (1:100	 RIPA	 buffer:	 Protease	 and	 Phosphatase	 Inhibitor)	 and	 centrifuged	 at	
13300rpm	 for	 15	 mins.	 The	 resultant	 supernatant	 was	 collected	 and	 the	 cell	 debris	
pellet	 discarded.	 To	 calculate	 the	 total	 protein	 concentration	 in	 each	 lysate,	 2.5µl	 of	
lysate	 was	 added	 to	 1ml	 of	 Coomassie	 reagent	 and	 protein	 in	 measured	 using	 a	









at	 15V	 for	 43	 minutes.	 Membranes	 were	 subsequently	 blocked	 for	 one	 hour	 on	 a	
rocking	platform	in	5%	milk	solution	in	TBST.	Membranes	were	washed	for	3x20minutes	
on	 the	 rocking	 platform	 in	 TBST	 before	 1:1000	 dilutions	 of	 primary	 antibody	 (anti-
MUC1-C	 (Thermo	 Scientific,	Waltham,	MA))	made	up	 in	%%	milk	 in	 TBST	were	 added	
and	membranes	 incubated	 overnight	 at	 4°C.	 The	 next	morning,	 the	 primary	 antibody	
was	 removed,	 membrane	 washed	 thrice	 as	 above,	 and	 the	 appropriate	 horseradish	
peroxidase-conjugated	secondary	antibody	added	 in	 the	same	manner	as	 the	primary.	
After	 one	hour,	 the	membranes	were	washed	 and	 activated	using	 a	 50:50	mixture	of	
luminol	and	oxidizing	reagent	(GE	Healthcare),	before	being	developed	on	radiographic	





RNA	 Quantitation	 System	 (System	 Biosciences)	 was	 used	 as	 per	 the	 manufacturer's	
protocol.	For	detection	of	Dicer1,	cJUN	and	c-Myc	mRNA,	total	RNA	was	extracted	using	
the	 RNeasy	 system	 (Qiagen,	Germany).	 cDNA	was	manufactured	 using	 ThermoFishers	
SuperScript	VILO	Mastermix	(ThermoFisher,	Waltham	MA)	and	RT-PCR	was	performed.	
The	 qPCR	 forward	 primers	 for	 detection	 of	 miR34a	 and	 pre-miR34a	 miRNA,	 and	 the	

















miRZip-34a	 anti-miR34a	microRNA	 construct	 (SystemBio,	 CA).	 Successfully	 transduced	
cells	were	isolated	by	FACS	for	GFP	positive	cells.	
Treatment	with	MUC1-C	inhibitor	
AML	cells	were	 treated	daily	with	varying	doses	of	 the	MUC1-C	 inhibitor	 “GO-203”	 to	
generate	dose	curves	(see	Appendix	D).	Apoptotic	and	dead	cells	were	measured	using	
Flow	Cytometry	staining	 for	Annexin	V	and	Propidium	 Iodide	 (ThermoFisher,	Waltham	
MA).	The	highest	sub-lethal	dose	(defined	as	<10%	dead	or	apoptotic	cells)	of	GO-203	
was	determined	to	be	1uM	for	MOLM-14	and	THP-1.	AML	cells	were	treated	with	1uM	
GO-203	or	 the	 inactive	control	compound	CP3,	daily	 for	72	hours.	After	72	hours	cells	
were	 harvested,	 washed	 twice	 in	 RPMI,	 pelleted	 and	 lysed	 in	 RIPA	 buffer	 for	 further	
analysis	by	Western	Blot.		
mRNA	Array	
RNA	 was	 isolated	 from	 paired	 GO-203	 treated	 and	 untreated	 AML	 samples	 from	 3	
subjects.	 Affymetrix	 gene	 array	 for	 small	 RNAs	was	 performed	 as	 per	manufacturer’s	









RNA	 was	 isolated	 from	 AML	 cells	 as	 described	 and	 run	 in	 triplicate	 on	 a	 NanoString	
(Seattle,	 WA)	 nCounter	 instrument	 using	 the	 human	miRNA	 Expression	 Assay	 Kit	 v3,	
according	 to	 the	manufacturer’s	 instructions.	 Data	 obtained	were	 then	 normalized	 to	
positive	 miRNA-ligation	 reaction	 controls	 and	 background	 noise	 was	 subtracted.	







To	elucidate	 if	 the	membrane	onco-protein	MUC1	might	be	 responsible	 for	 the	direct	
cell	contact	 required	expansion	of	MDSCs,	stably	 transduced	cell	 lines	silenced	for	 the	
expression	 of	 MUC1	 protein	 were	 generated	 by	 lentiviral	 transduction	 of	 shRNA	 or	
control	 vector	 (Figure	 16	 A),	 or	 CRISPR/Cas9	 technology	 (Figure	 16	 B).	 Healthy	 donor	
PBMCs	co-cultured	in	direct	contact	with	irradiated	MUC1	silenced	AML	cells	resulted	in	









cell	 lines	 silenced	 for	 the	 expression	 of	 MUC1	 protein	 were	 generated	 by	 lentiviral	
transduction	 of	 shRNA	 or	 control	 vector.	 (n=2)	 (A)	 Lysates	 were	 prepared	 and	 cells	
analysed	for	MUC1	expression	using	Western	blotting.	To	validate	the	silencing,	MOLM-
























collected.	 Cytokine	 array	 was	 performed	 on	 cell	 culture	 supernatant.	 Representative	




MUC1	 mediates	 tumour	 cell	 proliferation	 via	 downstream	 effectors	 including	
prominently	 the	 oncoprotein,	 c-Myc	 that	 regulates	 expression	 of	 cell	 cycle	
proteins489,490.	 However,	 the	 role	 of	 oncoproteins	 as	 immunoregulatory	 agents	 that	













































































































































The	 c-Myc	 protein	 is	 nuclear	 phospho-protein	 that	 plays	 a	 critical	 role	 in	 cell	 cycle	
progression	 and	 proliferation494.	 Recent	 studies	 in	 myeloma	 and	 lung	 cancer	 have	





MUC1	 mediates	 tumour	 cell	 proliferation	 via	 downstream	 effectors	 including	
prominently	the	oncoprotein,	c-Myc.	Of	note,	EVs	derived	from	MUC1	expressing	AML	











































































































IB: anti-cyclin D2 
IB: anti-cyclin E1 
cyclin E1 






of	 shRNA	 or	 CRISPR/Cas9	 technology.	 Control	 shRNA	 or	 wildtype	 cells	 were	 used	 as	




for	 48	 hours	with	 EVs	 isolated	 from	 the	 culture	medium	 of	 THP-1	 cells,	 PBMCs	were	
lysed	 and	 (C)	 subjected	 to	 immunoblot	 for	 c-Myc	 and	Cyclins	D2	 and	 E1.	GAPDH	was	
used	as	loading	control.(n=1).	
	
MDSCs	 exposed	 to	 AML-EVs	 have	 increased	 c-Myc	 and	 c-Myc	 dependent	 downstream	
mediators	of	proliferation	
To	 determine	 if	 the	 export	 of	 c-Myc	 containing	 EVs	 to	 myeloid	 cells	 in	 the	
microenvironment	 resulted	MDSC	 expansion,	MDSCs	were	 pulsed	with	 EVs	 from	wild	
type	 or	MUC1	 silenced	 AML	 cells.	 Figure	 18	 C	 shows	 that	 control	 EV	 treated	MDSCs	
contained	increased	levels	of	c-Myc	and	increased	expression	of	cyclin	E1	and	cyclin	D2,	






















binding	 target	 genes	 with	 complementary	 sequences497.	 miR34a	 has	 previously	 been	
reported	 to	be	a	key	 regulator	of	MDSC	expansion	and	 is	a	known	regulator	of	 c-Myc	
expression,	binding	to	a	complementary	sequence	in	the	3’UTR	of	c-Myc	mRNA498.	We	




We	 sought	 to	 validate	 that	miR34a	 regulates	 c-Myc	 expression	 in	 AML.	 Indeed,	 over-
expression	of	miR34a	using	lentiviral	transduction	of	mir34a	mimic,	led	to	a	reduction	in	
c-Myc	 expression	 in	 MOLM-14	 and	 THP-1	 (Figure	 20A).	 Alternatively,	 we	 sought	 to	






















































expression	 (Figure	 20B).	 Furthermore,	 in	 MUC1	 silenced	 THP-1	 AML	 cells,	 previously	
shown	 to	 have	 low	 c-Myc	 expression	 (Figure	 18B),	 silencing	 of	miR34a	 demonstrated	
similar	 results,	 with	 significant	 increase	 in	 c-Myc	 levels	 (Figure	 20C).	
	
Figure	 20.	 Transduction	 with	 miR34a	 mimic	 or	 ZIP-miR34a	 results	 in	 altered	 c-Myc	
expression	in	AML	blasts.	MUC1	regulates	c-Myc	expression	via	miR34a	in	AML	cells.	
MOLM-14	 and	 THP-1	 cells	 were	 transduced	 with	 miR34a-mimic	 or	 control,	 using	
lentiviral	 transduction.	 (A)	 Lysates	were	prepared	and	 c-Myc	expression	was	 assessed	
using	 western	 blot	 analysis.	 MOLM-14	 AML	 cells	 over-expressing	 miR34a	 were	 then	
silenced	 for	 miR34a,	 by	 lentiviral	 transduction	 of	 miR34a-ZIP	 or	 control	 (n=2).	 (B)	
Lysates	were	prepared	and	c-Myc	expression	was	assessed	using	western	blot	analysis.	
THP-1	 AML	 cells	 silenced	 for	 MUC1	 expression	 using	 specific	 MUC1	 shRNA,	 were	




miRNA34a	 levels	 are	 increased	 in	MUC1	 silenced	AML	 cells	 and	 Extra-cellular	 Vesicles	
derived	from	these	cells.	
To	determine	 if	MUC1	expression	effects	 the	expression	of	 the	miRNA	miR34a,	MUC1	





















































































quantified	 by	 q-PCR.	 Both	 MUC1	 silenced	 AML	 cell	 lines	 had	 a	 13-fold	 increase	 in	
miR34a	 expression	 (Figure	 21	 A	 and	 B).	 This	 finding	 was	 confirmed	 in	 Extra-cellular	
Vesicles	isolated	from	MUC1	silenced	AML	cells	(Figure	21	C	and	D).		
	
Figure	 21.	 miRNA34a	 levels	 are	 increased	 in	 MUC1	 silenced	 AML	 cells.	 Stably	
transduced	 cell	 lines	 silenced	 for	 the	 expression	 of	MUC1	 protein	were	 generated	 by	
lentiviral	 transduction	 of	 shRNA	 or	 control	 vector.	 RNA	 was	 isolated	 from	 cells	 and	
subjected	 to	qPCR	with	primers	 against	miR34a.	miR34a	expression	 in	MUC1	 silenced	
































































































































































































































































































Targeting	 miR34a	 in	 AML	 cells	 alters	 the	 expansion	 of	 MDSCs	 in	 co-cultured	 healthy	
donor	PBMCs.	
We	next	 confirmed	 the	 critical	 role	 of	miR34a	 in	 regulating	MDSC	 expansion	 in	 AML.		
Overexpression	 of	 miR34a	 in	 wild	 type	 MOLM-14	 and	 THP-1	 cells	 by	 lentiviral	
transduction	 resulted	 in	 decreased	 capacity	 of	 the	 AML	 cells	 to	 induce	 expansion	 of	
MDSCs	when	co-cultured	with	normal	PBMCs	(Figure	22A).	Furthermore,	a	co-culture	of	
healthy	 PBMCs	with	MOLM-14	 (Figure	 22B)	 and	 THP-1	 cells	 (Figure	 22C)	 silenced	 for	
miR34a	expression,	resulted	in	a	corresponding	increase	in	MDSCs.	Importantly,	altering	
MUC1	or	miR34a	 levels	 in	MOLM-14	or	THP-1	was	not	associated	with	changes	 in	 the	







Figure	 22.	 Targeting	 miR34a	 alters	 MDSC	 expansion	 in	 co-cultured	 PBMCs.	 Healthy	
PBMCs	 were	 co-cultured	 with	 irradiated,	 fluorescently	 labelled	 AML	 cells	 with	 over-
expressed	miR34a	levels,	for	five	days	at	a	ratio	of	100:1	(PBMC:AML).	After	co-culture,	
cells	 were	 analysed	 by	 Flow	 Cytometry	 and	 fluorescently	 labelled	 blast	 cells	 were	
excluded,	CD11b+/HLADR-/CD33+	MDSCs	were	quantified	as	a	percentage	of	immature	
CD11b+/HLADR-	myeloid	cells.	(A)	Summary	of	three	independent	experiments	is	shown	
for	 MOLM-14	 and	 THP-1	 (p<0.05).	 Similarly,	 MDSCs	 were	 detected	 in	 co-culture	 of	
PBMCs	with	miR34a	silenced	(B)	MOLM-14	(n=3,	p<0.05)	and	(C)	THP-1	AML	cells	(n=3,	
p<0.05).	(D)	MOLM-14	and	THP-1	were	silenced	for	MUC1	expression	or	over-expressed	





























































































































































































































































































































































































We	 had	 so	 far	 elucidated	 that	 MUC1	 induces	 the	 expansion	 of	 MDSCs	 via	 the	




are	 processed	 in	 the	 nucleus	 by	 the	 RNAse	 III	 enzymes	 Drosha	 and	 PASHA	 into	 pre-
miRNAs	 of	 roughly	 70-nucleotides	 in	 length.	 The	 pre-miRNAs	 are	 exported	 into	 the	
cytoplasm	and	undergo	processing	by	 the	RNAse	 III	enzyme	Dicer	generating	 the	 final	
mature	 miRNA,	 which	 consists	 of	 double-stranded	 RNA	 of	 roughly	 22	 nucleotides	 in	
length34,35.		
Following	this	processing,	DICER	bound	mature	miRNA	forms	a	complex	known	as	 the	
RNA-induced	 silencing	 complex	 (RISC),	made	up	of	DICER,	miRNA,	 a	 transport	 protein	
called	transactivating	response	RNA-binding	protein	(TRBP)	and	Argonaut2	(Ago2).	TRBP	
recruits	 Ago-2	 to	 the	 RISC,	 whereby	 it	 serves	 to	 cleave	 the	 target	 mRNA	 strand	
complementary	to	their	bound	miRNA36.	
In	order	to	elucidate	if	MUC1	affects	the	transcription	of	the	precursor	forms	of	miR34a	
or	 the	 processing	 of	 the	 pre-miRNA	 to	 the	 mature	 version,	 we	 performed	 q-PCR	 on	
MUC1	silenced	AML	cells,	and	their	respective	controls,	for	both	the	mature	miR34a	and	
the	precursor	pre-miR34a	transcripts.		
Figure	 24	 demonstrates	 that	 when	 MUC1	 is	 silenced,	 miR34a	 levels	 increase	 as	
previously	 seen.	However	 the	 levels	 of	 pre-miR34a	 stay	 the	 same,	 indicating	 that	 the	












Our	data	 suggested	 that	MUC1s	negative	 regulation	of	miR34a	expression	happens	at	
the	 post-transcriptional	 stage.	 The	 DICER	 protein	 processes	 pre-miRNAs	 into	 mature	
miRNAs	 so	we	 sought	 to	elucidate	 the	effect	of	MUC1	 signalling	on	 the	expression	of	
DICER.	Westerns	blots	for	DICER	were	performed	on	lysates	from	AML	cells	silenced	for	
MUC1	expression	(Figure	25A)	and	AML	cells	treated	with	the	MUC1	inhibitor	GO-203,	
or	 the	 control	 compound	 CP3	 (Figure	 25B).	 These	 immune-blots	 demonstrate	 that	









































































































































































































































































































AML	 cell	 lines	 showed	 increased	 total	 and	 phosphorylated	 (activated)	 cJUN	 in	MUC1	
silenced	cells	compared	to	control	(Figure	26A).	To	determine	if	MUC1	regulated	c-jun	at	
the	 transcription	 level,	q-PCR	 for	 cJUN	was	performed	showing	dramatically	 increased	
levels	of	cJUN	upon	MUC1	silencing	(Figure	26	C).	Similarly	an	mRNA	array	of	AML	blasts	
from	patient	samples	treated	with	control	or	the	MUC1	inhibitor	(GO-203),	showed	an	
increase	 in	 cJUN	mRNA	 (p=0.007)	 (Figure	26B).	 Finally,	 to	 confirm	 cJUN	as	 the	 critical	
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THP-1	 cells	 and	 CRISPR/Cas9	 in	 MOLM-14	 cells.	 Immunoblotting	 of	 lysates	 was	
performed	 for	 phosphorylated	 cJUN,	 total	 cJUN	 and	 GAPDH	 (A).	 MRNA	 array	 was	
performed	on	 three	GO-203	or	 control	 treated	primary	AML	 samples.	A	 plot	 showing	
the	 relative	 expression	 of	 cJUN	mRNA	 is	 shown	 (p=0.07)	 (B).	 RNA	was	 isolated	 from	
MUC1	silenced	AML	cell	 lines	and	qPCR	was	performed	to	quantitate	cJUN	transcripts	
(C)	 (n=2).	 MUC1	 silenced	 AML	 cells	 were	 treated	 for	 2	 hours	 with	 0uM,	 100uM	 or	
400uM	of	cJUN	inhibitor,	lysates	were	immunoblotted	for	DICER	and	GAPDH	(D)	(n=2).		
	
MUC1	 inhibition	 leads	 to	 increase	 in	 the	 majority	 of	 mRNAs	 in	 AML	 cells.	We	 next	
performed	 an	 array	 to	 identify	 other	 microRNAs	 that	 were	 similarly	 impacted	 by	
silencing	 with	 MUC1.	 MicroRNA	 array	 of	 MUC1	 silenced	 MOLM-14	 and	 THP-1	 cells	
demonstrated	 a	 profound	 global	 up-regulation	of	 the	 vast	majority	 of	microRNAs	 (Fig	
27),	 consistent	with	 the	 increase	 in	DICER	expression	we	had	previously	 observed.	Of	
the	panel	of	801	miRNAs	arrayed,	MUC1	silenced	MOLM-14	cells	showed	an	increase	in	
786/801	 (98.1%),	 of	 which	 340	 (42.4%)	 reached	 Bonferroni-corrected	 significance.	













































While	 the	 full	 elucidation	 of	 the	 mechanism	 by	 which	 MUC1	 may	 suppress	 cJUN	
transcription	 is	 beyond	 the	 scope	 of	 these	 studies,	 it	 has	 been	 recently	 shown	 that	
MUC1	 has	 hyper-methylating	 properties499,	 which	 may	 globally	 suppress	 gene	
transcription.	Treatment	with	 the	MUC1	 inhibitor	GO-203,	 lead	to	de-methylation	and	
increased	expression	of	several	critical	genes	in	a	model	of	AML	(Kufe	et	al	unpublished	





THP-1	 and	 MOLM-14	 AML	 cells	 were	 treated	 with	 a	 sub-lethal	 dose	 of	 the	 HMA	
Decitabine,	 (for	 dose	 curves	 see	 Appendix	 D),	 daily	 for	 three	 days	 and	 cells	 were	
harvested	 at	 day	 7.	 Day	 7	 was	 chosen	 as	 previous	 studies	 have	 suggested	 that	 peak	
demethylation	 occurs	 at	 this	 time	 point500.	 Immuno-blots	 for	 cJUN	 and	 DICER	
demonstrate	 an	 increase	 in	 expression	 with	 5nm	 of	 Decitabine,	 which	 is	 not	 further	


















To	 test	 this	 hypothesis,	 we	 generated	 AML	 cell	 lines	 silenced	 for	 the	 expression	 of	





cultured	 MUC1	 silenced	 AML	 cells	 with	 healthy	 donor	 PBMCs,	 demonstrating	 a	
significant	 abrogation	 in	 MDSC	 expansion.	 To	 support	 the	 argument	 that	 MUC1	 was	




We	 therefore	 sought	 to	 elucidate	 a	 soluble	 factor	 independent	mechanism	 by	 which	




its	 downstream	 targets	 the	 pro-proliferative	 cyclins	 D2	 and	 E1.	Moreover,	MUC1	 has	
been	 demonstrated	 to	 drive	 c-Myc	 expression	 in	 myeloma	 and	 lung	 cancer	 in	 a	







silencing	did	not	 result	 in	altered	 levels	of	c-Myc	mRNA,	we	 looked	 for	miRNAs	which	
might	mediate	a	post-transcriptional	mechanism	of	c-Myc	regulation.	Using	prediction	
software,	we	identified	miR34a	as	one	of	several	 likely	regulators	of	c-Myc	expression.	
Interestingly,	 miR34a,	 a	 target	 of	 p53,	 has	 been	 shown	 to	 be	 crucially	 involved	 in	
regulating	the	expansion	of	MDSCs24.	We	first	validated	miR34a	as	a	regulator	of	c-Myc	
expression	 by	 over-expressing	 and	 silencing	 miR34a	 in	 AML	 cells,	 demonstrating	






silencing	 resulted	 in	 a	 significant	 upregulation	 of	 tumour	 miR34a	 expression,	 and	
moreover,	 a	 dramatic	 upregulation	 of	 upwards	 of	 200	 fold	 increase	 in	 miR34a	
expression	 in	 AML	 derived	 EVs.	 This	 discordance	 between	 tumour	 and	 EV	 miR34a	
suggests	 that	miR34a	may	 be	 preferentially	 exported	 into	 EVs.	 The	 reasoning	 for	 this	
remains	unclear.	As	miR34a	is	a	tumour	suppressor,	MUC1	silenced	tumour	cells	may	be	
preferentially	 exporting	 miR34a	 as	 a	 means	 of	 disposing	 of	 this	 anti-tumour	 miRNA.	




was	 significantly	 abrogated.	 Subsequently	 miR34a	 expression	 was	 silenced,	 firstly	 in	
MUC1	silenced	THP1	cells,	and	subsequently	 in	miR34a	overexpressing	MOLM14	cells.	
miR34a	 silenced	 AML	 cells	 elicited	 a	 significant	 increase	 in	 MDSC	 expansion.	 In	 this	
study	we	have	demonstrated	that	MUC1	regulates	c-Myc	expression	in	AML	via	a	post-
transcriptional,	miR34a	dependent	mechanism.	




and	 the	 precursor	 pre-miR34a	 transcripts.	 We	 demonstrated	 that	 MUC1	 silencing	
increases	 miR34a	 levels,	 but	 not	 of	 precursor	 pre-miR34a,	 suggesting	 that	 MUC1s	
negative	regulation	of	miR34a	expression	happens	at	the	post-transcriptional	stage.	The	
DICER	 protein	 processes	 pre-miRNAs	 into	mature	 functional	miRNAs	 so	we	 sought	 to	
elucidate	the	effect	of	MUC1	signalling	on	the	expression	of	DICER.	AML	cells	silenced	
for	MUC1	 expression	 and	 AML	 cells	 treated	with	 the	MUC1	 inhibitor	 GO-203,	 or	 the	
control	 compound	 CP3,	 were	 immune-blotted	 for	 the	 DICER	 protein.	 The	 resultant	
immunoblots	demonstrate	that	MUC1	silencing	or	 inhibition	results	 in	a	significant	up-





Argonaut-2	 protein,	 which	 functions	 after	 the	 processing	 of	 pre-miRNA	 to	 mature	
miRNA.	
To	determine	if	MUC1	regulates	DICER	at	the	pre-	or	post-transcriptional	level,	q-PCR	for	




to	 an	 increase	 in	 the	 mRNA	 and	 protein	 levels	 of	 cJUN,	 as	 measured	 by	 qPCR	 and	
immune-blotting,	respectively.	 In	support	of	this	observation,	an	mRNA	array	of	MUC1	
inhibitor	 treated	 primary	 patient	 blasts	 demonstrated	 a	 significant	 increase	 in	 cJUN	
mRNA,	 when	 compared	 to	 control	 peptide	 treated	 cells.	 Furthermore,	 treatment	 of	
MUC1	 silenced	 AML	 cells	 with	 a	 peptide	 inhibitor	 of	 cJUN	 lead	 to	 a	 dose	 dependent	
reduction	in	DICER	expression,	confirming	cJUN	as	a	key	promoter	of	DICER	expression.		
As	there	is	emerging	evidence	that	MUC1	may	repress	gene	transcription	by	acting	as	a	
hyper-methylator503,504,	 we	 finally	 sought	 to	 elucidate	 if	 treatment	 with	 a	
hypomethylating	 agent	 could	 restore	 cJUN	 expression,	 and	 subsequently,	 DICER	








Chapter	 5.	 MDSCs	 can	 be	 targeted	 by	 MUC1	 inhibition,	 or	 by	 the	 use	 of	 a	 novel	
hypomethylation	agent	SGI-110.	
5.1.	Introduction	





represses	 DICER	 expression	 by	 down-regulating	 expression	 of	 the	 AP-1	 family	
transcription	factor	cJUN,	which	normally	drives	DICER	transcription.		
The	 elucidation	 of	 this	 important	 signalling	 pathway	 offers	 several	 possibilities	 for	
targeting	 immune-suppressive	 MDSCs.	 MUC1	 inhibition	 may	 most	 potently	 target	
MDSCs,	 as	 it	 is	 the	most	upstream	 in	 this	pathway,	but	 its	 effects	may	be	more	wide	
spread	and	not	just	specific	to	MDSC	targeting.	Similarly,	restoring	cJUN	expression	via	
the	 delivery	 of	 a	 recombinant	 protein	 offers	 another	 possibility,	 although	would	 also	
have	many	other	off-target	effects	as	cJUN	can	act	as	a	proto-oncogene505	causing	pro-
tumourigenic	 effects.	 Restoring	 DICER	 expression	 may	 increase	 anti-tumour	 miRNAs	
such	 as	 miR34a,	 thereby	 targeting	 MDSCs,	 but	 the	 DICER	 protein	 is	 very	 large	
(>220kDA),	rending	delivery	into	cells	functionally	challenging.	The	direct	restoration	of	
miR34a	 expression,	 via	 the	 delivery	 of	 recombinant	 miR34a,	 offers	 a	 more	 targeted	
approach	 to	 reduce	 MDSC	 expansion,	 although	 this	 will	 also	 have	 anti-proliferative	
effects	on	AML	cells,	as	described	in	Chapter	4.	
We	 decided	 to	 first	 attempt	 targeting	 MDSCs	 using	 MUC1	 inhibition,	 with	 the	
acceptance	that	the	effects	of	MUC1	inhibition	are	many,	and	some	will	be	not	specific	
to	MDSC	expansion.	While	high	doses	of	 the	MUC1	 inhibitor	GO-203	are	toxic	 to	AML	







Our	 previous	 work	 exploring	 the	 regulation	 of	 DICER	 expression	 (See	 Chapter	 4),	
demonstrated	 that	 DICER	 expression	 was	 both	 transcriptionally	 regulated,	 by	 the	
transcription	factor	cJUN,	and	also	epigenetically	regulated,	as	treatment	with	sub-lethal	
doses	of	the	hypomethylating	agent	decitabine,	was	shown	to	increase,	both	cJUN	and	
DICER	 expression	 in	 AML	 cells.	 This	 is	 in	 keeping	with	 published	work	 demonstrating	
that	 Histone	 deacetylase	 Inhibition	 increased	DICER	 expression	 in	 T	 cell	 leukaemia506.	
The	 caveat	 to	 these	 statements	 is	 that	 hypomethylation	may	 only	 indirectly	 increase	
DICER	expression,	 solely	via	 its	effect	on	cJUN	expression.	There	 is	emerging	evidence	
that	MUC1	may	be	 involved	 in	 the	hyper-methylation	of	 cancer	 cells503,504,	 raising	 the	
possibility	 that	 MUC1	 regulates	 the	 expression	 of	 DICER	 by	 both	 transcriptional	 and	
post-transcriptional	mechanisms.		
We	 therefore	 hypothesized	 that	 treatment	 with	 hypomethylating	 agents	 might	 also	
target	MDSCs,	as	part	of	their	panel	of	immune	modulatory	effects.	Supporting	evidence	




fit	 enough	 for	 conventional	 cytotoxic	 therapy.	 However,	 the	 half-life	 of	 decitabine	 is	
extremely	 short	 at	 15-25	 minutes508,	 due	 to	 rapid	 inactivation	 by	 liver	 cytidine	
deaminase,	and	the	dosing	schedule	in	humans	ranges	from	every	8	hours,	to	once	daily	
infusions.	 Second-generation	DNMT	 inhibitors	 have	 been	 developed	 such	 as	 the	 drug	
SGI-110,	 designed	 to	 enhance	 the	 efficacy	 of	 decitabine	 by	 combining	 it	 with	








In	 the	present	study	we	sought	 to	 target	MDSCs	using	MUC1	 inhibition	 in	vitro	and	 in	




To	 achieve	MUC1	 inhibition,	 we	 used	 the	 cell-penetrating	 peptide	 inhibitor	 (GO-203)	
which	 blocks	 the	 MUC1-C	 CQC	 motif	 and	 inhibit	 MUC1-C	 homodimerization131.	 To	
achieve	 a	 longer	 half-life	 in	 in	 vivo	 settings,	 GO-203	 was	 obtained	 pre-packaged	 in	 a	
nano-particle	formulation.		
On	day	1,	1x105	GFP	tagged	C1498	(TIB-49)	(C57BL/6	syngeneic)	murine	AML	cells	were	
injected	 retro-orbitally	 into	 C57BL/6	 mice	 (Jackson	 Laboratories,	 Bar	 Harbor,	 ME).	
Simultaneously,	mice	to	be	treated	with	GO-203	received	one	 intra-peritoneal	dose	of	
15mg/kg	of	GO-203	nano-particles.	At	day	14,	all	mice	were	euthanized.	Bone	marrow	
cells	were	 flushed	 from	 the	 femur	bone	marrow	 cavity	 into	 sterile	RPMI	1640	media.		
Spleens	were	emulsified	to	obtain	a	cell	suspension.	BM	and	spleen	cells	were	washed	







visible	 orbital	 tumour	 (chloroma)	 development.	Mice	 commenced	 daily	 subcutaneous	
treatments,	for	three	days,	of	1mg/kg	SGI-110	or	just	the	diluent	as	a	control	treatment.	






cells	were	 flushed	 from	 the	 femur	bone	marrow	 cavity	 into	 sterile	RPMI	1640	media.		
Spleens	were	emulsified	to	obtain	a	cell	suspension.		BM	and	spleen	cells	were	washed	





MUC1	 inhibition	 using	 a	 cell	 penetrating	 peptide	 GO-203,	 inhibits	 the	 expansion	 of	
MDSCs	in	vitro	and	in	vivo	
	
MOLM-14	 and	 THP-1	 AML	 cells	 were	 treated	 with	 a	 sub-lethal	 dose	 of	 the	 MUC1	
inhibitor	 GO-203	 or	 control	 peptide	 CP3	 and	 co-cultured	 with	 healthy	 donor	 PBMCs.	
Treating	 AML	 cells	 with	 GO-203	 lead	 to	 a	 significantly	 reduced	 expansion	 of	 MDSCs	
compared	 to	 control	 (Figure	 29	 A).	 Subsequently,	 immune-competent	 mice	 were	
injected	with	murine	AML	cells	 TIB-49	and	 simultaneously	either	a	 single	dose	of	GO-
203,	or	PBS.	At	day	14,	all	mice	were	euthanized	and	their	femurs	were	assessed	by	flow	
cytometry	 for	 bone	marrow	 engraftment	 and	MDSC	 burden.	 Figure	 29	 B	 shows	 that	











MOLM-14	 and	 THP-1	AML	 cells	were	 treated	with	 a	 sub-lethal	 dose	 of	GO-203,	 1um,	
once	 daily	 for	 three	 days,	 based	 on	 dose	 curves	 (Appendix	 1).	 After	 three	 days,	 cells	



















































PBMCs,	 as	 previously	 described.	 After	 five	 days,	 MDSCs	 in	 the	 PBMC	 fraction	 were	
quantified	by	flow	cytometry,	demonstrating	that	the	treatment	of	AML	cells	with	GO-
203	 inhibits	 the	 expansion	 of	 MDSCs	 (A)	 (n=3).	 C57BL/6	 mice	 were	 retro-orbitally	
injected	 with	 1x105	 GFP	 tagged	 C1498	 (TIB-49)	 cells	 and	 concurrently	 given	 one	
subcutaneous	dose	of	GO-203,	 or	 PBS.	At	 day	 14,	 all	mice	were	 euthanized	 and	 their	






THP-1	 and	 MOLM-14	 cells	 were	 treated	 with	 SGI-110	 or	 control	 (diluent)	 and	 co-
cultured	 with	 healthy	 donor	 PBMCs.	 Treating	 AML	 cells	 with	 SGI-110	 lead	 to	 a	
statistically	significant	reduction	in	expansion	of	MDSCs	compared	to	control	(Figure	30).		
	
Figure	 30.	 The	 hypomethylating	 agent	 SGI-110	 inhibits	 the	 expansion	 of	 MDSCs	 in	































out	 period,	 cells	 were	 washed,	 irradiated,	 fluorescently	 tagged	 and	 co-cultured	 with	
healthy	 donor	 PBMCs,	 as	 previously	 described.	 After	 five	 days,	 MDSCs	 in	 the	 PBMC	
fraction	were	quantified	by	flow	cytometry	(n=3).	














Control	 TIB-49	 Control	 TIB-49	
Control	 Diluent	 SGI-110	 Control	 Diluent	 SGI-110	
























































C57BL/6	 mice	 were	 retro-orbitally	 injected	 with	 1x105	 GFP	 tagged	 C1498	 (TIB-49)	
murine	AML	cells.	At	day	12,	mice	commenced	daily	subcutaneous	dosing	of	SGI-110,	at	
1mg/kg	 SGI-110	 or	 diluent	 as	 a	 control	 treatment	 for	 3	 days.	 Cohorts	 of	 mice	 were	
euthanized	at	day	12	 (before	commencing	 treatment),	day	16	 (one	day	after	 finishing	





























































































In	 the	 present	 study	 we	 have	 demonstrated	 that	 MUC1	 inhibition	 using	 a	 novel	 cell	













began	 to	 fall.	 This	 suggests	 a	 more	 direct	 effect	 of	 hypomethylation	 on	 MDSCs,	
independent	 of	 tumour	 burden,	 and	 might	 lead	 us	 to	 hypothesize	 that	 the	 trend	
towards	a	reduction	in	tumour	burden	in	SGI-110	treated	animals	seen	at	day	19,	might	






Tumour	 cells	 promote	 an	 immunosuppressive	 milieu	 that	 inhibits	 intrinsic	 immune	
effectors	 and	 promotes	 the	 growth	 of	 disease509.	 Immature	 myeloid	 cells	 such	 as	
Myeloid-derived	Suppressor	Cells	(MDSCs)	have	potent	immune	supressing	activity	and	
play	 a	 critical	 role	 in	 creating	 the	 immunosuppressive	 milieu	 of	 the	 tumour	
microenvironment30.		MDSCs	modulate	the	interactions	between	immune	effector	cells	
and	malignant	cells	resulting	in	tumour	progression510,	poor	outcomes266,	and	decreased	
effectiveness	 of	 immunotherapeutic	 strategies511.	 MDSCs	 have	 been	 identified	 in	
healthy	 patients512	 but	 have	 been	 demonstrated	 to	 be	 ubiquitously	 raised	 in	 patients	
with	 solid	 malignancies513	 and	 various	 inflammatory514	 and	 pre-malignant	
conditions216,515.		
In	contrast	to	solid	tumours,	little	is	known	about	MDSC	populations	or	their	function	in	
Acute	 Myeloid	 Leukaemia	 (AML).	 AML	 is	 an	 interesting	 setting	 to	 study	 immature	
myeloid	cells,	given	that	AML	blasts	themselves	result	from	the	early	maturation	arrest	
of	the	myeloid	lineage.	Furthermore,	it	has	been	suggested	that	AML	blasts	exert	their	
suppressive	 effects	 on	 T	 cells	 via	 a	 similar	 Arginase-1	 dependent	 mechanism	 to	
MDSCs275.	 These	 observations	 lead	 us	 to	 investigate	 the	 presence	 and	 importance	 of	
MDSCs	in	AML	and	the	critical	pathways	underlying	their	accumulation	and	function.	
	
In	 the	 present	 study,	 AML	 blasts	 directed	 the	 differentiation	 of	 healthy	 donor	 PB	
mononuclear	 cells	 towards	 a	 cell	 with	 the	 MDSC	 phenotype	 (CD11b+,	 HLADRlow/-,	








While	these	 findings	are	certainly	 interesting,	 the	model	of	co-culturing	healthy	donor	
PB	mononuclear	cells	with	allogeneic	AML	cells	from	cells	lines	or	patients	with	AML	has	
some	 significant	 limitations.	 While	 cell	 contact	 independent	 and	 cytokine	 driven	
interactions	 may	 not	 require	 a	 cell	 autologous	 system,	 one	 could	 imagine	 that	 cell	
contact	dependent	 interactions,	 such	as	we	report,	may	have	a	 requirement	 for	some	
level	 of	 recognition	 of	 self	 or	 non	 self	 for	 the	 full	 scale	 of	 their	 interaction	 to	 be	





remission.	Moreover,	 the	majority	of	patients	who	enter	a	 true	 cytogenetic	 remission	
then	 undergo	 allogeneic	 transplantation	 before	 their	 counts	 recover,	 rendering	 an	
autologous	system,	now	an	allogeneic	one.	As	such,	 the	allogeneic	 in	vitro	model	 that	
we	 used	 for	 studying	MDSCs	 has	 been	 previously	 published	 in	 other	 disease	 settings,	
and	our	 findings	were	 in	 keeping	with	other	 groups,	who	have	 reported	expansion	of	
MDSCs	in	similar	co-cultures256.	In	an	effort	to	replicate	a	more	physiologically	relevant	
autologous	 system,	 we	 studied	 the	 effects	 of	 engraftment	 of	 syngeneic	 AML	 in	 an	
immune	competent	mouse	model,	demonstrating	a	significant	expansion	of	MDSCs.	 In	
this	 model,	 both	 myeloid	 compartment	 and	 tumour	 cells	 are	 autologous,	 and	 their	
interaction	takes	place	in	the	BM	and	spleen,	where	AML	cells	home.	This	most	closely	




cells	 into	 the	mouse,	 by	 retro-orbital	 injection	 in	our	model,	must	 be	 associated	with	
















some	 in	 vivo	 experiments.	 However,	 in	 our	 experiments,	 the	 engraftment	 of	 AML	
resulted	in	a	significant	expansion	of	MDSCs	that	was	seen	in	all	successfully	engrafted	
mice,	suggesting	that	this	potential	limitation	did	not	affect	these	experiments.		
We	have	 identified	MUC1	as	a	uniquely	 important	oncoprotein	 in	AML	and	AML	stem	
cells	 that	 exerts	 immunomodulatory	 effects128.	We	 have	 demonstrated	 that	MUC1	 is	




silencing	 in	 AML,	 blunts	 the	 expansion	 of	 MDSCs	 in	 vitro.	 We	 have	 generated	 a	 cell	
penetrating	peptide,	GO-203,	 that	disrupts	dimerization	of	 the	 intracellular	portion	of	
MUC1-C,	 preventing	 its	 translocation	 to	 the	 nucleus	 which	 is	 critical	 for	 downstream	
signalling.	 	 Treatment	with	 the	MUC1-C	 inhibitor	GO-203	 results	 in	 a	dose	dependent	
killing	of	MUC1	expressing	cells,	including	AML	cells129.	Our	finding	that	MUC1	silencing	
partly	abrogates	expansion	of	MDSCs	in	vitro,	suggests	that	treating	patients	with	MUC1	
inhibition,	 might	 lead	 to	 a	 multi-mechanistic	 therapeutic	 benefit,	 killing	 MUC1	
expressing	 tumour	 cells	 and	 simultaneously	 disrupting	 mechanisms	 that	 lead	 to	 the	





have	 commenced	 a	 phase	 I/II	 trial	 of	 GO-203	 in	 the	 setting	 of	 relapsed-refractory	
AML517.		
Extracellular	 vesicles	 (EVs)	 are	 lipid	 membrane	 bound	 vesicles	 released	 by	 cells	 and	
mediating	inter-cellular	communication.	It	has	previously	been	demonstrated	that	AML	
cells	 release	 membrane	 bound	 extracellular	 vesicles412,414,416,436,	 which	 transport	
microRNAs415,	 mRNAs416,	 cytokines414	 and	 tumour-derived	 proteins412	 to	 surrounding	
cells.	In	AML,	EVs	were	shown	to	export	to	bystander	cells	and	modify	their	function	in	a	
mRNA	 and	miRNA	 dependent	 fashion416.	 In	 addition,	 it	 has	 been	 shown	 in	 a	 murine	
model	of	breast	cancer	that	 tumour	EVs	skew	the	BM	micro-environment	 in	 favour	of	
MDSC	accumulation272	a	mechanism	dependent	on	EV	inflammatory	cytokine	cargo.	In	
this	 study	 we	 have	 demonstrated	 that	 AML	 EVs	 alter	 the	 tumour	 microenvironment	
away	from	antigen	presentation	capable	dendritic	cells	and	towards	immature	immune	
suppressive	MDSCs.	AML	EV	passage	was	mostly	abrogated	by	using	a	0.4µM	Transwell	
dish,	 which	 is	 in	 keeping	 with	 our	 previous	 observation	 that	 MDSC	 expansion	 was	
abrogated	in	Transwell.		
The	 field	 of	 EV	 research	 is	 fraught	 with	 controversies	 that	 may	 influence	 how	 we	
interpret	 these	 experiments.	 Firstly,	 are	 what	 we	 are	 terming	 EVs	 actually	 EVs?	 The	
method	 of	 isolation	 of	 membrane	 bound	 vesicles	 can	 influence	 the	 contents	 of	 the	
resultant	 fraction	 heavily.	 For	 example,	 in	 some	 of	 our	 experiments	 EVs	 were	
precipitated	out	of	solution	by	SystemBio’s	ExoQuick444.	This	precipitation	method	can	
be	somewhat	non-specific	due	to	the	co-precipitation	of	other	proteins	and	cell	debris.	
It	 is	 therefore	 possible	 that	 the	 expansion	 of	MDSCs	 seen	 upon	 co-culture	 of	 healthy	
donor	PBMCs	and	AML	EVs,	could	be	due	to	a	non-EV	contained	protein.	To	control	for	










al,	 drug	 resistance	 AML	 cells	 secreted	 vesicles	 carrying	 anti-apoptotic	 proteins	 which	
were	taken	up	by	drug	sensitive	clones,	suggesting	TEVs	represent	a	mechanism	of	the	
propagation	 of	 therapeutic	 resistance440.	 This	 would	 suggest	 that	 EVs	 are	 indeed	 a	
biological	relevant	entity.	As	such,	the	pro-MDSC	effects	of	EVs	we	have	seen	in	our	 in	
vitro	experiments	may	well	be	able	to	be	extrapolated	to	patients	with	malignancies.	
We	 subsequently	 investigated	 how	 MUC1	 signalling,	 necessary	 for	 the	 expansion	 of	
MDSCs,	might	alter	AML	extracellular	vesicles	composition.	We	evaluated	AML	EVs	for	
the	presence	of	 the	pro-proliferative	oncoprotein	c-Myc	demonstrating	 that	AML	cells	
secrete	 c-Myc	 containing	 EVs	 in	 a	MUC1	 dependent	mechanism.	 Furthermore,	MUC1	
and	 c-Myc	 containing	 EVs	 led	 to	 an	 up-regulation	 of	 the	 c-Myc	 downstream	 targets	
cyclin	D2	and	cyclin	E1	in	co-cultured	MDSCs,	indicating	that	c-Myc	containing	EVs	may	
drive	MDSC	 proliferation.	 Critically,	 EVs	 from	MUC1	 silenced	 AML	 cells	 failed	 to	 elicit	
this	increase	in	c-Myc	and	cyclin	D2	and	E1	expression	in	EV	exposed	MDSCs.		
We	then	sought	to	determine	how	MUC1	signalling	promotes	c-Myc	signalling	in	AML.	
Micro	 RNAs	 are	 small	 non-encoding	 RNA	 molecules	 involved	 in	 post-translational	
regulation	of	 gene	expression.	miR34a,	 a	 known	p53	 inhibitor,	has	been	 implicated	 in	
regulating	the	expansion	of	MDSCs286	and	it	is	known	that	tumour	cells	suppress	miR34a	
expression	 as	 part	 of	 their	 self-protective	 armoury518.	 Furthermore,	 miR34a	 is	 a	
predicted	negative	regulator	of	c-Myc,	due	to	a	complementary	sequence	for	miR34a	in	
the	c-Myc	promoter	region.		
In	 the	present	 study,	we	have	demonstrated	 that	MUC1	 silencing	 results	 in	 increased	
expression	of	miRNA34a.	Furthermore,	over-expression	of	miR34a	in	AML	cells	led	to	a	
dramatic	 down-regulation	 of	 c-Myc,	 and	 conversely	 silencing	 of	 miR34a	 led	 to	 a	
significant	up-regulation	of	 c-Myc	expression,	 confirming	 that	miR34a	 regulates	 c-Myc	
expression	in	AML.	
One	 potential	 caveat	 to	 these	 experiments	 is	 the	 controversy	 over	 how	 biologically	





artificially	 forcing	 the	 silencing	 or	 over-expression	 of	 miRNAs	 in	 vitro,	 can	 lead	 to	
significant	 translational	changes	 in	downstream	protein	expression,	 the	activity	of	 this	







granulopoesis520.	Although	 the	authors	do	not	 investigate	 this	 importance	of	 c-Myc	 in	
this	pathway,	 they	do	comment	 that	c-Myc	 is	known	to	block	 the	 function	of	C/EBPα,	
which	was	critical	for	differentiation	in	this	pathway.		
To	confirm	miR34a	as	a	critical	negative	regulator	of	MDSC	expansion,	miR34a	altered	




study	 illustrates	a	hitherto	un-described	 role	of	 the	MUC1	oncoprotein	 in	 suppressing	
mechanisms	that	would	otherwise	regulate	MDSC	proliferation	and	expansion.		
In	 the	 present	 study	 we	 have	 shown	 that	 patients	 with	 active	 AML	 have	 increased	
numbers	 of	 circulating	 immune	 suppressive	MDSCs.	 The	main	 difficulty	 in	 conducting	
these	experiments	was	 the	 lack	of	 cell	makers	 that	 can	differentiate	an	MDSC	 from	a	
leukaemic	 blast.	 For	 the	 purposes	 of	 these	 studies,	 patients	were	 selected	 for	whom	
clinical	flow	cytometric	analysis	had	determined	a	phenotype	for	the	majority	of	blasts	
that	 could	 differentiate	 them	 from	 CD33+	 HLADR-	 CD11b+	 monocytic	 (CD15-)	 or	
granulocytic	 (CD15+)	 MDSCs.	 As	 an	 example,	 an	 AML	 sample	 was	 determined	 to	 be	
>99%	 strongly	 HLADR+,	 which	 is	 sufficiently	 different	 from	 CD33+	 HLADR-	 CD11b+	






populations,	 or	 that	 there	 were	 no	 differentiating	 markers.	 Moreover,	 the	
heterogeneity	of	some	samples	means	that	some	“MDSCs”,	may	in	fact	be	sub-clones	of	
the	AML,	which	have	acquired	different	cell	surface	markers.	In	an	attempt	to	overcome	
this,	 we	 were	 very	 stringent	 about	 the	 samples	 used	 in	 analysis,	 and	 heterogeneous	





by	 flow	 cytometric	 sorting	 were	 interrogated	 for	 the	 presence	 of	 cytogenetic	 or	
molecular	 abnormalities	 that	 had	 previously	 been	 identified	 in	 the	 leukaemic	 clone.	
These	studies	demonstrated	diversity	with	respect	to	the	origin	of	the	MDSC	population	
suggesting	they	do	not	exclusively	arise	from	the	leukaemic	clone.	In	a	patient	with	AML	
cells	 exhibiting	 3	 cytogenetic	 abnormalities,	 (del7,	 del20,	 and	 trisomy	 8),	 MDSCs	
expressed	 only	 del	 7	 and	 del20	 suggesting	 a	 common	 clonal	 origin	 with	 leukaemic	
precursor	prior	 to	 the	attainment	of	 the	 trisomy	8	mutation.	 In	a	 second	patient	with	
del7	AML,	only	50%	of	the	MDSCs	exhibited	the	cytogenetic	abnormality	consistent	with	
mixed	 derivation	 from	 malignant	 and	 non-malignant	 myeloid	 precursors.	 In	 a	 third	
patient	with	AML	 cells	 characterized	 by	 a	NPM1	mutation,	 the	MDSC	population	was	
found	to	have	the	wild	type	form	of	NPM1	consistent	with	their	lack	of	common	clonal	
derivation	with	the	AML	population.		These	studies	suggest	that	MDSC	expansion	in	the	
AML	microenvironment	 is	 not	 a	 reflection	of	myeloid	differentiation	of	 the	 leukaemic	
clone	 but	 rather	 appears	 to	 be	 an	 effect	 on	myeloid	 cells	 in	 the	 bone	marrow	 niche	
irrespective	of	their	derivation.		
The	main	difficulty	in	conducting	these	experiments	was	the	lack	of	cell	makers	that	can	
differentiate	 an	 MDSC	 from	 a	 leukaemic	 blast	 as	 described	 above.	 As	 AML	 can	





fact	 a	 sub-clone	 of	 the	 leukaemic	 cells,	 which	 had	 further	 differentiated	 into	 a	more	
mature	CD15+	and	granulocytic	phenotype.	However	the	results	from	the	first	patient,	
who’s	MDSCs	harboured	in	fact	one	fewer	cytogenetic	abnormality	than	the	leukaemic	




with	 the	AML	population.	As	NPM1	 is	 considered	a	 founder	mutation,	 it	 seems	highly	
unlikely	 that	 the	 CD15+	 MDSCs	 could	 be	 a	 leukaemic	 sub-clone	 that	 had	 somehow	
regained	NPM1	wildtype	status.		
The	second	patient,	who’s	MDSCs	appeared	to	be	a	mixed	population	of	clonally	related	





very	 different	 populations,	 which	 may	 be	 variably	 suppressive	 and	 as	 such,	 not	 true	
MDSCs.	 Ideally,	 in	 this	patient	one	would	attempt	 to	 isolate	and	 functionally	compare	




While	 it	 has	 been	 reported	 that	 MDSCs	 are	 ubiquitously	 expanded	 in	 patients	 with	
cancer30,	 including	 Renal	 Carcinoma220;	 Melanoma237;	 Prostate238;	 Hepatocellular	
Carcinoma239;	Head	and	neck	cancer240;	Rectal	Cancer92;	Colon	and	Breast	Carcinoma241;	
Glioma242;	 Pancreatic243	 and	 Non-small	 cell	 lung	 cancer244,	 this	 is	 the	 first	 report	





comprised	 of	 both	 monocytic	 and	 granulocytic	 subsets,	 in	 keeping	 with	 the	 most	
commonly	reported	phenotypes	of	these	cells	in	other	human	cancer	settings.		
However,	the	results	of	examining	the	clonality	of	MDSCs	demonstrated	that	in	one	of	
the	 two	 patients	 who	 had	 AML	 with	 antecedent	 MDS,	 the	 MDSCs	 appeared	 to	 be	
clonally	related	to	the	underlying	MDS	clone,	and	not	the	dominant	AML	clone.	This	is	in	
contrast	to	previous	work	published	in	patients	with	MDS216,	whereby	the	MDSCs	were	
all	 clonally	 distinct	 from	 the	MDS	 clone.	 This	 disparity	 could	 be	 due	 to	 a	 number	 of	
reasons.	 Firstly,	 it	 is	 possible	 that	 the	 given	 our	 small	 sample	 size,	 that	 our	 clonality	
results	 could	be	 incorrect	 and	due	 to	 a	 technical	 issue	 in	 separating	MDSCs,	 and	 that	
subsequent	 experiments	 may	 yield	 conflicting	 results.	 Secondly,	 it	 may	 be	 that	 the	
published	MDS	study	with	a	sample	size	of	just	5	patients,	did	not	capture	the	full	range	
of	this	heterogeneous	disease,	and	it	may	be	that	some	patients	have	clonally	related,	





MDSC	 expansion	 was	 abrogated	 in	 Transwell	 experiments,	 suggesting	 that	 the	
mechanism	for	MDSC	expansion	was	not	due	to	soluble	factors.	This	is	in	stark	contrast	
to	 the	 body	 of	 work	 in	 multiple	 other	 solid	 and	 haematological	 malignancies,	 where	
inflammatory	 cytokines	 have	 been	 implicated	 as	 the	 main	 mechanism	 of	 tumour	
induced	MDSC	expansion.	 In	the	present	study,	we	have	demonstrated	 in	vitro	 that	 in	
AML,	 the	 release	 of	 EVs,	 whose	 passage	 is	 abrogated	 in	 Transwell,	 mediates	 MDSC	
expansion.	There	have	been,	however,	 several	 recent	 reports	of	extra-cellular	 vesicles	
mediating	MDSC	expansion,	in	both	Breast	Cancer272	and	in	Melanoma273	and	it	may	be	






After	 demonstrating	 that	 MUC1	 mediates	 MDSC	 expansion	 by	 exporting	 c-Myc	
containing	EVs	to	nearby	cells,	we	sought	to	elucidate	the	mechanism	by	which	MUC1	
signalling	 regulates	 c-Myc	expression.	We	have	demonstrated	 that	MUC1	 regulates	 c-
Myc	 expression	 in	AML	 cells,	 and	 EVs	 derived	 from	 those	 cells,	 by	 repressing	miR34a	







may	 regulates	 both	 c-Myc	 expression	 and	 TGF-B	 secretion	 in	 AML,	 but	 only	 c-Myc	 is	






pri-miRNAs	which	 are	processed	 in	 the	nucleus	by	 the	RNAse	 III	 enzymes	Drosha	 and	
PASHA	 into	 pre-miRNAs	 of	 roughly	 70-nucleotides	 in	 length.	 The	 pre-miRNAs	 are	
exported	 into	 the	 cytoplasm	 and	 undergo	 processing	 by	 the	 RNAse	 III	 enzyme	 Dicer	
generating	the	final	mature	miRNA,	which	consists	of	double-stranded	RNA	of	roughly	




target	mRNA	 strand	 complementary	 to	 their	 bound	miRNA36.	We	 interrogated	MUC1	







of	 the	 transcription	 factor	 c-JUN.	 	 Given	 the	 observed	 effect	 of	 MUC1	 on	 miRNA	
processing	machinery	we	sought	to	determine	if	multiple	miRNA	species	were	affected	
by	MUC1	 regulation	of	DICER	expression.	 Indeed	miRNA	array	of	MUC1	 silenced	AML	
cell	 lines	MOLM-14	and	THP-1	demonstrated	an	 increase	 in	 the	majority	of	mRNAs	 in	
AML	cells,	reaching	Bonferroni-corrected	significance	in	a	subset.		
These	 data	 raise	 many	 interesting	 questions.	 Firstly,	 it	 is	 known	 that	 DICER	 activity	
mediates	maturation	of	miRNA	 in	all	but	one	known	miRNAs	 (miR-451).	As	 such,	why	
does	the	increase	in	DICER	expression	seen	upon	MUC1	silencing	only	increase	a	subset	
of	 miRNAs	 arrayed,	 and	 not	 all	 except	 miR-451,	 whose	 maturation	 is	 dependent	 on	
Argonaut2	alone521?	The	answer	may	 lie	 in	 the	 technical	 limitations	of	 the	microarray	
used.	The	calculation	of	fold	change	in	miRNA	expression	and	the	testing	of	the	change	





observations	 must	 be	 validated	 with	 quantitative	 PCR	 and	 functional	 tests	 of	 miRNA	
activity,	such	as	with	luciferase	based	reporter	assays.	While	it	was	beyond	the	scope	of	
this	 study	 to	 perform	qPCR	 and	 reporter	 assays	 on	 800+	miRNAs,	 the	 broad	 trend	 of	
miRNAs	increasing	upon	MUC1	silencing	is	most	provocative.		
Interestingly,	 while	 the	 levels	 of	 miR-451	 were	 unchanged	 upon	 MUC1	 silencing	 of	
MOLM-14	 cells,	 they	 were	 significantly	 increased	 in	 MUC1	 silenced	 THP-1	 cells,	
compared	to	control.	 If	miR-451	were	truly	DICER	 independent,	one	would	expect	 the	
expression	to	remain	unchanged	upon	MUC1	silencing.	While	it	is	possible	reports	of	its	
DICER-independent	 processing	may	 be	 flawed,	 another	 explanation	 is	 that	miR-451	 is	
also	 epigenetically	 regulated.	 There	 is	 increasing	 evidence	 that	 MUC1	 is	 involved	 in	











and	 DICER	 expression,	 we	 treated	 AML	 cells	 with	 a	 sub-lethal	 dose	 of	 the	 HMA	
Decitabine,	 and	 observed	 an	 increase	 in	 the	 expression	 of	 cJUN	 and	 DICER	 with	 a	
resultant	 reduction	 in	 c-Myc	 expression.	 We	 may	 infer	 that	 the	 reduction	 of	 c-Myc	
















We	 subsequently	 demonstrated	 that	 hypomethylation	 using	 a	 novel	 hypomethylating	
agent	SGI-110,	significantly	reduces	the	AML	induced	expansion	of	MDSCs.	Indeed,	the	













major	 area	 of	 investigation	 lies	 in	 developing	 novel	 immunotherapeutic	 strategies	 to	
selectively	target	the	tumour	cell.	Elucidating	the	role	of	MDSCs	in	AML	may	further	our	
understanding	 of	 the	 critical	 molecular	 pathways	 that	 hamper	 immune	 responses	 to	
immunotherapy.	In	the	present	study	we	have	demonstrated	that	MDSCs	are	expanded	
in	patients	with	AML	and	contribute	to	tumour	related	 immune	suppression.	We	have	
shown	 that	 the	MUC1	 oncoprotein	 is	 a	 critical	mediator	 of	MDSC	 expansion,	 via	 the	
promotion	 of	 c-Myc	 expression	 in	 secreted	 EVs.	 Finally	 we	 demonstrate	 that	 MUC1	
regulation	of	 c-Myc	 is	mediated	by	 the	 repression	of	 the	maturation	of	 the	microRNA	
miR34a,	occurring	via	the	down-regulation	of	DICER	expression.	MUC1s	effect	on	DICER	
expression	 results	 in	 a	 global	 down-regulation	 of	 miRNA-genesis,	 mediated	 by	
transcription	and	epigenetic	effects.		
Strategies	 that	 combine	 tumour-specific	 targeting	 while	 simultaneously	 reversing	 the	
immune	 suppressive	milieu,	 for	example	by	 targeting	MDSCs,	 represent	an	 innovative	





In	 the	 last	 chapter	 we	 demonstrated	 that	 hypomethylation	 using	 a	 novel	
hypomethylating	 agent	 SGI-110,	 significantly	 reduces	 the	 AML	 induced	 expansion	 of	
MDSCs	 in	 vitro	 and	 in	 vivo.	 Furthermore,	 in	 the	 in	 vivo	model	 of	murine	 AML,	MDSC	




immune	 suppressive	 MDSCs,	 perhaps	 leading	 to	 greater	 immune	 cell	 mediated	 anti-
tumour	cytotoxicity.	To	investigate	this	hypothesis,	the	same	murine	experiment	will	be	





see	 if	 tumour	 depletion	 then	 occurs.	 However	 if	 SGI-110	 causes	 the	 same	 pattern	 of	
MDSC	depletion	 followed	 by	 tumour	 depletion	 in	NSG	mice,	 then	we	might	 conclude	
that	the	effect	of	SGI-110	is	purely	cytotoxic	and	MDSCs	are	more	sensitive	to	this	and	
are	depleted	earlier	 than	AML	 cells.	 Further	 studies	will	 also	be	performed	 to	 look	 at	
DICER	 and	 miRNA	 expression	 in	 AML	 cells	 harvested	 from	 SGI-110	 treated	 tumour	
bearing	mice,	 to	 determine	 if	DICER	up-regulation	 is	 the	 critical	mediator	 of	 the	 anti-
tumour	and	anti-MDSC	effects	of	hypomethylation	with	SGI-110.	
	
Lastly,	 synergy	 studies,	 combining	 targeting	 of	 tumour	 cells	 with	 immune	 based	
therapies	and	depleting	MDSCs	will	be	undertaken	to	determine	if	targeting	MDSCs	can	
improve	 responses	 to	 immune	 based	 therapies.	 Our	 group	 has	 developed	 a	 novel	
dendritic	cell	(DC)	AML	cell	fusion	vaccine	in	which	patient	derived	leukaemia	cells	are	
fused	 with	 autologous	 dendritic	 cells	 such	 that	 a	 broad	 array	 of	 tumour	 associated	







dramatic	 induction	 of	 leukaemia	 specific	 immunity,	 as	 measured	 by	 a	 mean	 fold	
increase	 of	 CD4	 and	 CD8	 cells	 expressing	 IFN-γ	 in	 response	 to	 ex	 vivo	 exposure	 to	
autologous	 leukaemia	 cell	 lysates	 and	 the	 associated	 expansion	 of	 T	 cells	 in	 the	
peripheral	 blood	 and	 bone	marrow	 targeting	 the	 AML	 antigens	MUC1,	WT1	 and	 Pr1.	
Remarkably,	 despite	 an	 average	 age	 of	 61,	 75%	 of	 patients	 (12/16)	 undergoing	
vaccination	remain	 in	sustained	remission	with	a	median	follow	up	of	33	months.	 	We	
hypothesize	 that	 suppression	 of	 MDSC	 expansion	 in	 AML	 will	 help	 to	 reverse	 the	
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Antibody	 Clone	 Isotype	 Company	 Catalogue	No.		
CD11b-APCCy7	 M1/70	 Rat	IgG2b,	κ	 Biolegend	 101226	
CD33-PE	 P67.6	 Mouse	IgG1,	κ	 BDBioScience	 340679	
HLADR-FITC	 L243	 IgG2,	κ	 BDBioScience	 347363	
CD14-PB	 HCD14	 Mouse	IgG1,	κ	 Biolegend	 325615	
CD15-APC	 HI98	 Mouse	IgM,	κ	 Biolegend	 301907	
mGr1-APC	 RB6-8C5	 Rat	IgG2b,	κ	 Biolegend	 108411	
CD3-FITC	 UCHT1	 Mouse	 IgG1,	
kappa	
eBioscience	 11-0038-41	
CD69-PE		 L78	 Mouse	IgG1,	κ	 BDBioScience	 341652	
CD25-FITC	 2A3	 Mouse	IgG1,	κ	 BDBioScience	 340694	
CD4-PB	 GK1.5	 Rat	IgG2b,	κ	 Biolegend	 100438	
CD8-FITC	 SK1	 Mouse	IgG1,	κ	 eBioscience	 9011-0087	















c-Myc	 Y69	 Rabbit	IgG	 Abcam	 32072	
CD63	 EPR5702	 Rabbit	IgG	 Abcam	 ab134045	
B-actin	 D6A8	 Rabbit	IgG	 Cell	Signalling	 8457S	
Cyclin	E1	 HE12	 Mouse	IgG1	 Cell	Signalling	 4129P	
Cyclin	D2	 D52F9	 Rabbit	IgG	 Cell	Signalling	 3741S	
GAPDH	 14C10	 Rabbit	IgG	 Cell	Signalling	 2118S	
DICER	 D38E7	 Rabbit	IgG	 Cell	Signalling	 5362	
Argo2	 C34C6	 Rabbit	IgG	 Cell	Signalling	 2897P	
cJUN	 60A8	 Rabbit	IgG	 Cell	Signalling	 9165P	
phospho-cjUN	 Ser63	 Rabbit	IgG	 Cell	Signalling	 2361P	
NPM1	 376	 IgG1	 DAKO	 IR65261	
anti-mouse	
secondary	



































































































































































No	tumour	 MOLM-14	 THP-1	 AML	Patient	
Sample	a	 2.07	 7.8	 10	 4.02	
Sample	b	 2.9	 4.2	 9	 3.08	









	Sample	a	 6	 31	 10	
	Sample	b	 8	 21	 12	












Sample	a	 58678	 39826	 18373	 	
Sample	b	 59010	 29873	 18273	 	









Sample	a	 1	 3	 1.7	 	














Sample	a	 8	 12	 2	 	
Sample	b	 0.2	 0.8	 0.4	 	













Sample	a	 0.21	 0.4	 3	 	
Sample	b	 0.4	 0.01	 6	 	











Sample	a	 0.2	 3.1	 1.1	 	
Sample	b	 1.7	 6	 1.9	 	











Sample	a	 0.2	 0.01	 0.12	 	
Sample	b	 1.7	 0.04	 1	 	















Sample	b	 15	 10	 9.05	 7.23	










Sample	a	 7	 25	 16	 	
Sample	b	 2	 12	 4	 	
Sample	c	 2	 15	 1	 	
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Appendix	G:	Data	Sets	(mRNA	and	miRNA	arrays)	
1. mRNA	Array	
adj.P.Val	 SYMBOL	 FoldChange	
8.20E-09	 RN7SK	 3.03070728	
0.000258035	 RNU1-5	 2.151581152	
0.00039884	 RNU1G2	 1.868155269	
0.00056599	 RNU4ATAC	 4.089101983	
0.003231965	 LOC648927	 0.664340218	
0.003231965	 RNU1-3	 1.933928896	
0.003231965	 JUN	 2.215131546	
	
2. microRNA	Array	
Cell	Line:	MOLM-14	 	
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MiRNA	
Fold	change	after	MUC1	
silencing	
hsa-miR-150-5p	 13.45	
hsa-miR-548aa+hsa-miR-548t-3p	 9.26	
hsa-miR-122-5p	 7.47	
hsa-miR-125a-3p	 7.16	
hsa-miR-520d-3p	 6.78	
hsa-miR-877-5p	 6.75	
hsa-miR-16-5p	 6.35	
hsa-miR-219a-2-3p	 5.91	
hsa-miR-549a	 5.13	
hsa-miR-4443	 5.12	
hsa-miR-1290	 4.89	
hsa-miR-944	 4.86	
hsa-miR-146b-5p	 4.65	
hsa-miR-644a	 4.59	
hsa-miR-2116-5p	 4.46	
hsa-miR-548n	 4.39	
hsa-miR-4536-5p	 4.36	
hsa-miR-522-3p	 4.34	
hsa-miR-30e-5p	 4.32	
hsa-miR-548j-5p	 4.31	
hsa-miR-320c	 4.21	
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hsa-miR-494-5p	 4.14	
hsa-miR-26a-5p	 3.86	
hsa-miR-302a-5p	 3.86	
hsa-miR-2113	 3.83	
hsa-miR-519b-5p+hsa-miR-519c-5p+hsa-miR-523-5p+hsa-
miR-518e-5p+hsa-miR-522-5p+hsa-miR-519a-5p	 3.79	
hsa-miR-1266-5p	 3.73	
hsa-miR-4516	 3.73	
hsa-miR-3140-3p	 3.72	
hsa-miR-374c-5p	 3.7	
hsa-miR-128-2-5p	 3.66	
hsa-miR-152-3p	 3.64	
hsa-miR-4421	 3.61	
hsa-miR-483-3p	 3.59	
hsa-miR-561-5p	 3.59	
hsa-miR-6720-3p	 3.59	
hsa-miR-380-3p	 3.57	
hsa-miR-103a-3p	 3.51	
hsa-miR-520f-3p	 3.51	
hsa-miR-181a-5p	 3.49	
hsa-miR-504-5p	 3.49	
hsa-miR-548j-3p	 3.47	
hsa-miR-219b-3p	 3.4	
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hsa-miR-496	 3.4	
hsa-miR-591	 3.38	
hsa-miR-4455	 3.37	
hsa-miR-342-3p	 3.35	
hsa-miR-1269a	 3.34	
hsa-miR-1295a	 3.33	
hsa-miR-216b-5p	 3.33	
hsa-miR-651-3p	 3.33	
hsa-miR-383-5p	 3.32	
hsa-miR-2117	 3.3	
hsa-miR-4531	 3.3	
hsa-miR-146b-3p	 3.26	
hsa-miR-375	 3.26	
hsa-miR-374a-3p	 3.25	
hsa-miR-3136-5p	 3.2	
hsa-miR-320b	 3.2	
hsa-miR-875-3p	 3.19	
hsa-miR-182-5p	 3.17	
hsa-miR-556-5p	 3.17	
hsa-miR-451a	 3.16	
hsa-miR-548a-3p	 3.16	
hsa-miR-136-5p	 3.15	
hsa-miR-362-3p	 3.15	
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hsa-miR-548g-3p	 3.14	
hsa-miR-4647	 3.13	
hsa-miR-1250-5p	 3.12	
hsa-miR-152-5p	 3.11	
hsa-miR-21-5p	 3.11	
hsa-miR-24-3p	 3.09	
hsa-miR-328-3p	 3.07	
hsa-miR-194-5p	 3.06	
hsa-miR-1236-3p	 3.04	
hsa-miR-4435	 3.02	
hsa-miR-526b-5p	 3.02	
hsa-miR-767-3p	 3.02	
hsa-miR-1249-3p	 3	
hsa-miR-532-3p	 3	
hsa-miR-590-5p	 3	
hsa-miR-1244	 2.98	
hsa-miR-1262	 2.98	
hsa-miR-133b	 2.98	
hsa-miR-424-5p	 2.98	
hsa-miR-619-3p	 2.98	
hsa-miR-1287-3p	 2.97	
hsa-miR-196a-5p	 2.97	
hsa-miR-4454+hsa-miR-7975	 2.96	
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hsa-miR-542-3p	 2.96	
hsa-miR-577	 2.96	
hsa-miR-92a-1-5p	 2.96	
hsa-miR-578	 2.95	
hsa-miR-124-3p	 2.94	
hsa-miR-489-3p	 2.94	
hsa-miR-515-3p	 2.93	
hsa-miR-19b-3p	 2.92	
hsa-miR-30b-5p	 2.92	
hsa-miR-6511a-5p	 2.92	
hsa-miR-1323	 2.91	
hsa-miR-1469	 2.9	
hsa-miR-509-3p	 2.9	
hsa-miR-4461	 2.88	
hsa-miR-555	 2.87	
hsa-miR-208a-3p	 2.86	
hsa-miR-211-5p	 2.86	
hsa-miR-29b-3p	 2.86	
hsa-miR-1298-5p	 2.85	
hsa-miR-650	 2.85	
hsa-miR-1273c	 2.84	
hsa-miR-544a	 2.84	
hsa-miR-652-5p	 2.84	
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hsa-miR-1247-5p	 2.83	
hsa-miR-3130-3p	 2.83	
hsa-miR-892a	 2.82	
hsa-miR-939-5p	 2.82	
hsa-miR-3614-5p	 2.81	
hsa-miR-567	 2.81	
hsa-miR-188-5p	 2.8	
hsa-miR-203a-5p	 2.8	
hsa-miR-376a-3p	 2.8	
hsa-miR-599	 2.8	
hsa-miR-874-3p	 2.8	
hsa-miR-1271-5p	 2.79	
hsa-miR-3613-3p	 2.79	
hsa-miR-539-5p	 2.79	
hsa-miR-3182	 2.78	
hsa-miR-574-5p	 2.77	
hsa-miR-582-3p	 2.77	
hsa-miR-183-5p	 2.76	
hsa-miR-654-5p	 2.75	
hsa-miR-509-3-5p	 2.74	
hsa-miR-598-3p	 2.74	
hsa-miR-605-5p	 2.74	
hsa-miR-1202	 2.73	
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hsa-miR-548a-5p	 2.73	
hsa-miR-769-3p	 2.73	
hsa-miR-3614-3p	 2.71	
hsa-miR-421	 2.71	
hsa-miR-552-3p	 2.71	
hsa-miR-575	 2.71	
hsa-miR-1206	 2.7	
hsa-miR-200a-3p	 2.7	
hsa-miR-3934-5p	 2.7	
hsa-miR-1827	 2.69	
hsa-miR-1302	 2.68	
hsa-miR-600	 2.68	
hsa-miR-615-3p	 2.68	
hsa-miR-873-5p	 2.68	
hsa-miR-10a-5p	 2.67	
hsa-miR-1291	 2.66	
hsa-miR-548i	 2.66	
hsa-miR-548l	 2.66	
hsa-miR-3150b-3p	 2.65	
hsa-miR-329-3p	 2.65	
hsa-miR-499a-3p	 2.65	
hsa-miR-518e-3p	 2.65	
hsa-miR-654-3p	 2.65	
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hsa-miR-301b-3p	 2.64	
hsa-miR-4451	 2.64	
hsa-miR-1297	 2.63	
hsa-miR-1537-3p	 2.63	
hsa-miR-425-5p	 2.63	
hsa-miR-132-3p	 2.62	
hsa-miR-323b-3p	 2.62	
hsa-miR-484	 2.62	
hsa-miR-517a-3p	 2.62	
hsa-miR-593-3p	 2.62	
hsa-miR-764	 2.62	
hsa-miR-2053	 2.61	
hsa-miR-448	 2.61	
hsa-miR-127-5p	 2.6	
hsa-miR-135a-5p	 2.6	
hsa-miR-219a-5p	 2.6	
hsa-miR-187-3p	 2.59	
hsa-miR-1908-3p	 2.59	
hsa-miR-891b	 2.59	
hsa-miR-149-5p	 2.58	
hsa-miR-27b-3p	 2.58	
hsa-miR-486-3p	 2.58	
hsa-miR-1271-3p	 2.57	
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hsa-miR-186-5p	 2.57	
hsa-miR-1973	 2.57	
hsa-miR-432-5p	 2.57	
hsa-miR-302e	 2.56	
hsa-miR-3161	 2.56	
hsa-miR-572	 2.56	
hsa-miR-100-5p	 2.55	
hsa-miR-106b-5p	 2.55	
hsa-miR-1322	 2.55	
hsa-miR-378h	 2.55	
hsa-miR-758-3p+hsa-miR-411-3p	 2.55	
hsa-miR-200b-3p	 2.54	
hsa-miR-574-3p	 2.54	
hsa-miR-576-5p	 2.54	
hsa-miR-630	 2.54	
hsa-miR-23c	 2.53	
hsa-miR-499b-5p	 2.53	
hsa-miR-92b-3p	 2.53	
hsa-miR-1204	 2.52	
hsa-miR-1268b	 2.52	
hsa-miR-1277-3p	 2.52	
hsa-miR-1306-3p	 2.52	
hsa-miR-29c-3p	 2.52	
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hsa-miR-556-3p	 2.51	
hsa-miR-642a-5p	 2.51	
hsa-miR-671-3p	 2.51	
hsa-miR-210-5p	 2.49	
hsa-miR-219a-1-3p	 2.49	
hsa-miR-3144-5p	 2.49	
hsa-miR-524-3p	 2.49	
hsa-miR-548ai+hsa-miR-570-5p	 2.49	
hsa-miR-548z+hsa-miR-548h-3p	 2.49	
hsa-miR-7-5p	 2.49	
hsa-miR-107	 2.48	
hsa-miR-140-3p	 2.48	
hsa-miR-323a-5p	 2.48	
hsa-miR-585-3p	 2.48	
hsa-miR-1255b-5p	 2.47	
hsa-miR-151b	 2.47	
hsa-miR-30a-5p	 2.47	
hsa-miR-2278	 2.46	
hsa-miR-30c-5p	 2.46	
hsa-miR-1268a	 2.45	
hsa-miR-128-1-5p	 2.45	
hsa-miR-518d-3p	 2.45	
hsa-miR-520a-5p	 2.45	
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hsa-miR-548ah-5p	 2.45	
hsa-miR-1248	 2.44	
hsa-miR-337-5p	 2.43	
hsa-miR-548h-5p	 2.43	
hsa-miR-876-3p	 2.43	
hsa-miR-1255a	 2.42	
hsa-miR-1257	 2.42	
hsa-miR-153-3p	 2.42	
hsa-miR-31-5p	 2.42	
hsa-miR-4431	 2.42	
hsa-miR-1185-2-3p	 2.41	
hsa-miR-346	 2.41	
hsa-miR-1224-3p	 2.4	
hsa-miR-3065-5p	 2.4	
hsa-miR-373-3p	 2.4	
hsa-miR-508-3p	 2.4	
hsa-miR-517b-3p	 2.4	
hsa-miR-617	 2.4	
hsa-miR-640	 2.39	
hsa-miR-1178-3p	 2.38	
hsa-miR-454-3p	 2.38	
hsa-miR-499a-5p	 2.38	
hsa-miR-513b-5p	 2.38	
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hsa-miR-139-5p	 2.37	
hsa-miR-378d	 2.37	
hsa-miR-1301-3p	 2.36	
hsa-miR-130b-3p	 2.36	
hsa-miR-1915-3p	 2.36	
hsa-miR-302f	 2.36	
hsa-miR-4524a-5p	 2.36	
hsa-miR-4792	 2.36	
hsa-miR-487b-5p	 2.36	
hsa-miR-614	 2.36	
hsa-miR-626	 2.36	
hsa-miR-942-5p	 2.36	
hsa-miR-148b-3p	 2.35	
hsa-miR-26b-5p	 2.35	
hsa-miR-411-5p	 2.35	
hsa-miR-562	 2.35	
hsa-miR-134-3p	 2.33	
hsa-miR-512-3p	 2.33	
hsa-miR-516a-5p	 2.33	
hsa-miR-205-5p	 2.32	
hsa-miR-32-5p	 2.32	
hsa-miR-4521	 2.32	
hsa-miR-98-3p	 2.32	
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hsa-miR-1972	 2.31	
hsa-miR-199a-3p+hsa-miR-199b-3p	 2.31	
hsa-miR-326	 2.31	
hsa-miR-378g	 2.31	
hsa-miR-501-3p	 2.31	
hsa-miR-660-5p	 2.31	
hsa-miR-193b-3p	 2.3	
hsa-miR-518b	 2.3	
hsa-miR-606	 2.29	
hsa-miR-185-5p	 2.28	
hsa-miR-324-5p	 2.28	
hsa-miR-3605-5p	 2.28	
hsa-miR-1200	 2.27	
hsa-miR-151a-3p	 2.27	
hsa-miR-3190-3p	 2.27	
hsa-miR-342-5p	 2.27	
hsa-miR-4425	 2.27	
hsa-miR-520d-5p+hsa-miR-527+hsa-miR-518a-5p	 2.27	
hsa-miR-548q	 2.27	
hsa-miR-210-3p	 2.26	
hsa-miR-218-5p	 2.26	
hsa-miR-1908-5p	 2.25	
hsa-miR-195-5p	 2.25	
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hsa-miR-324-3p	 2.25	
hsa-miR-409-5p	 2.25	
hsa-miR-147b	 2.24	
hsa-miR-498	 2.24	
hsa-miR-514b-3p	 2.24	
hsa-miR-302b-3p	 2.23	
hsa-miR-1307-5p	 2.22	
hsa-miR-198	 2.22	
hsa-miR-302c-3p	 2.22	
hsa-miR-450b-5p	 2.22	
hsa-miR-25-5p	 2.21	
hsa-miR-323a-3p	 2.21	
hsa-miR-363-5p	 2.21	
hsa-miR-365a-3p+hsa-miR-365b-3p	 2.21	
hsa-miR-429	 2.21	
hsa-miR-490-3p	 2.21	
hsa-miR-525-3p	 2.21	
hsa-miR-193a-5p+hsa-miR-193b-5p	 2.2	
hsa-miR-196a-3p	 2.2	
hsa-miR-296-5p	 2.2	
hsa-miR-511-5p	 2.2	
hsa-miR-761	 2.2	
hsa-miR-941	 2.2	
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hsa-miR-23a-3p	 2.19	
hsa-miR-545-3p	 2.19	
hsa-miR-548b-3p	 2.19	
hsa-miR-3192-5p	 2.18	
hsa-miR-487b-3p	 2.18	
hsa-miR-509-5p	 2.18	
hsa-miR-548e-3p	 2.18	
hsa-miR-96-5p	 2.18	
hsa-miR-433-3p	 2.17	
hsa-miR-519e-3p	 2.17	
hsa-miR-664a-3p	 2.17	
hsa-miR-1-5p	 2.16	
hsa-miR-3127-5p	 2.16	
hsa-miR-3928-3p	 2.16	
hsa-miR-874-5p	 2.16	
hsa-miR-500a-5p+hsa-miR-501-5p	 2.15	
hsa-miR-548ad-3p	 2.15	
hsa-miR-548d-3p	 2.15	
hsa-miR-643	 2.15	
hsa-miR-655-3p	 2.15	
hsa-miR-142-3p	 2.14	
hsa-miR-144-3p	 2.14	
hsa-miR-208b-3p	 2.14	
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hsa-miR-221-3p	 2.14	
hsa-miR-2682-5p	 2.14	
hsa-miR-3195	 2.14	
hsa-miR-345-3p	 2.14	
hsa-miR-376a-2-5p	 2.14	
hsa-miR-182-3p	 2.13	
hsa-miR-214-3p	 2.13	
hsa-miR-335-5p	 2.13	
hsa-miR-339-3p	 2.13	
hsa-miR-4284	 2.13	
hsa-miR-455-5p	 2.13	
hsa-miR-936	 2.13	
hsa-miR-1281	 2.12	
hsa-miR-181c-5p	 2.12	
hsa-miR-211-3p	 2.12	
hsa-miR-323b-5p	 2.12	
hsa-miR-4707-5p	 2.12	
hsa-miR-548ak	 2.12	
hsa-miR-652-3p	 2.12	
ACTB	 2.12	
hsa-miR-34c-5p	 2.11	
hsa-miR-374a-5p	 2.11	
hsa-miR-384	 2.11	
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hsa-miR-566	 2.11	
hsa-miR-885-3p	 2.11	
hsa-miR-3690	 2.1	
hsa-miR-5010-5p	 2.1	
hsa-miR-506-3p	 2.1	
hsa-miR-6721-5p	 2.1	
hsa-miR-888-5p	 2.1	
hsa-miR-22-3p	 2.09	
hsa-miR-298	 2.09	
hsa-miR-29a-3p	 2.09	
hsa-miR-330-5p	 2.09	
hsa-miR-584-3p	 2.09	
hsa-miR-639	 2.09	
hsa-miR-10b-5p	 2.08	
hsa-miR-1185-5p	 2.08	
hsa-miR-302a-3p	 2.08	
hsa-miR-30a-3p	 2.08	
hsa-miR-3202	 2.08	
hsa-miR-362-5p	 2.08	
hsa-miR-550a-5p	 2.08	
hsa-miR-1193	 2.07	
hsa-miR-1264	 2.07	
hsa-miR-1289	 2.07	
Athalia	Rachel	Pyzer	 Appendix	G:	Data	Sets	(mRNA	and	miRNA	arrays)	
	
208	
hsa-miR-216a-5p	 2.07	
hsa-miR-382-3p	 2.07	
hsa-miR-493-3p	 2.07	
hsa-miR-1260a	 2.06	
hsa-miR-193a-3p	 2.06	
hsa-miR-221-5p	 2.06	
hsa-miR-301a-5p	 2.06	
hsa-miR-379-5p	 2.06	
hsa-miR-637	 2.06	
hsa-miR-137	 2.05	
hsa-miR-485-5p	 2.05	
hsa-miR-892b	 2.05	
hsa-miR-25-3p	 2.04	
hsa-miR-3185	 2.04	
hsa-miR-520g-3p	 2.04	
hsa-miR-573	 2.04	
hsa-miR-6511a-3p	 2.04	
hsa-miR-1245b-3p	 2.03	
hsa-miR-1304-5p	 2.03	
hsa-miR-133a-5p	 2.03	
hsa-miR-190a-5p	 2.03	
hsa-miR-450b-3p	 2.03	
hsa-miR-542-5p	 2.03	
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hsa-miR-620	 2.03	
hsa-miR-627-3p	 2.03	
hsa-miR-1279	 2.02	
hsa-miR-381-5p	 2.02	
hsa-miR-4286	 2.02	
hsa-miR-576-3p	 2.02	
hsa-miR-887-3p	 2.02	
hsa-miR-1203	 2.01	
hsa-miR-1276	 2.01	
hsa-miR-891a-5p	 2.01	
hsa-miR-940	 2.01	
hsa-miR-98-5p	 2.01	
hsa-miR-1249-5p	 2	
hsa-miR-1253	 2	
hsa-miR-128-3p	 2	
hsa-miR-1283	 2	
hsa-miR-143-3p	 2	
hsa-miR-18b-5p	 2	
hsa-miR-302d-3p	 2	
hsa-miR-3144-3p	 2	
hsa-miR-378e	 2	
hsa-miR-422a	 2	
hsa-miR-4755-5p	 2	
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hsa-miR-494-3p	 2	
hsa-miR-502-5p	 2	
hsa-miR-548ar-5p	 2	
hsa-miR-570-3p	 2	
hsa-miR-579-3p	 2	
hsa-miR-603	 2	
hsa-miR-610	 2	
hsa-miR-627-5p	 2	
hsa-miR-744-5p	 2	
hsa-miR-1299	 1.99	
hsa-miR-138-5p	 1.99	
hsa-miR-200c-3p	 1.99	
hsa-miR-217	 1.99	
hsa-miR-3613-5p	 1.99	
hsa-miR-518f-3p	 1.99	
hsa-miR-532-5p	 1.99	
hsa-miR-587	 1.99	
hsa-miR-1285-3p	 1.98	
hsa-miR-129-5p	 1.98	
hsa-miR-320e	 1.98	
hsa-miR-553	 1.98	
hsa-miR-885-5p	 1.98	
hsa-let-7f-5p	 1.97	
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hsa-miR-1183	 1.97	
hsa-miR-1306-5p	 1.97	
hsa-miR-18a-5p	 1.97	
hsa-miR-204-5p	 1.97	
hsa-miR-28-3p	 1.97	
hsa-miR-331-5p	 1.97	
hsa-miR-4787-5p	 1.97	
hsa-miR-548k	 1.97	
hsa-miR-126-3p	 1.96	
hsa-miR-497-5p	 1.96	
hsa-miR-508-5p	 1.96	
hsa-miR-597-5p	 1.96	
hsa-miR-934	 1.96	
hsa-miR-133a-3p	 1.95	
hsa-miR-1910-5p	 1.95	
hsa-miR-376b-3p	 1.95	
hsa-miR-376c-5p	 1.95	
hsa-miR-499b-3p	 1.95	
hsa-miR-519d-3p	 1.95	
hsa-miR-520h	 1.95	
hsa-miR-548e-5p	 1.95	
hsa-miR-628-3p	 1.95	
hsa-miR-770-5p	 1.95	
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hsa-miR-1270	 1.94	
hsa-miR-184	 1.94	
hsa-miR-371b-5p	 1.94	
hsa-miR-503-3p	 1.94	
hsa-miR-760	 1.94	
hsa-miR-1252-5p	 1.93	
hsa-miR-301b-5p	 1.93	
hsa-miR-34b-3p	 1.93	
hsa-miR-571	 1.93	
hsa-miR-589-5p	 1.93	
hsa-miR-641	 1.92	
hsa-miR-6503-5p	 1.92	
hsa-miR-1305	 1.91	
hsa-miR-142-5p	 1.91	
hsa-miR-4707-3p	 1.91	
hsa-miR-514a-3p	 1.91	
hsa-miR-561-3p	 1.91	
hsa-miR-582-5p	 1.91	
hsa-miR-648	 1.91	
hsa-miR-651-5p	 1.91	
hsa-miR-802	 1.91	
hsa-miR-181b-5p+hsa-miR-181d-5p	 1.9	
hsa-miR-3151-5p	 1.9	
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hsa-miR-328-5p	 1.9	
hsa-miR-452-5p	 1.9	
hsa-miR-4532	 1.9	
hsa-miR-890	 1.9	
hsa-miR-1976	 1.89	
hsa-miR-222-3p	 1.89	
hsa-miR-523-3p	 1.89	
hsa-miR-551b-3p	 1.89	
hsa-miR-592	 1.89	
hsa-miR-660-3p	 1.89	
hsa-miR-92a-3p	 1.89	
hsa-miR-146a-5p	 1.88	
hsa-miR-188-3p	 1.88	
hsa-miR-3168	 1.88	
hsa-miR-331-3p	 1.88	
hsa-miR-338-5p	 1.88	
hsa-miR-5001-3p	 1.88	
hsa-miR-1197	 1.87	
hsa-miR-3147	 1.87	
hsa-miR-320a	 1.87	
hsa-miR-490-5p	 1.87	
hsa-miR-507	 1.87	
hsa-miR-876-5p	 1.87	
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hsa-miR-154-5p	 1.86	
hsa-miR-181a-3p	 1.86	
hsa-miR-1205	 1.85	
hsa-miR-1286	 1.85	
hsa-miR-15a-5p	 1.85	
hsa-miR-3180-3p	 1.85	
hsa-miR-455-3p	 1.85	
hsa-miR-513c-5p	 1.85	
hsa-miR-889-3p	 1.85	
hsa-miR-1185-1-3p	 1.84	
hsa-miR-1303	 1.84	
hsa-miR-147a	 1.84	
hsa-miR-181a-2-3p	 1.84	
hsa-miR-28-5p	 1.84	
hsa-miR-377-3p	 1.84	
hsa-miR-4741	 1.84	
hsa-miR-580-3p	 1.84	
hsa-miR-224-5p	 1.83	
hsa-miR-3158-3p	 1.83	
hsa-miR-541-3p	 1.83	
hsa-miR-612	 1.83	
hsa-miR-192-5p	 1.82	
hsa-miR-370-5p	 1.82	
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hsa-miR-381-3p	 1.82	
hsa-miR-873-3p	 1.82	
hsa-miR-3074-3p	 1.81	
hsa-miR-3615	 1.81	
hsa-miR-367-3p	 1.81	
hsa-miR-378i	 1.81	
hsa-miR-431-5p	 1.81	
hsa-miR-510-3p	 1.81	
hsa-miR-1909-3p	 1.8	
hsa-miR-30e-3p	 1.8	
hsa-miR-4458	 1.8	
hsa-miR-450a-5p	 1.8	
hsa-miR-513a-5p	 1.8	
hsa-miR-595	 1.8	
hsa-miR-1260b	 1.79	
hsa-miR-206	 1.79	
hsa-miR-4485-3p	 1.79	
hsa-miR-564	 1.79	
hsa-miR-624-3p	 1.79	
hsa-miR-1245a	 1.78	
hsa-miR-223-3p	 1.78	
hsa-miR-378c	 1.78	
hsa-miR-371a-5p	 1.77	
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hsa-miR-548m	 1.77	
hsa-let-7c-5p	 1.76	
hsa-miR-20a-5p+hsa-miR-20b-5p	 1.76	
hsa-miR-33b-5p	 1.76	
hsa-miR-369-3p	 1.76	
hsa-miR-374b-5p	 1.76	
hsa-miR-568	 1.76	
hsa-miR-767-5p	 1.76	
hsa-miR-9-5p	 1.76	
hsa-miR-409-3p	 1.75	
hsa-miR-638	 1.75	
hsa-miR-937-3p	 1.75	
hsa-miR-1287-5p	 1.74	
hsa-miR-140-5p	 1.74	
hsa-miR-3164	 1.74	
hsa-miR-584-5p	 1.74	
hsa-miR-933	 1.74	
hsa-miR-433-5p	 1.73	
hsa-miR-495-3p	 1.73	
hsa-miR-526a+hsa-miR-518c-5p+hsa-miR-518d-5p	 1.73	
hsa-miR-769-5p	 1.73	
hsa-miR-95-3p	 1.73	
hsa-miR-3180-5p	 1.72	
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hsa-miR-412-3p	 1.72	
hsa-miR-6503-3p	 1.72	
hsa-miR-1-3p	 1.71	
hsa-miR-300	 1.71	
hsa-miR-369-5p	 1.71	
hsa-miR-299-5p	 1.7	
hsa-miR-512-5p	 1.7	
hsa-miR-516b-5p	 1.7	
hsa-miR-519b-3p	 1.7	
hsa-miR-548y	 1.7	
hsa-miR-579-5p	 1.7	
hsa-miR-99b-5p	 1.7	
hsa-miR-127-3p	 1.69	
hsa-miR-215-5p	 1.69	
hsa-miR-320d	 1.69	
hsa-miR-505-3p	 1.69	
hsa-miR-520b	 1.69	
hsa-miR-642a-3p	 1.69	
hsa-miR-758-5p	 1.69	
hsa-miR-1293	 1.68	
hsa-miR-1307-3p	 1.68	
hsa-miR-382-5p	 1.68	
hsa-miR-3918	 1.68	
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hsa-miR-521	 1.68	
hsa-miR-1261	 1.67	
hsa-miR-1272	 1.67	
hsa-miR-199a-5p	 1.67	
hsa-miR-199b-5p	 1.67	
hsa-miR-299-3p	 1.67	
hsa-miR-449c-5p	 1.67	
hsa-miR-519c-3p	 1.67	
hsa-miR-3196	 1.66	
hsa-miR-4448	 1.66	
hsa-miR-4787-3p	 1.66	
hsa-miR-491-5p	 1.66	
hsa-miR-5010-3p	 1.66	
hsa-miR-543	 1.66	
hsa-miR-604	 1.66	
hsa-miR-765	 1.66	
hsa-miR-27a-3p	 1.65	
hsa-miR-510-5p	 1.65	
hsa-miR-516a-3p+hsa-miR-516b-3p	 1.65	
hsa-miR-631	 1.65	
hsa-miR-1245b-5p	 1.64	
hsa-miR-518c-3p	 1.64	
hsa-miR-671-5p	 1.64	
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hsa-miR-23b-3p	 1.63	
hsa-miR-296-3p	 1.63	
hsa-miR-297	 1.63	
hsa-miR-197-5p	 1.62	
hsa-miR-212-3p	 1.62	
hsa-miR-551a	 1.62	
hsa-miR-548o-3p+hsa-miR-548ah-3p+hsa-miR-548av-3p	 1.61	
hsa-miR-935	 1.61	
hsa-miR-1910-3p	 1.6	
hsa-miR-202-3p	 1.6	
hsa-miR-548v	 1.6	
hsa-miR-596	 1.6	
hsa-miR-661	 1.6	
hsa-miR-1296-3p	 1.59	
hsa-miR-190a-3p	 1.59	
hsa-miR-378f	 1.59	
hsa-miR-5196-5p	 1.59	
hsa-miR-608	 1.59	
hsa-miR-6724-5p	 1.59	
hsa-miR-1234-3p	 1.58	
hsa-miR-125a-5p	 1.58	
hsa-miR-515-5p	 1.58	
hsa-miR-548d-5p	 1.58	
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hsa-miR-628-5p	 1.58	
hsa-miR-766-3p	 1.58	
hsa-miR-125b-5p	 1.57	
hsa-miR-139-3p	 1.57	
hsa-miR-34c-3p	 1.57	
hsa-miR-601	 1.57	
hsa-miR-656-3p	 1.57	
hsa-miR-181b-2-3p	 1.56	
hsa-miR-363-3p	 1.56	
hsa-miR-491-3p	 1.56	
hsa-miR-502-3p	 1.56	
hsa-miR-625-5p	 1.55	
hsa-miR-1258	 1.54	
hsa-miR-1285-5p	 1.54	
hsa-miR-330-3p	 1.54	
hsa-miR-607	 1.54	
hsa-miR-181d-3p	 1.53	
hsa-miR-203a-3p	 1.53	
hsa-miR-301a-3p	 1.53	
hsa-miR-339-5p	 1.53	
hsa-miR-101-3p	 1.52	
hsa-miR-105-5p	 1.52	
hsa-miR-34a-5p	 1.52	
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hsa-miR-361-3p	 1.52	
hsa-miR-488-3p	 1.52	
hsa-miR-504-3p	 1.52	
hsa-miR-663a	 1.52	
hsa-miR-1233-3p	 1.51	
hsa-miR-135b-5p	 1.51	
hsa-miR-370-3p	 1.51	
hsa-miR-145-5p	 1.5	
hsa-miR-155-5p	 1.5	
hsa-miR-5001-5p	 1.5	
hsa-miR-554	 1.5	
hsa-miR-99a-5p	 1.5	
hsa-miR-1275	 1.49	
hsa-miR-141-3p	 1.49	
hsa-miR-337-3p	 1.49	
hsa-miR-514b-5p	 1.49	
hsa-miR-1226-3p	 1.48	
hsa-miR-196b-5p	 1.48	
hsa-miR-665	 1.48	
hsa-miR-922	 1.48	
hsa-miR-1254	 1.47	
hsa-miR-1304-3p	 1.47	
hsa-miR-487a-3p	 1.47	
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hsa-miR-548al	 1.47	
hsa-miR-376c-3p	 1.46	
hsa-miR-664b-5p	 1.46	
hsa-miR-325	 1.45	
hsa-miR-5196-3p+hsa-miR-6732-3p	 1.44	
hsa-miR-151a-5p	 1.43	
hsa-miR-30d-5p	 1.43	
hsa-miR-3140-5p	 1.43	
hsa-miR-1180-3p	 1.42	
hsa-miR-410-3p	 1.42	
hsa-miR-450a-2-3p	 1.42	
hsa-miR-520e	 1.42	
hsa-miR-539-3p	 1.42	
hsa-miR-649	 1.42	
hsa-miR-675-5p	 1.42	
hsa-miR-361-5p	 1.41	
hsa-miR-450a-1-3p	 1.41	
hsa-miR-485-3p	 1.4	
hsa-miR-664b-3p	 1.4	
hsa-miR-423-5p	 1.39	
hsa-miR-4536-3p	 1.39	
hsa-miR-483-5p	 1.39	
hsa-miR-514a-5p	 1.39	
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hsa-miR-520c-3p	 1.39	
hsa-miR-590-3p	 1.39	
hsa-miR-129-2-3p	 1.38	
hsa-miR-345-5p	 1.38	
hsa-miR-513a-3p	 1.38	
hsa-miR-525-5p	 1.38	
hsa-miR-197-3p	 1.37	
hsa-miR-340-5p	 1.37	
hsa-miR-1278	 1.36	
hsa-miR-1296-5p	 1.36	
hsa-miR-517c-3p+hsa-miR-519a-3p	 1.36	
hsa-miR-329-5p	 1.35	
hsa-miR-372-3p	 1.35	
hsa-miR-423-3p	 1.35	
hsa-miR-924	 1.35	
hsa-let-7e-5p	 1.34	
hsa-miR-1288-3p	 1.34	
hsa-miR-942-3p	 1.34	
hsa-miR-548ar-3p	 1.33	
hsa-miR-1269b	 1.32	
hsa-miR-148a-3p	 1.31	
hsa-miR-19a-3p	 1.3	
hsa-miR-3180	 1.3	
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hsa-miR-887-5p	 1.3	
hsa-miR-3131	 1.29	
hsa-miR-449b-5p	 1.29	
hsa-miR-563	 1.29	
hsa-miR-616-3p	 1.29	
hsa-miR-629-5p	 1.29	
hsa-miR-3605-3p	 1.27	
hsa-miR-513c-3p	 1.26	
hsa-miR-613	 1.26	
hsa-miR-495-5p	 1.25	
hsa-miR-190b	 1.22	
hsa-miR-208b-5p	 1.22	
hsa-miR-1224-5p	 1.21	
hsa-miR-506-5p	 1.2	
hsa-miR-520a-3p	 1.19	
hsa-miR-2110	 1.16	
hsa-let-7b-5p	 1.14	
hsa-miR-615-5p	 1.14	
hsa-miR-3916	 1.13	
hsa-miR-708-5p	 1.13	
hsa-let-7g-5p	 1.12	
hsa-miR-492	 1.12	
hsa-miR-548c-5p+hsa-miR-548o-5p+hsa-miR-548am-5p	 1.11	
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Cell	Line:	THP-1	
hsa-miR-106a-5p+hsa-miR-17-5p	 1.08	
hsa-miR-130a-3p	 1.05	
hsa-miR-378b	 1.04	
hsa-miR-33a-5p	 1.03	
hsa-miR-3065-3p	 1.02	
hsa-miR-449a	 1.01	
hsa-miR-766-5p	 -1.01	
hsa-miR-503-5p	 -1.04	
hsa-miR-1228-3p	 -1.06	
hsa-miR-191-5p	 -1.07	
hsa-miR-365b-5p	 -1.07	
hsa-miR-134-5p+hsa-miR-6728-5p	 -1.14	
hsa-miR-15b-5p	 -1.16	
hsa-let-7i-5p	 -1.18	
hsa-miR-3179	 -1.27	
hsa-let-7d-5p	 -1.3	
hsa-miR-93-5p	 -1.39	
hsa-miR-4488	 -1.54	
B2M	 -1.62	
hsa-let-7a-5p	 -5.82	
hsa-miR-1246	 -5.97	
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MiRNA	 Fold	change	after	
MUC1	silencing	
hsa-miR-196a-5p	 11.69	
hsa-miR-512-3p	 4.04	
hsa-miR-3140-3p	 3.89	
hsa-miR-664a-3p	 3.79	
hsa-miR-1180-3p	 3.51	
hsa-miR-378c	 3.25	
hsa-miR-370-5p	 3.19	
hsa-miR-3140-5p	 3.17	
GAPDH	 3.14	
hsa-miR-525-5p	 3.01	
hsa-miR-503-3p	 2.98	
hsa-miR-1910-3p	 2.79	
hsa-miR-6503-3p	 2.76	
hsa-miR-744-5p	 2.73	
hsa-miR-649	 2.66	
hsa-miR-181b-2-3p	 2.59	
hsa-miR-19a-3p	 2.59	
hsa-miR-3180	 2.56	
hsa-miR-509-5p	 2.55	
hsa-miR-532-5p	 2.54	
hsa-miR-18b-5p	 2.53	
hsa-miR-2117	 2.52	
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hsa-miR-182-3p	 2.5	
hsa-miR-3164	 2.49	
hsa-miR-550a-5p	 2.47	
hsa-miR-369-5p	 2.45	
hsa-miR-1302	 2.42	
hsa-miR-4421	 2.4	
hsa-miR-539-3p	 2.39	
hsa-miR-103a-3p	 2.38	
hsa-miR-506-5p	 2.37	
hsa-miR-196a-3p	 2.35	
hsa-miR-3074-3p	 2.35	
hsa-miR-520g-3p	 2.35	
hsa-miR-876-3p	 2.35	
hsa-miR-664b-3p	 2.31	
hsa-miR-665	 2.3	
hsa-miR-372-3p	 2.28	
hsa-miR-380-3p	 2.28	
hsa-miR-4741	 2.28	
hsa-miR-708-5p	 2.28	
hsa-miR-3180-3p	 2.23	
hsa-miR-29a-3p	 2.22	
hsa-miR-33b-5p	 2.22	
hsa-miR-942-3p	 2.22	
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hsa-miR-548v	 2.21	
hsa-miR-3144-5p	 2.2	
hsa-miR-376a-2-5p	 2.2	
hsa-miR-487b-3p	 2.2	
hsa-miR-520b	 2.2	
hsa-miR-891a-5p	 2.2	
hsa-miR-3613-5p	 2.18	
hsa-miR-671-5p	 2.18	
hsa-miR-548l	 2.17	
hsa-miR-202-3p	 2.15	
hsa-miR-511-5p	 2.15	
hsa-miR-330-5p	 2.14	
hsa-miR-6503-5p	 2.14	
hsa-miR-3180-5p	 2.13	
hsa-miR-320c	 2.13	
hsa-miR-208b-5p	 2.12	
hsa-miR-144-3p	 2.11	
hsa-miR-769-3p	 2.1	
hsa-miR-382-5p	 2.09	
hsa-miR-526a+hsa-miR-518c-5p+hsa-miR-518d-5p	 2.09	
hsa-miR-615-5p	 2.09	
hsa-miR-296-3p	 2.08	
hsa-miR-1301-3p	 2.06	
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hsa-miR-210-5p	 2.05	
hsa-miR-340-5p	 2.05	
hsa-miR-641	 2.05	
hsa-miR-937-3p	 2.05	
hsa-miR-203a-5p	 2.04	
hsa-miR-302e	 2.03	
hsa-miR-373-3p	 2.03	
hsa-miR-3615	 2.02	
hsa-miR-369-3p	 2.02	
hsa-miR-1249-5p	 2.01	
hsa-miR-133a-5p	 2.01	
hsa-miR-34c-3p	 2.01	
hsa-miR-519d-3p	 2.01	
hsa-miR-544a	 2.01	
hsa-miR-664b-5p	 2.01	
hsa-miR-887-3p	 2.01	
hsa-miR-1291	 2	
hsa-miR-514a-3p	 2	
hsa-miR-597-5p	 2	
hsa-miR-190a-5p	 1.99	
hsa-miR-302a-5p	 1.99	
hsa-miR-378f	 1.99	
hsa-miR-409-5p	 1.99	
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hsa-miR-140-5p	 1.98	
hsa-miR-181d-3p	 1.98	
hsa-miR-568	 1.98	
hsa-miR-652-3p	 1.98	
hsa-miR-561-3p	 1.97	
hsa-miR-215-5p	 1.96	
hsa-miR-299-3p	 1.96	
hsa-miR-7-5p	 1.96	
hsa-miR-204-5p	 1.94	
hsa-miR-367-3p	 1.94	
hsa-miR-449b-5p	 1.94	
hsa-miR-624-3p	 1.94	
hsa-miR-331-5p	 1.93	
hsa-miR-589-5p	 1.93	
hsa-miR-892b	 1.93	
hsa-miR-1304-3p	 1.92	
hsa-miR-1537-3p	 1.92	
hsa-miR-513a-3p	 1.92	
hsa-miR-1281	 1.91	
hsa-miR-508-3p	 1.91	
hsa-miR-571	 1.91	
hsa-miR-580-3p	 1.91	
hsa-miR-4536-3p	 1.9	
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hsa-miR-1289	 1.89	
hsa-miR-296-5p	 1.89	
hsa-miR-516a-3p+hsa-miR-516b-3p	 1.89	
hsa-miR-197-5p	 1.88	
hsa-miR-3127-5p	 1.88	
hsa-miR-616-3p	 1.88	
hsa-miR-628-5p	 1.88	
hsa-miR-1254	 1.87	
hsa-miR-136-5p	 1.87	
hsa-miR-885-3p	 1.87	
hsa-miR-146b-3p	 1.86	
hsa-miR-3131	 1.86	
hsa-miR-323b-5p	 1.86	
hsa-miR-496	 1.86	
hsa-miR-548m	 1.86	
hsa-miR-592	 1.86	
hsa-miR-1185-1-3p	 1.85	
hsa-miR-1288-3p	 1.85	
hsa-miR-554	 1.85	
hsa-miR-615-3p	 1.85	
hsa-miR-660-5p	 1.85	
hsa-miR-205-5p	 1.84	
hsa-miR-1268b	 1.83	
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hsa-miR-1270	 1.83	
hsa-miR-363-5p	 1.83	
hsa-miR-4431	 1.83	
hsa-miR-4461	 1.83	
hsa-miR-567	 1.83	
hsa-miR-628-3p	 1.83	
hsa-miR-892a	 1.83	
hsa-miR-1197	 1.82	
hsa-miR-1287-3p	 1.82	
hsa-miR-301b-3p	 1.82	
hsa-miR-1261	 1.81	
hsa-miR-1296-3p	 1.81	
hsa-miR-151a-5p	 1.81	
hsa-miR-218-5p	 1.81	
hsa-miR-221-5p	 1.81	
hsa-miR-512-5p	 1.81	
hsa-miR-520c-3p	 1.81	
hsa-miR-548j-5p	 1.81	
hsa-miR-922	 1.81	
hsa-miR-1245b-5p	 1.8	
hsa-miR-3202	 1.8	
hsa-miR-577	 1.8	
hsa-miR-638	 1.8	
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hsa-miR-944	 1.8	
hsa-miR-206	 1.79	
hsa-miR-382-3p	 1.79	
hsa-miR-4516	 1.79	
hsa-miR-518b	 1.79	
hsa-miR-128-2-5p	 1.78	
hsa-miR-411-5p	 1.78	
hsa-miR-181a-2-3p	 1.77	
hsa-miR-3150b-3p	 1.77	
hsa-miR-370-3p	 1.77	
hsa-miR-450a-2-3p	 1.77	
hsa-miR-516b-5p	 1.77	
hsa-miR-1183	 1.76	
hsa-miR-1185-2-3p	 1.76	
hsa-miR-153-3p	 1.76	
hsa-miR-378b	 1.76	
hsa-miR-6511a-5p	 1.76	
hsa-miR-555	 1.75	
hsa-miR-626	 1.75	
hsa-miR-145-5p	 1.74	
hsa-miR-455-5p	 1.74	
hsa-miR-542-3p	 1.74	
hsa-miR-556-5p	 1.74	
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hsa-miR-598-3p	 1.74	
hsa-miR-643	 1.74	
hsa-miR-1285-3p	 1.73	
hsa-miR-329-3p	 1.73	
hsa-miR-3168	 1.72	
hsa-miR-548h-5p	 1.72	
hsa-miR-548k	 1.72	
hsa-miR-1278	 1.71	
hsa-miR-182-5p	 1.71	
hsa-miR-192-5p	 1.71	
hsa-miR-483-3p	 1.71	
hsa-miR-489-3p	 1.71	
hsa-miR-523-3p	 1.71	
hsa-miR-889-3p	 1.71	
hsa-miR-939-5p	 1.71	
hsa-miR-323a-3p	 1.7	
hsa-miR-338-5p	 1.7	
hsa-miR-520d-3p	 1.7	
hsa-miR-548a-3p	 1.7	
hsa-miR-590-5p	 1.7	
hsa-miR-1272	 1.69	
hsa-miR-25-5p	 1.69	
hsa-miR-337-3p	 1.69	
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hsa-miR-452-5p	 1.69	
hsa-miR-4787-5p	 1.69	
hsa-miR-490-3p	 1.69	
hsa-miR-216b-5p	 1.68	
hsa-miR-383-5p	 1.68	
hsa-miR-4451	 1.68	
hsa-miR-4531	 1.68	
hsa-miR-150-5p	 1.67	
hsa-miR-2682-5p	 1.67	
hsa-miR-508-5p	 1.67	
hsa-miR-548j-3p	 1.67	
hsa-miR-342-5p	 1.66	
hsa-miR-345-5p	 1.66	
hsa-miR-556-3p	 1.66	
hsa-miR-1226-3p	 1.65	
hsa-miR-1262	 1.65	
hsa-miR-1915-3p	 1.65	
hsa-miR-330-3p	 1.65	
hsa-miR-381-3p	 1.65	
hsa-miR-3934-5p	 1.65	
hsa-miR-495-5p	 1.65	
hsa-miR-601	 1.65	
hsa-miR-10a-5p	 1.64	
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hsa-miR-1264	 1.64	
hsa-miR-195-5p	 1.64	
hsa-miR-4286	 1.64	
hsa-miR-6721-5p	 1.64	
hsa-miR-148a-3p	 1.63	
hsa-miR-379-5p	 1.63	
hsa-miR-500a-5p+hsa-miR-501-5p	 1.63	
hsa-miR-518c-3p	 1.63	
hsa-miR-532-3p	 1.63	
hsa-miR-1299	 1.62	
hsa-miR-18a-5p	 1.62	
hsa-miR-299-5p	 1.62	
hsa-miR-519e-3p	 1.62	
hsa-miR-563	 1.62	
hsa-miR-6720-3p	 1.62	
hsa-miR-1224-5p	 1.61	
hsa-miR-1297	 1.61	
hsa-miR-302b-3p	 1.61	
hsa-miR-384	 1.61	
hsa-miR-4647	 1.61	
hsa-miR-517c-3p+hsa-miR-519a-3p	 1.61	
hsa-miR-593-3p	 1.61	
hsa-miR-758-3p+hsa-miR-411-3p	 1.61	
Athalia	Rachel	Pyzer	 Appendix	G:	Data	Sets	(mRNA	and	miRNA	arrays)	
	
237	
hsa-miR-211-3p	 1.6	
hsa-miR-412-3p	 1.6	
hsa-miR-551b-3p	 1.6	
hsa-miR-219a-1-3p	 1.59	
hsa-miR-320a	 1.59	
hsa-miR-519c-3p	 1.59	
hsa-miR-96-5p	 1.59	
hsa-miR-1258	 1.58	
hsa-miR-127-5p	 1.58	
hsa-miR-1279	 1.58	
hsa-miR-149-5p	 1.58	
hsa-miR-31-5p	 1.58	
hsa-miR-3179	 1.58	
hsa-miR-320d	 1.58	
hsa-miR-325	 1.58	
hsa-miR-506-3p	 1.58	
hsa-miR-548i	 1.58	
hsa-miR-637	 1.58	
hsa-miR-1185-5p	 1.57	
hsa-miR-1287-5p	 1.57	
hsa-miR-1305	 1.57	
hsa-miR-323b-3p	 1.57	
hsa-miR-449a	 1.57	
Athalia	Rachel	Pyzer	 Appendix	G:	Data	Sets	(mRNA	and	miRNA	arrays)	
	
238	
hsa-miR-4532	 1.57	
hsa-miR-485-5p	 1.57	
hsa-miR-498	 1.57	
hsa-miR-509-3-5p	 1.57	
hsa-miR-1271-3p	 1.56	
hsa-miR-28-5p	 1.56	
hsa-miR-490-5p	 1.56	
hsa-miR-599	 1.56	
hsa-miR-625-5p	 1.56	
hsa-miR-6511a-3p	 1.56	
hsa-miR-132-3p	 1.55	
hsa-miR-152-3p	 1.55	
hsa-miR-409-3p	 1.55	
hsa-miR-4755-5p	 1.55	
hsa-miR-484	 1.55	
hsa-miR-518f-3p	 1.55	
hsa-miR-675-5p	 1.55	
hsa-miR-1200	 1.54	
hsa-miR-1236-3p	 1.54	
hsa-miR-2116-5p	 1.54	
hsa-miR-301a-5p	 1.54	
hsa-miR-433-5p	 1.54	
hsa-miR-510-3p	 1.54	
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hsa-miR-541-3p	 1.54	
hsa-miR-566	 1.54	
hsa-miR-219a-2-3p	 1.53	
hsa-miR-27a-3p	 1.53	
hsa-miR-302a-3p	 1.53	
hsa-miR-3605-5p	 1.53	
hsa-miR-424-5p	 1.53	
hsa-miR-1306-3p	 1.52	
hsa-miR-193b-3p	 1.52	
hsa-miR-196b-5p	 1.52	
hsa-miR-23c	 1.52	
hsa-miR-3613-3p	 1.52	
hsa-miR-378g	 1.52	
hsa-miR-518e-3p	 1.52	
hsa-miR-524-3p	 1.52	
hsa-miR-549a	 1.52	
hsa-miR-663a	 1.52	
hsa-miR-942-5p	 1.52	
hsa-miR-1245a	 1.51	
hsa-miR-1275	 1.51	
hsa-miR-193a-3p	 1.51	
hsa-miR-335-5p	 1.51	
hsa-miR-365a-3p+hsa-miR-365b-3p	 1.51	
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hsa-miR-200a-3p	 1.5	
hsa-miR-2113	 1.5	
hsa-miR-374a-3p	 1.5	
hsa-miR-449c-5p	 1.5	
hsa-miR-548q	 1.5	
hsa-miR-552-3p	 1.5	
hsa-miR-576-3p	 1.5	
hsa-miR-758-5p	 1.5	
hsa-miR-92a-1-5p	 1.5	
hsa-miR-1245b-3p	 1.49	
hsa-miR-134-3p	 1.49	
hsa-miR-3196	 1.49	
hsa-miR-4485-3p	 1.49	
hsa-miR-4536-5p	 1.49	
hsa-miR-584-5p	 1.49	
hsa-miR-612	 1.49	
hsa-miR-1252-5p	 1.48	
hsa-miR-126-3p	 1.48	
hsa-miR-1266-5p	 1.48	
hsa-miR-1469	 1.48	
hsa-miR-29c-3p	 1.48	
hsa-miR-362-3p	 1.48	
hsa-miR-374c-5p	 1.48	
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hsa-miR-429	 1.48	
hsa-miR-4488	 1.48	
hsa-miR-513a-5p	 1.48	
hsa-miR-585-3p	 1.48	
hsa-miR-619-3p	 1.48	
hsa-miR-766-5p	 1.48	
hsa-miR-105-5p	 1.47	
hsa-miR-1244	 1.47	
hsa-miR-1306-5p	 1.47	
hsa-miR-208b-3p	 1.47	
hsa-miR-302f	 1.47	
hsa-miR-3185	 1.47	
hsa-miR-3190-3p	 1.47	
hsa-miR-324-3p	 1.47	
hsa-miR-374a-5p	 1.47	
hsa-miR-3928-3p	 1.47	
hsa-miR-504-5p	 1.47	
hsa-miR-548a-5p	 1.47	
hsa-miR-1228-3p	 1.46	
hsa-miR-1268a	 1.46	
hsa-miR-140-3p	 1.46	
hsa-miR-183-5p	 1.46	
hsa-miR-184	 1.46	
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hsa-miR-1910-5p	 1.46	
hsa-miR-200b-3p	 1.46	
hsa-miR-3161	 1.46	
hsa-miR-339-5p	 1.46	
hsa-miR-376c-5p	 1.46	
hsa-miR-425-5p	 1.46	
hsa-miR-640	 1.46	
hsa-miR-1193	 1.45	
hsa-miR-147b	 1.45	
hsa-miR-200c-3p	 1.45	
hsa-miR-28-3p	 1.45	
hsa-miR-302c-3p	 1.45	
hsa-miR-487a-3p	 1.45	
hsa-miR-5010-3p	 1.45	
hsa-miR-503-5p	 1.45	
hsa-miR-514b-3p	 1.45	
hsa-miR-548z+hsa-miR-548h-3p	 1.45	
hsa-miR-551a	 1.45	
hsa-miR-99a-5p	 1.45	
hsa-miR-139-3p	 1.44	
hsa-miR-211-5p	 1.44	
hsa-miR-497-5p	 1.44	
hsa-miR-654-3p	 1.44	
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hsa-miR-346	 1.43	
hsa-miR-548al	 1.43	
hsa-miR-553	 1.43	
hsa-miR-605-5p	 1.43	
hsa-miR-651-5p	 1.43	
hsa-miR-891b	 1.43	
hsa-miR-124-3p	 1.42	
hsa-miR-1249-3p	 1.42	
hsa-miR-1909-3p	 1.42	
hsa-miR-217	 1.42	
hsa-miR-219b-3p	 1.42	
hsa-miR-337-5p	 1.42	
hsa-miR-371b-5p	 1.42	
hsa-miR-513c-5p	 1.42	
hsa-miR-629-5p	 1.42	
RPL19	 1.42	
hsa-miR-1202	 1.41	
hsa-miR-141-3p	 1.41	
hsa-miR-363-3p	 1.41	
hsa-miR-590-3p	 1.41	
hsa-miR-650	 1.41	
hsa-miR-765	 1.41	
hsa-miR-181c-5p	 1.4	
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hsa-miR-2110	 1.4	
hsa-miR-26b-5p	 1.4	
hsa-miR-30a-3p	 1.4	
hsa-miR-3195	 1.4	
hsa-miR-32-5p	 1.4	
hsa-miR-365b-5p	 1.4	
hsa-miR-510-5p	 1.4	
hsa-miR-513b-5p	 1.4	
hsa-miR-760	 1.4	
hsa-miR-934	 1.4	
hsa-miR-1286	 1.39	
hsa-miR-1290	 1.39	
hsa-miR-1293	 1.39	
hsa-miR-19b-3p	 1.39	
hsa-miR-4425	 1.39	
hsa-miR-5001-5p	 1.39	
hsa-miR-587	 1.39	
hsa-miR-627-3p	 1.39	
hsa-miR-648	 1.39	
hsa-miR-1260b	 1.38	
hsa-miR-154-5p	 1.38	
hsa-miR-301b-5p	 1.38	
hsa-miR-381-5p	 1.38	
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hsa-miR-520e	 1.38	
hsa-miR-548ai+hsa-miR-570-5p	 1.38	
hsa-miR-614	 1.38	
hsa-miR-631	 1.38	
hsa-miR-339-3p	 1.37	
hsa-miR-548c-5p+hsa-miR-548o-5p+hsa-miR-548am-5p	 1.37	
hsa-miR-608	 1.37	
hsa-miR-873-5p	 1.37	
hsa-miR-151b	 1.36	
hsa-miR-1973	 1.36	
hsa-miR-214-3p	 1.36	
hsa-miR-331-3p	 1.36	
hsa-miR-345-3p	 1.36	
hsa-miR-4455	 1.36	
hsa-miR-483-5p	 1.36	
hsa-miR-548ad-3p	 1.36	
hsa-miR-613	 1.36	
hsa-miR-887-5p	 1.36	
hsa-miR-146b-5p	 1.35	
hsa-miR-186-5p	 1.35	
hsa-miR-3147	 1.35	
hsa-miR-329-5p	 1.35	
hsa-miR-933	 1.35	
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hsa-miR-122-5p	 1.34	
hsa-miR-1246	 1.34	
hsa-miR-1253	 1.34	
hsa-miR-1277-3p	 1.34	
hsa-miR-128-3p	 1.34	
hsa-miR-1283	 1.34	
hsa-miR-143-3p	 1.34	
hsa-miR-152-5p	 1.34	
hsa-miR-199a-3p+hsa-miR-199b-3p	 1.34	
hsa-miR-302d-3p	 1.34	
hsa-miR-3144-3p	 1.34	
hsa-miR-378e	 1.34	
hsa-miR-422a	 1.34	
hsa-miR-494-3p	 1.34	
hsa-miR-502-5p	 1.34	
hsa-miR-505-3p	 1.34	
hsa-miR-519b-3p	 1.34	
hsa-miR-548aa+hsa-miR-548t-3p	 1.34	
hsa-miR-548ar-5p	 1.34	
hsa-miR-570-3p	 1.34	
hsa-miR-579-3p	 1.34	
hsa-miR-603	 1.34	
hsa-miR-627-5p	 1.34	
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hsa-miR-767-5p	 1.34	
hsa-miR-185-5p	 1.33	
hsa-miR-219a-5p	 1.33	
hsa-miR-30b-5p	 1.33	
hsa-miR-30e-5p	 1.33	
hsa-miR-3690	 1.33	
hsa-miR-518d-3p	 1.33	
hsa-miR-542-5p	 1.33	
hsa-miR-548e-5p	 1.33	
hsa-miR-764	 1.33	
hsa-miR-873-3p	 1.33	
hsa-miR-1205	 1.32	
hsa-miR-29b-3p	 1.32	
hsa-miR-539-5p	 1.32	
hsa-miR-561-5p	 1.32	
hsa-miR-582-5p	 1.32	
hsa-miR-1178-3p	 1.31	
hsa-miR-193a-5p+hsa-miR-193b-5p	 1.31	
hsa-miR-3065-3p	 1.31	
hsa-miR-3182	 1.31	
hsa-miR-410-3p	 1.31	
hsa-miR-450b-3p	 1.31	
hsa-miR-522-3p	 1.31	
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hsa-miR-1-5p	 1.3	
hsa-miR-298	 1.3	
hsa-miR-328-3p	 1.3	
hsa-miR-3614-5p	 1.3	
hsa-miR-374b-5p	 1.3	
hsa-miR-4458	 1.3	
hsa-miR-499b-3p	 1.3	
hsa-miR-543	 1.3	
hsa-miR-595	 1.3	
hsa-miR-639	 1.3	
hsa-miR-1255a	 1.29	
hsa-miR-133a-3p	 1.29	
hsa-miR-142-5p	 1.29	
hsa-miR-212-3p	 1.29	
hsa-miR-222-3p	 1.29	
hsa-miR-3918	 1.29	
hsa-miR-454-3p	 1.29	
hsa-miR-504-3p	 1.29	
hsa-miR-520h	 1.29	
hsa-miR-575	 1.29	
hsa-miR-770-5p	 1.29	
hsa-miR-924	 1.29	
hsa-miR-1234-3p	 1.28	
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hsa-miR-548e-3p	 1.28	
hsa-miR-300	 1.27	
hsa-miR-3605-3p	 1.27	
hsa-miR-432-5p	 1.27	
hsa-miR-519b-5p+hsa-miR-519c-5p+hsa-miR-523-5p+hsa-
miR-518e-5p+hsa-miR-522-5p+hsa-miR-519a-5p	
1.27	
hsa-miR-582-3p	 1.27	
hsa-miR-1304-5p	 1.26	
hsa-miR-134-5p+hsa-miR-6728-5p	 1.26	
hsa-miR-216a-5p	 1.26	
hsa-miR-22-3p	 1.26	
hsa-miR-328-5p	 1.26	
hsa-miR-34c-5p	 1.26	
hsa-miR-433-3p	 1.26	
hsa-miR-491-3p	 1.26	
hsa-miR-10b-5p	 1.25	
hsa-miR-24-3p	 1.25	
hsa-miR-3130-3p	 1.25	
hsa-miR-4524a-5p	 1.25	
hsa-miR-487b-5p	 1.25	
hsa-miR-494-5p	 1.25	
hsa-miR-526b-5p	 1.25	
hsa-miR-572	 1.25	
hsa-miR-620	 1.25	
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hsa-miR-654-5p	 1.25	
hsa-miR-125a-3p	 1.24	
hsa-miR-135b-5p	 1.24	
hsa-miR-137	 1.24	
hsa-miR-224-5p	 1.24	
hsa-miR-34b-3p	 1.24	
hsa-miR-516a-5p	 1.24	
hsa-miR-767-3p	 1.24	
hsa-miR-890	 1.24	
hsa-miR-1285-5p	 1.23	
hsa-miR-130a-3p	 1.23	
hsa-miR-139-5p	 1.23	
hsa-miR-320b	 1.23	
hsa-miR-4435	 1.23	
hsa-miR-499a-5p	 1.23	
hsa-miR-146a-5p	 1.22	
hsa-miR-3192-5p	 1.22	
hsa-miR-3614-3p	 1.22	
hsa-miR-4448	 1.22	
hsa-miR-548ah-5p	 1.22	
hsa-miR-885-5p	 1.22	
hsa-miR-936	 1.22	
hsa-miR-125b-5p	 1.21	
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hsa-miR-210-3p	 1.21	
hsa-miR-23b-3p	 1.21	
hsa-miR-377-3p	 1.21	
hsa-miR-99b-5p	 1.21	
hsa-miR-100-5p	 1.2	
hsa-miR-1204	 1.2	
hsa-miR-1303	 1.2	
hsa-miR-181a-3p	 1.2	
hsa-miR-187-3p	 1.2	
hsa-miR-376a-3p	 1.2	
hsa-miR-421	 1.2	
hsa-miR-450b-5p	 1.2	
hsa-miR-4787-3p	 1.2	
hsa-miR-493-3p	 1.2	
hsa-let-7f-5p	 1.19	
hsa-miR-1224-3p	 1.19	
hsa-miR-1257	 1.19	
hsa-miR-1269a	 1.19	
hsa-miR-1295a	 1.19	
hsa-miR-142-3p	 1.19	
hsa-miR-485-3p	 1.19	
hsa-miR-488-3p	 1.19	
hsa-miR-1307-5p	 1.18	
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hsa-miR-151a-3p	 1.18	
hsa-miR-4707-5p	 1.18	
hsa-miR-495-3p	 1.18	
hsa-miR-5010-5p	 1.18	
hsa-miR-520a-3p	 1.18	
hsa-miR-579-5p	 1.18	
hsa-miR-1269b	 1.17	
hsa-miR-501-3p	 1.17	
hsa-miR-517a-3p	 1.17	
hsa-miR-521	 1.17	
hsa-miR-548b-3p	 1.17	
hsa-miR-101-3p	 1.16	
hsa-miR-1296-5p	 1.16	
hsa-miR-181b-5p+hsa-miR-181d-5p	 1.16	
hsa-miR-190a-3p	 1.16	
hsa-miR-129-2-3p	 1.15	
hsa-miR-1323	 1.15	
hsa-miR-3151-5p	 1.15	
hsa-miR-548g-3p	 1.15	
hsa-miR-576-5p	 1.15	
hsa-miR-1827	 1.14	
hsa-miR-491-5p	 1.14	
hsa-miR-941	 1.14	
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hsa-miR-1233-3p	 1.13	
hsa-miR-127-3p	 1.13	
hsa-miR-199a-5p	 1.13	
hsa-miR-2053	 1.13	
hsa-miR-507	 1.13	
hsa-miR-525-3p	 1.13	
hsa-miR-548o-3p+hsa-miR-548ah-3p+hsa-miR-548av-3p	 1.13	
hsa-miR-548y	 1.13	
hsa-miR-655-3p	 1.13	
hsa-miR-874-3p	 1.13	
hsa-miR-509-3p	 1.12	
hsa-miR-564	 1.12	
hsa-miR-617	 1.12	
hsa-miR-92b-3p	 1.12	
hsa-miR-1-3p	 1.11	
hsa-miR-27b-3p	 1.11	
hsa-miR-548n	 1.11	
hsa-miR-578	 1.11	
hsa-miR-584-3p	 1.11	
hsa-miR-769-5p	 1.11	
hsa-miR-1248	 1.1	
hsa-miR-1976	 1.1	
hsa-miR-362-5p	 1.1	
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hsa-miR-455-3p	 1.1	
hsa-miR-515-3p	 1.1	
hsa-miR-106b-5p	 1.09	
hsa-miR-138-5p	 1.09	
hsa-miR-188-3p	 1.09	
hsa-miR-34a-5p	 1.09	
hsa-miR-591	 1.09	
hsa-miR-651-3p	 1.09	
hsa-miR-1273c	 1.08	
hsa-miR-1908-3p	 1.08	
hsa-miR-198	 1.08	
hsa-miR-297	 1.08	
hsa-miR-30d-5p	 1.08	
hsa-miR-450a-5p	 1.08	
hsa-miR-630	 1.08	
hsa-miR-652-5p	 1.08	
hsa-miR-1307-3p	 1.07	
hsa-miR-376b-3p	 1.07	
hsa-miR-450a-1-3p	 1.07	
hsa-miR-5196-5p	 1.07	
hsa-miR-545-3p	 1.07	
hsa-miR-548ar-3p	 1.07	
hsa-miR-761	 1.07	
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hsa-miR-766-3p	 1.07	
hsa-miR-98-3p	 1.07	
hsa-miR-194-5p	 1.06	
hsa-miR-514a-5p	 1.06	
hsa-miR-548d-3p	 1.06	
hsa-miR-573	 1.06	
hsa-miR-876-5p	 1.06	
hsa-miR-95-3p	 1.06	
hsa-miR-1250-5p	 1.05	
hsa-miR-203a-3p	 1.05	
hsa-miR-33a-5p	 1.05	
hsa-miR-499a-3p	 1.05	
hsa-miR-1972	 1.04	
hsa-miR-371a-5p	 1.04	
hsa-miR-375	 1.04	
hsa-miR-431-5p	 1.04	
hsa-miR-4792	 1.04	
hsa-miR-642a-5p	 1.04	
hsa-let-7e-5p	 1.03	
hsa-miR-133b	 1.03	
hsa-miR-30e-3p	 1.03	
hsa-miR-378d	 1.03	
hsa-miR-492	 1.03	
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hsa-miR-671-3p	 1.03	
hsa-miR-502-3p	 1.02	
hsa-miR-888-5p	 1.02	
hsa-miR-1271-5p	 1.01	
hsa-miR-1322	 1.01	
hsa-miR-148b-3p	 1.01	
hsa-miR-596	 1.01	
hsa-miR-661	 1	
hsa-miR-1298-5p	 -1	
hsa-miR-326	 -1.01	
hsa-miR-4284	 -1.01	
hsa-miR-451a	 -1.01	
hsa-miR-517b-3p	 -1.01	
hsa-miR-600	 -1.01	
hsa-miR-26a-5p	 -1.02	
hsa-miR-499b-5p	 -1.02	
hsa-miR-548ak	 -1.02	
hsa-miR-129-5p	 -1.03	
hsa-miR-448	 -1.03	
hsa-miR-4707-3p	 -1.03	
hsa-miR-486-3p	 -1.03	
hsa-miR-514b-5p	 -1.03	
hsa-miR-5196-3p+hsa-miR-6732-3p	 -1.03	
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hsa-miR-199b-5p	 -1.04	
hsa-miR-361-5p	 -1.04	
hsa-miR-376c-3p	 -1.04	
hsa-miR-607	 -1.04	
hsa-miR-107	 -1.05	
hsa-miR-190b	 -1.05	
hsa-miR-320e	 -1.05	
hsa-miR-2278	 -1.06	
hsa-miR-520f-3p	 -1.06	
hsa-miR-642a-3p	 -1.06	
hsa-miR-1276	 -1.07	
hsa-miR-147a	 -1.07	
hsa-miR-15a-5p	 -1.07	
hsa-miR-3136-5p	 -1.07	
hsa-miR-656-3p	 -1.07	
hsa-miR-98-5p	 -1.07	
hsa-miR-1255b-5p	 -1.08	
hsa-miR-30a-5p	 -1.08	
hsa-miR-323a-5p	 -1.08	
hsa-miR-6724-5p	 -1.08	
hsa-miR-515-5p	 -1.09	
hsa-miR-606	 -1.1	
hsa-miR-802	 -1.1	
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hsa-miR-644a	 -1.11	
hsa-miR-660-3p	 -1.11	
hsa-miR-188-5p	 -1.12	
hsa-miR-610	 -1.12	
hsa-miR-513c-3p	 -1.13	
hsa-miR-135a-5p	 -1.14	
hsa-miR-378h	 -1.14	
hsa-miR-301a-3p	 -1.15	
hsa-miR-604	 -1.15	
hsa-miR-106a-5p+hsa-miR-17-5p	 -1.16	
hsa-miR-1203	 -1.16	
hsa-miR-125a-5p	 -1.16	
hsa-miR-324-5p	 -1.16	
hsa-miR-875-3p	 -1.17	
hsa-miR-16-5p	 -1.19	
hsa-miR-4521	 -1.19	
hsa-miR-342-3p	 -1.2	
hsa-miR-574-5p	 -1.2	
hsa-miR-378i	 -1.22	
hsa-miR-423-3p	 -1.22	
hsa-miR-874-5p	 -1.23	
hsa-miR-1260a	 -1.24	
hsa-miR-30c-5p	 -1.24	
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hsa-miR-520a-5p	 -1.26	
hsa-miR-935	 -1.3	
hsa-miR-562	 -1.32	
hsa-miR-9-5p	 -1.32	
hsa-miR-128-1-5p	 -1.33	
hsa-miR-361-3p	 -1.33	
hsa-miR-21-5p	 -1.34	
hsa-miR-1206	 -1.35	
hsa-miR-130b-3p	 -1.36	
hsa-miR-1247-5p	 -1.37	
hsa-miR-548d-5p	 -1.37	
hsa-miR-574-3p	 -1.38	
hsa-miR-5001-3p	 -1.39	
hsa-miR-208a-3p	 -1.42	
hsa-miR-877-5p	 -1.43	
hsa-miR-197-3p	 -1.44	
hsa-miR-940	 -1.46	
hsa-miR-221-3p	 -1.48	
hsa-miR-20a-5p+hsa-miR-20b-5p	 -1.52	
hsa-miR-3158-3p	 -1.52	
hsa-miR-520d-5p+hsa-miR-527+hsa-miR-518a-5p	 -1.52	
hsa-miR-1908-5p	 -1.58	
hsa-miR-4454+hsa-miR-7975	 -1.58	
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hsa-miR-25-3p	 -1.59	
hsa-miR-3916	 -1.61	
hsa-miR-4443	 -1.66	
hsa-miR-155-5p	 -1.7	
ACTB	 -1.7	
hsa-miR-423-5p	 -2.36	
hsa-miR-181a-5p	 -2.39	
B2M	 -2.78	
hsa-miR-93-5p	 -2.84	
hsa-let-7i-5p	 -2.9	
hsa-miR-92a-3p	 -2.95	
hsa-miR-223-3p	 -3.13	
hsa-let-7g-5p	 -3.18	
hsa-miR-23a-3p	 -3.41	
hsa-let-7d-5p	 -5.33	
hsa-miR-3065-5p	 -6.02	
hsa-let-7c-5p	 -6.14	
hsa-miR-15b-5p	 -6.27	
hsa-miR-191-5p	 -10.17	
hsa-let-7b-5p	 -11.63	
hsa-let-7a-5p	 -340.82	
	
	
	
Athalia	Rachel	Pyzer	 Appendix	G:	Data	Sets	(mRNA	and	miRNA	arrays)	
	
261	
	 	
Athalia	Rachel	Pyzer	 	 References		
References	
1.	 Billingham	RE,	Brent	L,	Medawar	PB.	“Actively	acquired	tolerance”	of	foreign	
cells.	1953.	J.	Immunol.	2010;184(1):5–8.		
2.	 BILLINGHAM	RE,	BRENT	L,	MEDAWAR	PB.	The	antigenic	stimulus	in	
transplantation	immunity.	Nature.	1956;178(4532):514–519.		
3.	 BURNET	M.	Cancer;	a	biological	approach.	I.	The	processes	of	control.	Br.	Med.	J.	
1957;1(5022):779–786.		
4.	 Thomas.	In	Cellular	and	Humoral	Aspects	of	the	Hypersensitive	States.	Hoeber-
Harper;	1959.		
5.	 Birkeland	SA,	Storm	HH,	Lamm	LU,	et	al.	Cancer	risk	after	renal	transplantation	in	
the	Nordic	countries,	1964-1986.	Int.	J.	Cancer.	1995;60(2):183–189.		
6.	 Butturini	A,	Bortin	MM,	Gale	RP.	Graft-versus-leukemia	following	bone	marrow	
transplantation.	Bone	Marrow	Transplant.	1987;2(3):233–242.		
7.	 Hassane	M.	Zarour,	MD,	Albert	DeLeo,	PhD,	Olivera	J.	Finn,	PhD,	and	Walter	J.	
Storkus	P.	Cancer	Medicine.		
8.	 Nath	S,	Mukherjee	P.	MUC1:	A	multifaceted	oncoprotein	with	a	key	role	in	cancer	
progression.	Trends	Mol.	Med.	2014;20(6):332–342.		
9.	 Ascierto	ML,	Melero	I,	Ascierto	PA.	Melanoma:	From	Incurable	Beast	to	a	Curable	
Bet.	The	Success	of	Immunotherapy.	Front.	Oncol.	2015;5:152.		
10.	 Dunn	GP,	Old	LJ,	Schreiber	RD.	The	three	Es	of	cancer	immunoediting.	Annu.	Rev.	
Immunol.	2004;22:329–360.		
11.	 Koebel	CM,	Vermi	W,	Swann	JB,	et	al.	Adaptive	immunity	maintains	occult	cancer	
in	an	equilibrium	state.	Nature.	2007;450(7171):903–907.		
12.	 Khong	HT,	Restifo	NP.	Natural	selection	of	tumor	variants	in	the	generation	of	
Athalia	Rachel	Pyzer	 	 References	
	
263	
“tumor	escape”	phenotypes.	Nat.	Immunol.	2002;3(11):999–1005.		
13.	 Chen	L,	Ashe	S,	Brady	WA,	et	al.	Costimulation	of	antitumor	immunity	by	the	B7	
counterreceptor	for	the	T	lymphocyte	molecules	CD28	and	CTLA-4.	Cell.	
1992;71(7):1093–1102.		
14.	 Speiser	DE,	Miranda	R,	Zakarian	A,	et	al.	Self	antigens	expressed	by	solid	tumors	
Do	not	efficiently	stimulate	naive	or	activated	T	cells:	implications	for	
immunotherapy.	J.	Exp.	Med.	1997;186(5):645–653.		
15.	 Gerlini	G,	Tun-Kyi	A,	Dudli	C,	et	al.	Metastatic	melanoma	secreted	IL-10	down-
regulates	CD1	molecules	on	dendritic	cells	in	metastatic	tumor	lesions.	Am.	J.	
Pathol.	2004;165(6):1853–1863.		
16.	 Gabrilovich	DI,	Chen	HL,	Girgis	KR,	et	al.	Production	of	vascular	endothelial	
growth	factor	by	human	tumors	inhibits	the	functional	maturation	of	dendritic	
cells.	Nat.	Med.	1996;2(10):1096–1103.		
17.	 Ma	Y,	Shurin	G	V.,	Peiyuan	Z,	Shurin	MR.	Dendritic	cells	in	the	cancer	
microenvironment.	J.	Cancer.	2013;4(1):36–44.		
18.	 Steinman	RM,	Hawiger	D,	Nussenzweig	MC.	Tolerogenic	dendritic	cells.	Annu.	
Rev.	Immunol.	2003;21:685–711.		
19.	 Almand	B,	Resser	JR,	Lindman	B,	et	al.	Clinical	significance	of	defective	dendritic	
cell	differentiation	in	cancer.	Clin.	Cancer	Res.	2000;6(5):1755–1766.		
20.	 Nestle	FO,	Burg	G,	Fäh	J,	Wrone-Smith	T,	Nickoloff	BJ.	Human	sunlight-induced	
basal-cell-carcinoma-associated	dendritic	cells	are	deficient	in	T	cell	co-
stimulatory	molecules	and	are	impaired	as	antigen-presenting	cells.	Am.	J.	Pathol.	
1997;150(2):641–651.		
21.	 Troy	A,	Davidson	P,	Atkinson	C,	Hart	D.	Phenotypic	characterisation	of	the	
dendritic	cell	infiltrate	in	prostate	cancer.	J.	Urol.	1998;160(1):214–219.		
Athalia	Rachel	Pyzer	 	 References	
	
264	
22.	 Hartmann	E,	Wollenberg	B,	Rothenfusser	S,	et	al.	Identification	and	functional	
analysis	of	tumor-infiltrating	plasmacytoid	dendritic	cells	in	head	and	neck	cancer.	
Cancer	Res.	2003;63(19):6478–6487.		
23.	 Facchetti	F,	Vermi	W,	Mason	D,	Colonna	M.	The	plasmacytoid	
monocyte/interferon	producing	cells.	Virchows	Arch.	2003;443(6):703–717.		
24.	 Zou	W,	Machelon	V,	Coulomb-L’Hermin	A,	et	al.	Stromal-derived	factor-1	in	
human	tumors	recruits	and	alters	the	function	of	plasmacytoid	precursor	
dendritic	cells.	Nat.	Med.	2001;7(12):1339–1346.		
25.	 Liyanage	UK,	Moore	TT,	Joo	H-G,	et	al.	Prevalence	of	regulatory	T	cells	is	
increased	in	peripheral	blood	and	tumor	microenvironment	of	patients	with	
pancreas	or	breast	adenocarcinoma.	J.	Immunol.	2002;169(5):2756–2761.		
26.	 Curiel	TJ,	Coukos	G,	Zou	L,	et	al.	Specific	recruitment	of	regulatory	T	cells	in	
ovarian	carcinoma	fosters	immune	privilege	and	predicts	reduced	survival.	Nat.	
Med.	2004;10(9):942–949.		
27.	 Halvorsen	EC,	Mahmoud	SM,	Bennewith	KL.	Emerging	roles	of	regulatory	T	cells	in	
tumour	progression	and	metastasis.	Cancer	Metastasis	Rev.	2014;33(4):1025–41.		
28.	 Berger	CL,	Tigelaar	R,	Cohen	J,	et	al.	Cutaneous	T-cell	lymphoma:	Malignant	
proliferation	of	T-regulatory	cells.	Blood.	2005;105(4):1640–1647.		
29.	 Beyer	M,	Kochanek	M,	Darabi	K,	et	al.	Reduced	frequencies	and	suppressive	
function	of	CD4+CD25hi	regulatory	T	cells	in	patients	with	chronic	lymphocytic	
leukemia	after	therapy	with	fludarabine.	Blood.	2005;106(6):2018–2025.		
30.	 Gabrilovich	DI,	Ostrand-Rosenberg	S,	Bronte	V.	Coordinated	regulation	of	myeloid	
cells	by	tumours.	Nat.	Rev.	Immunol.	2012;12(4):253–268.		
31.	 Dong	H,	Strome	SE,	Salomao	DR,	et	al.	Tumor-associated	B7-H1	promotes	T-cell	
apoptosis:	a	potential	mechanism	of	immune	evasion.	Nat.	Med.	2002;8(8):793–
Athalia	Rachel	Pyzer	 	 References	
	
265	
800.		
32.	 Malmberg	KJ,	Levitsky	V,	Norell	H,	et	al.	IFN-γ	protects	short-term	ovarian	
carcinoma	cell	lines	from	CTL	lysis	via	a	CD94/NKG2A-dependent	mechanism.	J.	
Clin.	Invest.	2002;110(10):1515–1523.		
33.	 Derré	L,	Corvaisier	M,	Charreau	B,	et	al.	Expression	and	release	of	HLA-E	by	
melanoma	cells	and	melanocytes:	potential	impact	on	the	response	of	cytotoxic	
effector	cells.	J.	Immunol.	2006;177(5):3100–3107.		
34.	 Srivastava	N,	Avigan	D,	Rosenblatt	J.	PD-1	blockade	in	cancer	immunotherapy.	
Drugs	Future.	2014;39(2):129–132.		
35.	 Weber	J.	Immune	checkpoint	proteins:	A	new	therapeutic	paradigm	for	
cancerpreclinical	background:	CTLA-4	and	PD-1	blockade.	Semin.	Oncol.	
2010;37(5):430–439.		
36.	 Borch	TH,	Donia	M,	Andersen	MH,	Svane	IM.	Reorienting	the	immune	system	in	
the	treatment	of	cancer	by	using	anti-PD-1	and	anti-PD-L1	antibodies.	Drug	
Discov.	Today.	2015;		
37.	 Munn	DH,	Shafizadeh	E,	Attwood	JT,	et	al.	Inhibition	of	T	cell	proliferation	by	
macrophage	tryptophan	catabolism.	J.	Exp.	Med.	1999;189(9):1363–1372.		
38.	 Zamarron	BF,	Chen	W.	Dual	roles	of	immune	cells	and	their	factors	in	cancer	
development	and	progression.	Int.	J.	Biol.	Sci.	2011;7(5):651–658.		
39.	 Society	AC.	Leukemia	AML	Guide.		
40.	 Falini	B,	Tiacci	E,	Martelli	MP,	Ascani	S,	Pileri	SA.	New	classification	of	acute	
myeloid	leukemia	and	precursor-related	neoplasms:	changes	and	unsolved	issues.	
Discov.	Med.	2010;10(53):281–292.		
41.	 Vardiman	J,	Reichard	K.	Acute	Myeloid	Leukemia	With	Myelodysplasia-Related	
Changes.	Am.	J.	Clin.	Pathol.	2015;144(1):29–43.		
Athalia	Rachel	Pyzer	 	 References	
	
266	
42.	 Feldman	EJ.	Novel	Therapeutics	for	Therapy-Related	Acute	Myeloid	Leukemia:	
2014.	Clin.	Lymphoma.	Myeloma	Leuk.	2015;15	Suppl:S91-3.		
43.	 Bueso-Ramos	CE,	Kanagal-Shamanna	R,	Routbort	MJ,	Hanson	CA.	Therapy-
Related	Myeloid	Neoplasms.	Am.	J.	Clin.	Pathol.	2015;144(2):207–18.		
44.	 Khalade	A,	Jaakkola	MS,	Pukkala	E,	Jaakkola	JJK.	Exposure	to	benzene	at	work	and	
the	risk	of	leukemia:	a	systematic	review	and	meta-analysis.	Environ.	Health.	
2010;9:31.		
45.	 Caldwell	JT,	Ge	Y,	Taub	JW.	Prognosis	and	management	of	acute	myeloid	
leukemia	in	patients	with	Down	syndrome.	Expert	Rev.	Hematol.	2014;7(6):831–
40.		
46.	 Alter	BP.	Fanconi	anemia	and	the	development	of	leukemia.	Best	Pract.	Res.	Clin.	
Haematol.	27(3–4):214–21.		
47.	 Bennett	JM,	Catovsky	D,	Daniel	MT,	et	al.	Proposals	for	the	classification	of	the	
acute	leukaemias.	French-American-British	(FAB)	co-operative	group.	Br.	J.	
Haematol.	1976;33(4):451–458.		
48.	 Bennett	JM,	Catovsky	D,	Daniel	MT,	et	al.	Proposed	revised	criteria	for	the	
classification	of	acute	myeloid	leukemia.	A	report	of	the	French-American-British	
Cooperative	Group.	Ann.	Intern.	Med.	1985;103(4):620–625.		
49.	 Grimwade	D,	Walker	H,	Oliver	F,	et	al.	The	importance	of	diagnostic	cytogenetics	
on	outcome	in	AML:	analysis	of	1,612	patients	entered	into	the	MRC	AML	10	trial.	
The	Medical	Research	Council	Adult	and	Children’s	Leukaemia	Working	Parties.	
1998.		
50.	 Ossenkoppele	G,	Löwenberg	B.	How	I	treat	the	older	patient	with	acute	myeloid	
leukemia.	Blood.	2015;125(5):767–74.		
51.	 Yates	JW,	Wallace	HJ,	Ellison	RR,	Holland	JF.	Cytosine	arabinoside	(NSC-63878)	
Athalia	Rachel	Pyzer	 	 References	
	
267	
and	daunorubicin	(NSC-83142)	therapy	in	acute	nonlymphocytic	leukemia.		
52.	 Billingham	RE.	The	biology	of	graft-versus-host	reactions.	Harvey	Lect.	62:21–78.		
53.	 Cornelissen	JJ,	Van	Putten	WLJ,	Verdonck	LF,	et	al.	Results	of	a	HOVON/SAKK	
donor	versus	no-donor	analysis	of	myeloablative	HLA-identical	sibling	stem	cell	
transplantation	in	first	remission	acute	myeloid	leukemia	in	young	and	middle-
aged	adults:	Benefits	for	whom?	Blood.	2007;109(9):3658–3666.		
54.	 Cornelissen	JJ,	Gratwohl	A,	Schlenk	RF,	et	al.	The	European	LeukemiaNet	AML	
Working	Party	consensus	statement	on	allogeneic	HSCT	for	patients	with	AML	in	
remission:	an	integrated-risk	adapted	approach.	Nat.	Rev.	Clin.	Oncol.	
2012;9(10):579–590.		
55.	 Gratwohl	A,	Baldomero	H,	Horisberger	B,	et	al.	Current	trends	in	hematopoietic	
stem	cell	transplantation	in	Europe.	Blood.	2002;100(7):2374–2386.		
56.	 Kurosawa	S,	Yamaguchi	T,	Uchida	N,	et	al.	Comparison	of	allogeneic	
hematopoietic	cell	transplantation	and	chemotherapy	in	elderly	patients	with	
non-M3	acute	myelogenous	leukemia	in	first	complete	remission.	Biol.	Blood	
Marrow	Transplant.	2011;17(3):401–411.		
57.	 Tsimberidou	A-M,	Stavroyianni	N,	Viniou	N,	et	al.	Comparison	of	allogeneic	stem	
cell	transplantation,	high-dose	cytarabine,	and	autologous	peripheral	stem	cell	
transplantation	as	postremission	treatment	in	patients	with	de	novo	acute	
myelogenous	leukemia.	2003.		
58.	 Büchner	T,	Berdel	WE,	Schoch	C,	et	al.	Double	induction	containing	either	two	
courses	or	one	course	of	high-dose	cytarabine	plus	mitoxantrone	and	
postremission	therapy	by	either	autologous	stem-cell	transplantation	or	by	
prolonged	maintenance	for	acute	myeloid	leukemia.	J.	Clin.	Oncol.	
2006;24(16):2480–2489.		
59.	 Rowe	JM,	Löwenberg	B.	Gemtuzumab	ozogamicin	in	acute	myeloid	leukemia:	a	
Athalia	Rachel	Pyzer	 	 References	
	
268	
remarkable	saga	about	an	active	drug.	Blood.	2013;121(24):4838–4841.		
60.	 Kim	TK,	Gore	SD,	Zeidan	AM.	Epigenetic	Therapy	in	Acute	Myeloid	Leukemia:	
Current	and	Future	Directions.	Semin.	Hematol.	2015;52(3):172–83.		
61.	 Dombret	H,	Seymour	J,	Butrym	A,	et	al.	International	phase	3	study	of	azacitidine	
vs	conventional	care	regimens	in	older	patients	with	newly	diagnosed	AML	with	
>30%	blasts.	Blood.	2015;		
62.	 Kantarjian	HM,	Thomas	XG,	Dmoszynska	A,	et	al.	Multicenter,	randomized,	open-
label,	phase	III	trial	of	decitabine	versus	patient	choice,	with	physician	advice,	of	
either	supportive	care	or	low-dose	cytarabine	for	the	treatment	of	older	patients	
with	newly	diagnosed	acute	myeloid	leukemia.	J.	Clin.	Oncol.	2012;30(21):2670–
2677.		
63.	 H.M.	Kantarjian,	E.	Jabbour,	K.	Yee		et	al.	No	Title.	Am.	Soc.	Hematol.	Annu.	Meet.	
Expo.	2013;		
64.	 Kuendgen	A,	Knipp	S,	Fox	F,	et	al.	Results	of	a	phase	2	study	of	valproic	acid	alone	
or	in	combination	with	all-trans	retinoic	acid	in	75	patients	with	myelodysplastic	
syndrome	and	relapsed	or	refractory	acute	myeloid	leukemia.	2005.		
65.	 Garcia-Manero	G,	Yang	H,	Bueso-Ramos	C,	et	al.	Phase	1	study	of	the	histone	
deacetylase	inhibitor	vorinostat	(suberoylanilide	hydroxamic	acid	[SAHA])	in	
patients	with	advanced	leukemias	and	myelodysplastic	syndromes.	Blood.	
2008;111(3):1060–1066.		
66.	 Zeidner	JF,	Foster	MC,	Blackford	AL,	et	al.	Randomized	multicenter	phase	2	study	
of	flavopiridol	(alvocidib),	cytarabine,	and	mitoxantrone	(FLAM)	versus	
cytarabine/daunorubicin	(7+3)	in	newly	diagnosed	acute	myeloid	leukemia.	
Haematologica.	2015;		
67.	 Levis	M,	Ravandi	F,	Wang	ES,	et	al.	Results	from	a	randomized	trial	of	salvage	
chemotherapy	followed	by	lestaurtinib	for	patients	with	FLT3	mutant	AML	in	first	
Athalia	Rachel	Pyzer	 	 References	
	
269	
relapse.	Blood.	2011;117(12):3294–3301.		
68.	 Borthakur	G,	Kantarjian	H,	Ravandi	F,	et	al.	Phase	I	study	of	sorafenib	in	patients	
with	refractory	or	relapsed	acute	leukemias.	Haematologica.	2011;96(1):62–68.		
69.	 Metzelder	S,	Wang	Y,	Wollmer	E,	et	al.	Compassionate	use	of	sorafenib	in	FLT3-
ITD-positive	acute	myeloid	leukemia:	sustained	regression	before	and	after	
allogeneic	stem	cell	transplantation.	2009.		
70.	 Ravandi	F,	Alattar	ML,	Grunwald	MR,	et	al.	Phase	2	study	of	azacytidine	plus	
sorafenib	in	patients	with	acute	myeloid	leukemia	and	FLT-3	internal	tandem	
duplication	mutation.	Blood.	2013;121(23):4655–4662.		
71.	 Tettamanti	S,	Marin	V,	Pizzitola	I,	et	al.	Targeting	of	acute	myeloid	leukaemia	by	
cytokine-induced	killer	cells	redirected	with	a	novel	CD123-specific	chimeric	
antigen	receptor.	Br.	J.	Haematol.	2013;161(3):389–401.		
72.	 Konopleva	M,	Hogge	DE,	Rizzieri	DA		et	al.	No	Title.	2012;		
73.	 Marcucci	G.,	Moser	B.,	Blum	W.,	Stock	W.,	Wetzler	M.,	Kolitz	J.E.,	Thakuri	M.,	
Carter	T.,	Stuart	R.K.	LRA.	No	Title.	ASCO.	2007;		
74.	 Moore	J,	Seiter	K,	Kolitz	J,	et	al.	A	Phase	II	study	of	Bcl-2	antisense	(oblimersen	
sodium)	combined	with	gemtuzumab	ozogamicin	in	older	patients	with	acute	
myeloid	leukemia	in	first	relapse.	Leuk.	Res.	2006;30(7):777–783.		
75.	 Stengel	C,	Jenner	E,	Meja	K,	Mayekar	S,	Khwaja	A.	Proliferation	of	PTEN-deficient	
haematopoietic	tumour	cells	is	not	affected	by	isoform-selective	inhibition	of	
p110??	PI3-kinase	and	requires	blockade	of	all	class	1	PI3K	activity.	Br.	J.	
Haematol.	2013;162(2):285–289.		
76.	 Kampa-Schittenhelm	KM,	Heinrich	MC,	Akmut	F,	et	al.	Cell	cycle-dependent	
activity	of	the	novel	dual	PI3K-MTORC1/2	inhibitor	NVP-BGT226	in	acute	
leukemia.	Mol.	Cancer.	2013;12:46.		
Athalia	Rachel	Pyzer	 	 References	
	
270	
77.	 Altman	JK,	Sassano	A,	Kaur	S,	et	al.	Dual	mTORC2/mTORC1	targeting	results	in	
potent	suppressive	effects	on	Acute	Myeloid	Leukemia	(AML)	progenitors.	Clin.	
Cancer	Res.	2011;17(13):4378–4388.		
78.	 Zeng	Z,	Shi	YX,	Tsao	T,	et	al.	Targeting	of	mTORC1/2	by	the	mTOR	kinase	inhibitor	
PP242	induces	apoptosis	in	AML	cells	under	conditions	mimicking	the	bone	
marrow	microenvironment.	Blood.	2012;120(13):2679–2689.		
79.	 Reuter	CW,	Morgan	MA,	Bergmann	L.	Targeting	the	Ras	signaling	pathway:	a	
rational,	mechanism-based	treatment	for	hematologic	malignancies?	Blood.	
2000;96(5):1655–1669.		
80.	 Erba	HP,	Othus	M,	Walter	RB,	et	al.	Four	different	regimens	of	farnesyltransferase	
inhibitor	tipifarnib	in	older,	untreated	acute	myeloid	leukemia	patients:	North	
American	Intergroup	Phase	II	study	SWOG	S0432.	Leuk.	Res.	2014;38(3):329–333.		
81.	 Burnett	AK,	Russell	NH,	Culligan	D,	et	al.	The	addition	of	the	farnesyl	transferase	
inhibitor,	tipifarnib,	to	low	dose	cytarabine	does	not	improve	outcome	for	older	
patients	with	AML.	Br.	J.	Haematol.	2012;158(4):519–522.		
82.	 Coley	WB.	The	treatment	of	malignant	tumors	by	repeated	inoculations	of	
erysipelas.	With	a	report	of	ten	original	cases.	1893.	Clin	Orthop	Relat	Res.	
1991;(262):3–11.		
83.	 Fozza	C,	Bellizzi	S,	Bonfigli	S,	et	al.	Cytogenetic	and	hematological	spontaneous	
remission	in	a	case	of	acute	myelogenous	leukemia.	Eur.	J.	Haematol.	
2004;73(3):219–222.		
84.	 Ifrah	N,	James	JM,	Viguie	F,	Marie	JP,	Zittoun	R.	Spontaneous	remission	in	adult	
acute	leukemia.	Cancer.	1985;56(5):1187–1190.		
85.	 Maywald	O,	Buchheidt	D,	Bergmann	J,	et	al.	Spontaneous	remission	in	adult	acute	
myeloid	leukemia	in	association	with	systemic	bacterial	infection-case	report	and	
review	of	the	literature.	Ann.	Hematol.	2004;83(3):189–194.		
Athalia	Rachel	Pyzer	 	 References	
	
271	
86.	 Trof	RJ,	Beishuizen	A,	Wondergem	MJ,	Strack	van	Schijndel	RJM.	Spontaneous	
remission	of	acute	myeloid	leukaemia	after	recovery	from	sepsis.	Neth.	J.	Med.	
2007;65(7):259–262.		
87.	 Horowitz	MM,	Gale	RP,	Sondel	PM,	et	al.	Graft-versus-leukemia	reactions	after	
bone	marrow	transplantation.	Blood.	1990;75(3):555–562.		
88.	 Brouwer	RE,	Zwinderman	KH,	Kluin-Nelemans	HC,	et	al.	Expression	and	induction	
of	costimulatory	and	adhesion	molecules	on	acute	myeloid	leukemic	cells:	
implications	for	adoptive	immunotherapy.	Exp.	Hematol.	2000;28(2):161–168.		
89.	 Vollmer	M,	Li	L,	Schmitt	A,	et	al.	Expression	of	human	leucocyte	antigens	and	co-
stimulatory	molecules	on	blasts	of	patients	with	acute	myeloid	leukaemia.	Br.	J.	
Haematol.	2003;120(6):1000–1008.		
90.	 Whiteway	A,	Corbett	T,	Anderson	R,	Macdonald	I,	Grant	Prentice	H.	Expression	of	
co-stimulatory	molecules	on	acute	myeloid	leukaemia	blasts	may	effect	duration	
of	first	remission.	Br.	J.	Haematol.	2003;120(3):442–451.		
91.	 Freeman-Keller	M,	Weber	JS.	Anti-programmed	death	receptor	1	immunotherapy	
in	melanoma:	rationale,	evidence	and	clinical	potential.	Ther	Adv	Med	Oncol.	
2015;7(1):12–21.		
92.	 Napolitano	M,	D’Alterio	C,	Cardone	E,	et	al.	Peripheral	myeloid-derived	
suppressor	and	T	regulatory	PD-1	positive	cells	predict	response	to	neoadjuvant	
short-course	radiotherapy	in	rectal	cancer	patients.	Oncotarget.	
2015;6(10):8261–70.		
93.	 Noman	MZ,	Desantis	G,	Janji	B,	et	al.	PD-L1	is	a	novel	direct	target	of	HIF-1α,	and	
its	blockade	under	hypoxia	enhanced	MDSC-mediated	T	cell	activation.	J.	Exp.	
Med.	2014;211(5):781–90.		
94.	 Kong	Y,	Zhang	J,	Claxton	DF,	et	al.	PD-1(hi)TIM-3(+)	T	cells	associate	with	and	
predict	leukemia	relapse	in	AML	patients	post	allogeneic	stem	cell	
Athalia	Rachel	Pyzer	 	 References	
	
272	
transplantation.	Blood	Cancer	J.	2015;5:e330.		
95.	 Berthon	C,	Driss	V,	Liu	J,	et	al.	In	acute	myeloid	leukemia,	B7-H1	(PD-L1)	
protection	of	blasts	from	cytotoxic	T	cells	is	induced	by	TLR	ligands	and	
interferon-gamma	and	can	be	reversed	using	MEK	inhibitors.	Cancer	Immunol.	
Immunother.	2010;59(12):1839–1849.		
96.	 Rosenblatt	J,	Glotzbecker	B,	Mills	H,	et	al.	PD-1	blockade	by	CT-011,	anti-PD-1	
antibody,	enhances	ex	vivo	T-cell	responses	to	autologous	dendritic	cell/myeloma	
fusion	vaccine.	J	Immunother.	2011;34(5):409–418.		
97.	 Zhou	Q,	Munger	ME,	Veenstra	RG,	et	al.	Coexpression	of	Tim-3	and	PD-1	
identifies	a	CD8+	T-cell	exhaustion	phenotype	in	mice	with	disseminated	acute	
myelogenous	leukemia.	Blood.	2011;117(17):4501–4510.		
98.	 Gao	L,	Yu	S,	Zhang	X.	Hypothesis:	Tim-3/galectin-9,	a	new	pathway	for	leukemia	
stem	cells	survival	by	promoting	expansion	of	myeloid-derived	suppressor	cells	
and	differentiating	into	tumor-associated	macrophages.	Cell	Biochem.	Biophys.	
2014;70(1):273–7.		
99.	 Kikushige	Y,	Miyamoto	T,	Yuda	J,	et	al.	A	TIM-3/Gal-9	Autocrine	Stimulatory	Loop	
Drives	Self-Renewal	of	Human	Myeloid	Leukemia	Stem	Cells	and	Leukemic	
Progression.	Cell	Stem	Cell.	2015;		
100.	 Folgiero	V,	Cifaldi	L,	Li	Pira	G,	et	al.	TIM-3/Gal-9	interaction	induces	IFNγ-
dependent	IDO1	expression	in	acute	myeloid	leukemia	blast	cells.	J.	Hematol.	
Oncol.	2015;8:36.		
101.	 Li	C,	Chen	X,	Yu	X,	et	al.	Tim-3	is	highly	expressed	in	T	cells	in	acute	myeloid	
leukemia	and	associated	with	clinicopathological	prognostic	stratification.	Int	J	
Clin	Exp	Pathol.	2014;7(10):6880–6888.		
102.	 Laurent	S,	Palmisano	GL,	Martelli	AM,	et	al.	CTLA-4	expressed	by	chemoresistant,	
as	well	as	untreated,	myeloid	leukaemia	cells	can	be	targeted	with	ligands	to	
Athalia	Rachel	Pyzer	 	 References	
	
273	
induce	apoptosis.	Br.	J.	Haematol.	2007;136(4):597–608.		
103.	 Zhong	RK,	Loken	M,	Lane	TA,	Ball	ED.	CTLA-4	blockade	by	a	human	MAb	enhances	
the	capacity	of	AML-derived	DC	to	induce	T-cell	responses	against	AML	cells	in	an	
autologous	culture	system.	Cytotherapy.	2006;8(1):3–12.		
104.	 Rodriguez	PC,	Quiceno	DG,	Zabaleta	J,	et	al.	Arginase	I	production	in	the	tumor	
microenvironment	by	mature	myeloid	cells	inhibits	T-cell	receptor	expression	and	
antigen-specific	T-cell	responses.	Cancer	Res.	2004;64(16):5839–5849.		
105.	 Rodriguez	PC,	Quiceno	DG,	Ochoa	AC.	L-arginine	availability	regulates	T-
lymphocyte	cell-cycle	progression.	Blood.	2007;109(4):1568–1573.		
106.	 Oberlies	J,	Watzl	C,	Giese	T,	et	al.	Regulation	of	NK	cell	function	by	human	
granulocyte	arginase.	J.	Immunol.	2009;182(9):5259–5267.		
107.	 Mussai	F,	Egan	S,	Higginbotham-Jones	J,	et	al.	Arginine	dependence	of	acute	
myeloid	leukemia	blast	proliferation:	a	novel	therapeutic	target.	Blood.	
2015;125(15):2386–96.		
108.	 Mussai	F,	De	Santo	C,	Abu-Dayyeh	I,	et	al.	Acute	myeloid	leukemia	creates	an	
arginase-dependent	immunosuppressive	microenvironment.	Blood.	
2013;122(5):749–758.		
109.	 Folgiero	V,	Goffredo	BM,	Filippini	P,	et	al.	Indoleamine	2,3-dioxygenase	1	(IDO1)	
activity	in	leukemia	blasts	correlates	with	poor	outcome	in	childhood	acute	
myeloid	leukemia.	Oncotarget.	2014;5(8):2052–64.		
110.	 Curti	A,	Trabanelli	S,	Salvestrini	V,	Baccarani	M,	Lemoli	RM.	The	role	of	
indoleamine	2,3-dioxygenase	in	the	induction	of	immune	tolerance:	Focus	on	
hematology.	Blood.	2009;113(11):2394–2401.		
111.	 El	Kholy	NM,	Sallam	MM,	Ahmed	MB,	et	al.	Expression	of	indoleamine	2,3-
dioxygenase	in	acute	myeloid	leukemia	and	the	effect	of	its	inhibition	on	cultured	
Athalia	Rachel	Pyzer	 	 References	
	
274	
leukemia	blast	cells.	Med.	Oncol.	2011;28(1):270–278.		
112.	 Chruscinski	A,	Sadozai	H,	Rojas-Luengas	V,	et	al.	Role	of	Regulatory	T	Cells	(Treg)	
and	the	Treg	Effector	Molecule	Fibrinogen-like	Protein	2	in	Alloimmunity	and	
Autoimmunity.	Rambam	Maimonides	Med.	J.	2015;6(3):.		
113.	 Schick	J,	Vogt	V,	Zerwes	M,	et	al.	Antileukemic	T-cell	responses	can	be	predicted	
by	the	composition	of	specific	regulatory	T-cell	subpopulations.	J.	Immunother.	
2013;36(4):223–37.		
114.	 Yang	W,	Xu	Y.	Clinical	significance	of	Treg	cell	frequency	in	acute	myeloid	
leukemia.	Int.	J.	Hematol.	2013;98(5):558–562.		
115.	 Shenghui	Z,	Yixiang	H,	Jianbo	W,	et	al.	Elevated	frequencies	of	CD4+	CD25+	
CD127lo	regulatory	T	cells	is	associated	to	poor	prognosis	in	patients	with	acute	
myeloid	leukemia.	Int.	J.	Cancer.	2011;129(6):1373–1381.		
116.	 Rooney	CM.	Can	Treg	elimination	enhance	NK	cell	therapy	for	AML?	Blood.	
2014;123(25):3848–9.		
117.	 Farag	SS,	Fehniger	TA,	Ruggeri	L,	Velardi	A,	Caligiuri	MA.	Natural	killer	cell	
receptors:	New	biology	and	insights	into	the	graft-versus-leukemia	effect.	Blood.	
2002;100(6):1935–1947.		
118.	 Sanchez-Correa	B,	Campos	C,	Pera	A,	et	al.	Natural	killer	cell	immunosenescence	
in	acute	myeloid	leukaemia	patients:	new	targets	for	immunotherapeutic	
strategies?	Cancer	Immunol.	Immunother.	2015;		
119.	 Lichtenegger	FS,	Lorenz	R,	Gellhaus	K,	et	al.	Impaired	NK	cells	and	increased	T	
regulatory	cell	numbers	during	cytotoxic	maintenance	therapy	in	AML.	Leuk.	Res.	
2014;38(8):964–9.		
120.	 Stringaris	K,	Sekine	T,	Khoder	A,	et	al.	Leukemia-induced	phenotypic	and	
functional	defects	in	natural	killer	cells	predict	failure	to	achieve	remission	in	
Athalia	Rachel	Pyzer	 	 References	
	
275	
acute	myeloid	leukemia.	Haematologica.	2014;99(5):836–847.		
121.	 Lowdell	MW,	Craston	R,	Samuel	D,	et	al.	Evidence	that	continued	remission	in	
patients	treated	for	acute	leukaemia	is	dependent	upon	autologous	natural	killer	
cells.	Br.	J.	Haematol.	2002;117(4):821–827.		
122.	 Lissoni	P,	Vigore	L,	Ferranti	R,	et	al.	Circulating	dendritic	cells	in	early	and	
advanced	cancer	patients:	diminished	percent	in	the	metastatic	disease.	J	Biol	
Regul	Homeost	Agents.	1999;13(4):216–219.		
123.	 Gabrilovich	D.	Mechanisms	and	functional	significance	of	tumour-induced	
dendritic-cell	defects.	Nat	Rev	Immunol.	2004;4(12):941–952.		
124.	 Demoulin	S,	Herfs	M,	Delvenne	P,	Hubert	P.	Tumor	microenvironment	converts	
plasmacytoid	dendritic	cells	into	immunosuppressive/tolerogenic	cells:	insight	
into	the	molecular	mechanisms.	J	Leukoc	Biol.	2013;93(3):343–352.		
125.	 Mohty	M,	Jarrossay	D,	Lafage-Pochitaloff	M,	et	al.	Circulating	blood	dendritic	cells	
from	myeloid	leukemia	patients	display	quantitative	and	cytogenetic	
abnormalities	as	well	as	functional	impairment.	Blood.	2001;98(13):3750–3756.		
126.	 Rosenblatt	J,	Avivi	I,	Vasir	B,	et	al.	Vaccination	with	dendritic	cell/tumor	fusions	
following	autologous	stem	cell	transplant	induces	immunologic	and	clinical	
responses	in	multiple	myeloma	patients.	Clin	Cancer	Res.	2013;19(13):3640–3648.		
127.	 Luptakova	K,	Rosenblatt	J,	Glotzbecker	B,	et	al.	Lenalidomide	enhances	anti-
myeloma	cellular	immunity.	Cancer	Immunol	Immunother.	2013;62(1):39–49.		
128.	 Stroopinsky	D,	Rosenblatt	J,	Ito	K,	et	al.	MUC1	is	a	potential	target	for	the	
treatment	of	acute	myeloid	leukemia	stem	cells.	Cancer	Res.	2013;73(17):5569–
5579.		
129.	 Liu	S,	Yin	L,	Stroopinsky	D,	et	al.	MUC1-C	oncoprotein	promotes	FLT3	receptor	
activation	in	acute	myeloid	leukemia	cells.	Blood.	2014;123(5):734–742.		
Athalia	Rachel	Pyzer	 	 References	
	
276	
130.	 Jain	S,	Stroopinsky	D,	Yin	L,	et	al.	Mucin	1	is	a	potential	therapeutic	target	in	
cutaneous	T-cell	lymphoma.	Blood.	2015;126(3):354–62.		
131.	 Raina	D,	Agarwal	P,	Lee	J,	et	al.	Characterization	of	the	MUC1-C	Cytoplasmic	
Domain	as	a	Cancer	Target.	PLoS	One.	2015;10(8):e0135156.		
132.	 Yin	L,	Ahmad	R,	Kosugi	M,	et	al.	Survival	of	human	multiple	myeloma	cells	is	
dependent	on	MUC1	C-terminal	transmembrane	subunit	oncoprotein	function.	
Mol.	Pharmacol.	2010;78(2):166–174.		
133.	 Nencioni	A,	Grünebach	F,	Schmidt	SM,	et	al.	The	use	of	dendritic	cells	in	cancer	
immunotherapy.	Crit	Rev	Oncol	Hematol.	2008;65(3):191–199.		
134.	 Avigan	D.	Dendritic	cells:	development,	function	and	potential	use	for	cancer	
immunotherapy.	Blood	Rev.	1999;13(1):51–64.		
135.	 Steinman	RM.	The	dendritic	cell	system	and	its	role	in	immunogenicity.	Annu	Rev	
Immunol.	1991;9:271–296.		
136.	 Dubois	B,	Massacrier	C,	Caux	C.	Selective	attraction	of	naive	and	memory	B	cells	
by	dendritic	cells.	J	Leukoc	Biol.	2001;70(4):633–641.		
137.	 Jonuleit	H,	Kühn	U,	Müller	G,	et	al.	Pro-inflammatory	cytokines	and	
prostaglandins	induce	maturation	of	potent	immunostimulatory	dendritic	cells	
under	fetal	calf	serum-free	conditions.	Eur	J	Immunol.	1997;27(12):3135–3142.		
138.	 Wimmers	F,	Schreibelt	G,	Sköld	AE,	Figdor	CG,	De	Vries	IJ.	Paradigm	Shift	in	
Dendritic	Cell-Based	Immunotherapy:	From	in	vitro	Generated	Monocyte-Derived	
DCs	to	Naturally	Circulating	DC	Subsets.	Front	Immunol.	2014;5:165.		
139.	 Märten	A,	Renoth	S,	Heinicke	T,	et	al.	Allogeneic	dendritic	cells	fused	with	tumor	
cells:	preclinical	results	and	outcome	of	a	clinical	phase	I/II	trial	in	patients	with	
metastatic	renal	cell	carcinoma.	Hum	Gene	Ther.	2003;14(5):483–494.		
140.	 Avigan	DE		Kantoff	PW	GDJ.	Interim	safety	and	efficacy	results	from	a	phase	I/II	
Athalia	Rachel	Pyzer	 	 References	
	
277	
study	of	vaccination	with	electrofused	allogeneic	dendritic	cells/autologous	
tumor-derived	cells	in	patients	with	stage	IV	renal	cell	carcinoma.	2004;		
141.	 Hus	I,	Roliński	J,	Tabarkiewicz	J,	et	al.	Allogeneic	dendritic	cells	pulsed	with	tumor	
lysates	or	apoptotic	bodies	as	immunotherapy	for	patients	with	early-stage	B-cell	
chronic	lymphocytic	leukemia.	Leukemia.	2005;19(9):1621–1627.		
142.	 Philip	R,	Alters	SE,	Brunette	E,	et	al.	Dendritic	cells	loaded	with	MART-1	peptide	or	
infected	with	adenoviral	construct	are	functionally	equivalent	in	the	induction	of	
tumor-specific	cytotoxic	T	lymphocyte	responses	in	patients	with	melanoma.	J	
Immunother.	2000;23(1):168–176.		
143.	 Minev	BR,	Chavez	FL,	Dudouet	BM,	Mitchell	MS.	Synthetic	insertion	signal	
sequences	enhance	MHC	class	I	presentation	of	a	peptide	from	the	melanoma	
antigen	MART-1.	Eur	J	Immunol.	2000;30(8):2115–2124.		
144.	 Cao	J,	Jin	Y,	Li	W,	et	al.	DNA	vaccines	targeting	the	encoded	antigens	to	dendritic	
cells	induce	potent	antitumor	immunity	in	mice.	BMC	Immunol.	2013;14:39.		
145.	 Li	D,	Hua	S,	Fan	Y,	et	al.	DNA	vaccine	expressing	repeated	carcinoembryonic	
antigen	(CEA)(625-667)	induces	strong	immunity	in	mice.	Immunol	Lett.	
2011;135(1–2):124–128.		
146.	 Signori	E,	Iurescia	S,	Massi	E,	et	al.	DNA	vaccination	strategies	for	anti-tumour	
effective	gene	therapy	protocols.	Cancer	Immunol	Immunother.	
2010;59(10):1583–1591.		
147.	 Boczkowski	D,	Nair	SK,	Snyder	D,	Gilboa	E.	Dendritic	cells	pulsed	with	RNA	are	
potent	antigen-presenting	cells	in	vitro	and	in	vivo.	J	Exp	Med.	1996;184(2):465–
472.		
148.	 Nair	SK,	Morse	M,	Boczkowski	D,	et	al.	Induction	of	tumor-specific	cytotoxic	T	
lymphocytes	in	cancer	patients	by	autologous	tumor	RNA-transfected	dendritic	
cells.	Ann	Surg.	2002;235(4):540–549.		
Athalia	Rachel	Pyzer	 	 References	
	
278	
149.	 Hamilton	DH,	Litzinger	MT,	Jales	A,	et	al.	Immunological	targeting	of	tumor	cells	
undergoing	an	epithelial-mesenchymal	transition	via	a	recombinant	brachyury-
yeast	vaccine.	Oncotarget.	2013;		
150.	 Litzinger	MT,	Foon	KA,	Sabzevari	H,	et	al.	Chronic	lymphocytic	leukemia	(CLL)	cells	
genetically	modified	to	express	B7-1,	ICAM-1,	and	LFA-3	confer	APC	capacity	to	T	
cells	from	CLL	patients.	Cancer	Immunol	Immunother.	2009;58(6):955–965.		
151.	 Litzinger	MT,	Foon	KA,	Tsang	KY,	Schlom	J,	Palena	C.	Comparative	analysis	of	
MVA-CD40L	and	MVA-TRICOM	vectors	for	enhancing	the	immunogenicity	of	
chronic	lymphocytic	leukemia	(CLL)	cells.	Leuk	Res.	2010;34(10):1351–1357.		
152.	 Palma	M,	Hansson	L,	Choudhury	A,	et	al.	Vaccination	with	dendritic	cells	loaded	
with	tumor	apoptotic	bodies	(Apo-DC)	in	patients	with	chronic	lymphocytic	
leukemia:	effects	of	various	adjuvants	and	definition	of	immune	response	criteria.	
Cancer	Immunol	Immunother.	2012;61(6):865–879.		
153.	 Avigan	D,	Rosenblatt	J,	Kufe	D.	Dendritic/tumor	fusion	cells	as	cancer	vaccines.	
Semin	Oncol.	2012;39(3):287–295.		
154.	 Koido	S,	Homma	S,	Okamoto	M,	et	al.	Fusions	between	dendritic	cells	and	whole	
tumor	cells	as	anticancer	vaccines.	Oncoimmunology.	2013;2(5):e24437.		
155.	 Amos	SM,	Duong	CP,	Westwood	JA,	et	al.	Autoimmunity	associated	with	
immunotherapy	of	cancer.	Blood.	2011;118(3):499–509.		
156.	 Rosenblatt	J,	Vasir	B,	Uhl	L,	et	al.	Vaccination	with	dendritic	cell/tumor	fusion	cells	
results	in	cellular	and	humoral	antitumor	immune	responses	in	patients	with	
multiple	myeloma.	Blood.	2011;117(2):393–402.		
157.	 Reichardt	VL,	Okada	CY,	Liso	A,	et	al.	Idiotype	vaccination	using	dendritic	cells	
after	autologous	peripheral	blood	stem	cell	transplantation	for	multiple	
myeloma--a	feasibility	study.	Blood.	1999;93(7):2411–2419.		
Athalia	Rachel	Pyzer	 	 References	
	
279	
158.	 Timmerman	JM,	Czerwinski	DK,	Davis	TA,	et	al.	Idiotype-pulsed	dendritic	cell	
vaccination	for	B-cell	lymphoma:	clinical	and	immune	responses	in	35	patients.	
Blood.	2002;99(5):1517–1526.		
159.	 Schuster	SJ.	Idiotype	vaccine	therapy	(BiovaxID)	in	follicular	lymphoma	in	first	
complete	remission:	Phase	III	clinical	trial	results.	Univ.	Pennsylvania.	2009;		
160.	 Lacy	MQ,	Mandrekar	S,	Dispenzieri	A,	et	al.	Idiotype-pulsed	antigen-presenting	
cells	following	autologous	transplantation	for	multiple	myeloma	may	be	
associated	with	prolonged	survival.	Am	J	Hematol.	2009;84(12):799–802.		
161.	 Röllig	C,	Schmidt	C,	Bornhäuser	M,	et	al.	Induction	of	cellular	immune	responses	
in	patients	with	stage-I	multiple	myeloma	after	vaccination	with	autologous	
idiotype-pulsed	dendritic	cells.	J	Immunother.	2011;34(1):100–106.		
162.	 Van	Tendeloo	VF,	Van	de	Velde	A,	Van	Driessche	A,	et	al.	Induction	of	complete	
and	molecular	remissions	in	acute	myeloid	leukemia	by	Wilms’	tumor	1	antigen-
targeted	dendritic	cell	vaccination.	Proc	Natl	Acad	Sci	U	S	A.	2010;107(31):13824–
13829.		
163.	 Kitawaki	T,	Kadowaki	N,	Fukunaga	K,	et	al.	Cross-priming	of	CD8(+)	T	cells	in	vivo	
by	dendritic	cells	pulsed	with	autologous	apoptotic	leukemic	cells	in	
immunotherapy	for	elderly	patients	with	acute	myeloid	leukemia.	Exp	Hematol.	
2011;39(4):424–433.e2.		
164.	 Rosenblatt	J,	Stone	R,	Uhl	L,	et	al.	Clinical	trial	evaluating	DC/AML	fusion	cell	
vaccination	in	AML	patients	who	achieve	a	chemotherapy-induced	remission.	ASH	
Annu.	Meet.	2013;		
165.	 Houtenbos	I,	Westers	TM,	Hess	CJ,	et	al.	Flt-3	internal	tandem	duplication	
hampers	differentiation	of	AML	blasts	towards	leukemic	dendritic	cells.	Leukemia.	
2006;20(10):1892–1895.		
166.	 Anguille	S,	Willemen	Y,	Lion	E,	Smits	EL,	Berneman	ZN.	Dendritic	cell	vaccination	
Athalia	Rachel	Pyzer	 	 References	
	
280	
in	acute	myeloid	leukemia.	Cytotherapy.	2012;14(6):647–656.		
167.	 Lindau	D,	Gielen	P,	Kroesen	M,	Wesseling	P,	Adema	GJ.	The	immunosuppressive	
tumour	network:	myeloid-derived	suppressor	cells,	regulatory	T	cells	and	natural	
killer	T	cells.	Immunology.	2013;138(2):105–115.		
168.	 Rosenblatt	J		Vasir	B,	Uhl	L,	Katz	T,	Avigan	D	et	al.	AI.	Blockade	of	PD-1	in	
Combination	with	Dendritic	Cell/Myeloma	Fusion	Cell	Vaccination	Following	
Autologous	Stem	Cell	Transplantation.	ASH	2012.	2012;(Abstract	578):		
169.	 Borrello	IM,	Levitsky	HI,	Stock	W,	et	al.	Granulocyte-macrophage	colony-
stimulating	factor	(GM-CSF)-secreting	cellular	immunotherapy	in	combination	
with	autologous	stem	cell	transplantation	(ASCT)	as	postremission	therapy	for	
acute	myeloid	leukemia	(AML).	Blood.	2009;114(9):1736–1745.		
170.	 Brune	M,	Castaigne	S,	Catalano	J,	et	al.	Improved	leukemia-free	survival	after	
postconsolidation	immunotherapy	with	histamine	dihydrochloride	and	
interleukin-2	in	acute	myeloid	leukemia:	Results	of	a	randomized	phase	3	trial.	
Blood.	2006;108(1):88–96.		
171.	 Lichtenegger	FS,	Krupka	C,	Köhnke	T,	Subklewe	M.	Immunotherapy	for	Acute	
Myeloid	Leukemia.	Semin.	Hematol.	2015;52(3):207–14.		
172.	 Topp	MS,	Gökbuget	N,	Zugmaier	G,	et	al.	Long-term	follow-up	of	hematologic	
relapse-free	survival	in	a	phase	2	study	of	blinatumomab	in	patients	with	MRD	in	
B-lineage	ALL.	Blood.	2012;120(26):5185–5187.		
173.	 Hussaini	A.L.,	Ritchey	J.	RMP.	Targeting	CD123	in	leukemic	stem	cells	using	dual	
affinity	re-targeting	molecules	(DARTs).	ASH.	2013;		
174.	 Kochenderfer	JN,	Dudley	ME,	Kassim	SH,	et	al.	Chemotherapy-refractory	diffuse	
large	B-cell	lymphoma	and	indolent	B-cell	malignancies	can	be	effectively	treated	
with	autologous	T	cells	expressing	an	anti-CD19	chimeric	antigen	receptor.	J.	Clin.	
Oncol.	2015;33(6):540–9.		
Athalia	Rachel	Pyzer	 	 References	
	
281	
175.	 Mauude	SL.	Chimeric	Antigen	Receptor	T	Cells	for	Sustained	Remissions	in	
Leukemia.	2014;		
176.	 Marin	V,	Pizzitola	I,	Agostoni	V,	et	al.	Cytokine-induced	killer	cells	for	cell	therapy	
of	acute	myeloid	leukemia:	Improvement	of	their	immune	activity	by	expression	
of	CD33-specific	chimeric	receptors.	Haematologica.	2010;95(12):2144–2152.		
177.	 Dutour	A,	Marin	V,	Pizzitola	I,	et	al.	In	Vitro	and	In	Vivo	Antitumor	Effect	of	Anti-
CD33	Chimeric	Receptor-Expressing	EBV-CTL	against	CD33+	Acute	Myeloid	
Leukemia.	Adv.	Hematol.	2012;2012:1–10.		
178.	 Wang	Q,	Wang	Y,	Lv	H,	et	al.	Treatment	of	CD33-directed	chimeric	antigen	
receptor-modified	T	cells	in	one	patient	with	relapsed	and	refractory	acute	
myeloid	leukemia.	Mol.	Ther.	2015;23(1):184–91.		
179.	 Mardiros	A,	Dos	Santos	C,	McDonald	T,	et	al.	T	cells	expressing	CD123-specific	
chimeric	antigen	receptors	exhibit	specific	cytolytic	effector	functions	and	
antitumor	effects	against	human	acute	myeloid	leukemia.	Blood.	
2013;122(18):3138–3148.		
180.	 Duwe	AK,	Singhal	SK.	The	immunoregulatory	role	of	bone	marrow.	I.	Suppression	
of	the	induction	of	antibody	responses	to	T-dependent	and	T-independent	
antigens	by	cells	in	the	bone	marrow.	Cell.	Immunol.	1979;43(2):362–371.		
181.	 Bronte	V,	Wang	M,	Overwijk	WW,	et	al.	Apoptotic	death	of	CD8+	T	lymphocytes	
after	immunization:	induction	of	a	suppressive	population	of	Mac-1+/Gr-1+	cells.	
J.	Immunol.	1998;161(10):5313–5320.		
182.	 Kusmartsev	SA,	Li	Y,	Chen	SH.	Gr-1+	myeloid	cells	derived	from	tumor-bearing	
mice	inhibit	primary	T	cell	activation	induced	through	CD3/CD28	costimulation.	J.	
Immunol.	2000;165(2):779–785.		
183.	 Gabrilovich	D,	Ishida	T,	Oyama	T,	et	al.	Vascular	endothelial	growth	factor	inhibits	
the	development	of	dendritic	cells	and	dramatically	affects	the	differentiation	of	
Athalia	Rachel	Pyzer	 	 References	
	
282	
multiple	hematopoietic	lineages	in	vivo.	Blood.	1998;92(11):4150–4166.		
184.	 Watson	GA,	Fu	YX,	Lopez	DM.	Splenic	macrophages	from	tumor-bearing	mice	co-
expressing	MAC-1	and	MAC-2	antigens	exert	immunoregulatory	functions	via	two	
distinct	mechanisms.	J.	Leukoc.	Biol.	1991;49(2):126–138.		
185.	 Mazzoni	A,	Bronte	V,	Visintin	A,	et	al.	Myeloid	suppressor	lines	inhibit	T	cell	
responses	by	an	NO-dependent	mechanism.	J.	Immunol.	2002;168(2):689–695.		
186.	 Kusmartsev	S,	Nefedova	Y,	Yoder	D,	Gabrilovich	DI.	Antigen-specific	inhibition	of	
CD8+	T	cell	response	by	immature	myeloid	cells	in	cancer	is	mediated	by	reactive	
oxygen	species.	J.	Immunol.	2004;172(2):989–999.		
187.	 Bronte	V,	Serafini	P,	De	Santo	C,	et	al.	IL-4-induced	arginase	1	suppresses	
alloreactive	T	cells	in	tumor-bearing	mice.	J.	Immunol.	2003;170(1):270–278.		
188.	 Bronte	V,	Apolloni	E,	Cabrelle	A,	et	al.	Identification	of	a	CD11b(+)/Gr-
1(+)/CD31(+)	myeloid	progenitor	capable	of	activating	or	suppressing	CD8(+)	T	
cells.	Blood.	2000;96(12):3838–3846.		
189.	 Mielcarek	M,	Martin	PJ,	Torok-Storb	B.	Suppression	of	alloantigen-induced	T-cell	
proliferation	by	CD14+	cells	derived	from	granulocyte	colony-stimulating	factor-
mobilized	peripheral	blood	mononuclear	cells.	Blood.	1997;89(5):1629–1634.		
190.	 Singh	RK,	Varney	ML,	Buyukberber	S,	et	al.	Fas-FasL-mediated	CD4+	T-cell	
apoptosis	following	stem	cell	transplantation.	Cancer	Res.	1999;59(13):3107–
3111.		
191.	 Laoui	D,	Van	Overmeire	E,	Movahedi	K,	et	al.	Mononuclear	phagocyte	
heterogeneity	in	cancer:	Different	subsets	and	activation	states	reaching	out	at	
the	tumor	site.	Immunobiology.	2011;216(11):1192–1202.		
192.	 Gabrilovich	DI,	Bronte	V,	Chen	SH,	Colombo	MP,	Ochoa	A,	Ostrand-Rosenberg	S	
SH.	The	terminology	issue	for	myeloid-derived	suppressor	cells.	Cancer	Res.	
Athalia	Rachel	Pyzer	 	 References	
	
283	
2007;67(1):425.		
193.	 Mucha	J,	Majchrzak	K,	Taciak	B,	Hellmén	E,	Król	M.	MDSCs	mediate	angiogenesis	
and	predispose	canine	mammary	tumor	cells	for	metastasis	via	IL-28/IL-28RA	
(IFN-λ)	signaling.	PLoS	One.	2014;9(7):e103249.		
194.	 Meirow	Y,	Kanterman	J,	Baniyash	M.	Paving	the	Road	to	Tumor	Development	and	
Spreading:	Myeloid-Derived	Suppressor	Cells	are	Ruling	the	Fate.	Front.	Immunol.	
2015;6:523.		
195.	 Zhang	G,	Huang	H,	Zhu	Y,	et	al.	A	novel	subset	of	B7-H3(+)CD14(+)HLA-DR(-/low)	
myeloid-derived	suppressor	cells	are	associated	with	progression	of	human	
NSCLC.	Oncoimmunology.	2015;4(2):e977164.		
196.	 Li	Z-L,	Ye	S-B,	OuYang	L-Y,	et	al.	COX-2	promotes	metastasis	in	nasopharyngeal	
carcinoma	by	mediating	interactions	between	cancer	cells	and	myeloid-derived	
suppressor	cells.	Oncoimmunology.	2015;4(11):e1044712.		
197.	 Huang	H,	Zhang	G,	Li	G,	Ma	H,	Zhang	X.	Circulating	CD14(+)HLA-DR(-/low)	
myeloid-derived	suppressor	cell	is	an	indicator	of	poor	prognosis	in	patients	with	
ESCC.	Tumour	Biol.	2015;		
198.	 Jeanbart	L,	Kourtis	IC,	van	der	Vlies	AJ,	Swartz	MA,	Hubbell	JA.	6-Thioguanine-
loaded	polymeric	micelles	deplete	myeloid-derived	suppressor	cells	and	enhance	
the	efficacy	of	T	cell	immunotherapy	in	tumor-bearing	mice.	Cancer	Immunol.	
Immunother.	2015;64(8):1033–46.		
199.	 Sheng	Sow	H,	Mattarollo	SR.	Combining	low-dose	or	metronomic	chemotherapy	
with	anticancer	vaccines:	A	therapeutic	opportunity	for	lymphomas.	
Oncoimmunology.	2013;2(12):e27058.		
200.	 Youn	J-I,	Nagaraj	S,	Collazo	M,	Gabrilovich	DI.	Subsets	of	myeloid-derived	
suppressor	cells	in	tumor-bearing	mice.	J.	Immunol.	2008;181(8):5791–5802.		
Athalia	Rachel	Pyzer	 	 References	
	
284	
201.	 Ramachandran	IR,	Martner	A,	Pisklakova	A,	et	al.	Myeloid-derived	suppressor	
cells	regulate	growth	of	multiple	myeloma	by	inhibiting	T	cells	in	bone	marrow.	J.	
Immunol.	2013;190(7):3815–23.		
202.	 Van	Valckenborgh	E,	Schouppe	E,	Movahedi	K,	et	al.	Multiple	myeloma	induces	
the	immunosuppressive	capacity	of	distinct	myeloid-derived	suppressor	cell	
subpopulations	in	the	bone	marrow.	Leukemia.	2012;		
203.	 Haile	LA,	Gamrekelashvili	J,	Manns	MP,	Korangy	F,	Greten	TF.	CD49d	is	a	new	
marker	for	distinct	myeloid-derived	suppressor	cell	subpopulations	in	mice.	J.	
Immunol.	2010;185(1):203–210.		
204.	 Virtuoso	LP,	Harden	JL,	Sotomayor	P,	et	al.	Characterization	of	iNOS+	Neutrophil-
like	ring	cell	in	tumor-bearing	mice.	J.	Transl.	Med.	2012;10(1):152.		
205.	 Huang	B,	Pan	PY,	Li	Q,	et	al.	Gr-1+CD115+	immature	myeloid	suppressor	cells	
mediate	the	development	of	tumor-induced	T	regulatory	cells	and	T-cell	anergy	in	
tumor-bearing	host.	Cancer	Res.	2006;66(2):1123–1131.		
206.	 Wu	J,	Zhang	R,	Tang	N,	et	al.	Dopamine	inhibits	the	function	of	Gr-1+CD115+	
myeloid-derived	suppressor	cells	through	D1-like	receptors	and	enhances	anti-
tumor	immunity.	J.	Leukoc.	Biol.	2015;97(1):191–200.		
207.	 Youn	J-I,	Collazo	M,	Shalova	IN,	Biswas	SK,	Gabrilovich	DI.	Characterization	of	the	
nature	of	granulocytic	myeloid-derived	suppressor	cells	in	tumor-bearing	mice.	J.	
Leukoc.	Biol.	2012;91(1):167–181.		
208.	 Kusmartsev	S,	Nagaraj	S,	Gabrilovich	DI.	Tumor-associated	CD8+	T	cell	tolerance	
induced	by	bone	marrow-derived	immature	myeloid	cells.	J.	Immunol.	
2005;175(7):4583–4592.		
209.	 Movahedi	K,	Guilliams	M,	Van	Den	Bossche	J,	et	al.	Identification	of	discrete	
tumor-induced	myeloid-derived	suppressor	cell	subpopulations	with	distinct	T	cell	
suppressive	activity.	Blood.	2008;111(8):4233–4244.		
Athalia	Rachel	Pyzer	 	 References	
	
285	
210.	 Cheng	P,	Corzo	CA,	Luetteke	N,	et	al.	Inhibition	of	dendritic	cell	differentiation	
and	accumulation	of	myeloid-derived	suppressor	cells	in	cancer	is	regulated	by	
S100A9	protein.	J.	Exp.	Med.	2008;205(10):2235–2249.		
211.	 Sawanobori	Y,	Ueha	S,	Kurachi	M,	et	al.	Chemokine-mediated	rapid	turnover	of	
myeloid-derived	suppressor	cells	in	tumor-bearing	mice.	Blood.	
2008;111(12):5457–5466.		
212.	 Dolcetti	L,	Peranzoni	E,	Ugel	S,	et	al.	Hierarchy	of	immunosuppressive	strength	
among	myeloid-derived	suppressor	cell	subsets	is	determined	by	GM-CSF.	Eur.	J.	
Immunol.	2010;40(1):22–35.		
213.	 Nicholson	LB,	Raveney	BJE,	Munder	M.	Monocyte	dependent	regulation	of	
autoimmune	inflammation.	Curr.	Mol.	Med.	2009;9(1):23–29.		
214.	 Van	Ginderachter	JA,	Beschin	A,	Baetselier	P	De,	Raes	G.	Myeloid-derived	
suppressor	cells	in	parasitic	infections.	Eur.	J.	Immunol.	2010;40(11):2976–2985.		
215.	 Cripps	JG,	Gorham	JD.	MDSC	in	autoimmunity.	Int.	Immunopharmacol.	
2011;11(7):789–793.		
216.	 Chen	X,	Eksioglu	EA,	Zhou	J,	et	al.	Induction	of	myelodysplasia	by	myeloid-derived	
suppressor	cells.	J.	Clin.	Invest.	2013;123(11):4595–4611.		
217.	 Solito	S,	Falisi	E,	Diaz-Montero	CM,	et	al.	A	human	promyelocytic-like	population	
is	responsible	for	the	immune	suppression	mediated	by	myeloid-derived	
suppressor	cells.	Blood.	2011;118(8):2254–2265.		
218.	 Youn	J-I,	Kumar	V,	Collazo	M,	et	al.	Epigenetic	silencing	of	retinoblastoma	gene	
regulates	pathologic	differentiation	of	myeloid	cells	in	cancer.	Nat.	Immunol.	
2013;14(3):211–20.		
219.	 De	Vlaeminck	Y,	González-Rascón	A,	Goyvaerts	C,	Breckpot	K.	Cancer-Associated	
Myeloid	Regulatory	Cells.	Front.	Immunol.	2016;7:113.		
Athalia	Rachel	Pyzer	 	 References	
	
286	
220.	 Rodriguez	PC,	Ernstoff	MS,	Hernandez	C,	et	al.	Arginase	I-producing	myeloid-
derived	suppressor	cells	in	renal	cell	carcinoma	are	a	subpopulation	of	activated	
granulocytes.	Cancer	Res.	2009;69(4):1553–1560.		
221.	 S.	George,	P.	Rayman,	S.	Biswas,	T.	Smith-Williams,	J.	S.	Ko,	L.	Wood,	P.	Elson,	B.	I.	
Rini	RMB	and	JHF.	No	Title.	ASCO.	2008;		
222.	 Mandruzzato	S,	Solito	S,	Falisi	E,	et	al.	IL4Ralpha+	myeloid-derived	suppressor	cell	
expansion	in	cancer	patients.	J.	Immunol.	2009;182(10):6562–6568.		
223.	 Feng	P-H,	Lee	K-Y,	Chang	Y-L,	et	al.	CD14(+)S100A9(+)	monocytic	myeloid-derived	
suppressor	cells	and	their	clinical	relevance	in	non-small	cell	lung	cancer.	Am.	J.	
Respir.	Crit.	Care	Med.	2012;186(10):1025–36.		
224.	 Wang	L,	Chang	EWY,	Wong	SC,	et	al.	Increased	myeloid-derived	suppressor	cells	
in	gastric	cancer	correlate	with	cancer	stage	and	plasma	S100A8/A9	
proinflammatory	proteins.	J.	Immunol.	2013;190(2):794–804.		
225.	 Zhao	F,	Hoechst	B,	Duffy	A,	et	al.	S100A9	a	new	marker	for	monocytic	human	
myeloid-derived	suppressor	cells.	Immunology.	2012;136(2):176–183.		
226.	 Qin	H,	Lerman	B,	Sakamaki	I,	et	al.	Generation	of	a	new	therapeutic	peptide	that	
depletes	myeloid-derived	suppressor	cells	in	tumor-bearing	mice.	Nat.	Med.	
2014;20(6):676–81.		
227.	 Brandau	S,	Trellakis	S,	Bruderek	K,	et	al.	Myeloid-derived	suppressor	cells	in	the	
peripheral	blood	of	cancer	patients	contain	a	subset	of	immature	neutrophils	
with	impaired	migratory	properties.	J.	Leukoc.	Biol.	2011;89(2):311–317.		
228.	 Heuvers	ME,	Muskens	F,	Bezemer	K,	et	al.	Arginase-1	mRNA	expression	correlates	
with	myeloid-derived	suppressor	cell	levels	in	peripheral	blood	of	NSCLC	patients.	
Lung	Cancer.	2013;81(3):468–74.		
229.	 Trellakis	S,	Bruderek	K,	Hütte	J,	et	al.	Granulocytic	myeloid-derived	suppressor	
Athalia	Rachel	Pyzer	 	 References	
	
287	
cells	are	cryosensitive	and	their	frequency	does	not	correlate	with	serum	
concentrations	of	colony-stimulating	factors	in	head	and	neck	cancer.	Innate	
Immun.	2013;19:328–36.		
230.	 Kotsakis	A,	Harasymczuk	M,	Schilling	B,	et	al.	Myeloid-derived	suppressor	cell	
measurements	in	fresh	and	cryopreserved	blood	samples.	J.	Immunol.	Methods.	
2012;381(1–2):14–22.		
231.	 Geissmann	F,	Manz	MG,	Jung	S,	et	al.	Development	of	monocytes,	macrophages,	
and	dendritic	cells.	Science.	2010;327(5966):656–661.		
232.	 Serafini	P.	Myeloid	derived	suppressor	cells	in	physiological	and	pathological	
conditions:	The	good,	the	bad,	and	the	ugly.	Immunol.	Res.	2013;57(1–3):172–
184.		
233.	 Porembka	MR,	Mitchem	JB,	Belt	BA,	et	al.	Pancreatic	adenocarcinoma	induces	
bone	marrow	mobilization	of	myeloid-derived	suppressor	cells	which	promote	
primary	tumor	growth.	Cancer	Immunol.	Immunother.	2012;61(9):1373–1385.		
234.	 Diaz-Montero	CM,	Salem	ML,	Nishimura	MI,	et	al.	Increased	circulating	myeloid-
derived	suppressor	cells	correlate	with	clinical	cancer	stage,	metastatic	tumor	
burden,	and	doxorubicin-cyclophosphamide	chemotherapy.	Cancer	Immunol.	
Immunother.	2009;58(1):49–59.		
235.	 Salvadori	S,	Martinelli	G,	Zier	K.	Resection	of	solid	tumors	reverses	T	cell	defects	
and	restores	protective	immunity.	J.	Immunol.	2000;164(4):2214–2220.		
236.	 Draghiciu	O,	Nijman	HW,	Hoogeboom	BN,	Meijerhof	T,	Daemen	T.	Sunitinib	
depletes	myeloid-derived	suppressor	cells	and	synergizes	with	a	cancer	vaccine	to	
enhance	antigen-specific	immune	responses	and	tumor	eradication.	
Oncoimmunology.	2015;4(3):e989764.		
237.	 Filipazzi	P,	Valenti	R,	Huber	V,	et	al.	Identification	of	a	new	subset	of	myeloid	
suppressor	cells	in	peripheral	blood	of	melanoma	patients	with	modulation	by	a	
Athalia	Rachel	Pyzer	 	 References	
	
288	
granulocyte-macrophage	colony-stimulation	factor-based	antitumor	vaccine.	J.	
Clin.	Oncol.	2007;25(18):2546–2553.		
238.	 Vuk-Pavlović	S,	Bulur	PA,	Lin	Y,	et	al.	Immunosuppressive	CD14+HLA-DRlow/-	
monocytes	in	prostate	cancer.	Prostate.	2010;70(4):443–455.		
239.	 Hoechst	B,	Ormandy	LA,	Ballmaier	M,	et	al.	A	New	Population	of	Myeloid-Derived	
Suppressor	Cells	in	Hepatocellular	Carcinoma	Patients	Induces	CD4+CD25+Foxp3+	
T	Cells.	Gastroenterology.	2008;135(1):234–243.		
240.	 Weed	DT,	Vella	JL,	Reis	IM,	et	al.	Tadalafil	reduces	myeloid-derived	suppressor	
cells	and	regulatory	T	cells	and	promotes	tumor	immunity	in	patients	with	head	
and	neck	squamous	cell	carcinoma.	Clin.	Cancer	Res.	2015;21(1):39–48.		
241.	 Aliper	AM,	Frieden-Korovkina	VP,	Buzdin	A,	Roumiantsev	SA,	Zhavoronkov	A.	
Interactome	analysis	of	myeloid-derived	suppressor	cells	in	murine	models	of	
colon	and	breast	cancer.	Oncotarget.	2014;5(22):11345–53.		
242.	 Gielen	PR,	Schulte	BM,	Kers-Rebel	ED,	et	al.	Increase	in	both	CD14-positive	and	
CD15-positive	myeloid-derived	suppressor	cell	subpopulations	in	the	blood	of	
patients	with	glioma	but	predominance	of	CD15-positive	myeloid-derived	
suppressor	cells	in	glioma	tissue.	J.	Neuropathol.	Exp.	Neurol.	2015;74(5):390–
400.		
243.	 Khaled	YS,	Ammori	BJ,	Elkord	E.	Increased	levels	of	granulocytic	myeloid-derived	
suppressor	cells	in	peripheral	blood	and	tumour	tissue	of	pancreatic	cancer	
patients.	J.	Immunol.	Res.	2014;2014:879897.		
244.	 Liu	CY,	Wang	YM,	Wang	CL,	et	al.	Population	alterations	of	l-arginase-	and	
inducible	nitric	oxide	synthase-expressed	CD11b+/CD14-/CD15+/CD33	+	myeloid-
derived	suppressor	cells	and	CD8+	T	lymphocytes	in	patients	with	advanced-stage	
non-small	cell	lung	cancer.	J.	Cancer	Res.	Clin.	Oncol.	2010;136(1):35–45.		
245.	 Lin	Y,	Gustafson	MP,	Bulur	PA,	et	al.	Immunosuppressive	CD14+HLA-DRlow/-	
Athalia	Rachel	Pyzer	 	 References	
	
289	
monocytes	in	B-cell	non-Hodgkin	lymphoma.	Blood.	2011;117(3):872–881.		
246.	 Sato	Y,	Shimizu	K,	Shinga	J,	et	al.	Characterization	of	the	myeloid-derived	
suppressor	cell	subset	regulated	by	NK	cells	in	malignant	lymphoma.	
Oncoimmunology.	2015;4(3):e995541.		
247.	 Romano	A,	Parrinello	NL,	Vetro	C,	et	al.	Circulating	myeloid-derived	suppressor	
cells	correlate	with	clinical	outcome	in	Hodgkin	Lymphoma	patients	treated	up-
front	with	a	risk-adapted	strategy.	Br.	J.	Haematol.	2015;168(5):689–700.		
248.	 Liu	J,	Zhou	Y,	Huang	Q,	Qiu	L.	CD14(+)HLA-DR(low/-)	expression:	A	novel	
prognostic	factor	in	chronic	lymphocytic	leukemia.	Oncol.	Lett.	2015;9(3):1167–
1172.		
249.	 Jitschin	R,	Braun	M,	Büttner	M,	et	al.	CLL-cells	induce	IDOhi	CD14+HLA-DRlo	
myeloid-derived	suppressor	cells	that	inhibit	T-cell	responses	and	promote	TRegs.	
Blood.	2014;124(5):750–760.		
250.	 De	Veirman	K,	Van	Ginderachter	JA,	Lub	S,	et	al.	Multiple	myeloma	induces	Mcl-1	
expression	and	survival	of	myeloid-derived	suppressor	cells.	Oncotarget.	
2015;6(12):10532–47.		
251.	 G"org̈un	GT,	Whitehill	G,	Anderson	JL,	et	al.	Tumor-promoting	immune-
suppressive	myeloid-derived	suppressor	cells	in	the	multiple	myeloma	
microenvironment	in	humans.	Blood.	2013;121(15):2975–2987.		
252.	 Brimnes	MK,	Vangsted	AJ,	Knudsen	LM,	et	al.	Increased	level	of	both	
CD4+FOXP3+	Regulatory	t	Cells	and	CD14+HLA-DR-/low	myeloid-derived	
suppressor	cells	and	decreased	level	of	dendritic	cells	in	patients	with	multiple	
myeloma.	Scand.	J.	Immunol.	2010;72(6):540–547.		
253.	 Görgün	GT,	Whitehill	G,	Anderson	JL,	et	al.	Tumor-promoting	immune-
suppressive	myeloid-derived	suppressor	cells	in	the	multiple	myeloma	
microenvironment	in	humans.	Blood.	2013;121(15):2975–2987.		
Athalia	Rachel	Pyzer	 	 References	
	
290	
254.	 Christiansson	L,	Söderlund	S,	Svensson	E,	et	al.	Increased	Level	of	Myeloid-
Derived	Suppressor	Cells,	Programmed	Death	Receptor	Ligand	1/Programmed	
Death	Receptor	1,	and	Soluble	CD25	in	Sokal	High	Risk	Chronic	Myeloid	Leukemia.	
PLoS	One.	2013;8(1):.		
255.	 Al.	MS	et.	Myeloid	Leukemias	Directly	Suppress	T	Cell	Proliferation	Through	
STAT3	and	Arginase	Pathways.	ASH.	2013;		
256.	 Lechner	MG,	Megiel	C,	Russell	SM,	et	al.	Functional	characterization	of	human	
Cd33+	and	Cd11b+	myeloid-derived	suppressor	cell	subsets	induced	from	
peripheral	blood	mononuclear	cells	co-cultured	with	a	diverse	set	of	human	
tumor	cell	lines.	J.	Transl.	Med.	2011;9:90.		
257.	 Dufait	I,	Schwarze	JK,	Liechtenstein	T,	et	al.	Ex	vivo	generation	of	myeloid-derived	
suppressor	cells	that	model	the	tumor	immunosuppressive	environment	in	
colorectal	cancer.	Oncotarget.	2015;6(14):12369–82.		
258.	 Bayne	LJ,	Beatty	GL,	Jhala	N,	et	al.	Tumor-Derived	Granulocyte-Macrophage	
Colony-Stimulating	Factor	Regulates	Myeloid	Inflammation	and	T	Cell	Immunity	in	
Pancreatic	Cancer.	Cancer	Cell.	2012;21(6):822–835.		
259.	 Bronte	V,	Chappell	DB,	Apolloni	E,	et	al.	Unopposed	production	of	granulocyte-
macrophage	colony-stimulating	factor	by	tumors	inhibits	CD8+	T	cell	responses	by	
dysregulating	antigen-presenting	cell	maturation.	J.	Immunol.	
1999;162(10):5728–5737.		
260.	 Morales	JK,	Kmieciak	M,	Knutson	KL,	Bear	HD,	Manjili	MH.	GM-CSF	is	one	of	the	
main	breast	tumor-derived	soluble	factors	involved	in	the	differentiation	of	
CD11b-Gr1-	bone	marrow	progenitor	cells	into	myeloid-derived	suppressor	cells.	
Breast	Cancer	Res.	Treat.	2010;123(1):39–49.		
261.	 Liechtenstein	T,	Perez-Janices	N,	Gato	M,	et	al.	A	highly	efficient	tumor-infiltrating	
MDSC	differentiation	system	for	discovery	of	anti-neoplastic	targets,	which	
Athalia	Rachel	Pyzer	 	 References	
	
291	
circumvents	the	need	for	tumor	establishment	in	mice.	Oncotarget.	
2014;5(17):7843–57.		
262.	 Zhou	Z,	French	DL,	Ma	G,	et	al.	Development	and	function	of	myeloid-derived	
suppressor	cells	generated	from	mouse	embryonic	and	hematopoietic	stem	cells.	
Stem	Cells.	2010;28(3):620–32.		
263.	 Waight	JD,	Hu	Q,	Miller	A,	Liu	S,	Abrams	SI.	Tumor-derived	G-CSF	facilitates	
neoplastic	growth	through	a	granulocytic	myeloid-derived	suppressor	cell-
dependent	mechanism.	PLoS	One.	2011;6(11):.		
264.	 Pan	PY,	Wang	GX,	Yin	B,	et	al.	Reversion	of	immune	tolerance	in	advanced	
malignancy:	Modulation	of	myeloid-derived	suppressor	cell	development	by	
blockade	of	stem-cell	factor	function.	Blood.	2008;111(1):219–228.		
265.	 Priceman	SJ,	Sung	JL,	Shaposhnik	Z,	et	al.	Targeting	distinct	tumor-infiltrating	
myeloid	cells	by	inhibiting	CSF-1	receptor:	Combating	tumor	evasion	of	
antiangiogenic	therapy.	Blood.	2010;115(7):1461–1471.		
266.	 Chen	M-F,	Kuan	F-C,	Yen	T-C,	et	al.	IL-6-stimulated	CD11b+	CD14+	HLA-DR-	
myeloid-derived	suppressor	cells,	are	associated	with	progression	and	poor	
prognosis	in	squamous	cell	carcinoma	of	the	esophagus.	Oncotarget.	
2014;5(18):8716–28.		
267.	 Elkabets	M,	Ribeiro	VSG,	Dinarello	CA,	et	al.	IL-1??	regulates	a	novel	myeloid-
derived	suppressor	cell	subset	that	impairs	NK	cell	development	and	function.	
Eur.	J.	Immunol.	2010;40(12):3347–3357.		
268.	 Zhao	X,	Rong	L,	Zhao	X,	et	al.	TNF	signaling	drives	myeloid-derived	suppressor	cell	
accumulation.	J.	Clin.	Invest.	2012;122(11):4094–4104.		
269.	 Villanueva	MT.	Microenvironment:	small	containers,	important	cargo.	Nat.	Rev.	
Cancer.	2014;14(12):764.		
Athalia	Rachel	Pyzer	 	 References	
	
292	
270.	 Balaj	L,	Atai	NA,	Chen	W,	et	al.	Heparin	affinity	purification	of	extracellular	
vesicles.	Sci.	Rep.	2015;5:10266.		
271.	 Webber	J,	Yeung	V,	Clayton	A.	Extracellular	vesicles	as	modulators	of	the	cancer	
microenvironment.	Semin.	Cell	Dev.	Biol.	2015;40:27–34.		
272.	 Xiang	X,	Poliakov	A,	Liu	C,	et	al.	Induction	of	myeloid-derived	suppressor	cells	by	
tumor	exosomes.	Int.	J.	Cancer.	2009;124(11):2621–2633.		
273.	 Valenti	R,	Huber	V,	Filipazzi	P,	et	al.	Human	tumor-released	microvesicles	
promote	the	differentiation	of	myeloid	cells	with	transforming	growth	factor-
beta-mediated	suppressive	activity	on	T	lymphocytes.	Cancer	Res.	
2006;66(18):9290–8.		
274.	 Rébé	C,	Végran	F,	Berger	H,	Ghiringhelli	F.	STAT3	activation:	A	key	factor	in	tumor	
immunoescape.	JAK-STAT.	2013;2(1):e23010.		
275.	 Miner	S,	Ito	S,	Tanimoto	K,	Hensel	N,	Barrett	J.	Myeloid	Leukemias	directly	
suppress	T	cell	proliferation	through	STAT3	and	Arginase	pathways.	ASH	2013.	
2013;(3885):.		
276.	 Trikha	P,	Carson	WE.	Signaling	pathways	involved	in	MDSC	regulation.	Biochim.	
Biophys.	Acta	-	Rev.	Cancer.	2014;1846(1):55–65.		
277.	 Dufait	I,	Van	Valckenborgh	E,	Menu	E,	et	al.	Signal	transducer	and	activator	of	
transcription	3	in	myeloid-derived	suppressor	cells:	an	opportunity	for	cancer	
therapy.	Oncotarget.	2016;		
278.	 Cohen	PA,	Ko	JS,	Storkus	WJ,	et	al.	Myeloid-derived	suppressor	cells	adhere	to	
physiologic	STAT3-	vs	STAT5-dependent	hematopoietic	programming,	
establishing	diverse	tumor-mediated	mechanisms	of	immunologic	escape.	
Immunol.	Invest.	2012;41(6–7):680–710.		
279.	 Yu	S,	Liu	C,	Su	K,	et	al.	Tumor	exosomes	inhibit	differentiation	of	bone	marrow	
Athalia	Rachel	Pyzer	 	 References	
	
293	
dendritic	cells.	J.	Immunol.	2007;178(11):6867–75.		
280.	 Vasquez-Dunddel	D,	Pan	F,	Zeng	Q,	et	al.	STAT3	regulates	arginase-I	in	myeloid-
derived	suppressor	cells	from	cancer	patients.	J.	Clin.	Invest.	2013;123(4):1580–9.		
281.	 Kujawski	M,	Kortylewski	M,	Lee	H,	et	al.	Stat3	mediates	myeloid	cell-dependent	
tumor	angiogenesis	in	mice.	J.	Clin.	Invest.	2008;118(10):3367–3377.		
282.	 Xin	H,	Zhang	C,	Herrmann	A,	et	al.	Sunitinib	inhibition	of	Stat3	induces	renal	cell	
carcinoma	tumor	cell	apoptosis	and	reduces	immunosuppressive	cells.	Cancer	
Res.	2009;69(6):2506–2513.		
283.	 Wu	L,	Du	H,	Li	Y,	Qu	P,	Yan	C.	Signal	Transducer	and	Activator	of	Transcription	3	
(Stat3C)	Promotes	Myeloid-Derived	Suppressor	Cell	Expansion	and	Immune	
Suppression	during	Lung	Tumorigenesis.	Am.	J.	Pathol.	2011;179(4):2131–2141.		
284.	 Mundy-Bosse	BL,	Young	GS,	Bauer	T,	et	al.	Distinct	myeloid	suppressor	cell	
subsets	correlate	with	plasma	IL-6	and	IL-10	and	reduced	interferon-alpha	
signaling	in	CD4	+	T	cells	from	patients	with	GI	malignancy.	Cancer	Immunol.	
Immunother.	2011;60(9):1269–1279.		
285.	 Sinha	P,	Clements	VK,	Ostrand-Rosenberg	S.	Reduction	of	myeloid-derived	
suppressor	cells	and	induction	of	M1	macrophages	facilitate	the	rejection	of	
established	metastatic	disease.	J.	Immunol.	2005;174(2):636–645.		
286.	 Wang	X,	Chang	X,	Zhuo	G,	Sun	M,	Yin	K.	Twist	and	miR-34a	are	involved	in	the	
generation	of	tumor-educated	myeloid-derived	suppressor	cells.	Int.	J.	Mol.	Sci.	
2013;14(10):20459–20477.		
287.	 Downward	J.	Targeting	RAS	signalling	pathways	in	cancer	therapy.	Nat.	Rev.	
Cancer.	2003;3(1):11–22.		
288.	 Behre	G,	Singh	SM,	Liu	H,	et	al.	Ras	signaling	enhances	the	activity	of	C/EBPα	to	
induce	granulocytic	differentiation	by	phosphorylation	of	serine	248.	J.	Biol.	
Athalia	Rachel	Pyzer	 	 References	
	
294	
Chem.	2002;277(29):26293–26299.		
289.	 Clark	CE,	Hingorani	SR,	Mick	R,	et	al.	Dynamics	of	the	immune	reaction	to	
pancreatic	cancer	from	inception	to	invasion.	Cancer	Res.	2007;67(19):9518–
9527.		
290.	 Enioutina	EY,	Bareyan	D,	Daynes	RA.	A	role	for	immature	myeloid	cells	in	immune	
senescence.	J.	Immunol.	2011;186(2):697–707.		
291.	 Cully	M,	You	H,	Levine	AJ,	Mak	TW.	Beyond	PTEN	mutations:	the	PI3K	pathway	as	
an	integrator	of	multiple	inputs	during	tumorigenesis.	Nat.	Rev.	Cancer.	
2006;6(3):184–192.		
292.	 Ghansah	T.	A	novel	strategy	for	modulation	of	MDSC	to	enhance	cancer	
immunotherapy.	Oncoimmunology.	2012;1(6):984–985.		
293.	 Li	L,	Zhang	J,	Diao	W,	et	al.	MicroRNA-155	and	MicroRNA-21	promote	the	
expansion	of	functional	myeloid-derived	suppressor	cells.	J.	Immunol.	
2014;192(3):1034–43.		
294.	 Chen	S,	Wang	L,	Fan	J,	et	al.	Host	miR155	promotes	tumor	growth	through	a	
myeloid-derived	suppressor	cell-dependent	mechanism.	Cancer	Res.	
2015;75(3):519–31.		
295.	 Kim	S,	Song	JH,	Kim	S,	et	al.	Loss	of	oncogenic	miR-155	in	tumor	cells	promotes	
tumor	growth	by	enhancing	C/EBP-β-mediated	MDSC	infiltration.	Oncotarget.	
2016;7(10):11094–112.		
296.	 Semenza	GL.	Hypoxia-inducible	factors:	mediators	of	cancer	progression	and	
targets	for	cancer	therapy.	Trends	Pharmacol.	Sci.	2012;33(4):207–14.		
297.	 Zhao	C,	Zhang	Q,	Yu	T,	et	al.	Hypoxia	promotes	drug	resistance	in	osteosarcoma	
cells	via	activating	AMP-activated	protein	kinase	(AMPK)	signaling.	J.	bone	Oncol.	
2016;5(1):22–9.		
Athalia	Rachel	Pyzer	 	 References	
	
295	
298.	 Syu	J-P,	Chi	J-T,	Kung	H-N.	Nrf2	is	the	key	to	chemotherapy	resistance	in	MCF7	
breast	cancer	cells	under	hypoxia.	Oncotarget.	2016;		
299.	 Rankin	EB,	Giaccia	AJ.	Hypoxic	control	of	metastasis.	Science	(80-.	).	
2016;352(6282):175–180.		
300.	 Sceneay	J,	Parker	BS,	Smyth	MJ,	Möller	A.	Hypoxia-driven	immunosuppression	
contributes	to	the	pre-metastatic	niche.	Oncoimmunology.	2013;2(1):e22355.		
301.	 Duechler	M,	Peczek	L,	Zuk	K,	et	al.	The	heterogeneous	immune	
microenvironment	in	breast	cancer	is	affected	by	hypoxia-related	genes.	
Immunobiology.	2014;219(2):158–65.		
302.	 Kumar	V,	Gabrilovich	DI.	Hypoxia-inducible	factors	in	regulation	of	immune	
responses	in	tumour	microenvironment.	Immunology.	2014;143(4):512–9.		
303.	 Corzo	CA,	Condamine	T,	Lu	L,	et	al.	HIF-1α	regulates	function	and	differentiation	
of	myeloid-derived	suppressor	cells	in	the	tumor	microenvironment.	J.	Exp.	Med.	
2010;207(11):2439–53.		
304.	 Noman	MZ,	Janji	B,	Hu	S,	et	al.	Tumor-Promoting	Effects	of	Myeloid-Derived	
Suppressor	Cells	Are	Potentiated	by	Hypoxia-Induced	Expression	of	miR-210.	
Cancer	Res.	2015;75(18):3771–87.		
305.	 Mikysková	R,	Indrová	M,	Vlková	V,	et	al.	DNA	demethylating	agent	5-azacytidine	
inhibits	myeloid-derived	suppressor	cells	induced	by	tumor	growth	and	
cyclophosphamide	treatment.	J.	Leukoc.	Biol.	2014;		
306.	 Sevko	A,	Sade-Feldman	M,	Kanterman	J,	et	al.	Cyclophosphamide	promotes	
chronic	inflammation-dependent	immunosuppression	and	prevents	antitumor	
response	in	melanoma.	J.	Invest.	Dermatol.	2013;133(6):1610–9.		
307.	 Ding	Z-C,	Lu	X,	Yu	M,	et	al.	Immunosuppressive	myeloid	cells	induced	by	
chemotherapy	attenuate	antitumor	CD4+	T-cell	responses	through	the	PD-1-PD-
Athalia	Rachel	Pyzer	 	 References	
	
296	
L1	axis.	Cancer	Res.	2014;74(13):3441–53.		
308.	 Dang	Y,	Wagner	WM,	Gad	E,	et	al.	Dendritic	cell-activating	vaccine	adjuvants	
differ	in	the	ability	to	elicit	antitumor	immunity	due	to	an	adjuvant-specific	
induction	of	immunosuppressive	cells.	Clin.	Cancer	Res.	2012;18(11):3122–31.		
309.	 Bogdan	C.	Nitric	oxide	and	the	immune	response.	Nat.	Immunol.	2001;2(10):907–
916.		
310.	 Wu	G,	Morris	SM.	Arginine	metabolism:	nitric	oxide	and	beyond.	Biochem.	J.	
1998;336	(	Pt	1:1–17.		
311.	 Popovic	PJ,	Zeh	HJ,	Ochoa	JB.	Arginine	and	immunity.	J.	Nutr.	2007;137(6	Suppl	
2):1681S–1686S.		
312.	 Bingisser	RM,	Tilbrook	PA,	Holt	PG,	Kees	UR.	Macrophage-derived	nitric	oxide	
regulates	T	cell	activation	via	reversible	disruption	of	the	Jak3/STAT5	signaling	
pathway.	J.	Immunol.	1998;160(12):5729–5734.		
313.	 Harari	O,	Liao	JK.	Inhibition	of	MHC	II	gene	transcription	by	nitric	oxide	and	
antioxidants.	Curr.	Pharm.	Des.	2004;10(8):893–898.		
314.	 Mannick	JB,	Hausladen	A,	Liu	L,	et	al.	Fas-induced	caspase	denitrosylation.	
Science.	1999;284(5414):651–654.		
315.	 Schmielau	J,	Finn	OJ.	Activated	granulocytes	and	granulocyte-derived	hydrogen	
peroxide	are	the	underlying	mechanism	of	suppression	of	T-cell	function	in	
advanced	cancer	patients.	Cancer	Res.	2001;61(12):4756–4760.		
316.	 Nagaraj	S,	Gupta	K,	Pisarev	V,	et	al.	Altered	recognition	of	antigen	is	a	mechanism	
of	CD8+	T	cell	tolerance	in	cancer.	Nat.	Med.	2007;13(7):828–835.		
317.	 Bronte	V,	Zanovello	P.	Regulation	of	immune	responses	by	L-arginine	metabolism.	
Nat.	Rev.	Immunol.	2005;5(8):641–654.		
Athalia	Rachel	Pyzer	 	 References	
	
297	
318.	 Youn	J-I,	Gabrilovich	DI.	The	biology	of	myeloid-derived	suppressor	cells:	the	
blessing	and	the	curse	of	morphological	and	functional	heterogeneity.	Eur.	J.	
Immunol.	2010;40(11):2969–2975.		
319.	 Mougiakakos	D,	Jitschin	R,	von	Bahr	L,	et	al.	Immunosuppressive	CD14+HLA-
DRlow/neg	IDO+	myeloid	cells	in	patients	following	allogeneic	hematopoietic	
stem	cell	transplantation.	Leukemia.	2012;		
320.	 Sakuishi	K,	Jayaraman	P,	Behar	SM,	Anderson	AC,	Kuchroo	VK.	Emerging	Tim-3	
functions	in	antimicrobial	and	tumor	immunity.	Trends	Immunol.	2011;32(8):345–
349.		
321.	 Liechtenstein	T,	Perez-Janices	N,	Blanco-Luquin	I,	et	al.	Anti-melanoma	vaccines	
engineered	to	simultaneously	modulate	cytokine	priming	and	silence	PD-L1	
characterized	using	ex	vivo	myeloid-derived	suppressor	cells	as	a	readout	of	
therapeutic	efficacy.	Oncoimmunology.	3(7):e945378.		
322.	 Chavan	R,	Salvador	D,	Gustafson	MP,	et	al.	Untreated	stage	IV	melanoma	patients	
exhibit	abnormal	monocyte	phenotypes	and	decreased	functional	capacity.	
Cancer	Immunol.	Res.	2014;2(3):241–8.		
323.	 Young	MR,	Wright	MA,	Matthews	JP,	Malik	I,	Prechel	M.	Suppression	of	T	cell	
proliferation	by	tumor-induced	granulocyte-macrophage	progenitor	cells	
producing	transforming	growth	factor-beta	and	nitric	oxide.	J.	Immunol.	
1996;156(5):1916–1922.		
324.	 Terabe	M,	Matsui	S,	Park	J-M,	et	al.	Transforming	growth	factor-beta	production	
and	myeloid	cells	are	an	effector	mechanism	through	which	CD1d-restricted	T	
cells	block	cytotoxic	T	lymphocyte-mediated	tumor	immunosurveillance:	
abrogation	prevents	tumor	recurrence.	J.	Exp.	Med.	2003;198(11):1741–1752.		
325.	 Liu	Y,	Lai	L,	Chen	Q,	et	al.	MicroRNA-494	is	required	for	the	accumulation	and	
functions	of	tumor-expanded	myeloid-derived	suppressor	cells	via	targeting	of	
Athalia	Rachel	Pyzer	 	 References	
	
298	
PTEN.	J.	Immunol.	2012;188(11):5500–10.		
326.	 Li	H,	Han	Y,	Guo	Q,	Zhang	M,	Cao	X.	Cancer-expanded	myeloid-derived	suppressor	
cells	induce	anergy	of	NK	cells	through	membrane-bound	TGF-beta	1.	J.	Immunol.	
2009;182(1):240–249.		
327.	 Eruslanov	E,	Daurkin	I,	Ortiz	J,	Vieweg	J,	Kusmartsev	S.	Pivotal	Advance:	Tumor-
mediated	induction	of	myeloid-derived	suppressor	cells	and	M2-polarized	
macrophages	by	altering	intracellular	PGE₂	catabolism	in	myeloid	cells.	J.	Leukoc.	
Biol.	2010;88(5):839–848.		
328.	 Rodriguez	PC,	Hernandez	CP,	Quiceno	D,	et	al.	Arginase	I	in	myeloid	suppressor	
cells	is	induced	by	COX-2	in	lung	carcinoma.	J.	Exp.	Med.	2005;202(7):931–939.		
329.	 Zhang	Y,	Liu	Q,	Zhang	M,	et	al.	Fas	signal	promotes	lung	cancer	growth	by	
recruiting	myeloid-derived	suppressor	cells	via	cancer	cell-derived	PGE2.	J.	
Immunol.	2009;182(6):3801–3808.		
330.	 Tu	S,	Bhagat	G,	Cui	G,	et	al.	Overexpression	of	interleukin-1beta	induces	gastric	
inflammation	and	cancer	and	mobilizes	myeloid-derived	suppressor	cells	in	mice.	
Cancer	Cell.	2008;14(5):408–419.		
331.	 Yu	J,	Wang	Y,	Yan	F,	et	al.	Noncanonical	NF-κB	Activation	Mediates	STAT3-
Stimulated	IDO	Upregulation	in	Myeloid-Derived	Suppressor	Cells	in	Breast	
Cancer.	J.	Immunol.	2014;		
332.	 Nagaraj	S,	Schrum	AG,	Cho	H-I,	Celis	E,	Gabrilovich	DI.	Mechanism	of	T	cell	
tolerance	induced	by	myeloid-derived	suppressor	cells.	J.	Immunol.	
2010;184(6):3106–3116.		
333.	 Gabrilovich	DI,	Velders	MP,	Sotomayor	EM,	Kast	WM.	Mechanism	of	immune	
dysfunction	in	cancer	mediated	by	immature	Gr-1+	myeloid	cells.	J.	Immunol.	
2001;166(9):5398–5406.		
Athalia	Rachel	Pyzer	 	 References	
	
299	
334.	 Chalmin	F,	Ladoire	S,	Mignot	G,	et	al.	Membrane-associated	Hsp72	from	tumor-
derived	exosomes	mediates	STAT3-dependent	immunosuppressive	function	of	
mouse	and	human	myeloid-derived	suppressor	cells.	J.	Clin.	Invest.	
2010;120(2):457–471.		
335.	 Kodumudi	KN,	Woan	K,	Gilvary	DL,	et	al.	A	novel	chemoimmunomodulating	
property	of	docetaxel:	Suppression	of	myeloid-derived	suppressor	cells	in	tumor	
bearers.	Clin.	Cancer	Res.	2010;16(18):4583–4594.		
336.	 Serafini	P,	Mgebroff	S,	Noonan	K,	Borrello	I.	Myeloid-derived	suppressor	cells	
promote	cross-tolerance	in	B-cell	lymphoma	by	expanding	regulatory	T	cells.	
Cancer	Res.	2008;68(13):5439–5449.		
337.	 Nagaraj	S,	Nelson	A,	Youn	J	-i.,	et	al.	Antigen-Specific	CD4+	T	Cells	Regulate	
Function	of	Myeloid-Derived	Suppressor	Cells	in	Cancer	via	Retrograde	MHC	Class	
II	Signaling.	Cancer	Res.	2012;72(4):928–938.		
338.	 Chan	LLY,	Cheung	BKW,	Li	JCB,	Lau	ASY.	A	role	for	STAT3	and	cathepsin	S	in	IL-10	
down-regulation	of	IFN-gamma-induced	MHC	class	II	molecule	on	primary	human	
blood	macrophages.	J.	Leukoc.	Biol.	2010;88(2):303–311.		
339.	 Adeegbe	D,	Serafini	P,	Bronte	V,	et	al.	In	Vivo	Induction	of	Myeloid	Suppressor	
Cells	and	CD4(+)Foxp3(+)	T	Regulatory	Cells	Prolongs	Skin	Allograft	Survival	in	
Mice.	Cell	Transplant.	2011;20(6):941–954.		
340.	 Hoechst	B,	Gamrekelashvili	J,	Manns	MP,	Greten	TF,	Korangy	F.	Plasticity	of	
human	Th17	cells	and	iTregs	is	orchestrated	by	different	subsets	of	myeloid	cells.	
Blood.	2011;117(24):6532–6541.		
341.	 Pan	PY,	Ma	G,	Weber	KJ,	et	al.	Immune	stimulatory	receptor	CD40	is	required	for	
T-cell	suppression	and	T	regulatory	cell	activation	mediated	by	myeloid-derived	
suppressor	cells	in	cancer.	Cancer	Res.	2010;70(1):99–108.		
342.	 Hoechst	B,	Voigtlaender	T,	Ormandy	L,	et	al.	Myeloid	derived	suppressor	cells	
Athalia	Rachel	Pyzer	 	 References	
	
300	
inhibit	natural	killer	cells	in	patients	with	hepatocellular	carcinoma	via	the	NKp30	
receptor.	Hepatology.	2009;50(3):799–807.		
343.	 Sinha	P,	Clements	VK,	Fulton	AM,	Ostrand-Rosenberg	S.	Prostaglandin	E2	
promotes	tumor	progression	by	inducing	myeloid-derived	suppressor	cells.	
Cancer	Res.	2007;67(9):4507–4513.		
344.	 Narita	Y,	Wakita	D,	Ohkur	T,	Chamoto	K,	Nishimura	T.	Potential	differentiation	of	
tumor	bearing	mouse	CD11b+Gr-1+	immature	myeloid	cells	into	both	suppressor	
macrophages	and	immunostimulatory	dendritic	cells.	Biomed.	Res.	2009;30(1):7–
15.		
345.	 Hu	C-E,	Gan	J,	Zhang	R-D,	Cheng	Y-R,	Huang	G-J.	Up-regulated	myeloid-derived	
suppressor	cell	contributes	to	hepatocellular	carcinoma	development	by	
impairing	dendritic	cell	function.	Scand.	J.	Gastroenterol.	2011;46(2):156–164.		
346.	 Poschke	I,	Mao	Y,	Adamson	L,	et	al.	Myeloid-derived	suppressor	cells	impair	the	
quality	of	dendritic	cell	vaccines.	Cancer	Immunol.	Immunother.	2012;61(6):827–
838.		
347.	 Sinha	P,	Clements	VK,	Bunt	SK,	Albelda	SM,	Ostrand-Rosenberg	S.	Cross-talk	
between	myeloid-derived	suppressor	cells	and	macrophages	subverts	tumor	
immunity	toward	a	type	2	response.	J.	Immunol.	2007;179(2):977–983.		
348.	 Kumar	V,	Cheng	P,	Condamine	T,	et	al.	CD45	Phosphatase	Inhibits	STAT3	
Transcription	Factor	Activity	in	Myeloid	Cells	and	Promotes	Tumor-Associated	
Macrophage	Differentiation.	Immunity.	2016;44(2):303–15.		
349.	 Xu	J,	Escamilla	J,	Mok	S,	et	al.	CSF1R	signaling	blockade	stanches	tumor-
infiltrating	myeloid	cells	and	improves	the	efficacy	of	radiotherapy	in	prostate	
cancer.	Cancer	Res.	2013;73(9):2782–94.		
350.	 Zhu	Y,	Knolhoff	BL,	Meyer	MA,	et	al.	CSF1/CSF1R	blockade	reprograms	tumor-
infiltrating	macrophages	and	improves	response	to	T-cell	checkpoint	
Athalia	Rachel	Pyzer	 	 References	
	
301	
immunotherapy	in	pancreatic	cancer	models.	Cancer	Res.	2014;74(18):5057–69.		
351.	 Fujita	M,	Kohanbash	G,	Fellows-Mayle	W,	et	al.	COX-2	blockade	suppresses	
gliomagenesis	by	inhibiting	myeloid-derived	suppressor	cells.	Cancer	Res.	
2011;71(7):2664–74.		
352.	 Obermajer	N,	Muthuswamy	R,	Odunsi	K,	Edwards	RP,	Kalinski	P.	PGE(2)-induced	
CXCL12	production	and	CXCR4	expression	controls	the	accumulation	of	human	
MDSCs	in	ovarian	cancer	environment.	Cancer	Res.	2011;71(24):7463–70.		
353.	 Suzuki	E,	Kapoor	V,	Jassar	AS,	Kaiser	LR,	Albelda	SM.	Gemcitabine	selectively	
eliminates	splenic	Gr-1+/CD11b	+	myeloid	suppressor	cells	in	tumor-bearing	
animals	and	enhances	antitumor	immune	activity.	Clin.	Cancer	Res.	
2005;11(18):6713–6721.		
354.	 Ko	HJ,	Kim	YJ,	Kim	YS,	et	al.	A	combination	of	chemoimmunotherapies	can	
efficiently	break	self-tolerance	and	induce	antitumor	immunity	in	a	tolerogenic	
murine	tumor	model.	Cancer	Res.	2007;67(15):7477–7486.		
355.	 Kusmartsev	S,	Cheng	F,	Yu	B,	et	al.	All-trans-retinoic	acid	eliminates	immature	
myeloid	cells	from	tumor-bearing	mice	and	improves	the	effect	of	vaccination.	
Cancer	Res.	2003;63(15):4441–4449.		
356.	 Bose	A,	Taylor	JL,	Alber	S,	et	al.	Sunitinib	facilitates	the	activation	and	recruitment	
of	therapeutic	anti-tumor	immunity	in	concert	with	specific	vaccination.	Int.	J.	
Cancer.	2011;129(9):2158–2170.		
357.	 Ozao-Choy	J,	Ge	M,	Kao	J,	et	al.	The	novel	role	of	tyrosine	kinase	inhibitor	in	the	
reversal	of	immune	suppression	and	modulation	of	tumor	microenvironment	for	
immune-based	cancer	therapies.	Cancer	Res.	2009;69(6):2514–2522.		
358.	 Maus	M	V.,	Grupp	SA,	Porter	DL,	June	CH.	Antibody-modified	T	cells:	CARs	take	
the	front	seat	for	hematologic	malignancies.	Blood.	2014;123(17):2625–2635.		
Athalia	Rachel	Pyzer	 	 References	
	
302	
359.	 Highfill	S,	Smith	J,	Long	A,	et	al.	Neutralization	of	murine	myeloid	suppressor	cells	
enhances	the	efficacy	of	GD2-specific	CAR	T	cells	directed	against	human	sarcoma	
in	a	xenograft	model	(VAC11P.1010).	J.	Immunol.	2014;192(1	
Supplement):205.11.		
360.	 Burga	RA,	Thorn	M,	Point	GR,	et	al.	Liver	myeloid-derived	suppressor	cells	expand	
in	response	to	liver	metastases	in	mice	and	inhibit	the	anti-tumor	efficacy	of	anti-
CEA	CAR-T.	Cancer	Immunol.	Immunother.	2015;64(7):817–29.		
361.	 John	LB,	Devaud	C,	Duong	CPM,	et	al.	Anti-PD-1	antibody	therapy	potently	
enhances	the	eradication	of	established	tumors	by	gene-modified	T	cells.	Clin.	
Cancer	Res.	2013;19(20):5636–5646.		
362.	 Dahan	R,	Sega	E,	Engelhardt	J,	et	al.	FcγRs	Modulate	the	Anti-tumor	Activity	of	
Antibodies	Targeting	the	PD-1/PD-L1	Axis.	Cancer	Cell.	2015;28(3):285–95.		
363.	 Bill	MA,	Fuchs	JR,	Li	C,	et	al.	The	small	molecule	curcumin	analog	FLLL32	induces	
apoptosis	in	melanoma	cells	via	STAT3	inhibition	and	retains	the	cellular	response	
to	cytokines	with	anti-tumor	activity.	Mol.	Cancer.	2010;9:165.		
364.	 Lu	P,	Yu	B,	Xu	J.	Cucurbitacin	B	Regulates	Immature	Myeloid	Cell	Differentiation	
and	Enhances	Antitumor	Immunity	in	Patients	with	Lung	Cancer.	Cancer	Biother.	
Radiopharm.	2012;27(8):495–503.		
365.	 Tu	SP,	Jin	H,	Shi	JD,	et	al.	Curcumin	induces	the	differentiation	of	myeloid-derived	
suppressor	cells	and	inhibits	their	interaction	with	cancer	cells	and	related	tumor	
growth.	Cancer	Prev.	Res.	(Phila).	2012;5(2):205–15.		
366.	 Ko	JS,	Rayman	P,	Ireland	J,	et	al.	Direct	and	differential	suppression	of	myeloid-
derived	suppressor	cell	subsets	by	sunitinib	is	compartmentally	constrained.	
Cancer	Res.	2010;70(9):3526–3536.		
367.	 Kodera	Y,	Katanasaka	Y,	Kitamura	Y,	et	al.	Sunitinib	inhibits	lymphatic	endothelial	
cell	functions	and	lymph	node	metastasis	in	a	breast	cancer	model	through	
Athalia	Rachel	Pyzer	 	 References	
	
303	
inhibition	of	vascular	endothelial	growth	factor	receptor	3.	Breast	Cancer	Res.	
2011;13(3):R66.		
368.	 Finke	JH,	Rini	B,	Ireland	J,	et	al.	Sunitinib	reverses	type-1	immune	suppression	and	
decreases	T-regulatory	cells	in	renal	cell	carcinoma	patients.	Clin.	Cancer	Res.	
2008;14(20):6674–6682.		
369.	 Raymond	E,	Dalgleish	A,	Damber	JE,	Smith	M,	Pili	R.	Mechanisms	of	action	of	
tasquinimod	on	the	tumour	microenvironment.	Cancer	Chemother.	Pharmacol.	
2014;73(1):1–8.		
370.	 Schilling	B,	Sucker	A,	Griewank	K,	et	al.	Vemurafenib	reverses	
immunosuppression	by	myeloid	derived	suppressor	cells.	Int.	J.	Cancer.	
2013;133(7):1653–1663.		
371.	 Mirza	N,	Fishman	M,	Fricke	I,	et	al.	All-trans-retinoic	acid	improves	differentiation	
of	myeloid	cells	and	immune	response	in	cancer	patients.	Cancer	Res.	
2006;66(18):9299–9307.		
372.	 Nefedova	Y,	Fishman	M,	Sherman	S,	et	al.	Mechanism	of	all-trans	retinoic	acid	
effect	on	tumor-associated	myeloid-derived	suppressor	cells.	Cancer	Res.	
2007;67(22):11021–11028.		
373.	 Waldron	TJ,	Quatromoni	JG,	Karakasheva	T	a,	Singhal	S,	Rustgi	AK.	Myeloid	
derived	suppressor	cells:	Targets	for	therapy.	Oncoimmunology.	
2013;2(4):e24117.		
374.	 Testa	U,	Masciulli	R,	Tritarelli	E,	et	al.	Transforming	growth	factor-beta	
potentiates	vitamin	D3-induced	terminal	monocytic	differentiation	of	human	
leukemic	cell	lines.	J.	Immunol.	1993;150(6):2418–2430.		
375.	 Zhou	J,	Wu	J,	Chen	X,	et	al.	Icariin	and	its	derivative,	ICT,	exert	anti-inflammatory,	
anti-tumor	effects,	and	modulate	myeloid	derived	suppressive	cells	(MDSCs)	
functions.	Int.	Immunopharmacol.	2011;11(7):887–895.		
Athalia	Rachel	Pyzer	 	 References	
	
304	
376.	 Wu	H,	Tao	N,	Liu	X,	et	al.	Polysaccharide	from	Lentinus	edodes	Inhibits	the	
Immunosuppressive	Function	of	Myeloid-Derived	Suppressor	Cells.	PLoS	One.	
2012;7(12):.		
377.	 Kusmartsev	S,	Eruslanov	E,	Kübler	H,	et	al.	Oxidative	stress	regulates	expression	
of	VEGFR1	in	myeloid	cells:	link	to	tumor-induced	immune	suppression	in	renal	
cell	carcinoma.	J.	Immunol.	2008;181(1):346–353.		
378.	 Roelofs	AJ,	Ebetino	FH,	Reszka	AA,	Russell	RGG,	Rogers	MJ.	Bisphosphonates:	
Mechanisms	of	Action.	Princ.	Bone	Biol.	Two-Volume	Set.	2008;2:1737–1767.		
379.	 Heissig	B,	Hattori	K,	Dias	S,	et	al.	Recruitment	of	stem	and	progenitor	cells	from	
the	bone	marrow	niche	requires	MMP-9	mediated	release	of	Kit-ligand.	Cell.	
2002;109(5):625–637.		
380.	 Melani	C,	Sangaletti	S,	Barazzetta	FM,	Werb	Z,	Colombo	MP.	Amino-
biphosphonate-mediated	MMP-9	inhibition	breaks	the	tumor-bone	marrow	axis	
responsible	for	myeloid-derived	suppressor	cell	expansion	and	macrophage	
infiltration	in	tumor	stroma.	Cancer	Res.	2007;67(23):11438–11446.		
381.	 Serafini	P,	Meckel	K,	Kelso	M,	et	al.	Phosphodiesterase-5	inhibition	augments	
endogenous	antitumor	immunity	by	reducing	myeloid-derived	suppressor	cell	
function.	J.	Exp.	Med.	2006;203(12):2691–2702.		
382.	 De	Santo	C,	Serafini	P,	Marigo	I,	et	al.	Nitroaspirin	corrects	immune	dysfunction	in	
tumor-bearing	hosts	and	promotes	tumor	eradication	by	cancer	vaccination.	Proc.	
Natl.	Acad.	Sci.	U.	S.	A.	2005;102(11):4185–4190.		
383.	 Gao	P,	Zhang	H,	Dinavahi	R,	et	al.	HIF-Dependent	Antitumorigenic	Effect	of	
Antioxidants	In	Vivo.	Cancer	Cell.	2007;12(3):230–238.		
384.	 Shirota	Y,	Shirota	H,	Klinman	DM.	Intratumoral	injection	of	CpG	oligonucleotides	
induces	the	differentiation	and	reduces	the	immunosuppressive	activity	of	
myeloid-derived	suppressor	cells.	J.	Immunol.	2012;188(4):1592–9.		
Athalia	Rachel	Pyzer	 	 References	
	
305	
385.	 Heckelsmiller	K,	Rall	K,	Beck	S,	et	al.	Peritumoral	CpG	DNA	elicits	a	coordinated	
response	of	CD8	T	cells	and	innate	effectors	to	cure	established	tumors	in	a	
murine	colon	carcinoma	model.	J.	Immunol.	2002;169(7):3892–3899.		
386.	 Kawarada	Y,	Ganss	R,	Garbi	N,	et	al.	NK-	and	CD8(+)	T	cell-mediated	eradication	of	
established	tumors	by	peritumoral	injection	of	CpG-containing	
oligodeoxynucleotides.	J.	Immunol.	2001;167(9):5247–5253.		
387.	 Liby	KT,	Yore	MM,	Sporn	MB.	Triterpenoids	and	rexinoids	as	multifunctional	
agents	for	the	prevention	and	treatment	of	cancer.	Nat.	Rev.	Cancer.	
2007;7(5):357–369.		
388.	 Konopleva	M,	Zhang	W,	Shi	Y-X,	et	al.	Synthetic	triterpenoid	2-cyano-3,12-
dioxooleana-1,9-dien-28-oic	acid	induces	growth	arrest	in	HER2-overexpressing	
breast	cancer	cells.	Mol.	Cancer	Ther.	2006;5(2):317–328.		
389.	 Muralikrishnan	G,	Dinda	AK,	Shakeel	F.	Immunomodulatory	effects	of	Withania	
somnifera	on	azoxymethane	induced	experimental	colon	cancer	in	mice.	
Immunol.	Invest.	2010;39(7):688–698.		
390.	 Sinha	P,	Ostrand-Rosenberg	S.	Myeloid-derived	suppressor	cell	function	is	
reduced	by	Withaferin	A,	a	potent	and	abundant	component	of	Withania	
somnifera	root	extract.	Cancer	Immunol.	Immunother.	2013;62(11):1663–1673.		
391.	 Seung	LP,	Rowley	DA,	Dubey	P,	Schreiber	H.	Synergy	between	T-cell	immunity	and	
inhibition	of	paracrine	stimulation	causes	tumor	rejection.	Proc.	Natl.	Acad.	Sci.	U.	
S.	A.	1995;92(14):6254–6258.		
392.	 Roth	F,	De	La	Fuente	AC,	Vella	JL,	et	al.	Aptamer-mediated	blockade	of	IL4R??	
triggers	apoptosis	of	MDSCs	and	limits	tumor	progression.	Cancer	Res.	
2012;72(6):1373–1383.		
393.	 Gallina	G,	Dolcetti	L,	Serafini	P,	et	al.	Tumors	induce	a	subset	of	inflammatory	
monocytes	with	immunosuppressive	activity	on	CD8+	T	cells.	J.	Clin.	Invest.	
Athalia	Rachel	Pyzer	 	 References	
	
306	
2006;116(10):2777–2790.		
394.	 Le	HK,	Graham	L,	Cha	E,	et	al.	Gemcitabine	directly	inhibits	myeloid	derived	
suppressor	cells	in	BALB/c	mice	bearing	4T1	mammary	carcinoma	and	augments	
expansion	of	T	cells	from	tumor-bearing	mice.	Int.	Immunopharmacol.	2009;9(7–
8):900–909.		
395.	 Vincent	J,	Mignot	G,	Chalmin	F,	et	al.	5-Fluorouracil	selectively	kills	tumor-
associated	myeloid-derived	suppressor	cells	resulting	in	enhanced	T	cell-
dependent	antitumor	immunity.	Cancer	Res.	2010;70(8):3052–3061.		
396.	 Bruchard	M,	Mignot	G,	Derangère	V,	et	al.	Chemotherapy-triggered	cathepsin	B	
release	in	myeloid-derived	suppressor	cells	activates	the	Nlrp3	inflammasome	
and	promotes	tumor	growth.	Nat.	Med.	2013;19(1):57–64.		
397.	 Amato	RJ,	Hawkins	RE,	Kaufman	HL,	et	al.	Vaccination	of	metastatic	renal	cancer	
patients	with	MVA-5T4:	a	randomized,	double-blind,	placebo-controlled	phase	III	
study.	Clin.	Cancer	Res.	2010;16(22):5539–5547.		
398.	 Iclozan	C,	Antonia	S,	Chiappori	A,	Chen	D-T,	Gabrilovich	D.	Therapeutic	regulation	
of	myeloid-derived	suppressor	cells	and	immune	response	to	cancer	vaccine	in	
patients	with	extensive	stage	small	cell	lung	cancer.	Cancer	Immunol.	
Immunother.	2013;62(5):909–18.		
399.	 	clinicaltrials.gov.	2015;		
400.	 Khan	IN,	Al-Karim	S,	Bora	RS,	Chaudhary	AG,	Saini	KS.	Cancer	stem	cells:	a	
challenging	paradigm	for	designing	targeted	drug	therapies.	Drug	Discov.	Today.	
2015;		
401.	 Grosicki	S,	Holowiecki	J,	Kuliczkowski	K,	et	al.	Assessing	the	efficacy	of	allogeneic	
hematopoietic	stem	cells	transplantation	(allo-HSCT)	by	analyzing	survival	end	
points	in	defined	groups	of	acute	myeloid	leukemia	patients;	a	retrospective,	
multicenter	Polish	Adult	Leukemia	Group	study.	Am.	J.	Hematol.	2015;		
Athalia	Rachel	Pyzer	 	 References	
	
307	
402.	 Odero	MD,	Zeleznik-Le	NJ,	Chinwalla	V,	Rowley	JD.	Cytogenetic	and	molecular	
analysis	of	the	acute	monocytic	leukemia	cell	line	THP-1	with	anMLL-AF9	
translocation.	Genes,	Chromosom.	Cancer.	2000;29(4):333–338.		
403.	 Matsuo	Y,	MacLeod	RA,	Uphoff	CC,	et	al.	Two	acute	monocytic	leukemia	(AML-
M5a)	cell	lines	(MOLM-13	and	MOLM-14)	with	interclonal	phenotypic	
heterogeneity	showing	MLL-AF9	fusion	resulting	from	an	occult	chromosome	
insertion,	ins(11;9)(q23;p22p23).	Leukemia.	1997;11(9):1469–77.		
404.	 Verschoor	CP,	Johnstone	J,	Millar	J,	et	al.	Blood	CD33(+)HLA-DR(-)	myeloid-
derived	suppressor	cells	are	increased	with	age	and	a	history	of	cancer.	J.	Leukoc.	
Biol.	2013;93(4):633–7.		
405.	 Shlush	LI,	Zandi	S,	Mitchell	A,	et	al.	Identification	of	pre-leukaemic	
haematopoietic	stem	cells	in	acute	leukaemia.	Nature.	2014;506(7488):328–33.		
406.	 Rechavi	O,	Erlich	Y,	Amram	H,	et	al.	Cell	contact-dependent	acquisition	of	cellular	
and	viral	nonautonomously	encoded	small	RNAs.	Genes	Dev.	2009;23(16):1971–9.		
407.	 Zomer	A,	Vendrig	T,	Hopmans	ES,	et	al.	Exosomes:	Fit	to	deliver	small	RNA.	
Commun.	Integr.	Biol.	2010;3(5):447–50.		
408.	 Di	Vizio	D,	Kim	J,	Hager	MH,	et	al.	Oncosome	formation	in	prostate	cancer:	
association	with	a	region	of	frequent	chromosomal	deletion	in	metastatic	
disease.	Cancer	Res.	2009;69(13):5601–9.		
409.	 Zhang	J,	Li	S,	Li	L,	et	al.	Exosome	and	Exosomal	MicroRNA:	Export,	Sorting,	and	
Function.	Genomics.	Proteomics	Bioinformatics.	2015;13(1):17–24.		
410.	 Théry	C,	Zitvogel	L,	Amigorena	S.	Exosomes:	composition,	biogenesis	and	
function.	Nat.	Rev.	Immunol.	2002;2(8):569–79.		
411.	 Raposo	G,	Stoorvogel	W.	Extracellular	vesicles:	exosomes,	microvesicles,	and	
friends.	J.	Cell	Biol.	2013;200(4):373–83.		
Athalia	Rachel	Pyzer	 	 References	
	
308	
412.	 Hong	CS,	Muller	L,	Boyiadzis	M,	Whiteside	TL.	Isolation	and	characterization	of	
CD34+	blast-derived	exosomes	in	acute	myeloid	leukemia.	PLoS	One.	
2014;9(8):e103310.		
413.	 Perez-Hernandez	D,	Gutiérrez-Vázquez	C,	Jorge	I,	et	al.	The	intracellular	
interactome	of	tetraspanin-enriched	microdomains	reveals	their	function	as	
sorting	machineries	toward	exosomes.	J.	Biol.	Chem.	2013;288(17):11649–61.		
414.	 Tzoran	I,	Rebibo-Sabbah	A,	Brenner	B,	Aharon	A.	Disease	dynamics	in	patients	
with	acute	myeloid	leukemia:	New	biomarkers.	Exp.	Hematol.	2015;43(11):936–
43.		
415.	 Hornick	NI,	Huan	J,	Doron	B,	et	al.	Serum	Exosome	MicroRNA	as	a	Minimally-
Invasive	Early	Biomarker	of	AML.	Sci.	Rep.	2015;5:11295.		
416.	 Huan	J,	Hornick	NI,	Shurtleff	MJ,	et	al.	RNA	export	by	acute	myelogenous	
leukemia	exosomes.	Cancer	Res.	2013;73(2):918–29.		
417.	 Valadi	H,	Ekström	K,	Bossios	A,	et	al.	Exosome-mediated	transfer	of	mRNAs	and	
microRNAs	is	a	novel	mechanism	of	genetic	exchange	between	cells.	Nat.	Cell	
Biol.	2007;9(6):654–9.		
418.	 Gibbings	DJ,	Ciaudo	C,	Erhardt	M,	Voinnet	O.	Multivesicular	bodies	associate	with	
components	of	miRNA	effector	complexes	and	modulate	miRNA	activity.	Nat.	Cell	
Biol.	2009;11(9):1143–9.		
419.	 Crescitelli	R,	Lässer	C,	Szabo	TG,	et	al.	Distinct	RNA	profiles	in	subpopulations	of	
extracellular	vesicles:	apoptotic	bodies,	microvesicles	and	exosomes.	J.	Extracell.	
Vesicles.	2013;2:.		
420.	 Ekström	K,	Valadi	H,	Sjöstrand	M,	et	al.	Characterization	of	mRNA	and	microRNA	
in	human	mast	cell-derived	exosomes	and	their	transfer	to	other	mast	cells	and	
blood	CD34	progenitor	cells.	J.	Extracell.	Vesicles.	2012;1:.		
Athalia	Rachel	Pyzer	 	 References	
	
309	
421.	 Chevillet	JR,	Kang	Q,	Ruf	IK,	et	al.	Quantitative	and	stoichiometric	analysis	of	the	
microRNA	content	of	exosomes.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	
2014;111(41):14888–93.		
422.	 Stevanato	L,	Thanabalasundaram	L,	Vysokov	N,	Sinden	JD.	Investigation	of	
Content,	Stoichiometry	and	Transfer	of	miRNA	from	Human	Neural	Stem	Cell	Line	
Derived	Exosomes.	PLoS	One.	2016;11(1):e0146353.		
423.	 Blanc	L,	De	Gassart	A,	Géminard	C,	Bette-Bobillo	P,	Vidal	M.	Exosome	release	by	
reticulocytes--an	integral	part	of	the	red	blood	cell	differentiation	system.	Blood	
Cells.	Mol.	Dis.	35(1):21–6.		
424.	 Meckes	DG,	Raab-Traub	N.	Microvesicles	and	viral	infection.	J.	Virol.	
2011;85(24):12844–54.		
425.	 André	F,	Chaput	N,	Schartz	NEC,	et	al.	Exosomes	as	potent	cell-free	peptide-based	
vaccine.	I.	Dendritic	cell-derived	exosomes	transfer	functional	MHC	class	
I/peptide	complexes	to	dendritic	cells.	J.	Immunol.	2004;172(4):2126–36.		
426.	 Vincent-Schneider	H,	Stumptner-Cuvelette	P,	Lankar	D,	et	al.	Exosomes	bearing	
HLA-DR1	molecules	need	dendritic	cells	to	efficiently	stimulate	specific	T	cells.	Int.	
Immunol.	2002;14(7):713–22.		
427.	 Théry	C,	Duban	L,	Segura	E,	et	al.	Indirect	activation	of	naïve	CD4+	T	cells	by	
dendritic	cell-derived	exosomes.	Nat.	Immunol.	2002;3(12):1156–62.		
428.	 Ristorcelli	E,	Beraud	E,	Verrando	P,	et	al.	Human	tumor	nanoparticles	induce	
apoptosis	of	pancreatic	cancer	cells.	FASEB	J.	2008;22(9):3358–69.		
429.	 Skog	J,	Würdinger	T,	van	Rijn	S,	et	al.	Glioblastoma	microvesicles	transport	RNA	
and	proteins	that	promote	tumour	growth	and	provide	diagnostic	biomarkers.	
Nat.	Cell	Biol.	2008;10(12):1470–6.		
430.	 Qu	J-L,	Qu	X-J,	Zhao	M-F,	et	al.	Gastric	cancer	exosomes	promote	tumour	cell	
Athalia	Rachel	Pyzer	 	 References	
	
310	
proliferation	through	PI3K/Akt	and	MAPK/ERK	activation.	Dig.	Liver	Dis.	
2009;41(12):875–880.		
431.	 Park	JE,	Tan	H	Sen,	Datta	A,	et	al.	Hypoxic	tumor	cell	modulates	its	
microenvironment	to	enhance	angiogenic	and	metastatic	potential	by	secretion	
of	proteins	and	exosomes.	Mol.	Cell.	Proteomics.	2010;9(6):1085–99.		
432.	 Robbins	PD,	Morelli	AE.	Regulation	of	immune	responses	by	extracellular	vesicles.	
Nat.	Rev.	Immunol.	2014;14(3):195–208.		
433.	 Liu	C,	Yu	S,	Kappes	J,	et	al.	Expansion	of	spleen	myeloid	suppressor	cells	represses	
NK	cell	cytotoxicity	in	tumor-bearing	host.	Blood.	2007;109(10):4336–42.		
434.	 Liu	Y,	Xiang	X,	Zhuang	X,	et	al.	Contribution	of	MyD88	to	the	tumor	exosome-
mediated	induction	of	myeloid	derived	suppressor	cells.	Am.	J.	Pathol.	
2010;176(5):2490–9.		
435.	 Xiang	X,	Liu	Y,	Zhuang	X,	et	al.	TLR2-mediated	expansion	of	MDSCs	is	dependent	
on	the	source	of	tumor	exosomes.	Am.	J.	Pathol.	2010;177(4):1606–10.		
436.	 Szczepanski	MJ,	Szajnik	M,	Welsh	A,	Whiteside	TL,	Boyiadzis	M.	Blast-derived	
microvesicles	in	sera	from	patients	with	acute	myeloid	leukemia	suppress	natural	
killer	cell	function	via	membrane-associated	transforming	growth	factor-beta1.	
Haematologica.	2011;96(9):1302–9.		
437.	 Hong	CS,	Muller	L,	Boyiadzis	M,	Whiteside	TL.	Isolation	and	characterization	of	
CD34+	blast-derived	exosomes	in	acute	myeloid	leukemia.	PLoS	One.	
2014;9(8):e103310.		
438.	 Whiteside	TL.	Immune	modulation	of	T-cell	and	NK	(natural	killer)	cell	activities	by	
TEXs	(tumour-derived	exosomes).	Biochem.	Soc.	Trans.	2013;41(1):245–51.		
439.	 Ohyashiki	JH,	Umezu	T,	Ohyashiki	K.	Exosomes	promote	bone	marrow	
angiogenesis	in	hematologic	neoplasia:	the	role	of	hypoxia.	Curr.	Opin.	Hematol.	
Athalia	Rachel	Pyzer	 	 References	
	
311	
2016;		
440.	 Wojtuszkiewicz	A,	Schuurhuis	GJ,	Kessler	FL,	et	al.	Exosomes	secreted	by	
apoptosis-resistant	AML	blasts	harbor	regulatory	network	proteins	potentially	
involved	in	antagonism	of	apoptosis.	Mol.	Cell.	Proteomics.	2016;		
441.	 Kalinkovich	A,	Tavor	S,	Avigdor	A,	et	al.	Functional	CXCR4-expressing	
microparticles	and	SDF-1	correlate	with	circulating	acute	myelogenous	leukemia	
cells.	Cancer	Res.	2006;66(22):11013–20.		
442.	 Ford	T,	Graham	J,	Rickwood	D.	Iodixanol:	a	nonionic	iso-osmotic	centrifugation	
medium	for	the	formation	of	self-generated	gradients.	Anal.	Biochem.	
1994;220(2):360–6.		
443.	 Vlassov	A	V,	Magdaleno	S,	Setterquist	R,	Conrad	R.	Exosomes:	current	knowledge	
of	their	composition,	biological	functions,	and	diagnostic	and	therapeutic	
potentials.	Biochim.	Biophys.	Acta.	2012;1820(7):940–8.		
444.	 Peterson	MF,	Otoc	N,	Sethi	JK,	Gupta	A,	Antes	TJ.	Integrated	systems	for	exosome	
investigation.	Methods.	2015;87:31–45.		
445.	 Shin	H,	Han	C,	Labuz	JM,	et	al.	High-yield	isolation	of	extracellular	vesicles	using	
aqueous	two-phase	system.	Sci.	Rep.	2015;5:13103.		
446.	 Enderle	D,	Spiel	A,	Coticchia	CM,	et	al.	Characterization	of	RNA	from	Exosomes	
and	Other	Extracellular	Vesicles	Isolated	by	a	Novel	Spin	Column-Based	Method.	
PLoS	One.	2015;10(8):e0136133.		
447.	 Oksvold	MP,	Neurauter	A,	Pedersen	KW.	Magnetic	bead-based	isolation	of	
exosomes.	Methods	Mol.	Biol.	2015;1218:465–81.		
448.	 VAN	DER	POL	E,	HOEKSTRA	AG,	STURK	A,	et	al.	Optical	and	non-optical	methods	
for	detection	and	characterization	of	microparticles	and	exosomes.	J.	Thromb.	
Haemost.	2010;8(12):2596–2607.		
Athalia	Rachel	Pyzer	 	 References	
	
312	
449.	 Wright	M.	Nanoparticle	tracking	analysis	for	the	multiparameter	characterization	
and	counting	of	nanoparticle	suspensions.	Methods	Mol.	Biol.	2012;906:511–24.		
450.	 Soo	CY,	Song	Y,	Zheng	Y,	et	al.	Nanoparticle	tracking	analysis	monitors	
microvesicle	and	exosome	secretion	from	immune	cells.	Immunology.	
2012;136(2):192–7.		
451.	 Erdbrügger	U,	Lannigan	J.	Analytical	challenges	of	extracellular	vesicle	detection:	
A	comparison	of	different	techniques.	Cytometry.	A.	2016;89(2):123–34.		
452.	 Nolte-’t	Hoen	ENM,	van	der	Vlist	EJ,	Aalberts	M,	et	al.	Quantitative	and	
qualitative	flow	cytometric	analysis	of	nanosized	cell-derived	membrane	vesicles.	
Nanomedicine.	2012;8(5):712–20.		
453.	 Groot	Kormelink	T,	Arkesteijn	GJA,	Nauwelaers	FA,	et	al.	Prerequisites	for	the	
analysis	and	sorting	of	extracellular	vesicle	subpopulations	by	high-resolution	
flow	cytometry.	Cytometry.	A.	2016;89(2):135–47.		
454.	 El-Andaloussi	S,	Lee	Y,	Lakhal-Littleton	S,	et	al.	Exosome-mediated	delivery	of	
siRNA	in	vitro	and	in	vivo.	Nat.	Protoc.	2012;7(12):2112–26.		
455.	 Pospichalova	V,	Svoboda	J,	Dave	Z,	et	al.	Simplified	protocol	for	flow	cytometry	
analysis	of	fluorescently	labeled	exosomes	and	microvesicles	using	dedicated	flow	
cytometer.	J.	Extracell.	Vesicles.	2015;4:.		
456.	 Campanella	C,	Rappa	F,	Sciumè	C,	et	al.	Heat	shock	protein	60	levels	in	tissue	and	
circulating	exosomes	in	human	large	bowel	cancer	before	and	after	ablative	
surgery.	Cancer.	2015;121(18):3230–9.		
457.	 Hegmans	JPJJ,	Bard	MPL,	Hemmes	A,	et	al.	Proteomic	analysis	of	exosomes	
secreted	by	human	mesothelioma	cells.	Am.	J.	Pathol.	2004;164(5):1807–15.		
458.	 Roberg-Larsen	H,	Lund	K,	Seterdal	KE,	et	al.	Mass	spectrometric	detection	of	27-
hydroxycholesterol	in	breast	cancer	exosomes.	J.	Steroid	Biochem.	Mol.	Biol.	
Athalia	Rachel	Pyzer	 	 References	
	
313	
2016;		
459.	 Caby	M-P,	Lankar	D,	Vincendeau-Scherrer	C,	Raposo	G,	Bonnerot	C.	Exosomal-like	
vesicles	are	present	in	human	blood	plasma.	Int.	Immunol.	2005;17(7):879–87.		
460.	 Lekchnov	EA,	Zaporozhchenko	IA,	Morozkin	ES,	et	al.	Protocol	for	miRNA	isolation	
from	biofluids.	Anal.	Biochem.	2016;499:78–84.		
461.	 El-Khoury	V,	Pierson	S,	Kaoma	T,	Bernardin	F,	Berchem	G.	Assessing	cellular	and	
circulating	miRNA	recovery:	the	impact	of	the	RNA	isolation	method	and	the	
quantity	of	input	material.	Sci.	Rep.	2016;6:19529.		
462.	 Delić	D,	Eisele	C,	Schmid	R,	et	al.	Urinary	Exosomal	miRNA	Signature	in	Type	II	
Diabetic	Nephropathy	Patients.	PLoS	One.	2016;11(3):e0150154.		
463.	 Bretz	NP,	Ridinger	J,	Rupp	A-K,	et	al.	Body	fluid	exosomes	promote	secretion	of	
inflammatory	cytokines	in	monocytic	cells	via	Toll-like	receptor	signaling.	J.	Biol.	
Chem.	2013;288(51):36691–702.		
464.	 Sivadasan	P,	Gupta	MK,	Sathe	GJ,	et	al.	Human	salivary	proteome--a	resource	of	
potential	biomarkers	for	oral	cancer.	J.	Proteomics.	2015;127(Pt	A):89–95.		
465.	 Grigor’eva	AE,	Tamkovich	SN,	Eremina	A	V,	et	al.	[Characteristics	of	exosomes	
andmicroparticles	discovered	in	human	tears].	Biomed.	Khim.	2016;62(1):99–106.		
466.	 Oksvold	MP,	Kullmann	A,	Forfang	L,	et	al.	Expression	of	B-cell	surface	antigens	in	
subpopulations	of	exosomes	released	from	B-cell	lymphoma	cells.	Clin.	Ther.	
2014;36(6):847–862.e1.		
467.	 Taylor	DD,	Gercel-Taylor	C.	MicroRNA	signatures	of	tumor-derived	exosomes	as	
diagnostic	biomarkers	of	ovarian	cancer.	Gynecol.	Oncol.	2008;110(1):13–21.		
468.	 Rabinowits	G,	Gerçel-Taylor	C,	Day	JM,	Taylor	DD,	Kloecker	GH.	Exosomal	
microRNA:	a	diagnostic	marker	for	lung	cancer.	Clin.	Lung	Cancer.	2009;10(1):42–
6.		
Athalia	Rachel	Pyzer	 	 References	
	
314	
469.	 Chen	X,	Ba	Y,	Ma	L,	et	al.	Characterization	of	microRNAs	in	serum:	a	novel	class	of	
biomarkers	for	diagnosis	of	cancer	and	other	diseases.	Cell	Res.	2008;18(10):997–
1006.		
470.	 Bryant	RJ,	Pawlowski	T,	Catto	JWF,	et	al.	Changes	in	circulating	microRNA	levels	
associated	with	prostate	cancer.	Br.	J.	Cancer.	2012;106(4):768–74.		
471.	 Manier	S,	Avet-Loiseau	H,	Campigotto	F,	et	al.	Prognostic	Value	of	Circulating	
Exosomal	microRNAs	in	112	Patients	with	Multiple	Myeloma.	Blood.	
2014;124(21):2056.		
472.	 Hornick	NI,	Huan	J,	Doron	B,	et	al.	Serum	Exosome	MicroRNA	as	a	Minimally-
Invasive	Early	Biomarker	of	AML.	Sci.	Rep.	2015;5:11295.		
473.	 Takeshita	N,	Hoshino	I,	Mori	M,	et	al.	Serum	microRNA	expression	profile:	miR-
1246	as	a	novel	diagnostic	and	prognostic	biomarker	for	oesophageal	squamous	
cell	carcinoma.	Br.	J.	Cancer.	2013;108(3):644–52.		
474.	 Viaud	S,	Théry	C,	Ploix	S,	et	al.	Dendritic	cell-derived	exosomes	for	cancer	
immunotherapy:	what’s	next?	Cancer	Res.	2010;70(4):1281–5.		
475.	 Dai	S,	Wei	D,	Wu	Z,	et	al.	Phase	I	clinical	trial	of	autologous	ascites-derived	
exosomes	combined	with	GM-CSF	for	colorectal	cancer.	Mol.	Ther.	
2008;16(4):782–90.		
476.	 Morse	MA,	Garst	J,	Osada	T,	et	al.	A	phase	I	study	of	dexosome	immunotherapy	
in	patients	with	advanced	non-small	cell	lung	cancer.	J.	Transl.	Med.	2005;3(1):9.		
477.	 Escudier	B,	Dorval	T,	Chaput	N,	et	al.	Vaccination	of	metastatic	melanoma	
patients	with	autologous	dendritic	cell	(DC)	derived-exosomes:	results	of	thefirst	
phase	I	clinical	trial.	J.	Transl.	Med.	2005;3(1):10.		
478.	 Akao	Y,	Iio	A,	Itoh	T,	et	al.	Microvesicle-mediated	RNA	molecule	delivery	system	
using	monocytes/macrophages.	Mol.	Ther.	2011;19(2):395–9.		
Athalia	Rachel	Pyzer	 	 References	
	
315	
479.	 Ohno	S,	Takanashi	M,	Sudo	K,	et	al.	Systemically	injected	exosomes	targeted	to	
EGFR	deliver	antitumor	microRNA	to	breast	cancer	cells.	Mol.	Ther.	
2013;21(1):185–91.		
480.	 Alvarez-Erviti	L,	Seow	Y,	Yin	H,	et	al.	Delivery	of	siRNA	to	the	mouse	brain	by	
systemic	injection	of	targeted	exosomes.	Nat.	Biotechnol.	2011;29(4):341–5.		
481.	 Mizrak	A,	Bolukbasi	MF,	Ozdener	GB,	et	al.	Genetically	engineered	microvesicles	
carrying	suicide	mRNA/protein	inhibit	schwannoma	tumor	growth.	Mol.	Ther.	
2013;21(1):101–8.		
482.	 Tian	Y,	Li	S,	Song	J,	et	al.	A	doxorubicin	delivery	platform	using	engineered	natural	
membrane	vesicle	exosomes	for	targeted	tumor	therapy.	Biomaterials.	
2014;35(7):2383–90.		
483.	 Kooijmans	SAA,	Vader	P,	van	Dommelen	SM,	van	Solinge	WW,	Schiffelers	RM.	
Exosome	mimetics:	a	novel	class	of	drug	delivery	systems.	Int.	J.	Nanomedicine.	
2012;7:1525–41.		
484.	 Sun	D,	Zhuang	X,	Xiang	X,	et	al.	A	novel	nanoparticle	drug	delivery	system:	the	
anti-inflammatory	activity	of	curcumin	is	enhanced	when	encapsulated	in	
exosomes.	Mol.	Ther.	2010;18(9):1606–14.		
485.	 Hung	ME,	Leonard	JN.	Stabilization	of	exosome-targeting	peptides	via	engineered	
glycosylation.	J.	Biol.	Chem.	2015;290(13):8166–72.		
486.	 Marleau	AM,	Chen	C-S,	Joyce	JA,	Tullis	RH.	Exosome	removal	as	a	therapeutic	
adjuvant	in	cancer.	J.	Transl.	Med.	2012;10:134.		
487.	 Gusnard	D,	Kirschner	RH.	Cell	and	organelle	shrinkage	during	preparation	for	
scanning	electron	microscopy:	effects	of	fixation,	dehydration	and	critical	point	
drying.	J.	Microsc.	1977;110(1):51–7.		
488.	 van	der	Pol	E,	Coumans	FAW,	Grootemaat	AE,	et	al.	Particle	size	distribution	of	
Athalia	Rachel	Pyzer	 	 References	
	
316	
exosomes	and	microvesicles	determined	by	transmission	electron	microscopy,	
flow	cytometry,	nanoparticle	tracking	analysis,	and	resistive	pulse	sensing.	J.	
Thromb.	Haemost.	2014;12(7):1182–92.		
489.	 Bouillez	A,	Rajabi	H,	Pitroda	S,	et	al.	Inhibition	of	MUC1-C	Suppresses	MYC	
Expression	and	Attenuates	Malignant	Growth	in	KRAS	Mutant	Lung	
Adenocarcinomas.	Cancer	Res.	2016;76(6):1538–48.		
490.	 Tagde	A,	Rajabi	H,	Bouillez	A,	et	al.	MUC1-C	drives	MYC	in	multiple	myeloma.	
Blood.	2016;127(21):2587–97.		
491.	 Tagde	A,	Rajabi	H,	Stroopinsky	D,	et	al.	MUC1-C	induces	DNA	methyltransferase	1	
and	represses	tumor	suppressor	genes	in	acute	myeloid	leukemia.	Oncotarget.	
2016;		
492.	 Yin	L,	Kosugi	M,	Kufe	D.	Inhibition	of	the	MUC1-C	oncoprotein	induces	multiple	
myeloma	cell	death	by	down-regulating	TIGAR	expression	and	depleting	NADPH.	
Blood.	2012;119(3):810–6.		
493.	 David	JM,	Hamilton	DH,	Palena	C.	MUC1	upregulation	promotes	immune	
resistance	in	tumor	cells	undergoing	brachyury-mediated	epithelial-mesenchymal	
transition.	Oncoimmunology.	2016;5(4):e1117738.		
494.	 Eilers	M,	Picard	D,	Yamamoto	KR,	Bishop	JM.	Chimaeras	of	myc	oncoprotein	and	
steroid	receptors	cause	hormone-dependent	transformation	of	cells.	Nature.	
1989;340(6228):66–8.		
495.	 Tagde	A,	Rajabi	H,	Bouillez	A,	et	al.	MUC1-C	drives	MYC	in	multiple	myeloma.	
Blood.	2016;		
496.	 Bouillez	A,	Rajabi	H,	Pitroda	S,	et	al.	Inhibition	of	MUC1-C	Suppresses	MYC	
Expression	and	Attenuates	Malignant	Growth	in	KRAS	Mutant	Lung	
Adenocarcinomas.	Cancer	Res.	2016;76(6):1538–48.		
Athalia	Rachel	Pyzer	 	 References	
	
317	
497.	 Hu	W,	Coller	J.	What	comes	first:	translational	repression	or	mRNA	degradation?	
The	deepening	mystery	of	microRNA	function.	Cell	Res.	2012;22(9):1322–4.		
498.	 Sun	M,	Chen	H,	Liu	J,	Tong	C,	Meng	T.	MicroRNA-34a	inhibits	human	trophoblast	
cell	invasion	by	targeting	MYC.	BMC	Cell	Biol.	2015;16:21.		
499.	 Rajabi	H,	Tagde	A,	Alam	M,	et	al.	DNA	methylation	by	DNMT1	and	DNMT3b	
methyltransferases	is	driven	by	the	MUC1-C	oncoprotein	in	human	carcinoma	
cells.	Oncogene.	2016;		
500.	 Srivastava	P,	Paluch	BE,	Matsuzaki	J,	et	al.	Immunomodulatory	action	of	SGI-110,	
a	hypomethylating	agent,	in	acute	myeloid	leukemia	cells	and	xenografts.	Leuk.	
Res.	2014;38(11):1332–1341.		
501.	 Guan	H,	Xie	L,	Klapproth	K,	et	al.	Decitabine	represses	translocated	MYC	
oncogene	in	Burkitt	lymphoma.	J.	Pathol.	2013;229(5):775–83.		
502.	 Ng	GZ,	Sutton	P.	The	MUC1	mucin	specifically	inhibits	activation	of	the	NLRP3	
inflammasome.	Genes	Immun.	2016;17(3):203–6.		
503.	 Rajabi	H,	Tagde	A,	Alam	M,	et	al.	DNA	methylation	by	DNMT1	and	DNMT3b	
methyltransferases	is	driven	by	the	MUC1-C	oncoprotein	in	human	carcinoma	
cells.	Oncogene.	2016;		
504.	 Tagde	A,	Rajabi	H,	Stroopinsky	D,	et	al.	MUC1-C	induces	DNA	methyltransferase	1	
and	represses	tumor	suppressor	genes	in	acute	myeloid	leukemia.	Oncotarget.	
2016;		
505.	 Halazonetis	TD,	Georgopoulos	K,	Greenberg	ME,	Leder	P.	c-Jun	dimerizes	with	
itself	and	with	c-Fos,	forming	complexes	of	different	DNA	binding	affinities.	Cell.	
1988;55(5):917–24.		
506.	 Gazon	H,	Belrose	G,	Terol	M,	et	al.	Impaired	expression	of	DICER	and	some	
microRNAs	in	HBZ	expressing	cells	from	acute	adult	T-cell	leukemia	patients.	
Athalia	Rachel	Pyzer	 	 References	
	
318	
Oncotarget.	2016;		
507.	 Triozzi	PL,	Aldrich	W,	Achberger	S,	et	al.	Differential	eVects	of	low-dose	
decitabine	on	immune	effector	and	suppressor	responses	in	melanoma-bearing	
mice.	Cancer	Immunol.	Immunother.	2012;61(9):1441–1450.		
508.	 Momparler	RL.	Pharmacology	of	5-Aza-2’-deoxycytidine	(decitabine).	Semin.	
Hematol.	2005;42(3	Suppl	2):S9-16.		
509.	 Klemm	F,	Joyce	JA.	Microenvironmental	regulation	of	therapeutic	response	in	
cancer.	Trends	Cell	Biol.	2014;		
510.	 Wang	Z,	Zhang	L,	Wang	H,	et	al.	Tumor-induced	CD14(+)HLA-DR	(-/low)	myeloid-
derived	suppressor	cells	correlate	with	tumor	progression	and	outcome	of	
therapy	in	multiple	myeloma	patients.	Cancer	Immunol	Immunother.	2014;		
511.	 Laborde	RR,	Lin	Y,	Gustafson	MP,	Bulur	PA,	Dietz	AB.	Cancer	Vaccines	in	the	
World	of	Immune	Suppressive	Monocytes	(CD14(+)HLA-DR(lo/neg)	Cells):	The	
Gateway	to	Improved	Responses.	Front	Immunol.	2014;5:147.		
512.	 Gabrilovich	DI,	Nagaraj	S.	Myeloid-derived	suppressor	cells	as	regulators	of	the	
immune	system.	Nat.	Rev.	Immunol.	2009;9(3):162–174.		
513.	 Greten	TF,	Manns	MP,	Korangy	F.	Myeloid	derived	suppressor	cells	in	human	
diseases.	Int	Immunopharmacol.	2011;11(7):802–807.		
514.	 Baniyash	M,	Sade-Feldman	M,	Kanterman	J.	Chronic	inflammation	and	cancer:	
suppressing	the	suppressors.	Cancer	Immunol	Immunother.	2014;63(1):11–20.		
515.	 Katoh	H,	Wang	D,	Daikoku	T,	et	al.	CXCR2-expressing	myeloid-derived	suppressor	
cells	are	essential	to	promote	colitis-associated	tumorigenesis.	Cancer	Cell.	
2013;24(5):631–644.		
516.	 Vedell	PT,	Svenson	KL,	Churchill	GA,	et	al.	Stochastic	variation	of	transcript	
abundance	in	C57BL/6J	mice.	BMC	Genomics.	2011;12(1):167.		
Athalia	Rachel	Pyzer	 	 References	
	
319	
517.	 Health	USNI	of.	Clinicaltrials.gov.	-.	2013;		
518.	 Li	XJ,	Ren	ZJ,	Tang	JH.	MicroRNA-34a:	a	potential	therapeutic	target	in	human	
cancer.	Cell	Death	Dis.	2014;5:e1327.		
519.	 Baek	D,	Villén	J,	Shin	C,	et	al.	The	impact	of	microRNAs	on	protein	output.	Nature.	
2008;455(7209):64–71.		
520.	 Pulikkan	JA,	Peramangalam	PS,	Dengler	V,	et	al.	C/EBPα	regulated	microRNA-34a	
targets	E2F3	during	granulopoiesis	and	is	down-regulated	in	AML	with	CEBPA	
mutations.	Blood.	2010;116(25):5638–5649.		
521.	 Cifuentes	D,	Xue	H,	Taylor	DW,	et	al.	A	novel	miRNA	processing	pathway	
independent	of	Dicer	requires	Argonaute2	catalytic	activity.	Science.	
2010;328(5986):1694–8.		
522.	 Tagde	A,	Singh	H,	Kang	MH,	Reynolds	CP.	The	glutathione	synthesis	inhibitor	
buthionine	sulfoximine	synergistically	enhanced	melphalan	activity	against	
preclinical	models	of	multiple	myeloma.	Blood	Cancer	J.	2014;4:e229.		
523.	 Yang	Y,	Wang	L-L,	Li	Y-H,	et	al.	Effect	of	CpG	island	methylation	on	microRNA	
expression	in	the	k-562	cell	line.	Biochem.	Genet.	2012;50(1–2):122–34.		
524.	 Pan	X,	Wang	R,	Wang	Z-X,	et	al.	The	potential	role	of	miR-451	in	cancer	diagnosis,	
prognosis,	and	therapy.	Mol.	Cancer	Ther.	2013;12(7):1153–62.		
525.	 Villela	D,	Ramalho	RF,	Silva	ART,	et	al.	Differential	DNA	Methylation	of	MicroRNA	
Genes	in	Temporal	Cortex	from	Alzheimer’s	Disease	Individuals.	Neural	Plast.	
2016;2016:2584940.		
	
